

Alliance to leave no-one behind



## Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso: **A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi**

Promosso da



e da

**INMI**, Istituto Nazionale per le Malattie Infettive

**ISS**, Istituto Superiore di Sanità

**AMCLI**, Associazione Microbiologi Clinici Italiani

**SIICA**, Società Italiana di Immunologia, Immunologia Clinica e Allergologia

**SIMaST**, Società Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili

**SITA**, Società italiana per la Terapia Antinfettiva

**SIV-ISV**, Società Italiana di Virologia - Italian Society for Virology

**ANLAIDS**, Associazione Nazionale per la lotta all'AIDS

**ARCIGAY**, Associazione LGBT Italiana

**ARCOBALENO Aids ODV**, Associazione ARCOBALENO Aids ODV

**ASA Onlus**, Associazione Solidarietà AIDS Onlus

**C.I.C.A.**, Coordinamento Italiano delle case alloggio per persone con HIV/AIDS

**EpaC Onlus**, Associazione EpaC Onlus

**LILA**, Lega Italiana per la Lotta contro l'AIDS

**MARIO MIELI**, Circolo di Cultura Omosessuale

**Milano Check Point**, Associazione Milano Check Point

**NADIR**, Associazione Nadir

**NPS Italia Onlus**, Network Persone Sieropositive

**PLUS**, Rete persone LGBT+ sieropositive Aps

Con il Patrocinio di

Ministero della Salute



Consiglio Nazionale delle Ricerche



## Scientific Programme

[www.icar2022.it](http://www.icar2022.it)





*Restate connessi al sito e alle pagine social!*

Seguici su



[www.icar2022.it](http://www.icar2022.it)

### **Sedi Congressuali**

#### **Centro Congressi Giovanni XXIII**

Viale Papa Giovanni XXIII, 106 - 24121 Bergamo

#### **Bergamo Science Center**

Viale Papa Giovanni XXIII, 57 - 24121 Bergamo

### **Provider e Segreteria Organizzativa**

#### **Effetti srl**

Via G.B. Giorgini, 16 - 20151 Milano

Tel. +39 02 3343281 - Fax +39 02 38002105 - [icar2022@effetti.it](mailto:icar2022@effetti.it) - @ICARcongress





## Endorsements

### INSTITUTIONS

Ministero della Salute



Consiglio Nazionale delle Ricerche



Provincia di Bergamo



COMUNE DI BERGAMO



CONSIGLIO DEI SINDACI  
BERGAMO



Bergamo  
Capitale Italiana del  
Volontariato 2022

### INSTITUTES

Ospedale di Bergamo  
ASST Papa Giovanni XXIII

INMI Lazzaro  
Spallanzani

IRCCS Ospedale  
San Raffaele

Università  
di Siena

### SCIENTIFIC SOCIETIES

**AIMI**, Associazione Infermieri Malattie Infettive

**AISF**, Associazione Italiana per lo Studio del Fegato

**AMCLI**, Associazione Microbiologi Clinici Italiani

**SIICA**, Società Italiana di Immunologia, Immunologia Clinica e Allergologia

**SIMaST**, Società Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili

**SIM**, Società Italiana di Microbiologia

**SIMIT**, Società Italiana di Malattie Infettive e Tropicali

**SITA**, Società italiana per la Terapia Antinfettiva

**SIV-ISV**, Società Italiana di Virologia - Italian Society for Virology

### FOUNDATIONS

**Fondazione ICONA**, Italian Cohort Naive Antiretrovirals

**Fondazione Villa Maraini Onlus**, Agenzia Nazionale di Croce Rossa Italiana per le dipendenze patologiche

### ASSOCIATIONS

**ANLAIDS**, Associazione Nazionale per la lotta all'AIDS

**ARCIGAY**, Associazione LGBT Italiana

**ARCOBALENO Aids ODV**, Associazione ARCOBALENO Aids ODV

**ASA Onlus**, Associazione Solidarietà AIDS Onlus

**Bergamo Fast-Track City**

**C.I.C.A.**, Coordinamento Italiano delle case alloggio per persone con HIV/AIDS

**Differenza Lesbica**, Associazione culturale laica, antifascista, antirazzista per le donne lesbiche, bisessuali, transessuali

**EpaC Onlus**, Associazione EpaC Onlus

**Gay Center**, casa di tutte le persone LGBT+ (lesbiche, gay, bisex e trans)

**IAPAC**, International Association of Providers of AIDS care

**LILA**, Lega Italiana per la Lotta contro l'AIDS

**MARIO MIELI**, Circolo di Cultura Omosessuale

**Milano Check Point**, Associazione Milano Check Point

**NADIR**, Associazione Nadir

**NPS Italia Onlus**, Network Persone Sieropositive

**PLUS**, Rete persone LGBT+ sieropositive Aps





## Scientific Committee

### Chairs

**Andrea Antinori**, Roma  
**Massimo Cernuschi**, Milano  
**Franco Maggiolo**, Bergamo  
**Maurizio Zazzi**, Siena

### Abstract Coordinator

**Antonio Di Biagio**, Genova

### Scientific Secretariat

**Chiara Agrati**, Roma  
**Guido Antonelli**, Roma  
**Alessandra Bandera**, Milano  
**Andrea Calcagno**, Torino  
**Annapaola Callegaro**, Bergamo  
**Daniele Calzavara**, Milano  
**Anna Maria Cattelan**, Padova  
**Francesca Ceccherini-Silberstein**, Roma  
**Stefania Cicalini**, Roma  
**Antonella Cingolani**, Roma  
**Paola Cinque**, Milano  
**Nicola Coppola**, Napoli  
**Giulio Maria Corbelli**, Bologna  
**Andrea Cossarizza**, Modena  
**Gabriella d'Ettore**, Roma  
**Anna Maria Geretti**, Roma  
**Cristina Gervasoni**, Milano

**Enrico Girardi**, Roma  
**Giovanni Guaraldi**, Modena  
**Miriam Lichtner**, Latina  
**Sergio Lo Caputo**, Foggia  
**Giordano Madeddu**, Sassari  
**Giulia Marchetti**, Milano  
**Paolo Meli**, Bergamo  
**Silvia Nozza**, Milano  
**Giuseppe Nunnari**, Messina  
**Stefano Rusconi**, Legnano (MI)  
**Francesco Saladini**, Siena  
**Mariella Santoro**, Roma  
**Annalisa Saracino**, Bari  
**Valentina Svicher**, Roma  
**Lucia Taramasso**, Genova  
**Alessandra Vergori**, Roma  
**Ilaria Vicenti**, Siena

### Pre-Conference Course Secretariat

**Giorgia Fracca**, Milano  
**Roberta Gagliardini**, Roma

**Michele Lanza**, Milano  
**Valentina Mazzotta**, Roma  
**Valeria Micheli**, Milano  
**Roberto Rossotti**, Milano  
**Ombretta Turriziani**, Roma

### Annual Programme Committee

**Massimo Andreoni**, Roma  
**Andrea Antinori**, Roma  
**Antonella Castagna**, Milano  
**Massimo Cernuschi**, Milano  
**Antonella d'Arminio Monforte**, Milano  
**Massimo Farinella**, Roma  
**Andrea Gori**, Milano  
**Franco Maggiolo**, Bergamo  
**Cristina Mussini**, Modena  
**Massimo Puoti**, Milano  
**Maurizio Zazzi**, Siena

## Government Bodies

### SPC (Scientific Programme Committee)

**Massimo Andreoni**, Roma  
**Andrea Antinori**, Roma  
**Guido Antonelli**, Roma  
**Matteo Bassetti**, Genova  
**Paolo Bonfanti**, Monza  
**Stefano Bonora**, Torino  
**Sergio Carbonara**, Bari

**Arnaldo Caruso**, Brescia  
**Antonio Cascio**, Palermo  
**Antonella Castagna**, Milano  
**Francesco Castelli**, Brescia  
**Anna Maria Cattelan**, Padova  
**Benedetto Maurizio Cesia**, Catania  
**Antonella Cingolani**, Roma  
**Massimo Clementi**, Milano  
**Andrea Cossarizza**, Modena  
**Marco Cusini**, Milano  
**Antonella d'Arminio Monforte**, Milano

**Antonio Di Biagio**, Genova  
**Giovanni Di Perri**, Torino  
**Massimo Di Pietro**, Firenze  
**Vincenzo Esposito**, Napoli  
**Enrico Girardi**, Roma  
**Andrea Gori**, Milano  
**Sergio Lo Caputo**, Foggia  
**Fabrizio Maggi**, Varese  
**Paolo Maggi**, Napoli  
**Franco Maggiolo**, Bergamo  
**Giulia Marchetti**, Milano





**Claudio Maria Mastroianni**, Roma  
**Cristina Mussini**, Modena  
**Silvia Nozza**, Milano  
**Giuseppe Nunnari**, Messina  
**Giustino Parruti**, Pescara  
**Carlo Federico Perno**, Roma  
**Massimo Puoti**, Milano  
**Giuliano Rizzardini**, Milano  
**Stefano Rusconi**, Legnano (MI)  
**Laura Sighinolfi**, Ferrara

**Guido Silvestri**, Atlanta USA  
**Barbara Suligoj**, Roma  
**Marcello Tavio**, Ancona  
**Carlo Torti**, Catanzaro  
**Maurizio Zazzi**, Siena

### **CsC (Community sub-Committee)**

**Alberto Bignardi**, Bologna  
**Daniele Calzavara**, Milano

**Giulio Maria Corbelli**, Bologna  
**Maria Grazia Di Benedetto**, Catania  
**Massimo Farinella**, Roma  
**Nicoletta Frattini**, Milano  
**Ivan Gardini**, Forlì  
**Bruno Marchini**, Roma  
**Paolo Meli**, Bergamo  
**Ada Moznich**, Milano  
**Stefano Patrucco**, Torino  
**Filippo von Schloesser**, Roma

## Faculty

**Chiara Agrati**, Roma  
**Claudia Alteri**, Milano  
**Massimo Andreoni**, Roma  
**Andrea Antinori**, Roma  
**Guido Antonelli**, Roma  
**Max Appenroth**, Berlin D  
**Bertrand Audoin**, Paris F  
**Alessandra Bandera**, Milano  
**Matteo Bassetti**, Genova  
**Alessandra Bianchi**, Milano  
**Teresa Bini**, Milano  
**Isabella Bon**, Bologna  
**Paolo Bonfanti**, Monza  
**Stefano Bonora**, Torino  
**Marco Borderi**, Bologna  
**Vanni Borghi**, Modena  
**Michele Breveglieri**, Bologna  
**Raffaele Bruno**, Pavia  
**Francesca Caccuri**, Brescia  
**Andrea Calcagno**, Torino  
**Annapaola Callegaro**, Bergamo  
**Giulia Valeria Calvino**, Roma  
**Leonardo Calza**, Bologna  
**Daniele Calzavara**, Milano  
**Diana Canetti**, Milano  
**Anna Caraglia**, Roma  
**Sergio Carbonara**, Bisceglie (BT)  
**Antonio Cascio**, Palermo  
**Antonella Castagna**, Milano  
**Francesco Castelli**, Brescia  
**Dario Cattaneo**, Milano  
**Anna Maria Cattelan**, Padova  
**Roberto Cauda**, Roma  
**Francesca Ceccherini-Silberstein**, Roma

**Benedetto Maurizio Celesia**, Catania  
**Giovanni Cenderello**, Sanremo  
**Valeria Cento**, Rozzano (MI)  
**Massimo Cernuschi**, Milano  
**Stefania Cicalini**, Roma  
**Antonella Cingolani**, Roma  
**Paola Cinque**, Milano  
**Massimo Clementi**, Milano  
**Mario Salvatore Clerici**, Milano  
**Pietro Colletti**, Marsala  
**Nicola Coppola**, Napoli  
**Giulio Maria Corbelli**, Bologna  
**Davide Corti**, Bellinzona CH  
**Maria Luisa Cosmaro**, Milano  
**Andrea Cossarizza**, Modena  
**Marco Cusini**, Milano  
**Antonella d'Arminio Monforte**, Milano  
**Gabriella d'Ettore**, Roma  
**Gianpiero D'Offizi**, Roma  
**Michele De Gennaro**, Lucca  
**Fabio De Iaco**, Torino  
**Andrea De Maria**, Genova  
**Steven G. Deeks**, San Francisco USA  
**Maria Grazia Di Benedetto**, Catania  
**Antonio Di Biagio**, Genova  
**Tania Di Giovanni**, Roma  
**Speranza Di Maggio**, Padova  
**Giovanni Di Perri**, Torino  
**Massimo Antonio Di Pietro**, Firenze  
**Vincenzo Esposito**, Napoli  
**Marco Falcone**, Pisa  
**Massimo Farinella**, Roma  
**Emanuele Focà**, Brescia  
**Giorgia Fracca**, Milano

**Nicoletta Frattini**, Milano  
**Giovanni Gabutti**, Lavagna (GE)  
**Roberta Gagliardini**, Roma  
**Giovanni Gaiera**, Milano  
**Rosario Galipò**, Roma  
**Massimo Galli**, Milano  
**Cecilia Garlanda**, Pieve Emanuele (MI)  
**Lidia Gazzola**, Milano  
**Anna Maria Geretti**, Roma  
**Cristina Gervasoni**, Milano  
**Vania Giacomet**, Milano  
**Nicola Gianotti**, Milano  
**Enrico Girardi**, Roma  
**Andrea Gori**, Milano  
**Giovanni Guaraldi**, Modena  
**Roberto Gulminetti**, Pavia  
**Fiona Lampe**, London UK  
**Pietro Lampertico**, Milano  
**Michele Lanza**, Milano  
**Giuseppe Lapadula**, Monza  
**Adriano Lazzarin**, Milano  
**Filippo Leserri**, Roma  
**Miriam Lichtner**, Latina  
**Sergio Lo Caputo**, Foggia  
**Giordano Madeddu**, Sassari  
**Fabrizio Maggi**, Varese  
**Paolo Maggi**, Caserta  
**Franco Maggiolo**, Bergamo  
**Lara Manganaro**, Milano  
**Giulia Marchetti**, Milano  
**Bruno Marchini**, Roma  
**Maria Giulia Marini**, Milano  
**Massimo Marra**, Roma  
**Claudio Maria Mastroianni**, Roma





**Alberto Matteelli**, Brescia  
**Sandro Mattioli**, Bologna  
**Giovanni Mazzola**, Caltanissetta  
**Valentina Mazzotta**, Roma  
**Paolo Meli**, Bergamo  
**Valeria Micheli**, Milano  
**Francesca Moccia**, Roma  
**Perry Mohammed**, London UK  
**Ada Moznich**, Milano  
**Cristina Mussini**, Modena  
**Paola Nasta**, Brescia  
**Alice Nava**, Milano  
**Emanuele Nicastrì**, Roma  
**Filippo M. Nimbi**, Roma  
**Silvia Nozza**, Milano  
**Giuseppe Nunnari**, Messina  
**William Richard Nutland**, London UK  
**Giancarlo Orofino**, Torino  
**Saverio Parisi**, Padova  
**Giustino Parruti**, Pescara

**Stefano Patrucco**, Torino  
**Dimitra Peppà**, London UK  
**Carlo Federico Perno**, Roma  
**Carmela Pinnetti**, Roma  
**Silvia Pittalis**, Roma  
**Guido Poli**, Milano  
**Massimo Puoti**, Milano  
**Maria Eugenia Quiros Roldan**, Brescia  
**Laura Amelia Rachele Rancilio**, Milano  
**Diego Ripamonti**, Bergamo  
**Agostino Riva**, Milano  
**Giuliano Rizzardini**, Milano  
**Marco Rizzi**, Bergamo  
**Roberto Rossotti**, Milano  
**Stefano Rusconi**, Legnano (MI)  
**Francesco Saladini**, Siena  
**Maria Santoro**, Roma  
**Annalisa Saracino**, Bari  
**Lolita Sasset**, Padova  
**Gabriella Scarlatti**, Milano

**Laura Sighinolfi**, Ferrara  
**Francesco Roberto Simonetti**, Baltimore USA  
**Vincenzo Spagnuolo**, Milano  
**Nicola Squillace**, Monza  
**Valentina Svicher**, Roma  
**Lucia Taramasso**, Genova  
**Marcello Tavio**, Ancona  
**Camilla Tincati**, Milano  
**Ombretta Turriziani**, Roma  
**Stefano Vella**, Roma  
**Alessandra Vergori**, Roma  
**Pierluigi Viale**, Bologna  
**Ilaria Vicenti**, Siena  
**Francesca Vichi**, Firenze  
**Giovanni Villa**, Brighton UK  
**Pietro Leone Giovanni Vinti**, Milano  
**Eleonora Volpato**, Milano  
**Donatello Zagato**, Milano  
**Maurizio Zazzi**, Siena

## Abstract Reviewers

**Isabella Abbate**, Roma  
**Chiara Agrati**, Roma  
**Guido Antonelli**, Roma  
**Lorenzo Badia**, Bologna  
**Alessandra Bandera**, Milano  
**Teresa Bini**, Milano  
**Paolo Bonfanti**, Monza  
**Stefano Bonora**, Torino  
**Marco Borderi**, Bologna  
**Andrea Calcagno**, Torino  
**Annapaola Callegaro**, Bergamo  
**Daniele Calzavara**, Milano  
**Antonella Castagna**, Milano  
**Dario Cattaneo**, Milano  
**Anna Maria Cattelan**, Padova  
**Francesca Ceccherini-Silberstein**, Roma  
**Benedetto Maurizio Celesia**, Catania  
**Stefania Cicalini**, Roma  
**Antonella Cingolani**, Roma  
**Paola Cinque**, Milano  
**Nicola Coppola**, Napoli  
**Giulio Maria Corbelli**, Bologna  
**Maria Luisa Cosmaro**, Milano

**Andrea Cossarizza**, Modena  
**Gabriella d'Ettore**, Roma  
**Antonio Di Biagio**, Genova  
**Carlo Ferrari**, Parma  
**Giorgia Fracca**, Milano  
**Roberta Gagliardini**, Roma  
**Anna Maria Geretti**, Roma  
**Cristina Gervasoni**, Milano  
**Nicola Gianotti**, Milano  
**Enrico Girardi**, Roma  
**Andrea Gori**, Milano  
**Giovanni Guaraldi**, Modena  
**Miriam Lichtner**, Latina  
**Giuseppina Liuzzi**, Roma  
**Sergio Lo Caputo**, Foggia  
**Lucia Lopalco**, Milano  
**Giordano Madeddu**, Sassari  
**Paolo Maggi**, Caserta  
**Franco Maggiolo**, Bergamo  
**Giulia Marchetti**, Milano  
**Valentina Mazzotta**, Roma  
**Paolo Meli**, Bergamo  
**Valeria Micheli**, Milano

**Ada Moznich**, Milano  
**Silvia Nozza**, Milano  
**Giuseppe Nunnari**, Messina  
**Giancarlo Orofino**, Torino  
**Carmela Pinnetti**, Roma  
**Tullio Prestileo**, Palermo  
**Diego Ripamonti**, Bergamo  
**Roberto Rossotti**, Milano  
**Stefano Rusconi**, Legnano (MI)  
**Francesco Saladini**, Siena  
**Maria Santoro**, Roma  
**Annalisa Saracino**, Bari  
**Loredana Sarmati**, Roma  
**Nicola Squillace**, Monza  
**Valentina Svicher**, Roma  
**Gloria Taliani**, Roma  
**Lucia Taramasso**, Genova  
**Camilla Tincati**, Milano  
**Ombretta Turriziani**, Roma  
**Alessandra Vergori**, Roma  
**Ilaria Vicenti**, Siena  
**Francesca Vichi**, Firenze





Andrea Antinori



Massimo Cernuschi



Franco Maggiolo



Maurizio Zazzi

## Dear Colleagues and Friends

It is our great pleasure to welcome you to the **14<sup>th</sup> ICAR**, the Italian Conference on AIDS and Antiviral Research.

This year, the Conference claim **“alliance to leave no one behind”** highlights the spirit of 2022 edition. The HIV transmission curve is being influenced, perhaps for the first time, by ARV therapies and by the effort of the entire Italian scientific and clinical society to widely apply the concept of therapy for all, without limitations induced by immune or clinical levels.

It is time to make a qualitative leap in two directions. The first, to strengthen the alliance between all the scientific, clinical and social components that are committed in various ways in the fight against HIV/AIDS. The second, to reach the most fragile and exposed populations, whom the COVID-19 pandemic has made even more fragile.

Crises can be profound catalysts for change and generate new opportunities to create much more value over time: recent years have clearly shown that only by working together we can effectively address the multidimensional consequences of a pandemic. Based on what we learnt from the recent pandemic, we need to reflect on how the fight against HIV can be strengthened and become even more effective.

With this spirit we choose to support, through **Scholarships and Special Awards**, our young researchers, the non-medical health personnel, the Community of patient associations and volunteers.

At the same time, ICAR 2022 maintains its commitment to civil society in the prevention of infectious diseases, by offering **free HIV, HCV and Syphilis Rapid Test** to the local population, and by continuing to promote the **RaccontART contest**, now at its 8th edition, that involves high school students.


**Special thanks** go to the Scientific Committee and Secretariat, to the Abstract Coordinator and Reviewers, to our Faculty Members, to the ICAR Governing Board, SIMIT, to the Community of Patient Associations and Volunteers, Institutions, Scientific Societies, Schools and Students, to the Municipality and the Province of Bergamo and to our Sponsors who enabled us to involve and host hundreds of participants from all over the Country.

We are greatly honored to welcome you and **leave no one behind in Bergamo!**

## Welcome to **ICAR 2022**

The Chairs







*Alliance to leave no-one behind*



**Italian Conference on AIDS and Antiviral Research**

Presidenza del Congresso: **A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi**

# **PROGRAMME AT A GLANCE**



ORARI	AUDITORIUM SALA OGGIONI	SALA STUCCHI	ALABASTRO A	ALABASTRO B
13.30 16.30	SPECIAL SESSION <b>Incontro scuole RaccontART</b> 13.30-16.00	PRE-CONFERENCE ADVANCED COURSE <b>Focus on viral resistance and variability</b> 14.30-16.30	PRE-CONFERENCE ADVANCED COURSE <b>Clinical and point of care diagnostics for STIs in a PrEP service</b> 14.30-16.30	PRE-CONFERENCE ADVANCED COURSE <b>New psychoactive substances and chemsex. David Stuart Course</b> 14.30-16.30
	<b>AUDITORIUM SALA OGGIONI</b>			
17.00 18.00	SATELLITE SYMPOSIUM <b>Defining new patient-centric goals to improve long-term treatment success in HIV</b>			
18.20 20.00	<b>ICAR 2022</b> <i>Opening Session</i> 18.00-18.20 <b>Introducing ICAR 2022 - Chairs and Authorities' Welcome addresses</b> 18.20-18.40 <b>RaccontART contest Awards</b> 18.40-19.10 Mauro Moroni Memorial Lecture <b>COVID-19 past, present and future. Will Covid ever retire?</b> 19.10-19.40 <b>HIV as a chronic disease: myth or truth?</b> 19.40-20.00 <b>Opening session closing remarks</b>			
20.00 22.00	<b>ICAR 2022</b> <b>Welcome Reception</b>			

CONFERENCE SESSIONS

ORAL POSTERS

ORAL COMMUNICATIONS

SPONSORED SESSIONS

SATELLITE SESSIONS





ORARI	AUDITORIUM SALA OGGIONI	SALA STUCCHI	ALABASTRO A	ALABASTRO B	BERGAMO SCIENCE CENTER
09.00 10.00	<b>Keynote Lectures</b>				
10.05 11.05	SPONSORED SYMPOSIUM <b>Being pioneers of a new paradigm: what have we learned so far?</b>	ORAL COMMUNICATIONS <b>PrEP: new data and issues</b>	SATELLITE SYMPOSIUM <b>Hepatitis Delta in HIV/HBV Infected Patients</b>		ORAL POSTER <b>COVID-19: treatment strategies I</b> 10.05-10.55
11.10 12.10	SATELLITE SYMPOSIUM <b>HIV: act in the present and challenge the future</b>	ORAL COMMUNICATIONS <b>Immunological efficacy of SARS-CoV-2 vaccine I</b>	ORAL POSTER <b>COVID-19: treatment strategies II</b> 11.10-12.00	ORAL POSTER <b>Treatment of naive PLWH: current strategies and rapid start of ART</b> 11.10-12.00	ORAL POSTER <b>PrEP: real life experience</b> 11.10-12.00
12.15 13.15	SYMPOSIUM <b>New Insights and Challenges on Hepatitis and HIV Co-infections</b>	EXPERT MEETING <b>Narrative Medicine applied to Vaccination during COVID-19 pandemic</b>	SPONSORED SYMPOSIUM <b>Cabotegravir + rilpivirine long-acting: are we ready for the new era?</b>		ORAL POSTER <b>Access test and educational aspects</b> 12.15-13.05
13.15 14.30		SPECIAL SESSION <b>How to use U=U to fight stigma</b>	ORAL COMMUNICATIONS <b>Metabolic issues in effective HAART</b> 13.15-14.15	ORAL POSTER <b>Predictors of COVID-19 severity</b> 13.25-14.15	ORAL POSTER <b>HCV eradication: general and key populations</b> 13.25-14.15
14.30 15.30	SPONSORED SYMPOSIUM <b>Long Term Treatment Success for PLWH: from clinical trials to real world experience with B/F/TAF</b>	ORAL COMMUNICATIONS <b>COVID-19: clinical management</b>	EXPERT MEETING <b>The new recombinant adjuvanted vaccine against Herpes Zoster: clinical data and recommendations</b>	ORAL POSTER <b>Viro-immunological correlates of COVID-19 severity</b> 14.30-15.20	ORAL POSTER <b>Issues on mental health, sexual health and STIs</b> 14.30-15.20
15.35 16.35	SYMPOSIUM <b>At the edge of PrEP</b>	ORAL COMMUNICATIONS <b>Pathogenesis and Immunology</b>	INTERACTIVE EXPERT MEETING <b>Affairs of the heart in HIV: redundant or a key challenge?</b>	ORAL POSTER <b>Neuropsychological complications in COVID-19</b> 15.35-16.25	ORAL POSTER <b>New issues on dual therapy</b> 15.35-16.25
16.40 17.40	SYMPOSIUM <b>Monoclonal antibodies and antiviral agents in COVID-19: rational for use and best candidates</b>	ORAL COMMUNICATIONS <b>From HIV to SARS-CoV-2</b>	EXPERT MEETING <b>Evolving models of care in the management of Gram+ infectious diseases: the role of long-acting antibiotic therapies</b>	ORAL POSTER <b>Cardiovascular diseases, osteoporosis but not only</b> 16.40-17.30	ORAL POSTER <b>Vulnerable and key population: local experiences</b> 16.40-17.30
17.45 18.45	SYMPOSIUM <b>Challenges in HIV cure: getting to zero reservoir</b>	ORAL COMMUNICATIONS <b>Metabolic alterations: effect of drugs and diseases</b>	ORAL COMMUNICATIONS <b>Special issues in clinical HIV</b>	ORAL POSTER <b>Measuring HIV stigma and disclosure</b> 17.45-18.35	ORAL POSTER <b>Models of COVID-19 pathogenesis and response to vaccination</b> 17.45-18.35



ORARI	AUDITORIUM SALA OGGIONI	SALA STUCCHI	ALABASTRO A	ALABASTRO B	BERGAMO SCIENCE CENTER
09.00 10.00	<b>Keynote Lectures</b>				
10.05 11.05	SYMPOSIUM <b>Comorbidities of contemporary relevance</b>	EXPERT MEETING <b>Heavily-treatment experienced (HTE) patients: who are they? And how should be managed?</b>	SYMPOSIUM <b>The Italian Fast-Track Cities Network</b> 10.05-12.10	ORAL POSTER <b>COVID-19: considerations of special populations</b> 10.05-10.55	ORAL POSTER <b>Toxicity of antiretroviral therapy</b> 10.05-10.55
11.10 12.10	SPONSORED SYMPOSIUM <b>Remdesivir: key-role in COVID-19 management</b>	ORAL COMMUNICATIONS <b>Resistance to antiretroviral</b>		ORAL POSTER <b>HIV and SARS-CoV-2: from in vivo to in vitro</b> 11.10-12.00	
12.15 13.15	SYMPOSIUM <b>A practical approach to HIV patients' management</b>	ORAL COMMUNICATIONS <b>HIV and SARS-CoV-2: two intersecting epidemics</b>	EXPERT MEETING <b>Redefining manage- ment and treatment goals in antiretroviral triple therapy: results of a Delphi Consensus</b>	ORAL POSTER <b>Acute COVID-19 and post COVID-19 syndrome</b> 12.15-13.05	ORAL POSTER <b>Immunological efficacy of COVID-19 vaccination in vulnerable populations</b> 12.15-13.05
13.15 14.15	SYMPOSIUM <b>Immunological control over HIV: from models of spontaneous control to immunotherapeutic approaches</b>	ORAL COMMUNICATIONS <b>Diabetes, cardiovascular diseases and STIs. A wide range of comorbidities</b>	ORAL COMMUNICATIONS <b>Immunological efficacy of SARS-CoV-2 vaccine II</b>	ORAL POSTER <b>Open questions about ART efficacy</b> 13.15-14.05	ORAL POSTER <b>Immunological complexity in COVID-19</b> 13.15-14.05
14.15 15.15	SYMPOSIUM <b>COVID-19 from early treatment to long-term care</b>	ORAL COMMUNICATIONS <b>Dual therapy in naive and switched PLWH</b>	ORAL COMMUNICATIONS <b>Mental health and predictors of AIDS and non-AIDS defining co-pathologies</b>	ORAL POSTER <b>Prevention and access to services during COVID pandemic</b> 14.20-15.10	ORAL POSTER <b>SARS-CoV-2: from in vivo to in vitro</b> 14.20-15.10
15.20 16.20	SYMPOSIUM <b>Update on antiretroviral therapy: answers and suggestions during a pandemic era</b>	ORAL COMMUNICATIONS <b>Complexities of SARS-CoV-2 infection</b>	ORAL COMMUNICATIONS <b>Insights on epidemiological and clinical management of hepatitis viruses</b>	ORAL POSTER <b>Immunopathogenesis of HIV</b> 15.20-16.10	
16.25 16.45	<b>ICAR 2022 Special Awards and Closing Remarks</b>				



*Alliance to leave no-one behind*



**Italian Conference on AIDS and Antiviral Research**

Presidenza del Congresso: **A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi**

**PRE-CONFERENCE  
ADVANCED COURSES**


**PRE-CONFERENCE ADVANCED COURSE** 14.30-16.30

**SALA STUCCHI**
**Focus on viral resistance and variability**

Chairs: R. Gagliardini (Roma), V. Micheli (Milano), O. Turriziani (Roma)

RNA viruses show a great potential for genetic variation, rapid evolution and adaptation. Genetic variability may affect pathogenesis, epidemiology and the success of antiviral therapy. In the past months, several SARS-CoV-2 variants of concern (VOCs) have emerged and an intense monitoring of their circulation worldwide plays a crucial role not only in surveillance but also as part of containment and mitigation strategies. Different molecular methods to detect and characterize a specific viral variant have been developed. Many of these assays can accurately identify the variants, while others require confirmation by sequencing. Viral genetic variability is also responsible for drug resistance, a well known phenomenon in HIV infection. Despite successful antiretroviral therapy, a minority of people living with HIV (PLWH) still have difficulty in achieving and maintaining virological suppression, mainly due to HIV drug resistance, and a small group of them harbor multi-drug resistant viruses. In this scenario, the emergence of drug resistance mutations to the latest antiretroviral drugs should be carefully investigated. Nowadays, more than 90% of PLWH have undetectable viral load. ART optimization or simplification in this clinical setting can be critical, especially when previous ART history is complex or unknown. The current transition from Sanger sequencing to Next Generation Sequencing to detect archived HIV drug resistance mutations could offer novel treatment-relevant insights and improve the management of virologically suppressed patients.

14.30-15.00	<b>HIV drug resistance mutations to new antiretroviral drugs</b>	F. Saladini, Siena
15.00-15.30	<b>Detection of archived HIV drug resistance mutations in virologically suppressed individuals by different genotyping techniques: from Sanger to NGS</b>	M. Santoro, Roma
15.30-16.00	<b>Molecular assays to characterize SARS-CoV-2 viral variants</b>	F. Caccuri, Brescia
16.00-16.30	<b>Discussion on Course issues</b>	


**PRE-CONFERENCE ADVANCED COURSE** 14.30-16.30

**ALABASTRO A**
**Clinical and point of care diagnostics for STIs in a PrEP service**

Chairs: V. Mazzotta (Roma), R. Rossotti (Milano)

The syndromic approach for the management of sexually transmitted infections (STIs) relies on the assessment of patient's general complaints: clinical evaluation represents the best and fastest way to choose the appropriate treatment. Laboratory tests provide the correct etiologic diagnosis but turn-around times could be an issue in a clinic dedicated to PrEP care, where a high burden of STIs and heavily interconnected sexual networks require a rapid handling. Overtreatment and spread of antimicrobial resistance are additional drawbacks if microbial diagnosis is not readily available. Point-of-care diagnostics could be helpful both in hospital- and community-based services for rapid diagnosis and epidemiological monitoring of people in PrEP.

14.30-15.00	<b>Traditional versus point of care diagnostics for STIs: pros and cons</b>	A. Nava, Milano
15.00-15.30	<b>Clinical approach to the diagnosis of STIs, treatment criteria and concerns about microbial resistance</b>	S. Pittalis, Roma
15.30-16.00	<b>Management of STIs diagnosis in a community-based, peer-run PrEP service</b>	P.L.G. Vinti, Milano
16.00-16.30	<b>Discussion on Course issues</b>	





**PRE-CONFERENCE ADVANCED COURSE** 14.30-16.30

**ALABASTRO B**


**New psychoactive substances and chemsex.  
David Stuart Course**

*Chairs:* G. Fracca (Milano), M. Lanza (Milano)

*Chemsex can be defined as the use of specific drugs (chems), in a sexualized context, by gay men and other men who have sex with men. Chemsex is associated with peculiar socio-cultural aspects of MSM sexuality. Chems use also varies in different geographical areas according to availability, affordability or other circumstances. Initially three substances only have been named as chems. Other substances now are added to chems. Chemsex adds ritual aspects, often driven by dating networks, to MSM sexual behavior. It is a complex phenomenon that involves different areas and can have different impact on different people and require different approaches. There is a need for more information about substances and how to reduce risks associated with their use, while for more problematic aspects (social, behavioral, psychologic, psychiatric, and medical), a therapeutic group's experience - supervised by a psychotherapist - can be an opportunity to cope with abuse.*

14.30-14.50	<b>Definition and evolution of sexualized psychoactive substances' use in Italy</b>	F.M. Nimbi, Roma
14.50-15.10	<b>MPDV and free coke as chems. Harm reduction</b>	M. Lanza, Milano
15.10-15.30	<b>Chemsex as social ritual among MSM</b>	G.M. Corbelli, Bologna
15.30-15.50	<b>Chemsex addiction: dealing with the unconscious as a pathway for treatment</b>	G. Fracca; Milano
15.50-16.30	<b>Discussion on Course issues</b>	







*Alliance to leave no-one behind*



**Italian Conference on AIDS and Antiviral Research**

Presidenza del Congresso: **A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi**

# SCIENTIFIC PROGRAMME

13.30-16.00 **AUDITORIUM SALA OGGIONI**



**SPECIAL SESSION**

**ARTISTIC CONTEST**

**"RACCONTART"**

**INCONTRO CON LE SCUOLE FINALISTE**

Chairs: A. Caraglia (Roma), F. Ceccherini-Silberstein (Roma), D. Zagato (Milano) Con la sponsorizzazione non condizionante di Gilead Sciences

13.30-13.40 **Benvenuto dei Presidenti ICAR** A. Antinori (Roma), M. Cernuschi (Milano), F. Maggiolo (Bergamo), M. Zazzi (Siena)

13.40-14.10 **Introduzione e presentazione della Giuria Artistica e Tecnico-Scientifica** A. Caraglia (Roma), F. Ceccherini-Silberstein (Roma), D. Zagato (Milano)

#### **La Giuria Artistica**

- **Elena Capparelli** *Direttrice di RaiPlay e Digital*
- **Alessandro Castellano** *Graphic Designer*
- **Andrea Maggiolo** *Video Maker*
- **Nefeli Misuraca** *Montatrice e regista di cortometraggi*
- **Enzo Porcelli** *Produttore cinematografico*
- **Francesco Suriano** *Scrittore di teatro, sceneggiatore e regista*

#### **La Giuria Tecnico-Scientifica**

- **Giulia Valeria Calvino** *ANLAIDS, Roma*
- **Daniele Calzavara** *Milano Check Point, Milano*
- **Anna Caraglia** *Direzione prevenzione sanitaria – Ministero della Salute, Roma*
- **Monica Maria Carlevari** *Gilead Sciences, Milano*
- **Francesca Ceccherini-Silberstein** *Università degli Studi di Roma Tor Vergata*
- **Massimo Cernuschi** *IRCCS Ospedale San Raffaele - ASA, Milano*
- **Antonella Cingolani** *Fondazione Policlinico Universitario Agostino Gemelli, Roma*
- **Paola Cinque** *IRCCS Ospedale San Raffaele, Università Vita-Salute, Milano*
- **Maria Luisa Cosmaro** *LILA, Milano*
- **Giovanni Del Bene** *ANLAIDS, Milano*
- **Antonio Di Biagio** *Ospedale Policlinico San Martino, Genova*
- **Margherita Errico** *NPS Italia, Milano*
- **Massimo Farinella** *Circolo di Cultura Omosessuale Mario Mieli, Roma*
- **Rosario Galipò** *ANLAIDS Lazio, Roma*



- **Donatella Mainieri** ANLAIDS, Milano
- **Sandro Mattioli** Plus aps, Bologna
- **Paolo Meli** Associazione Comunità Emmaus, Bergamo
- **Silvia Nozza** IRCCS Ospedale San Raffaele, Università Vita-Salute, Milano
- **Laura Sighinolfi** Azienda Ospedaliero-Universitaria, Ferrara
- **Donatello Zagato** A.S.A. Onlus - Associazione Solidarietà AIDS

14.10-15.45 **Presentazione delle Opere finaliste al Concorso a cura degli Istituti Scolastici**

#### **Gli Istituti Scolastici e le opere finaliste**

- **Centro Studi Casnati - Liceo Artistico Giuseppe Terragni** Como
- **I.I.S. Caterina Caniana** Bergamo
- **I.I.S. Papareschi** Roma
- **I.I.S.S MK Gandhi** Besana (MB)
- **I.I.S.S. Francesco Orioli** Viterbo
- **I.S. Lorenzo Lotto** Trescore Balneario (BG)
- **I.S. Puecher-Olivetti** Rho (MI)
- **Liceo Artistico Andrea Fantoni** Bergamo
- **Liceo Artistico Simone Weil** Treviglio (BG)
- **Liceo Don Lorenzo Milani** Romano di Lombardia (BG)

15.45-16.00 **Conclusioni**

A. Caraglia (Roma), F. Ceccherini-Silberstein (Roma), D. Zagato (Milano)





**SATELLITE SYMPOSIUM** 17.00-18.00

**AUDITORIUM SALA OGGIONI**

## Defining new patient-centric goals to improve long-term treatment success in HIV

Chair: G. Di Perri (Torino)

Con la sponsorizzazione non condizionante di Gilead Sciences

Although 30 years of research and pharmacological innovation have transformed HIV infection into a chronic disease, the persistence of issues related to direct and indirect harm of the virus, life-long ART exposure, higher risk of comorbidities and host peculiarities mean that life-expectancy and QoL of PLWH are still significantly lower compared with general population. In this scenario, the definition of a new and broader concept of long-term treatment success able to meet not only the clinical goals but also needs and expectations of PLWH, becomes even more crucial. A "tailored" approach based on the complexities of the individual (often not manifested) together with the availability of ARVs optimized in terms of efficacy, genetic barrier, forgiveness, tolerability, and convenience are probably the key to reach this ambitious goal. Through an interactive talk, experts will discuss on current challenges and available strategies to fill these gaps, also with the support of real-life data.

17.00-17.15	<b>How to define long-term treatment success for PLWH and which attributes are requested to ARV?</b>	M. Andreoni, Roma
17.15-17.55	<b>Round-table discussion on how to improve outcomes with current antiretroviral therapy:</b> - How important are high genetic barrier, forgiveness and adherence? - How to optimize the long-term treatment outcomes in experienced patients? - What is the added value of real-world evidence?	Conductor: A. Gori, Milano A. Calcagno, Torino R. Gagliardini, Roma L. Taramasso, Genova
17.55-18.00	<b>Take-home messages and conclusions</b>	G. Di Perri, Torino



Martedì  
14 giugno

14° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research



## ICAR 2022 OPENING SESSION

AUDITORIUM SALA OGGIONI

Conduce: T. Cartolano (Milano)

Chairs: A. Antinori (Roma), M. Cernuschi (Milano), F. Maggiolo (Bergamo), M. Zazzi (Siena)

18.00-18.20

### Introducing ICAR 2022. Chairs and Authorities' Welcome addresses

Chairs: A. Antinori (Roma), M. Cernuschi (Milano), F. Maggiolo (Bergamo), M. Zazzi (Siena)

18.20-18.40

### RaccontART contest Awards

A. Caraglia (Roma), F. Ceccherini-Silberstein (Roma), D. Zagato (Milano)

18.40-19.10

Mauro Moroni Memorial Lecture

### COVID-19 past, present and future. Will Covid ever retire?

M. Andreoni (Roma)

19.10-19.40

### HIV as a chronic disease: myth or truth?

F. Maggiolo (Bergamo), S. Mattioli (Bologna)

19.40-20.00

### Opening session closing remarks




**KEYNOTE LECTURES** 09.00-10.00

**AUDITORIUM SALA OGGIONI**

Chairs: M.G. Di Benedetto (Catania), A. Lazzarin (Milano)

 09.00-09.30 **Virus spillover**

G. Antonelli, Roma

 09.30-10.00 **Innate immunity and COVID-19**

C. Garlanda, Pieve Emanuele (MI)


**SPONSORED SYMPOSIUM** 10.05-11.05

**AUDITORIUM SALA OGGIONI**
**Being pioneers of a new paradigm: what have we learned so far?**

Chairs: S. Cicalini (Roma), R. Gulminetti (Pavia)

Con il supporto di ViiV Healthcare

The life expectancy of people living with HIV (PLHIV) is now close to the one of HIV negative people. This important milestone has been achieved thanks to the continuous evolution of antiretroviral therapy (ART), the basis of which continuous improvement placed on providing optimal therapeutic options for long-term management. In this context, ART therapy has evolved in the direction of 2-drug regimens (2DR), which represent a new paradigm supported by solid evidence from clinical trials confirmed in real-life. In particular, dolutegravir/lamivudine (DTG/3TC) represents an important therapeutic option, both in the initial phase of treatment and in the switch from ARV. Starting from these assumptions, the session will focus on the learnings coming from the validation of this new paradigm which bases its foundations on robust data, and which means having an additional option to personalize treatment for PLHIV naïve and virologically suppressed. Regarding these aspects, the most recent data available for regimens containing dolutegravir and lamivudine (DTG / 3TC; DTG + 3TC) will be discussed.

 10.05-10.15 **Introduction**

 10.15-10.30 **The relevance of robust and valuable data**

P. Mohammed, London

 10.30-10.50 **The meaning of personalizing treatments**

C. Mussini, Modena

 10.50-11.05 **Questions & Answers**

**ORAL COMMUNICATIONS** 10.05-11.05

**SALA STUCCHI**
**PrEP: new data and issues**

Chairs: M. G. Di Benedetto (Catania), P. Meli (Bergamo)

**OC 1 10.05-10.15 Impact of SIMIT PrEP eligibility criteria on retention in care and new sexually transmitted infections acquisition**

 R. Rossotti<sup>1,5</sup>, G. Mulè<sup>2,5</sup>, A. Tavelli<sup>3</sup>, A. De Bona<sup>2,5</sup>, C. Muccini<sup>4,5</sup>, D. Moschese<sup>5,6</sup>, S. Bossolasco<sup>4,5</sup>, D. Calzavara<sup>5</sup>, A. Foschi<sup>5,6</sup>, V. Ferrara<sup>5</sup>, R. Repossi<sup>5</sup>, M. Cernuschi<sup>4,5</sup>, A. d'Arminio Monforte<sup>2,7</sup>
<sup>1</sup>Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, <sup>2</sup>Department of Infectious Diseases, ASST Santi Paolo e Carlo, Milan, <sup>3</sup>ICONA Foundation, Milan, <sup>4</sup>Unit of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, <sup>5</sup>Milano Checkpoint, Milan, <sup>6</sup>I Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, <sup>7</sup>University of Milano, Milan

**OC 2 10.17-10.27 Sexually transmitted infection and adherence in an Italian access program of HIV pre-exposure prophylaxis (ItaPrEP)**

 V. Mazzotta<sup>1</sup>, S. Lanini<sup>1</sup>, D. Calzavara<sup>2</sup>, A. Tavelli<sup>3</sup>, A. De Bona<sup>3</sup>, F. De Zottis<sup>1</sup>, V. Ferrara<sup>2</sup>, S. La Monica<sup>4</sup>, S. Mattioli<sup>5</sup>, A. Bianchi<sup>6</sup>, G. Mulè<sup>3</sup>, L. Badia<sup>5</sup>, S. Bossolasco<sup>2</sup>, E. Rozenn<sup>7</sup>, R. Bellagamba<sup>1</sup>, D. Tesoro<sup>3</sup>, R. Rossotti<sup>8</sup>, M. Pedone<sup>5</sup>, S. Nozza<sup>9</sup>, P. Tomasi<sup>5</sup>, L. Biasoli<sup>3</sup>, F. Gili<sup>7</sup>, M. Bonanni<sup>5</sup>, A. Copes<sup>3</sup>, A. Castagna<sup>9</sup>, A. Gori<sup>10</sup>, M. Puoti<sup>8</sup>, G. Rizzardini<sup>11</sup>, M. Andreoni<sup>12</sup>, C. Mastroianni<sup>13</sup>, R. Cauda<sup>4</sup>, V. Puro<sup>7</sup>, A. Cingolani<sup>4</sup>, G.M. Corbelli<sup>5</sup>, M. Cernuschi<sup>2,6</sup>, A. d'Arminio Monforte<sup>3</sup>, A. Antinori<sup>1</sup>
<sup>1</sup>HIV/AIDS Unit, INMI L. Spallanzani IRCCS, Roma, <sup>2</sup>Milano Checkpoint, Milano, <sup>3</sup>ASST Santi Paolo e Carlo, University of Milano, <sup>4</sup>Fondazione Policlinico A. Gemelli, Catholic University, Roma, <sup>5</sup>PLUS aps (BLQ Checkpoint), Bologna, <sup>6</sup>ASA Onlus, Milano, <sup>7</sup>CRAIDS, INMI L. Spallanzani IRCCS, Roma, <sup>8</sup>ASST Niguarda Hospital, Milano, <sup>9</sup>HSR San Raffaele Scientific Institute, Milano, <sup>10</sup>IRCCS Policlinico Ospedale Maggiore, Milano, <sup>11</sup>ASST L. Sacco Hospital, Milano, <sup>12</sup>Tor Vergata University, Roma, <sup>13</sup>Sapienza University, Roma

**OC 3 10.29-10.39 Prevalence of anal HPV infection among PrEP users screened through a self-administered Point-of-Care test: data from a community-based PrEP programme in Milan**

 L. Biasoli<sup>1,3</sup>, R. Rossotti<sup>1,4</sup>, A. Tavelli<sup>1,3</sup>, A. De Bona<sup>1,3</sup>, C. Tincati<sup>3</sup>, D. Calzavara<sup>1</sup>, P. Vinti<sup>1</sup>, C. Baiguera<sup>1,4</sup>, R. Repossi<sup>1</sup>, V. Ferrara<sup>1</sup>, S. Bossolasco<sup>1,2</sup>, C. Muccini<sup>1,2</sup>, D. Tesoro<sup>1,3</sup>, A. D'Arminio Monforte<sup>1,3</sup>, M. Cernuschi<sup>1,2</sup> on behalf of the Milano Check Point Group

<sup>1</sup>Milano Check Point, Milano, <sup>2</sup>IRCCS San Raffaele Scientific Institute, Milano, <sup>3</sup>ASST Santi Paolo e Carlo, Milano, <sup>4</sup>ASST Niguarda Hospital, Milano


**OC 4 10.41-10.51 PrEP use disclosure to sexual partners, friends and relatives: a psycho-social analysis**

A. Bianchi<sup>1,2</sup>, A. Tavelli<sup>3</sup>, P.L. Vinti<sup>2</sup>, D. Calzavara<sup>2</sup>, V. Ferrara<sup>2</sup>, A. Antonino<sup>1,2</sup>, F. Rossi<sup>1,2</sup>, M. Massa<sup>2</sup>, A. De Bona<sup>3</sup>, D. Rossotti<sup>2,4</sup>, S. Bossolasco<sup>2,5</sup>, D. Canetti<sup>5</sup>, A. Foschi<sup>2,6</sup>, D. Tesoro<sup>3</sup>, G. Mulé<sup>2,3</sup>, R. Repossi<sup>1,2</sup>, N. Frattini<sup>1,2</sup>, E. Garavaglia<sup>1,2</sup>, C. Ferrara<sup>1,2</sup>, D. De Cia Warzanowski<sup>2</sup>, M. Cernuschi<sup>1,2,5</sup>

<sup>1</sup>ASA. Associazione Solidarietà AIDS, Milan, Italy, <sup>2</sup>Milano Checkpoint, Milan, <sup>3</sup>San Paolo Hospital, Milan, Italy, <sup>4</sup>ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, <sup>5</sup>San Raffaele Hospital, Milan, Italy, <sup>6</sup>Luigi Sacco Hospital, Milan, Italy



**SATELLITE SYMPOSIUM 10.05-11.05**

**ALABASTRO A + ALABASTRO B**

**Hepatitis Delta in HIV/HBV Infected Patients**

Chair: M. Puoti (Milano)

Con la sponsorizzazione non condizionante di Gilead Sciences

Viral liver diseases are frequent comorbidities and major contributors to death in HIV-positive individuals on antiretroviral therapy. Due to similarities in transmission routes, persons living with HIV (PLWH) are at risk for HDV infection. The lack of satisfactory treatment for hepatitis delta virus (HDV) infection has meant a major threat for developing cirrhosis and liver cancer in this population. Recent data gathered from HIV ICONA cohort suggest that HDV infection among PLWH is underdiagnosed, although HDV entails a high risk of liver disease progression. Because effective drugs to treat HDV are now available, it is even more crucial increase awareness to identify patients at an early stage of liver disease. During the meeting we will provide an exceptional overview of HDV disease among PLWH, from its diagnosis to its management, sharing the most up to date evidences of HDV treatment.

10.05-10.10 **Introduction**

10.10-10.30 **Epidemiological characteristics of HDV infection in HIV patients - Coorte ICONA** A. d'Arminio Monforte, Milano

10.30-10.50 **Managing Viral Hepatitis D and new treatment option for HDV** P. Lampertico, Milano

10.50-11.05 **Discussion on Symposium issues**



**ORAL POSTER 10.05-10.55**

**BERGAMO SCIENCE CENTER**

**COVID-19: treatment strategies I**

Chairs: C. Alteri (Milano), G. Cenderello (Sanremo)

**OP 1 10.05-10.10 Real-life data on early treatment with antivirals in outpatients with mild COVID-19 symptoms**

A. Rugova<sup>1</sup>, G. Ghilardi<sup>2</sup>, G. Lapadula<sup>1,2</sup>, N. Squillace<sup>1</sup>, A. Cappelletti<sup>1</sup>, F. Sabbatini<sup>1</sup>, A. Ranzani<sup>1</sup>, M. Rossi<sup>1</sup>, F. Iannuzzi<sup>1</sup>, E. Pollastri<sup>1</sup>, P. Columpsi<sup>1</sup>, L. Bisi<sup>1</sup>, E. Colella<sup>1</sup>, S. Limonta<sup>1</sup>, I. De Benedetto<sup>1</sup>, N. Corti<sup>1,2</sup>, G.M. Migliorino<sup>1</sup>, S. Foresti<sup>1</sup>, A. Soria<sup>1</sup>, P. Bonfanti<sup>1,2</sup>

<sup>1</sup>Clinic of Infectious Diseases San Gerardo Hospital ASST Monza, Monza, <sup>2</sup>School of Medicine and Surgery University of Milano-Bicocca, Monza

**OP 2 10.12-10.17 Efficacy of licensed monoclonal antibodies and antiviral agents against the SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 and delta sub-lineage AY.4.2**

L. Fiaschi<sup>1</sup>, F. Dragoni<sup>1</sup>, E. Schiaroli<sup>2</sup>, A. Bergna<sup>3</sup>, B. Rossetti<sup>4</sup>, F. Giammarino<sup>1</sup>, C. Biba<sup>1</sup>, A. Gidari<sup>2</sup>, A. Lai<sup>3</sup>, C. Nencioni<sup>4</sup>, D. Francisci<sup>2</sup>, M. Zazzi<sup>1</sup>, I. Vicenti<sup>1</sup>

<sup>1</sup>Department of Medical Biotechnologies, University of Siena, Siena, Italy, <sup>2</sup>Department of Medicine and Surgery, Clinic of Infectious Diseases, University of Perugia, Perugia, Italy, <sup>3</sup>Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Milan, Italy, <sup>4</sup>Infectious Disease Department, USL SUDEST, Toscana, Misericordia Hospital, Grosseto, Italy

**OP 3 10.19-10.24 Sarilumab plus standard of care versus standard of care for the treatment of severe COVID-19: a phase 3, randomized, openlabeled, multi-center study (ESCAPE Study)**

I. Mastroianni<sup>1</sup>, R. Gagliardini<sup>1</sup>, F.V. Segala<sup>2</sup>, A. Mondini<sup>1</sup>, P. Lorenzini<sup>1</sup>, C. Cerva<sup>1</sup>, E. Taddei<sup>2</sup>, F. Bai<sup>3</sup>, M. Negri<sup>2</sup>, C. Pinnetti<sup>1</sup>, S. Cicalini<sup>1</sup>, R. Murri<sup>2</sup>, V. Mazzotta<sup>1</sup>, M. Camici<sup>1</sup>, S. Mosti<sup>1</sup>, T. Bini<sup>3</sup>, A. Beccacece<sup>1</sup>, E. Milozzi<sup>1</sup>, M. Iannetta<sup>4</sup>, M. Fusto<sup>1</sup>, M.M. Plazzi<sup>1</sup>, M. Lichtenner<sup>5</sup>, M. Fantoni<sup>2</sup>, M. Andreoni<sup>4</sup>, L. Sarmati<sup>4</sup>, R. Cauda<sup>2</sup>, E. Nicastrì<sup>1</sup>, A. D'Arminio Monforte<sup>3</sup>, F. Palmieri<sup>1</sup>, A. Cingolani<sup>2</sup>, A. Antinori<sup>1</sup>

<sup>1</sup>Lazzaro Spallanzani National Institute for Infectious Diseases, Rome, Italy, <sup>2</sup>Fondazione Policlinico A. Gemelli IRCCS- Università Cattolica S. Cuore, Rome, Italy, <sup>3</sup>Azienda Ospedaliera San Paolo, Milan, Italy, <sup>4</sup>University of Rome Tor Vergata, Rome, Italy, <sup>5</sup>Sapienza University of Rome, Italy, Polo Pontino

**OP 4 10.26-10.31 Safety and efficacy of antiviral agents in SARS-CoV-2 infected patients: a real-life experience**

A. De Vito, A. Colpani, A. Bitti, V. Manca, B. Zauli, M.C. Meloni, M. Fois, L. Denti, S. Bacciu, C. Marcia, I. Maida, S. Babudieri, G. Madeddu

Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy



**OP 5 10.33-10.38 Efficacy of Early Antiviral Therapies among High-Risk Patients with Mild to Moderate COVID-19**  
S. Amadasi<sup>1</sup>, M. Degli Antoni<sup>1</sup>, P. Grechi<sup>2</sup>, A. Tregambe<sup>2</sup>, S. Arsuffi<sup>1</sup>, F. Pennati<sup>1</sup>, M.A. Forleo<sup>1</sup>, F. Castelli<sup>1</sup>, E. Quiros-Roldan<sup>1</sup>

<sup>1</sup>Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, <sup>2</sup>Unit of Infectious and Tropical Diseases, ASST Spedali Civili di Brescia, Brescia

**OP 6 10.40-10.45 Real life experience on the use of anti-SARS-CoV-2 monoclonal antibodies to prevent COVID-19 progression among inpatients and outpatients: a monocentric experience**

C. Leanza<sup>1</sup>, S. Di Bari<sup>1</sup>, N. Perrotta<sup>2</sup>, L.A. Fiorito<sup>2</sup>, R. Gentile<sup>3</sup>, V. Cioffi<sup>2</sup>, G. Casini<sup>2</sup>, F. Cogliati Dezza<sup>1</sup>, D. Fago<sup>1</sup>, C. Ajassa<sup>1</sup>, G. Iaiani<sup>1</sup>, R. Lobello<sup>2</sup>, E.M. Prolì<sup>2</sup>, C.M. Mastroianni<sup>1</sup>, G. Russo<sup>1</sup>

<sup>1</sup>Infectious Diseases Unit, AOU Policlinico Umberto 1st Sapienza University, Rome, Italy, <sup>2</sup>Pharmacy, AOU Policlinico Umberto 1st, Rome, Italy, <sup>3</sup>Pharmacy, G. D'annunzio University, Chieti Pescara, Italy



**SATELLITE SYMPOSIUM 11.10-12.10**

**AUDITORIUM SALA OGGIONI**

**HIV: act in the present and challenge the future**

Chairs: A. Cingolani (Roma), G.M. Corbelli (Bologna)

Con la sponsorizzazione non condizionante di Janssen-Cilag

Since the introduction of ART there has been increased survival in PLWH; nowadays it is important to answer to needs of every single HIV-positive patient - requiring long-life antiretroviral treatments providing durability and tolerability- but also to consider the challenges raising from HIV-negative at-risk population. The aim of this Symposium is to deepen the challenge coming from the HIV vaccine as public health measure, focusing on clinical and social aspects. Furthermore, it is of utmost importance keep the focus in the present days for discussing the appropriate treatment strategies to adopt in daily practice for improving patients care.


11.10-11.30 **What we know about HIV Vaccine?**

S. Nozza, Milano

11.30-11.50 **PI-based learning**

S. Rusconi, Legnano (MI)

11.50-12.10 **Discussion on Symposium issues**



**ORAL COMMUNICATIONS 11.10-12.10**

**SALA STUCCHI**

**Immunological efficacy of SARS-CoV-2 vaccine I**

Chairs: A. Castagna (Milano), S. Parisi (Padova)

**OC 5 11.10-11.20 Poor humoral immunogenicity to SARS-CoV-2 vaccination in people living with HIV (PLWH) with low CD4 count**

A. Vergori<sup>1</sup>, A. Cozzi-Lepri<sup>2</sup>, M. Giannella<sup>3</sup>, A. Tavelli<sup>4</sup>, A.M. Azzini<sup>5</sup>, L. Marconi<sup>3</sup>, S. Cicalini<sup>1</sup>, A. Rodanò<sup>4</sup>, S. Meschi<sup>1</sup>, M. Fusto<sup>1</sup>, A. Sartor<sup>6</sup>, G. Matusali<sup>1</sup>, S. Piconi<sup>7</sup>, G. Pellicano<sup>8</sup>, A. Cascio<sup>9</sup>, G. Levy-Hara<sup>10</sup>, A. Costantini<sup>11</sup>, G. Madeddu<sup>12</sup>, G. Marchetti<sup>4</sup>, P. Viale<sup>3</sup>, E. Tacconelli<sup>5</sup>, A. d'Arminio Monforte<sup>4</sup>, A. Antinori<sup>1</sup> for the VAXICONA-ORCHESTRA Study Group

<sup>1</sup>National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy, <sup>2</sup>CREME, Institute for Global Health, UCL, London, UK, <sup>3</sup>Unit of Infectious Diseases, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, <sup>4</sup>Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy, <sup>5</sup>Division of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy, <sup>6</sup>Microbiology Unit, Udine University Hospital, Udine, Italy, <sup>7</sup>Infectious Diseases Unit, A. Manzoni ASST Lecco, Lecco, Italy, <sup>8</sup>Department of Human Pathology of the Adult and the Developmental Age "G. Barresi", Unit of Infectious Diseases, University of Messina, Messina, Italy, <sup>9</sup>Infectious and Tropical Diseases Unit, PROMISE, University of Palermo, Palermo, Italy, <sup>10</sup>Istituto Alberto Taquini de Investigación en Medicina Traslacional, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina, <sup>11</sup>Clinical Immunology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti, Marche Polytechnic University, Ancona, Italy, <sup>12</sup>Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy

**OC 6 11.22-11.32 Humoral immunogenicity to SARS-CoV-2 mRNA vaccine third additional/booster shot in people living with HIV (PLWH) by current CD4 count**

A. Antinori<sup>1</sup>, A. Cozzi-Lepri<sup>2</sup>, A. Vergori<sup>1</sup>, A. Tavelli<sup>3</sup>, M. Giannella<sup>4</sup>, S. Cicalini<sup>1</sup>, L. Marconi<sup>4</sup>, V. Yellenki<sup>3</sup>, S. Meschi<sup>1</sup>, G. Pellicano<sup>5</sup>, N. Carroccia<sup>4</sup>, G. Matusali<sup>1</sup>, A. Latini<sup>6</sup>, M. Lichtner<sup>7</sup>, S. Lo Caputo<sup>8</sup>, F.M. Fusco<sup>9</sup>, G. Marchetti<sup>3</sup>, E. Tacconelli<sup>10</sup>, A. d'Arminio Monforte<sup>3</sup> for the VAXICONAORCHESTRA Study Group

<sup>1</sup>National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy, <sup>2</sup>CREME, Institute for Global Health, UCL, London, UK, <sup>3</sup>Unit of Infectious Diseases, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, <sup>4</sup>Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy, <sup>5</sup>Department of Human Pathology of the Adult and the Developmental Age "G. Barresi", Unit of Infectious Diseases, University of Messina, Messina, Italy, <sup>6</sup>Department of Dermatology, San Gallicano Institute IRCCS, Roma, Italy, <sup>7</sup>Santa M. Goretti Hospital, Sapienza University, Latina, Italy, <sup>8</sup>Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy, <sup>9</sup>AORN Ospedali Dei Colli, Cotugno Hospital, Naples, Italy, <sup>10</sup>Division of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy





- OC 7** 11.34-11.44 **Longitudinal characterization of interferon and antibody response following vaccination against SARS-CoV-2 in patients with HIV-1 infection**  
*M. Scordio<sup>1</sup>, F. Frasca<sup>1</sup>, L. Santinelli<sup>2</sup>, L. Maddaloni<sup>2</sup>, L. Sorrentino<sup>1</sup>, M. Fracella<sup>1</sup>, E.N. Cavallari<sup>2</sup>, A. Napoli<sup>2</sup>, L. Cinti<sup>2</sup>, P. Roberto<sup>2</sup>, G. Ceccarelli<sup>2</sup>, A. Gaeta<sup>2</sup>, G. Antonelli<sup>1,3</sup>, C. M. Mastroianni<sup>2</sup>, G. d'Ettore<sup>2</sup>, C. Scagnolari<sup>1</sup>*  
<sup>1</sup>Laboratory of Virology, Department of Molecular Medicine, Sapienza University, Rome, Italy, <sup>2</sup>Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy, <sup>3</sup>Microbiology and Virology Unit, Sapienza University Hospital "Policlinico Umberto I", Rome, Italy
- OC 8** 11.46-11.56 **T-cell and humoral responses to mRNA-1273 vaccine up to 6 months in late presenter people living with HIV (PLWH)**  
*M. Augello, V. Bono, R. Rovito, M. Hadla, V. Yellenki, C. Tincati, A. d'Arminio Monforte, G. Marchetti*  
 Clinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy



ORAL POSTER 11.10-12.00

## COVID-19: treatment strategies II

ALABASTRO A

Chairs: V. Cento (Rozzano MI), L. Sasset (Padova)

- OP 7** 11.10-11.15 **Use of Sotrovimab in a cohort of Pregnant Women with a high risk of COVID 19 progression: a single-center experience**  
*L. Frallonardo<sup>1</sup>, A. Vimercati<sup>1</sup>, R. Novara<sup>1</sup>, D.F. Bavaro<sup>1</sup>, G. Brindicci<sup>1</sup>, C.R. Santoro<sup>1</sup>, I. Ferrante<sup>2</sup>, G. Chiarello<sup>2</sup>, C. Lepera<sup>2</sup>, M. Mongelli<sup>2</sup>, R. Cicinelli<sup>2</sup>, F. Di Gennaro<sup>1</sup>, E. Cicinelli<sup>2</sup>, A. Saracino<sup>1</sup>*  
<sup>1</sup>Clinic of Infectious Diseases, University of "Aldo Moro", Department of Biomedical Sciences and Human Oncology, Bari, Italy, <sup>2</sup>Clinic of Obstetrics & Gynaecology, University of "Aldo Moro", Department of Biomedical Sciences and Human Oncology, Bari, Italy
- OP 8** 11.17-11.22 **Remdesivir does not influence SARS-CoV-2 RNA viral load kinetics in nasopharyngeal swab specimens of COVID-19 hospitalized patients: a real-life experience**  
*L. Campogiani<sup>1,2</sup>, M. Iannetta<sup>1,2</sup>, A. Di Lorenzo<sup>1,2</sup>, M. Zordan<sup>1,2</sup>, L. Coppola<sup>1,2</sup>, M. Compagno<sup>1,2</sup>, V. Malagnino<sup>1,2</sup>, E. Teti<sup>1,2</sup>, M. Andreoni<sup>1,2</sup>, L. Sarmati<sup>1,2</sup>*  
<sup>1</sup>Department of System Medicine, Tor Vergata University, Rome, Italy, <sup>2</sup>Infectious Disease Clinic, Policlinico Tor Vergata, Rome Italy
- OP 9** 11.24-11.29 **Anti-spike monoclonal antibodies to prevent hospitalization in mild COVID-19: preliminary data of an ongoing large observational multicenter study (CONDIVIDIAMO)**  
*A. Soria<sup>1</sup>, G. Ghilardi<sup>2</sup>, F. Graziano<sup>3</sup>, S.V. Benatti<sup>4</sup>, G. Lapadula<sup>1,2</sup>, A. Ferraresi<sup>5</sup>, P. Brambilla<sup>6</sup>, D. Pocater<sup>7</sup>, M.E. Quiros Roldan<sup>7</sup>, M. Franzetti<sup>8</sup>, L. Bradanini<sup>9</sup>, A. Cappelletti<sup>1</sup>, A. Rugova<sup>1</sup>, M.L. Borghesi<sup>1</sup>, S. Piconi<sup>9</sup>, S. Rusconi<sup>8,10</sup>, F. Castelli<sup>7</sup>, P. Morelli<sup>6</sup>, A. Pan<sup>5</sup>, M. Rizzi<sup>4</sup>, S. Galimberti<sup>3</sup>, M.G. Valsecchi<sup>3</sup>, P. Bonfanti<sup>1,2</sup>*  
<sup>1</sup>San Gerardo Hospital ASST Monza, Monza, <sup>2</sup>School of Medicine and Surgery University of Milano-Bicocca, Monza, <sup>3</sup>Bicocca Bioinformatics Biostatistics and Bioimaging Center B4 School of Medicine and Surgery University of Milano-Bicocca, Monza, <sup>4</sup>ASST Papa Giovanni XXIII, Bergamo, <sup>5</sup>ASST Cremona, Cremona, <sup>6</sup>Humanitas Clinical and Research Center, Milan, <sup>7</sup>ASST Spedali Civili University of Brescia, Brescia, <sup>8</sup>Legnano Hospital ASST Ovest Milanese, Legnano, <sup>9</sup>ASST A Manzoni, Lecco, <sup>10</sup>DIBIC "Luigi Sacco" Università degli Studi di Milano, Milan
- OP 10** 11.31-11.36 **Early Use of Short-Course Remdesivir and Monoclonal Antibodies May Reduce The Risk of Disease Progression in Hospitalized Patients With COVID-19: a Single Center Retrospective Study**  
*D.F. Bavaro<sup>1</sup>, L. Diella<sup>1</sup>, A. Belati<sup>1</sup>, G. Brindicci<sup>1</sup>, F. Balena<sup>1</sup>, D. Fiordelisi<sup>1</sup>, M.F. Mariani<sup>1</sup>, F. Signorile<sup>1</sup>, G. Metrangolo<sup>1</sup>, L. De Santis<sup>1</sup>, V. Spada<sup>1</sup>, M. Camporeale<sup>1</sup>, A. Dargenio<sup>1</sup>, G. Nicoletta<sup>2</sup>, F. Di Gennaro<sup>1</sup>, M. Dell'Aera<sup>2</sup>, A. Saracino<sup>1</sup>*  
<sup>1</sup>Clinic of Infectious Diseases, University Hospital of Bari, Bari, Italy, <sup>2</sup>Hospital Pharmacy Department, University Hospital of Bari, Bari, Italy
- OP 11** 11.38-11.43 **Continuous Positive Airway Pressure in SARS-CoV-2 associated Acute Respiratory Distress Syndrome: timing to maximize results**  
*R. Nevola<sup>1,3</sup>, A. Russo<sup>2</sup>, S. Scuotto<sup>2</sup>, S. Imbriani<sup>1</sup>, C. Aprea<sup>1</sup>, M. Abitabile<sup>1</sup>, D. Beccia<sup>1</sup>, C. Brin<sup>1</sup>, C. Carusone<sup>1</sup>, F. Cinone<sup>1</sup>, G. Cirigliano<sup>1</sup>, S. Colantuoni<sup>1</sup>, D. Cozzolino<sup>1</sup>, G. Cuomo<sup>1</sup>, M. Del Core<sup>1</sup>, K. Gjeshi<sup>1</sup>, A. Marrone<sup>1</sup>, G. Medicamento<sup>1</sup>, L. Meo<sup>1</sup>, F. Nappo<sup>1</sup>, A. Padula<sup>1</sup>, P.C. Pafundi<sup>1</sup>, R. Ranieri<sup>1</sup>, C. Ricozzi<sup>1</sup>, L. Rinaldi<sup>1</sup>, C.P. Romano<sup>1</sup>, R. Ruocco<sup>1</sup>, C. Ruosi<sup>1</sup>, A. Salvati<sup>2</sup>, F.C. Sasso<sup>1</sup>, A. Sellitto<sup>1</sup>, P. Sommesse<sup>1</sup>, A. Villani<sup>1</sup>, N. Coppola<sup>2</sup>, L.E. Adinolfi<sup>1</sup>*  
<sup>1</sup>Internal Medicine Unit, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy, <sup>2</sup>Infectious Diseases Unit, Department of Mental Health and Public Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy, <sup>3</sup>Internal Medicine and Hepatology Unit, Betania Evangelical Hospital, Naples, Italy
- OP 12** 11.45-11.50 **EpCOT: an open-label, controlled, randomized clinical trial on the efficacy of early prone-positioning in patients with mild pneumonia due to SARS-CoV-2**  
*M. Fezzi<sup>1</sup>, G. Lapadula<sup>1,2</sup>, L. Antolini<sup>1</sup>, A. Soria<sup>2</sup>, A. Rugova<sup>2</sup>, M. Rossi<sup>2</sup>, L. Bisi<sup>2</sup>, F. Sabbatini<sup>2</sup>, A. Cappelletti<sup>2</sup>, S. Limonta<sup>2</sup>, A. Ranzani<sup>2</sup>, I. De Benedetto<sup>2</sup>, N. Corti<sup>1,2</sup>, P. Bonfanti<sup>1,2</sup>*  
<sup>1</sup>Università degli Studi di Milano Bicocca - Dipartimento di Medicina e Chirurgia, Monza, <sup>2</sup>ASST Monza Ospedale San Gerardo, Monza





ORAL POSTER 11.10-12.00

ALABASTRO B

## Treatment of naive PLWH: current strategies and rapid start of ART

Chairs: M. E. Quiros Roldan (Brescia), L. Sighinolfi (Ferrara)

### OP 13 11.10-11.15 Reasons for choosing DRV/cob/FTC/TAF in ART-naïve and ART-experienced patients: data from the Icona Cohort

A. Tavelli<sup>1</sup>, D. Tomasoni<sup>2</sup>, N. Gianotti<sup>3</sup>, R. Gagliardini<sup>4</sup>, E. Bruzzesi<sup>3</sup>, P. Milini<sup>5</sup>, B. Menzaghi<sup>6</sup>, G. Lapadula<sup>7</sup>, P. Cinque<sup>8</sup>, L. Taramasso<sup>9</sup>, A. Antinori<sup>4</sup>, A. d'Arminio Monforte<sup>2</sup>

<sup>1</sup>ICONA Foundation, Milan, Italy, <sup>2</sup>Clinic of Infectious Diseases and Tropical Diseases, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, <sup>3</sup>Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>4</sup>National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Rome, Italy, <sup>5</sup>Infectious Diseases Unit, Macerata Hospital, Macerata, Italy, <sup>6</sup>Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio Hospital, Busto Arsizio, Italy, <sup>7</sup>Clinic of Infectious Diseases, San Gerardo Hospital - ASST Monza, University of Milano-Bicocca, Monza, Italy, <sup>8</sup>Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, San Raffaele Vita-Salute University, Milan, Italy, <sup>9</sup>Infectious Diseases Unit, Ospedale Policlinico San Martino-IRCCS, Genoa, Italy

### OP 14 11.17-11.22 Blood telomere length in treatment-naïve HIV-infected adults starting dolutegravir plus lamivudine versus triple regimen with two nucleosides

F. Lombardi<sup>1</sup>, A. Sanfilippo<sup>2</sup>, M. Fabbiani<sup>3</sup>, A. Borghetti<sup>1</sup>, A. Ciccullo<sup>4</sup>, S. Di Giambenedetto<sup>1,2</sup>

<sup>1</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Malattie Infettive, Roma, Italia, <sup>2</sup>Università Cattolica del Sacro Cuore, Dipartimento di Sicurezza e Bioetica, Roma Italia, <sup>3</sup>UOC Malattie Infettive e Tropicali, Azienda Ospedaliero-Universitaria Senese, Siena, Italia, <sup>4</sup>Unità di Malattie infettive, Ospedale San Salvatore, L'Aquila, Italia

### OP 15 11.24-11.29 BIC/FTC/TAF in ART-naïve key populations: real-life data from the Icona cohort

A. Tavelli<sup>1</sup>, G. Marchetti<sup>2</sup>, A. Vergori<sup>3</sup>, E. Quiros-Roldan<sup>4</sup>, V. Malagnino<sup>5</sup>, F. Vichi<sup>6</sup>, M. Lichtner<sup>7</sup>, S. Nozza<sup>8</sup>, R. Rossotti<sup>9</sup>, L. Sarmati<sup>5</sup>, A. Antinori<sup>3</sup>, A. d'Arminio Monforte<sup>2</sup>

<sup>1</sup>Icona Foundation, Milan, Italy, <sup>2</sup>Department of Health Sciences, Clinic of Infectious Diseases, 'San Paolo' Hospital, University of Milan, Milan, Italy, <sup>3</sup>Clinical Department, HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>4</sup>Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy, <sup>5</sup>Unit of Clinical Infectious Disease, Department of System Medicine, Tor Vergata University, Rome, Italy, <sup>6</sup>Infectious Diseases Unit 1, Santa Maria Annunziata Hospital, Azienda USL Toscana Centro, Florence, Italy, <sup>7</sup>Infectious Diseases Unit, Santa Maria Goretti Hospital, Sapienza University of Rome, Latina, Italy, <sup>8</sup>Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>9</sup>Department of Infectious Diseases Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

### OP 16 11.31-11.36 A pilot study of the impact of a rapid ART initiation in advanced HIV disease

M. Camici, R. Gagliardini, S. Lanini, S. Ottou, A. Mondì, M.M. Plazzi, C. Pinnetti, A. Vergori, E. Grilli, F. De Zottis, I. Mastroi, V. Mazzotta, J. Paulicelli, R. Bellagamba, S. Cicalini, A. Antinori

HIV/AIDS Clinical Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy

### OP 17 11.38-11.43 Rapid ART initiation in a single-center Italian cohort: an observational analysis

R. Pincino<sup>1,3</sup>, L. Taramasso<sup>2</sup>, M. Berruti<sup>1</sup>, G. Cenderello<sup>1</sup>, M. Bassetti<sup>2,3</sup>, A. Di Biagio<sup>2,3</sup>

<sup>1</sup>Infectious diseases unit, Borea Hospital, ASL-1 Imperiese, Sanremo, Italy, <sup>2</sup>Infectious diseases unit, Policlinico San Martino Hospital, Genoa, Italy, <sup>3</sup>Health and science department, Genoa University, Genoa, Italy

### OP 18 11.45-11.50 Viro-immunological effectiveness of different integrase strand-transfer inhibitor-based antiretroviral therapy regimens. A single center retrospective study

M. Ceccarelli<sup>1,2,3</sup>, D. Scuderi<sup>4</sup>, R. Bruno<sup>1,3</sup>, G. Bruno<sup>5</sup>, A. Marino<sup>3,6</sup>, V. Moscatt<sup>3,7</sup>, Y. Rusotto<sup>7</sup>, C. Micali<sup>7</sup>, E. Venanzi Rullo<sup>7</sup>, G. Nunnari<sup>7</sup>, B. Santi Cacopardo<sup>1</sup>, B.M. Celesia<sup>3</sup>

<sup>1</sup>Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, University of Catania, Catania, Italy, <sup>2</sup>Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, Unit of Infectious Diseases, University of Messina, Messina, Italy, <sup>3</sup>Unit of Infectious Diseases, ARNAS "Garibaldi", "Nesima" Hospital, Catania, Italy, <sup>4</sup>Unit of Infectious Diseases, "Cannizzaro" Hospital, Catania, Italy, <sup>5</sup>Department of Medical and Surgical Sciences, Unit of Infectious Diseases, "Magna Graecia" University of Catanzaro, Catanzaro, Italy, <sup>6</sup>Department of Biomedical and Biotechnological Sciences, Unit of Infectious Diseases, University of Catania, Catania, Italy, <sup>7</sup>Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, University of Messina, Messina, Italy





ORAL POSTER 11.10-12.00

## PrEP: real life experience

BERGAMO SCIENCE CENTER

Chairs: F. Leserri (Roma), M. Marra (Roma)

- OP 19** 11.10-11.15 **PrEP in Italy: how many people access it and what kind of services are offered?**  
M. Stizioli<sup>1</sup>, G.M. Corbelli<sup>2</sup>, M. Falaguasta<sup>1</sup>, E. Nittolo<sup>1</sup>  
<sup>1</sup>PrEP in Italia, <sup>2</sup>Plus Roma
- OP 20** 11.17-11.22 **HIV Pre-Exposure Prophylaxis (PrEP): the experience of the outpatient clinic of Perugia**  
G. Gamboni, C. Gabrielli, C. Papalini, C. Pallotto, G. De Socio, F. Paciosi, A. Zoffoli, S.Tordi, E. Schiaroli, D. Francisci  
Department of Medicine and Surgery, Clinic of Infectious Diseases, "Santa Maria della Misericordia" Hospital, University of Perugia, Perugia, Italy
- OP 21** 11.24-11.29 **Impact of a pre-exposure prophylaxis program on HIV and other sexually transmitted infections over the last three years in a third level hospital: the experience from Padua**  
F. Barbaro, S. Cavinato, M. Mazzitelli, L. Sasset, D. Leoni, A. Cattelan  
Unità Operativa Complessa Malattie Infettive e Tropicali, Azienda Ospedale Università Padova, Padova, Italy
- OP 22** 11.31-11.36 **Pre-Exposure Prophylaxis (PrEP) Service in Bergamo: three-year experience**  
S. Venturelli, F. Borghi, L. Baldassari, D. Ripamonti, F. Maggiolo, M. Rizzi  
ASST Papa Giovanni XXIII, Bergamo
- OP 23** 11.38-11.43 **HIV Pre-exposure Prophylaxis in a Large Teaching Hospital in Milan: the CSL-PrEP Cohort experience**  
A.R. Raccagnì<sup>1</sup>, R. Lolatto<sup>2</sup>, L. Galli<sup>2</sup>, F. Alberton<sup>1</sup>, E. Bruzzesi<sup>1</sup>, D. Canetti<sup>2</sup>, M. Strano<sup>1</sup>, M. Ripa<sup>2</sup>, A. Castagna<sup>1,2</sup>, S. Nozza<sup>2</sup>  
<sup>1</sup>Vita-Salute San Raffaele University, Milan, Italy, <sup>2</sup>Infectious Diseases Unit IRCCS San Raffaele, Milan, Italy
- OP 24** 11.45-11.50 **The Italian experience of Pre-Exposure Prophylaxis (PrEP) users and serum creatinine variation: a two centers retrospective analysis**  
M. Menozzi<sup>1</sup>, S. Volpi<sup>1</sup>, G.J. Burastero<sup>1</sup>, S. Colombaioni<sup>1</sup>, B. Fontana<sup>1</sup>, E. Martini<sup>1</sup>, M. Martini Fasce<sup>2</sup>, L. Labate<sup>2</sup>, A. Di Biagio<sup>3</sup>, C. Mussini<sup>1</sup>  
<sup>1</sup>Infectious Disease Clinic, University Hospital of Modena, Italy, <sup>2</sup>Infectious Diseases Unit, Ospedale Policlinico San Martino IRCCS – Genoa, Italy, <sup>3</sup>Department of Health Sciences (DISSAL), University of Genoa – Genoa, Italy



SYMPOSIUM 12.15-13.15

## New Insights and Challenges on Hepatitis and HIV Co-infections

AUDITORIUM SALA OGGIONI

Chairs: N. Coppola (Napoli), V. Svicher (Roma)

This symposium is aimed at providing new insights on three topics in the field of hepatitis and HIV coinfections. In particular, the first lecture will provide a comprehensive overview on novel anti-HBV drugs, targeting different phases of HBV life cycle, that should go beyond the concept of virological suppression and aim at achieving HBV functional cure. Particular attention will be dedicated to the challenges that virologists and clinicians will have to cope to reach this important end-point. With a decade left to reach the ambitious WHO goals for viral hepatitis elimination, many challenges still remain concerning the need to scale-up HCV testing and expand access to HCV treatment particularly in marginalized populations at risk for HCV infection. The importance of these aspects in elimination efforts, with an emphasis on micro-elimination strategies, will be explored in the second lecture of the symposium. Finally, the third lecture will be dedicated to HIV+CMV coinfection, an intriguing and crucial aspect contributing to HIV pathogenesis. Indeed, persistent CMV replication or reactivation have been demonstrated to fuel HIV reservoir and to exacerbate the process of inflammaging and immune-senescence.

- 12.15-12.30 **Novel anti-HBV drugs on the horizon** A.M. Geretti, Roma
- 12.30-12.45 **The road towards HCV elimination: is the WHO target achievable in time?** M. Puoti, Milano
- 12.45-13.00 **What's new on HIV & CMV coinfection?** M. Lichtner, Latina
- 13.00-13.15 **Discussion on Symposium issues**





**EXPERT MEETING** 12.15-13.15

**SALA STUCCHI**

## Narrative Medicine applied to Vaccination during Covid-19 pandemic

Moderator: S. Vella (Roma)

Con il supporto di Janssen-Cilag

Discussants: M.G. Marini (Milano), F. Moccia (Roma), E. Volpato (Milano)

Considering SARS-CoV-2 rapid spread and mortality rate, effective vaccines are needed to control the pandemic. Population is called to make a choice: to accept or refuse vaccination. Data of vaccination clinical trials have shown good results both in efficacy and safety, however long-term data are still to come; meanwhile the virus mutates, and the polarization between the Pro Vax and the No Vax groups, with a number in between identified as the Hesitancy group, is growing, despite the majority of people are Pro Vax. The aim of the Expert Meeting is to debate on different perceptions of people around vaccines and understand propensity to remain vaccinated against infectious diseases, taking advantage of the results of a research based on Narrative Medicine applied to COVID-19 vaccination.



**SPONSORED SYMPOSIUM** 12.15-13.15

**ALABASTRO A + ALABASTRO B**

## Cabotegravir + rilpivirine long-acting: are we ready for the new era?

Chairs: S. Bonora (Torino), G. Rizzardini (Milano)

Con il supporto di ViiV Healthcare

Advances in the efficacy of antiretroviral therapy led to a shift in treatment focus to emphasize convenience, tolerability, and overall acceptability of HIV therapy. This has culminated in the development of efficacious single-tablet daily oral regimens, which offer simplicity and convenience. Despite this, the need for life-long daily pill-taking can present substantial challenges that can be broadly grouped into three categories: adherence issues, emotional issues (including stigmatization concerns and the daily reminder of HIV status) and medical issues, such as difficulty swallowing, drug-food and drug-drug interactions, and pill burden. Innovations and treatment options that can fill the unmet needs of people living with HIV, such as long-acting non-oral regimens, could support patients to overcome treatment barriers and improve their quality of life. Objective of this symposium is to discuss the clinical trials data about Cabotegravir + Rilpivirine long-acting regimen, both in terms of efficacy and safety as well as Patient Reported Outcomes and treatment preference reported by patients.

12.15-12.35 **Cabotegravir + rilpivirine long-acting therapy: what the data tell us**

S. Nozza, Milano

12.35-12.55 **Patient reporting outcomes and treatment preferences**

A. Cingolani, Roma

12.55-13.15 **Questions & answers**



**ORAL POSTER** 12.15-13.05

**BERGAMO SCIENCE CENTER**

## Access test and educational aspects

Chairs: A. Bianchi (Milano), G. D'Offizi (Roma)

**OP 25** 12.15-12.20 **HIV testing in community-based centers and MSM premises: different settings, same needs**

A. Bianchi<sup>1,2</sup>, D. Zagato<sup>1</sup>, D. Calzavara<sup>2</sup>, R. Repossi<sup>1,2</sup>, P. Testoni<sup>1,2</sup>, A. Antonino<sup>1,2</sup>, G. Fracca<sup>1</sup>, F. Rossi<sup>1,2</sup>, A.J. Gallucci<sup>2,3</sup>, I. Gott<sup>2,4</sup>, N. Frattini<sup>1,2</sup>, R. Rossotti<sup>2,6</sup>, G. Pigliapochi<sup>2</sup>, P. Russo<sup>2,3</sup>, M. Albiani<sup>2</sup>, M. Cernuschi<sup>1,2,5</sup>

<sup>1</sup>ASA Associazione Solidarietà AIDS Onlus, Milan, Italy, <sup>2</sup>Milano CheckPoint, Milan, Italy, <sup>3</sup>CIG Arcigay Milano, Milan, Italy, <sup>4</sup>Anlaidi Sez. Lombarda, Milan, Italy, <sup>5</sup>San Raffaele Hospital, Milan, Italy, <sup>6</sup>ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

**OP 26** 12.22-12.27 **HIV testing: are we missing some opportunities?**

M. Mazzitelli, L. Sasset, D. Leoni, F. Barbaro, A.M. Cattelan

Infectious and Tropical Diseases Unit, Azienda Ospedale Università Padova, Italy

**OP 27** 12.29-12.34 **Population of the Bergamo Check-Point. A first analysis of Cobatest data**

I. Mercurio<sup>1</sup>, C. Pellegris<sup>2</sup>, P. Meli<sup>2</sup>, E. Zanetti<sup>2</sup>, F. Maggiolo<sup>3</sup>, F. Radici<sup>4</sup>, R. Carissoli<sup>4</sup>

<sup>1</sup>Croce Rossa Italiana – Comitato di Bergamo, <sup>2</sup>Società Cooperativa Sociale Don Giuseppe Monticelli, <sup>3</sup>ASST Papa Giovanni XXIII, <sup>4</sup>Arcigay Bergamo Cives

**OP 28** 12.36-12.41 **Veneto Region "RECALL" project to discover HCV+people: the experience of the "Osservatorio Infettivologico" in Verona**

V. Del Punta, M. Fiscon, G. Giammarresi, S. Nardi, M. Malena

UOS Osservatorio Infettivologico Aziendale Azienda ULSS 9 Scaligera





**OP 29** 12.43-12.48 **Prejudice and perceived HIV risk among High School Students**

C. Pellegris<sup>1</sup>, I. Mercurio<sup>1</sup>, P. Meli<sup>1</sup>, E. Zanetti<sup>1</sup>, F. Maggiolo<sup>2</sup>, I. Fontana<sup>3</sup>

<sup>1</sup>Società Cooperativa Sociale Don Giuseppe Monticelli, <sup>2</sup>ASST Papa Giovanni XXIII, <sup>3</sup>Ufficio Scolastico Territoriale Bergamo

**OP 30** 12.50-12.55 **Pilot experience of comprehensive sexuality education among Italian adolescents: preliminary results from the EduForIST project, April 2022**

A. Chinelli<sup>1</sup>, D. Martinelli<sup>2</sup>, L. Ceccarelli<sup>1</sup>, E. Torri<sup>1</sup>, R. Galipò<sup>3</sup>, P. Meli<sup>4</sup>, A. Camposeragna<sup>5</sup>, L. Rancilio<sup>6</sup>, M. Farinella<sup>7</sup>, L. Colaprico<sup>8</sup>, M. Oldrini<sup>9</sup>, M.C. Salfa<sup>10</sup>, A. Cellini<sup>11</sup>, M. Ubbiali<sup>12</sup>, A. Caraglia<sup>13</sup>, L. Mortari<sup>12</sup>, A.T. Palamara<sup>11</sup>, B. Suligo<sup>10</sup>, L. Tavoschi<sup>1</sup>

<sup>1</sup>University of Pisa, Department of Translational Research on New Technologies in Medicine and Surgery, <sup>2</sup>University of Foggia, Department of Medical and Surgical Sciences, <sup>3</sup>ANLAIDS - National Association for the Fight against AIDS, Rome, <sup>4</sup>CICA - Italian Coordination of HIV/AIDS Housing Homes, Bergamo, <sup>5</sup>CNCA - National Coordination of the Hospitality Community, Rome, <sup>6</sup>Caritas Ambrosiana, Milan, <sup>7</sup>Circolo di cultura omosessuale Mario Mieli, Rome, <sup>8</sup>Italian Red Cross, Rome, <sup>9</sup>LILA - Italian league for the fight against AIDS, Rome, <sup>10</sup>Italian National Institute of Health, Rome, <sup>11</sup>Sapienza University of Rome, <sup>12</sup>University of Verona, Department of Human Sciences, <sup>13</sup>Ministry of Health, Department of Prevention, Rome



**SPECIAL SESSION** 13.15-14.30

**How to use U=U to fight stigma**

**SALA STUCCHI**

Chairs: G.V. Calvino (Roma), A. Moznich (Milano)

Undetectable=Untransmittable (U=U) concept represents a revolution for people living with HIV. It means the end of fear of transmitting the infection, even through unprotected sex. The end of stigma. In Italy, the Consensus Conference (published by sections L and M of Ministry of Health's CTS - Technical Scientific Committee) formulated U=U concept in an extensive, clear, doubt free approach. This evidence has neither been acquired by many doctors, nor explained to many people living with HIV. There is no communication campaign directed to the general population. In this session we share different experiences, showing how U=U positively improved the social life of people living with HIV, and how on the other hand the absence of adequate information directed to the general population and institutions, contributes to maintain heavy stigma against HIV.



**ORAL COMMUNICATIONS** 13.15-14.15

**Metabolic issues in effective HAART**

**ALABASTRO A**

Chairs: E. Focà (Brescia), C. Gervasoni (Milano)

**OC 9** 13.15-13.25 **Role of Emtricitabine/Tenofovir Alafenamide/Bictegravir on metabolic and hepatic safety: data from Surveillance Cohort Longterm Toxicity Antiretrovirals/antivirals (SCOLTA) project**

N. Squillace<sup>1</sup>, E. Ricci<sup>2</sup>, B. Menzaghi<sup>3</sup>, G.V. De Socio<sup>4</sup>, G. Orofino<sup>5</sup>, B.M. Celesia<sup>6</sup>, F. Vichi<sup>7</sup>, A. Di Biagio<sup>8</sup>, L. Taramasso<sup>8</sup>, C. Molteni<sup>9</sup>, E. Sarchi<sup>10</sup>, L. Valsecchi<sup>11</sup>, G.F. Pellicanò<sup>12</sup>, P. Bonfanti<sup>1</sup>, for the CISAI Study Group

<sup>1</sup>Infectious Diseases Unit ASST-MONZA, San Gerardo Hospital-University of Milano-Bicocca, Monza, <sup>2</sup>Fondazione ASIA Onlus, Buccinasco (MI), Italy, <sup>3</sup>Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio, Varese, <sup>4</sup>Unit of Infectious Diseases, Santa Maria Hospital, Perugia, <sup>5</sup>Division I of Infectious and Tropical Diseases, ASL Città di Torino, <sup>6</sup>Unit of Infectious Diseases, Garibaldi Hospital, Catania, <sup>7</sup>Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, <sup>8</sup>Infectious Diseases, San Martino Hospital Genoa, University of Genoa, Genoa, <sup>9</sup>Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, <sup>10</sup>Infectious Diseases Unit, S. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, <sup>11</sup>1st Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy, <sup>12</sup>Infectious Diseases, G. Martino Hospital -University of Messina, Messina

**OC 10** 13.27-13.37 **Machine learning algorithm to predict weight change in ART experienced PWH**

F. Motta<sup>1</sup>, J. Milic<sup>1</sup>, S. Barbieri<sup>1</sup>, L. Gozzi<sup>2</sup>, E. Aprile<sup>2</sup>, M. Belli<sup>2</sup>, M. Venuta<sup>2</sup>, G. Cuomo<sup>2</sup>, F. Carli<sup>2</sup>, G. Dolci<sup>2</sup>, V. Iadisernia<sup>2</sup>, G. Bura-stero<sup>2</sup>, C. Mussini<sup>1,2</sup>, F. Mandreoli<sup>3</sup>, G. Guaraldi<sup>1,2</sup>

<sup>1</sup>Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, <sup>2</sup>Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy, <sup>3</sup>Department of Physics, Informatics and Mathematics, University of Modena and Reggio Emilia, Modena, Italy

**OC 11** 13.39-13.49 **In vitro model of adipocyte differentiation under TAF, TDF and INSTIs selective challenge**

M.A. Carleo<sup>1</sup>, A. Perna<sup>2</sup>, A. Guida<sup>1</sup>, P. Rosario<sup>1</sup>, S. Mascolo<sup>1</sup>, A. Lucariello<sup>3</sup>, G. Palmiero<sup>1</sup>, V. Rizzo<sup>1</sup>, A. M. Rossomando<sup>1</sup>, A. Baldi<sup>4</sup>, A. De Luca<sup>5</sup>, P. Maggi<sup>6</sup>, V. Esposito<sup>1</sup>

<sup>1</sup>Infectious Diseases and Gender Medicine Unit "D. Cotugno" Hospital - AO dei Colli, Naples Italy, <sup>2</sup>Department of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Campobasso, Italy, <sup>3</sup>Department of Sport Sciences and Wellness, University of Naples "Parthenope", Naples, Italy, <sup>4</sup>Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, Università degli Studi della Campania "L. Vanvitelli", Caserta, Italy, <sup>5</sup>Department of Mental and Physical Health and Preventive Medicine, Section of Human Anatomy, University of Campania "Luigi Vanvitelli", Naples, Italy, <sup>6</sup>University of Campania "Luigi Vanvitelli", Caserta Italy



**OC 12 13.51-14.01 Liver enzymes levels, metabolic and renal profile modifications after switching from TDF to TAF-based regimens among ART experienced PLWH in ICONA cohort**

*M. Poliseno*<sup>1</sup>, *S. Lo Caputo*<sup>1</sup>, *A. Tavelli*<sup>2</sup>, *R. Gagliardini*<sup>3</sup>, *L. Gazzola*<sup>2</sup>, *A. Saracino*<sup>4</sup>, *T.A. Santantonio*<sup>1</sup>, *M. Puoti*<sup>5</sup>, *S. Cicalini*<sup>3</sup>, *A. Antinori*<sup>3</sup>, *A. d'Arminio Monforte*<sup>2</sup>, *A. Cozzi-Lepri*<sup>6</sup>

<sup>1</sup>Unit of Infectious Diseases, University of Foggia, Foggia, Italy, <sup>2</sup>Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, <sup>3</sup>National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Rome, Italy, <sup>4</sup>Operative Unit of Infectious Diseases, Hospital-University Polyclinic of Bari, Bari, Italy, <sup>5</sup>Infectious Diseases Unit, Niguarda Hospital, Milan, Italy, <sup>6</sup>Institute for Global Health UCL, University College London, London, UK



ORAL POSTER 13.25-14.15

ALABASTRO B

**Predictors of COVID-19 severity**

Chairs: G. Lapadula (Monza), P. Nasta (Brescia)

**OP 31 13.25-13.30 Hospitalization for COVID-19 or with SARS-CoV-2 infection during two different epidemic periods in Milan, Italy: data from Luigi Sacco Hospital registry**

*A. Giacomelli*<sup>1</sup>, *A.L. Ridolfo*<sup>1</sup>, *L. Pezzati*<sup>1,2</sup>, *M. Piscaglia*<sup>1,2</sup>, *S. Caronni*<sup>1,2</sup>, *F. Sabaini*<sup>1,2</sup>, *L. Oreni*<sup>1</sup>, *F. Borgonovo*<sup>1,2</sup>, *M. Matone*<sup>1,2</sup>, *M. Galimberti*<sup>1,2</sup>, *M. Zacheo*<sup>1,2</sup>, *A. Civati*<sup>1,2</sup>, *A. Behring*<sup>1,2</sup>, *M. Schiavini*<sup>1</sup>, *G. Rizzardini*<sup>1</sup>, *S. Antinori*<sup>1,2</sup>

<sup>1</sup>Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy, <sup>2</sup>Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, Università degli Studi di Milano, Milan, Italy

**OP 32 13.32-13.37 Prognostic value of transaminases and bilirubin levels at admission to hospital on disease progression and mortality in patients with COVID-19 - an observational retrospective study**

*R. Palladino*, *A. Russo*, *M. Pisaturo*, *P. Maggi*, *F.G. Numis*, *I. Gentile*, *V. Sangiovanni*, *V. Esposito*, *R. Punzi*, *G. Calabria*, *C. Rescigno*, *A. Salomone Megna*, *A. Masullo*, *E. Manzillo*, *G. Russo*, *R. Parrella*, *G. Dell'Aquila*, *M. Gambardella*, *A. Ponticello*, *N. Coppola* on behalf of CoviCam group

Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania "L. Vanvitelli", Napoli, Italy, Infectious Diseases Unit, A.O. S Anna e S Sebastiano Caserta, Italy, Emergency unit, PO Santa Maria delle Grazie, Pozzuoli, Italy, Infectious disease unit; University Federico II, Naples, Italy, Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, IV Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, Hepatic Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, IX Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, First Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, Infectious Disease Unit, A.O. San Pio, PO Rummo, Benevento, Italy, Infectious disease unit, A.O. San Giovanni di Dio e Ruggi D'Aragona Salerno, Italy, VIII Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, Infectious Disease Unit, Ospedale Maria S.S. Addolorata di Eboli, ASL Salerno, Italy, Respiratory Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, Infectious Diseases Unit, AO Avellino, Italy, Infectious Disease Unit, PO S. Luca, Vallo della Lucania, ASL Salerno, Italy, Pneumology Unit, AORN Caserta, Italy

**OP 33 13.39-13.44 Early predictors of clinical deterioration in a cohort of outpatients with COVID-19 in Southern Italy: a multicenter observational study**

*C. Monari*<sup>1</sup>, *M. Pisaturo*<sup>1</sup>, *P. Maggi*<sup>2</sup>, *M. Macera*<sup>2</sup>, *G. Di Caprio*<sup>2</sup>, *R. Pisapia*<sup>3</sup>, *V. Gentile*<sup>1</sup>, *M. Fordellone*<sup>4</sup>, *P. Chiodini*<sup>4</sup>, *N. Coppola*<sup>1</sup> on behalf of CoviCam group

<sup>1</sup>Department of Mental Health and Public Medicine - Infectious Diseases Unit. University of Campania Luigi Vanvitelli, Naples, Italy, <sup>2</sup>Infectious Disease Unit, AORN Caserta, <sup>3</sup>Infectious Diseases Unit, AORN dei Colli, Naples, <sup>4</sup>Medical Statistics Unit, University of Campania Luigi Vanvitelli, Naples, Italy

**OP 34 13.46-13.51 Risk factors for in-hospital mortality in COVID-19 patients with end stage renal diseases requiring maintenance hemodialysis**

*A. Cingolani*<sup>1</sup>, *M. Ambrogio*<sup>2</sup>, *G. Micheli*<sup>1</sup>, *G. De Luca*<sup>2</sup>, *M. Chiuchiarelli*<sup>1</sup>, *A. Spasiano*<sup>2</sup>, *P. L. Salvo*<sup>1</sup>, *E. Rosati*<sup>2</sup>, *S.L. Cutuli*<sup>3</sup>, *E. Rando*<sup>1</sup>, *G. De Pascale*<sup>3</sup> and *Nicola Panocchia*<sup>2</sup> for COVIDialysis-FPG Working Group: *M. Ambrogio*, *G. De Luca*, *A. Spasiano*, *E. Rosati*, *N. Panocchia*, *R. Baccaro*, *M. Liberatori*, *A. Naticchia*, *F. D'Ascenzo*, *G. Grandaliano*, *G. Scoppettuolo*, *F. Damiano*, *P. Del Giacomo*, *F. Raffaelli*, *R. Losito*, *G. Maiuro*, *I. IZZI*, *A. Dusina*, *R. Passerotto*, *F. Iamanna*, *S. Guerriero*, *B. Liguoro*, *F. Salvati*, *V. Iannone*, *R. Cauda*

<sup>1</sup>Infectious Diseases, <sup>2</sup>Nefrology, <sup>3</sup>Intensive Care Unit, Fondazione Policlinico A. Gemelli, IRCCS, Roma

**OP 35 13.53-13.58 Clinical characteristics and outcomes of COVID-19 hospitalized patients in the current pandemic phase**

*E.P. Drago*<sup>1</sup>, *M. Poliseno*<sup>1</sup>, *M.A. Poli*<sup>3</sup>, *M. Altamura*<sup>2</sup>, *S.R. Bruno*<sup>2</sup>, *A. Calamo*<sup>2</sup>, *A. Giannelli*<sup>2</sup>, *G. Infante*<sup>2</sup>, *M. Mazzola*<sup>2</sup>, *S.B. Morella*<sup>2</sup>, *D. Moschetta*<sup>2</sup>, *M. Tarallo*<sup>2</sup>, *S. Lo Caputo*<sup>1</sup>, *T.A. Santantonio*<sup>1</sup>, *S. Carbonara*<sup>2</sup>

<sup>1</sup>Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Foggia, <sup>2</sup>Infectious Disease Unit, Vittorio Emanuele II Hospital, Bisceglie, Barletta-Andria-Trani, <sup>3</sup>Dermatology Unit, Department Internal Medicine, University of Bari





**OP 36 14.00-14.05 Laboratory and clinical biomarkers helps to predict severity of CT score in COVID19 patients: an observational study**

*I. de Luca<sup>1</sup>, A. Russo<sup>1</sup>, F. Schettino<sup>2</sup>, M.A. Pisaturo<sup>1</sup>, P. Maggi<sup>1</sup>, F.G. Numis<sup>3</sup>, I. Gentile<sup>4</sup>, V. Sangiovanni<sup>5</sup>, V. Esposito<sup>6</sup>, R. Punzi<sup>7</sup>, G. Calabria<sup>8</sup>, C. Rescigno<sup>9</sup>, A. Salomone Megna<sup>10</sup>, A. Masullo<sup>11</sup>, E. Manzillo<sup>12</sup>, G. Russo<sup>13</sup>, R. Parrella<sup>14</sup>, G. Dell'Aquila<sup>15</sup>, M. Gambardella<sup>16</sup>, A. Ponticello<sup>17</sup>, A. Reginelli<sup>2</sup>, N. Coppola<sup>1</sup> on behalf of CoviCam group*

<sup>1</sup>Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania "L. Vanvitelli", Napoli, Italy, <sup>2</sup>Radiology Unit, Department of Precision Medicine, University of Campania "L. Vanvitelli", Napoli, Italy, <sup>3</sup>Emergency Unit, PO Santa Maria delle Grazie, Pozzuoli, Italy, <sup>4</sup>Infectious Disease Unit; University Federico II, Naples, Italy, <sup>5</sup>Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, <sup>6</sup>IV Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>7</sup>Hepatic Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>8</sup>IX Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>9</sup>First Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>10</sup>Infectious Disease Unit, A.O. San Pio, PO Rummo, Benevento, Italy, <sup>11</sup>Infectious disease unit, A.O. San Giovanni di Dio e Ruggi D'Aragona Salerno, Italy, <sup>12</sup>VIII Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>13</sup>Infectious Disease Unit, Ospedale Maria S.S. Addolorata di Eboli, ASL Salerno, Italy, <sup>14</sup>Respiratory Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>15</sup>Infectious Diseases Unit, AO Avellino, Italy, <sup>16</sup>Infectious Disease Unit, PO S. Luca, Vallo della Lucania, ASL Salerno, Italy, <sup>17</sup>Pneumology Unit, AORN Caserta, Italy



ORAL POSTER 13.25-14.15

BERGAMO SCIENCE CENTER

**HCV eradication: general and key populations**

Chairs: P. Colletti (Marsala), M. Cusini (Milano)

**OP 37 13.25-13.30 Long-term outcomes in GT3 HCV/HIV co-infected subjects treated with DAAs: impact on metabolic profile**

*A. Siribelli<sup>1</sup>, D. Ceccarelli<sup>2</sup>, E. Messina<sup>2</sup>, C. Bertoni<sup>1</sup>, R. Lolatto<sup>2</sup>, G. Morsica<sup>2</sup>, C. Uberti-Foppa<sup>1,2</sup>, A. Castagna<sup>1,2</sup>, H. Hasson<sup>2</sup>*

<sup>1</sup>Vita-Salute University, Milan, Italy, <sup>2</sup>Dept. of Infectious Diseases, San Raffaele Hospital, Milan, Italy

**OP 38 13.32-13.37 Chronic Hepatitis C cascade of care in Prisoners. Is there still some work to be done? Analysis of two penitentiaries in northern Italy**

*A. Cambianica<sup>1</sup>, V. Marchese<sup>1</sup>, F. Pennati<sup>1</sup>, A. Faustinelli<sup>1</sup>, M. Tonni<sup>2</sup>, F. Roda<sup>2</sup>, A. Spinetti<sup>1</sup>, S. Zaltron<sup>1</sup>, S. Fiorentini<sup>3</sup>, E. Quiros-Roldan<sup>1</sup>, F. Castelli<sup>1</sup>, E. Focà<sup>1</sup>*

<sup>1</sup>Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy, <sup>2</sup>Unit of Prison Health ASST Spedali Civili Hospital, Brescia, Italy, <sup>3</sup>Unit Of Microbiology and Virology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy

**OP 39 13.39-13.44 HCV point of care screening in people tested for SARS-CoV-2 in a social-housing neighbourhood of Milan, Italy**

*M. Beltrami<sup>1,2</sup>, G. Pagani<sup>3</sup>, F. Conti<sup>1,2</sup>, L. Pezzati<sup>1,2</sup>, G. Casalini<sup>1,2</sup>, R. Rondanin<sup>4</sup>, A. Prina<sup>4</sup>, A. Zagari<sup>5</sup>, M. Galli<sup>1,2</sup>, A. Giacomelli<sup>1</sup>*

<sup>1</sup>Malattie Infettive III Divisione, ASST FBF-Sacco, Milan, Italy, <sup>2</sup>Dipartimento di Scienze Biomediche e Cliniche "L. Sacco", Università degli Studi di Milano, Milan, Italy, <sup>3</sup>Malattie Infettive, Ospedale Nuovo di Legnano, ASST Ovest Milanese, Legnano, Italy, <sup>4</sup>Medispa S.r.l., Milan, Italy, <sup>5</sup>Direzione Socio-Sanitaria, ASST FBF-Sacco, Milan, Italy

**OP 40 13.46-13.51 Hepatitis C virus (HCV) micro-elimination in the hospital setting: the results of the HCV Caserta hospital project**

*V. Messina<sup>1</sup>, M. Pisaturo<sup>2</sup>, L. Alessio<sup>2</sup>, A. Russo<sup>2</sup>, E. Tripaldelli<sup>3</sup>, A. Petruziello<sup>3</sup>, A. Annechiaro<sup>4</sup>, M.R. Romano<sup>5</sup>, P. Maggi<sup>1,2</sup>, N. Coppola<sup>2</sup>*

<sup>1</sup>Infectious Disease Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy, <sup>2</sup>Department of Mental and Physical Health and Preventive Medicine, Infectious Diseases section, University of Campania Luigi Vanvitelli, Naples, <sup>3</sup>Clinical Pathology, AORN Sant'Anna e San Sebastiano, Caserta, Italy, <sup>4</sup>Direzione Sanitaria, AORN Sant'Anna e San Sebastiano, Caserta, Italy, <sup>5</sup>Regione Campania, Naples, Italy

**OP 41 13.53-13.58 Patients' reported experiences with direct acting antiviral therapy in an integrated model of hepatitis C care and treatment**

*L. Ceccarelli<sup>1,2</sup>, G. Moretti<sup>2</sup>, I. Corazza<sup>2</sup>, L. Tavoschi<sup>1</sup>, M. Vainieri<sup>2</sup>*

<sup>1</sup>Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, <sup>2</sup>Management and Healthcare Laboratory, Sant'Anna School of Advanced Studies, Pisa, Italy

**OP 42 14.00-14.05 Characterisation of viral infections in a cohort of migrants living in southern Italy**

*S. Capuano<sup>1,9</sup>, M. Pisaturo<sup>1,7</sup>, A. Loredana<sup>1,7</sup>, L. Occhiello<sup>1</sup>, M. Macera<sup>1,4</sup>, M. Starace<sup>1</sup>, E. Cordua<sup>1</sup>, L. Onorato<sup>1</sup>, G. Scotto<sup>8</sup>, G. Di Caprio<sup>3,7</sup>, F. Calò<sup>1,6</sup>, C. Sagnelli<sup>1,5</sup>, N. Coppola<sup>1</sup>*

<sup>1</sup>Department of Mental and Physical Health and Preventive Medicine, Infectious Diseases section, University of Campania Luigi Vanvitelli, Naples, <sup>2</sup>L. Vanvitelli University Hospital, Naples, <sup>3</sup>UOC of Infectious Diseases, AORN Sant'Anna and San Sebastiano, Caserta, <sup>4</sup>Abraham Tent; Reception Center, Caserta, <sup>5</sup>Missionary Sisters of Charity Center, Naples, <sup>6</sup>Center for the Protection of Immigrant Health, Naples, <sup>7</sup>Social center "ex-canapificio", Caserta, <sup>8</sup>UOC of Infectious Diseases, Foggia, <sup>9</sup>Social center "ex-opg Je so Pazz", Napoli





**SPONSORED SYMPOSIUM** 14.30-15.30

**AUDITORIUM SALA OGGIONI**

**Long Term Treatment Success for PLWH: from clinical trials to real world experience with B/F/TAF**

Chair: A. Castagna (Milano)

Simposio promozionale di Gilead Sciences


Despite all the advances in therapeutic strategies, HIV remains a complex disease that has a significant impact on the lives of PLWH. To address this complexity, Gilead emphasizes the importance of Long-Term Treatment Success (LTTS). The LTTS has the patient's long-term therapeutic success as its objective. This is achieved not only with the classic parameters of effectiveness and safety but also with a whole series of other aspects that impact the quality of life of the patient living with HIV. Long Term Treatment Success should be the goal for every clinician when facing PLWH. Every person living with HIV must be able to live their lives in the best possible way. The Symposium will analyze how B/F/TAF ensures Long Term Treatment Success both through 5-year follow-up data from clinical trials and with numerous Real World Evidence data from various Italian centers that will be discussed in a roundtable.

14.30-14.45 **Long term treatment success in the clinical trials: 5 years data with B/F/TAF** S. Lo Caputo, Foggia

14.45-15.25 **Experiences from Italian cohorts: Round Table** Conductor: G. Madeddu, Sassari

Discussants: S. Cicalini, Roma; G. d'Etorre, Roma; V. Esposito, Napoli; L. Gazzola, Milano; N. Gianotti, Milano

15.25-15.30 **Discussion on Symposium issues**



**ORAL COMMUNICATIONS** 14.30-15.30

**SALA STUCCHI**

**COVID-19: clinical management**

Chairs: M. Bassetti (Genova), R. Cauda (Roma)

**OC 13 14.30-14.40 Home prescription treatment and mortality risk after hospitalization with symptomatic COVID-19 disease**

A. Dessilani, A. Cozzi-Lepri, E. Franceschini, G. Guaraldi, V. Borghi, M. D. Di Trapani, M. Del Monte, F. Medioli, I. Baldisserotto, S. Esperti, A. Mazzocchi, J. Conti, A. Gallerani, N. Barp, A. Spadoni, V. Menozzi, C. Mussini  
Struttura Complessa di Malattie Infettive, AOU Policlinico di Modena, Modena

**OC 14 14.42-14.52 In vivo efficacy of monoclonal antibodies and direct antiviral agents against the SARS-CoV-2 BA.1 and BA.2 Omicron sublineages**

V. Mazzotta<sup>1,2</sup>, A. Cozzi Lepri<sup>3</sup>, F. Colavita<sup>1</sup>, S. Lanini<sup>1</sup>, R. Rosati<sup>1</sup>, E. Lalle<sup>1</sup>, C. Cimaglia<sup>1</sup>, I. Mastrosera<sup>1</sup>, J. Paulicelli<sup>1</sup>, S. Vita<sup>1</sup>, E. Caraffa<sup>1</sup>, G. Matusali<sup>1</sup>, A. Vergori<sup>1</sup>, G. Giannico<sup>1</sup>, G. Maffongelli<sup>1</sup>, E. Milozzi<sup>1</sup>, D. Donno<sup>1</sup>, P. Vittozzi<sup>1</sup>, F. De Zottis<sup>1</sup>, P. Piselli<sup>1</sup>, E. Girardi<sup>1</sup>, A.R. Garbuglia<sup>1</sup>, F. Vaia<sup>1</sup>, E. Nicastri<sup>1</sup>, A. Antinori<sup>1</sup>

<sup>1</sup>National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>2</sup>PhD course in Microbiology, Immunology, Infectious Diseases, and Transplants (MIMIT), University of Rome Tor Vergata, Rome, Italy, <sup>3</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK

**OC 15 14.54-15.04 Anemia is strongly associated with severity and mortality of COVID-19 in hospitalized patients**

F. Di Gennaro, G. Brindicci, M. Cormio, V. Guerra, A. Lugli, L. De Santis, A. Procopio, D.F. Bavaro, E. Milano, N. De Gennaro, G. De Iaco, R. Lattanzio, C.R. Santoro, A. Saracino  
Clinic of Infectious Diseases, University of Bari, University Hospital Policlinico, Bari Italy

**OC 16 15.06-15.16 Clinical characteristics and outcomes of COVID-19 in vaccinated versus not-vaccinated hospitalized patients: data from an Italian reference hospital**

A. Mondì, I. Mastrosera, A. Navarra, S. Lanini, A. D'Annunzio, F. Vaia, E. Girardi, A. Antinori  
National Institute for Infectious Diseases L. Spallanzani IRCCS, Rome, Italy







**EXPERT MEETING** 14.30-15.30

**ALABASTRO A**

**The new recombinant adjuvanted vaccine against Herpes Zoster: clinical data and recommendations**

Chair: C.M. Mastroianni (Roma)

Con il supporto di GSK

There is a substantial unmet medical need associated with herpes zoster (HZ) and its complications, particularly in older adults and those who are immunocompromised (IC). Current disease management of HZ is not optimal. Early treatment with antiviral drugs, initiated within 72 hours of rash onset, decreases the incidence of new lesion formation, accelerates healing and the resolution of acute pain. Populations at increased risk for developing HZ are those having a decline in immune function, including older adults or individuals who are IC. Individuals who are IC due to haematological malignancies (HM) and solid tumours, human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), treatments such as chemo- or radiotherapy, haematopoietic stem cell transplantation (HSCT), immune suppression following organ transplantation or therapy with high doses of corticosteroids are also at increased risk of developing HZ. Individuals who are IC also have an increased risk of disseminated disease. The Recombinant Zoster Vaccine (RZV) is available in Italy since 2021. RZV has been shown to be highly effective at preventing shingles and post-herpetic neuralgia in adults older than 50 years. The vaccine is also effective at protecting adults older than 18 years who are at increased risk of herpes zoster. In the "Recommendations of the Italian society for infectious and tropical diseases (SIMIT) for adult vaccinations" document, published in 2021, SIMIT recommended RZV for the prevention of HZ and PHN in older adults (>65 yo) and for several categories of at higher risk subjects including HIV+ patients.

- 14.30-14.45 **Scientific and clinical profile of the new recombinant adjuvanted vaccine against HZ** G. Gabutti, Lavagna (GE)
- 14.45-15.00 **The prevention of HZ in at higher risk subjects: the Recommendations of the Italian Society for Infectious and Tropical Diseases (SIMIT)** M. Andreoni, Roma
- 15.00-15.15 **Vaccination against HZ directly offered in the Infectious Diseases center: the «Milan» experience** G. Rizzardini, Milano
- 15.15-15.30 **Discussion on Expert Meeting issues**



**ORAL POSTER** 14.30-15.20

**ALABASTRO B**

**Viro-immunological correlates of COVID-19 severity**

Chairs: I. Bon (Bologna), I. Vicenti (Siena)

- OP 43** 14.30-14.35 **PTX3 is a strong predictor of death among patients with COVID-19**  
G. Lapadula<sup>1,2</sup>, R. Leone<sup>3</sup>, D.P. Bernasconi<sup>4</sup>, A. Biondi<sup>1,5</sup>, E. Rossi<sup>4</sup>, M. D'Angiò<sup>5</sup>, B. Bottazzi<sup>3</sup>, L.R. Bettini<sup>5</sup>, I. Beretta<sup>2</sup>, C. Garlanda<sup>3,6</sup>, M.G. Valsecchi<sup>4</sup>, A. Mantovani<sup>3,6,7</sup>, P. Bonfanti<sup>1,2</sup> for the COVID-19 STORM Study Group  
<sup>1</sup>University of Milano-Bicocca, Milan, Italy, <sup>2</sup>Department of Infectious Diseases, San Gerardo Hospital, Monza, Italy, <sup>3</sup>Humanitas Clinical and Research Institute – IRCCS, Rozzano (MI), Italy, <sup>4</sup>Bicocca Bioinformatics Biostatistics and Bioimaging Center - B4, University of Milano-Bicocca, Milan, Italy, <sup>5</sup>Department of Pediatrics, European Reference Network (ERN) PaedCan, EuroBloodNet, MetabERN, Fondazione MBBM/Ospedale San Gerardo, Monza, Italy, <sup>6</sup>Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy, <sup>7</sup>William Harvey Research Institute, Queen Mary University, London, UK
- OP 44** 14.37-14.42 **The role of antigen load on viral clearance and severity in SARS-CoV-2 infection**  
T. Clemente<sup>1,2</sup>, P.E. Rovatti<sup>3</sup>, M. Punta<sup>3,4</sup>, C. Muccini<sup>1,2</sup>, L. Galli<sup>2</sup>, C. Toffalori<sup>3</sup>, R. Papaioannu Borjesson<sup>1,2</sup>, M. Bottanelli<sup>1,2</sup>, C. Tresoldi<sup>5</sup>, F. Ciceri<sup>1,5,6</sup>, A. Castagna<sup>1,2</sup>, L. Vago<sup>3,6</sup>, V. Spagnuolo<sup>2</sup>, on the behalf of COVID-BioB Study Group  
<sup>1</sup>School of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, Italy, <sup>2</sup>Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, Italy, <sup>3</sup>Unit of Immunogenetics, Leukemia Genomics and Immunobiology, San Raffaele Scientific Institute, Milan, Italy, <sup>4</sup>Center for Omics Sciences, San Raffaele Scientific Institute, Milan, Italy, <sup>5</sup>Immuno-hematology and Transfusion Medicine Unit, San Raffaele Scientific Institute, Milan, Italy, <sup>6</sup>Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milan, Italy
- OP 45** 14.44-14.49 **Dysregulation in IFN-omega levels and anti-IFN-omega neutralizing antibodies correlate with biochemical and hematological parameters predictive of disease severity in COVID-19 male patients**  
F. Frasca<sup>1</sup>, M. Scordio<sup>1</sup>, L. Sorrentino<sup>1</sup>, M. Fracella<sup>1</sup>, L. Santinelli<sup>2</sup>, E. N. Cavallari<sup>2</sup>, C. Bitossi<sup>1</sup>, A. Viscido<sup>1</sup>, G. Ceccarelli<sup>2</sup>, A. Pierangeli<sup>1</sup>, O. Turriziani<sup>1</sup>, C. M. Mastroianni<sup>2</sup>, G. Antonelli<sup>1</sup>, G. d'Ettore<sup>2</sup>, C. Scagnolari<sup>1</sup>  
<sup>1</sup>Laboratory of Microbiology and Virology, Department of Molecular Medicine, Sapienza University of Rome, Italy, <sup>2</sup>Department of Public Health and Infectious Diseases, Policlinico Umberto I, Sapienza University of Rome, Italy



- OP 46** 14.51-14.56 **Characterization of IFN response in PBMC from children and adolescent after SARS-CoV-2 infection**  
*L. Sorrentino<sup>1</sup>, M.G. Conti<sup>2</sup>, G. Oliveto<sup>1</sup>, F. Frasca<sup>1</sup>, M. Fracella, M. Scordio<sup>1</sup>, A. D'Auria, M. Ardone<sup>1</sup>, M. Di Lieto<sup>1</sup>, L. Petrarca<sup>2</sup>, R. Nenna<sup>2</sup>, C. Scagnolari<sup>1</sup>, G. Antonelli<sup>1</sup>, F. Midulla<sup>2</sup>, A. Pierangeli<sup>1</sup>*  
<sup>1</sup>Virology laboratory, molecular medicine department, Sapienza University, Rome, <sup>2</sup>Maternal-Infantile and Urological Science Department, Sapienza University, Rome
- OP 47** 14.58-15.03 **Immunological profiles of SARS-CoV-2 infection: the link between cytokine storm, clinical severity and post-COVID syndrome**  
*A. Parente<sup>2</sup>, M. Iuliano<sup>1</sup>, R. Mongiovi<sup>1</sup>, B. Kertusha<sup>2</sup>, A. Carraro<sup>2</sup>, R. Marocco<sup>2</sup>, G. Mancarella<sup>2</sup>, C. Del Borgo<sup>2</sup>, T. Tieghi<sup>2</sup>, L. Fondaco<sup>2</sup>, G. Mangino<sup>1</sup>, G. Romeo<sup>1</sup>, M. Lichtner<sup>2</sup>*  
<sup>1</sup>Dept. of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Italy, <sup>2</sup>Dept. of Public Health and Infectious Disease, S. Maria Goretti Hospital, Sapienza University of Rome, Latina, Italy
- OP 48** 15.05-15.10 **Respiratory and peripheral IFN response and frequency of T cell activation in COVID-19 patients**  
*L. Santinelli<sup>1</sup>, L. Maddaloni<sup>1</sup>, F. Frasca<sup>2</sup>, M. Scordio<sup>2</sup>, C.M. Lofaro<sup>1</sup>, L. Sorrentino<sup>2</sup>, M. Fracella<sup>2</sup>, E.N. Cavallari<sup>1</sup>, G. Ceccarelli<sup>1</sup>, A. Pierangeli<sup>2</sup>, C.M. Mastroianni<sup>1</sup>, G. Antonelli<sup>2,3</sup>, C. Scagnolari<sup>2</sup>, G. d'Ettore<sup>1</sup>*  
<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy, <sup>2</sup>Virology Laboratory, Department of Molecular Medicine, Sapienza University of Rome, Italy, <sup>3</sup>Microbiology and Virology Unit, Sapienza University Hospital "Policlinico Umberto I", Rome, Italy



ORAL POSTER 14.30-15.20

BERGAMO SCIENCE CENTER

## Issues on mental health, sexual health and STIs

Chairs: R. Galipò (Roma), D. Ripamonti (Bergamo)

- OP 49** 14.30-14.35 **Predictors of mental and sexual health after COVID-19 Pandemic in a group of MSM living with HIV**  
*F.M. Nimbi<sup>1</sup>, G.M. Corbelli<sup>2</sup>, G. Giovanardi<sup>1</sup>, A. Tanzilli<sup>1</sup>, V. Lingardi<sup>1</sup>*  
<sup>1</sup>Dept. Dynamic, Clinical and Health Psychology, Sapienza University of Rome, <sup>2</sup>Plus Roma – APS, Rome
- OP 50** 14.37-14.42 **Single nucleotide polymorphisms affecting neuroinflammation biomarkers in different clinical groups of HIV-affected patients**  
*J. Cusato<sup>1</sup>, M. Antonucci<sup>1</sup>, A. Palermi<sup>1</sup>, A. Manca<sup>1</sup>, J. Mula<sup>1</sup>, V. Avataneo<sup>1</sup>, M. Trunfio<sup>2</sup>, G. Di Perri<sup>2</sup>, A. D'Avolio<sup>1</sup>, A. Calcagno<sup>2</sup>*  
<sup>1</sup>Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy, <sup>2</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy
- OP 51** 14.44-14.49 **Treatment response in syphilis reinfection among People living with HIV: high baseline titer and delayed assessment affects the risk of serological-non-response**  
*G. Tiecco, V. Marchese, S. Storti, M. Degli Antoni, M. Gulletta, F. Viola, E. Focà, F. Castelli, E. Quiros-Roldan*  
 Division of Infectious and Tropical Diseases, ASST Spedali Civili di Brescia, Brescia, Italy; Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
- OP 52** 14.51-14.56 **Increasing incidence of Mycoplasma genitalium infection in PLWHIV and PrEP users**  
*R. Rossotti<sup>1</sup>, A. Nava<sup>2</sup>, C. Baiguera<sup>1</sup>, F. D'Amico<sup>1</sup>, E. Inglese<sup>2</sup>, C. Rogati<sup>1</sup>, D. Fanti<sup>1</sup>, N.B. Bana<sup>1</sup>, C. Vismara<sup>2</sup>, M. Puoti<sup>1</sup>*  
<sup>1</sup>Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, <sup>2</sup>Chemical-Clinical and Microbiological Analyses, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
- OP 53** 14.58-15.03 **Alteration of IFN pathways in anal cells from HIV-1/HPV co-infected men**  
*M. Fracella<sup>1</sup>, M. Scordio<sup>1</sup>, L. Sorrentino<sup>1</sup>, F. Frasca<sup>1</sup>, G. Oliveto<sup>1</sup>, A. Viscido<sup>1</sup>, L. Santinelli<sup>2</sup>, E.N. Cavallari<sup>2</sup>, G. D'Ettore<sup>2</sup>, P. Gozzo<sup>2</sup>, G. Antonelli<sup>1</sup>, C. Scagnolari<sup>1</sup>, A. Pierangeli<sup>1</sup>*  
<sup>1</sup>Department of Molecular Medicine, Virology Laboratory, Sapienza University of Rome, Rome, <sup>2</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome
- OP 54** 15.05-15.10 **Efficacy of late HPV vaccination in young HIV+ MSM**  
*E. Cavallari<sup>1</sup>, L. Santinelli<sup>1</sup>, L. Maddaloni<sup>1</sup>, M. Ridolfi<sup>1</sup>, M. Scordio<sup>2</sup>, A. Pierangeli<sup>2</sup>, G. Ceccarelli<sup>1</sup>, C.M. Mastroianni<sup>1</sup>, G. d'Ettore<sup>1</sup>*  
<sup>1</sup>Department of Public Health and Infectious Diseases "Sapienza" University of Rome, Rome, <sup>2</sup>Department of Molecular Medicine "Sapienza" University of Rome, Rome





**SYMPOSIUM** 15.35-16.35

**At the edge of PrEP**

**AUDITORIUM SALA OGGIONI**

Chairs: D. Calzavara (Milano), S. Mattioli (Bologna)

The efficacy of PrEP as an HIV prevention tool is universally recognized. However, most literature data demonstrating PrEP efficacy and effectiveness come from studies on MSM. Some aspects of PrEP still need to be defined in order to understand its effectiveness and maximize its implementation. In this symposium we want to explore some aspects that still represent gray areas with regard to PrEP, in particular the effectiveness and efficacy in populations less represented in clinical trials, such as women, transgender population, IVDU population, etc., with an eye both to real world experiences in these populations and to regulatory aspects of use, or how PrEP can fit within protocols of vaccine prevention.

- |             |   |                        |
|-------------|---|------------------------|
| 15.35-15.45 | <b>Populations not represented in clinical trials: regulatory aspects</b>       | W. Nutland, London UK  |
| 15.45-15.55 | <b>Populations not represented in clinical trials: experiences on the field</b> | M. Appenroth, Berlin D |
| 15.55-16.10 | <b>Ethicality of PrEP in vaccine protocols and beyond</b>                       | G.M. Corbelli, Bologna |
| 16.10-16.25 | <b>Cost-efficacy of PrEP</b>  | E. Girardi, Roma       |
| 16.25-16.35 | <b>Discussion on Symposium issues</b>   |                        |



**ORAL COMMUNICATIONS** 15.35-16.35

**Pathogenesis and Immunology**

**SALA STUCCHI**

Chairs: C. Agrati (Roma), G. Marchetti (Milano)

- OC 17 15.35-15.45 Impact of SARS-CoV-2 infection in a relevant three-dimensional human bronchial cell culture model of Cystic Fibrosis**  
*L. Pagani<sup>1</sup>, L. JV. Galiotta<sup>2</sup>, N. Pedemonte<sup>3</sup>, V. Capurro<sup>3</sup>, A. Venturini<sup>2</sup>, C. Cigana<sup>4</sup>, B. A. Franco<sup>4</sup>, A. Bragonzi<sup>4</sup>, E. Vicenzi<sup>1</sup>*  
<sup>1</sup>Viral Pathogenesis and Biosafety Unit, IRCCS-Ospedale San Raffaele, Milan, Italy, <sup>2</sup>Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, NA, Italy, <sup>3</sup>UOC Genetica Medica, IRCCS Istituto Giannina Gaslini, Genova, Italy, <sup>4</sup>Infections and Cystic Fibrosis Unit, IRCCS-Ospedale San Raffaele, Milan, Italy
- OC 18 15.47-15.57 Oral immunity characterization in saliva from asymptomatic and severe COVID19 patients**  
*L. Saulle<sup>1,2</sup>, M. Garziano<sup>1,2</sup>, O. Utyro<sup>2</sup>, S. Lo Caputo<sup>3</sup>, M. Polisenò<sup>3</sup>, T.A. Santantonio<sup>3</sup>, M. Clerici<sup>1,4</sup>, M. Biasin<sup>2</sup>*  
<sup>1</sup>Laboratory of Immunology, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, <sup>2</sup>Laboratory of Immunobiology, Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Milan, Italy, <sup>3</sup>Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy, <sup>4</sup>Don C. Gnocchi Foundation, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Foundation, Milan, Italy
- OC 19 15.59-16.09 Therapeutic monoclonal antibody treatment restores immune homeostasis and did not prevent the expansion of anti-SARS-CoV-2 adaptive immune response in mild/moderate COVID-19 patients**  
*R. Casetti<sup>1</sup>, A. Sacchi<sup>1</sup>, V. Mazzotta<sup>2</sup>, F. Cristofanelli<sup>1</sup>, E. Cimini<sup>1</sup>, S. Notari<sup>1</sup>, G. Grassi<sup>1</sup>, V. Bordoni<sup>1</sup>, I. Mastroiosa<sup>2</sup>, M.L. Giancola<sup>2</sup>, A. Vergori<sup>2</sup>, M. Tempestilli<sup>1</sup>, S. Vita<sup>2</sup>, M. Rubino<sup>1</sup>, D. Mariotti<sup>1</sup>, S. Gili<sup>1</sup>, E. Lalle<sup>3</sup>, S. Meschi<sup>3</sup>, F. Colavita<sup>3</sup>, A.R. Garbuglia<sup>3</sup>, E. Girardi<sup>4</sup>, E. Nicastri<sup>2</sup>, A. Antinori<sup>2</sup>, C. Agrati<sup>1</sup>*  
<sup>1</sup>Cellular Immunology and Pharmacology Laboratory, INMI L Spallanzani, Rome, Italy, <sup>2</sup>Clinical Department, INMI L Spallanzani, Rome, Italy, <sup>3</sup>Virology Laboratory, INMI L Spallanzani, Rome, Italy, <sup>4</sup>Scientific Directorate, INMI L Spallanzani, Rome, Italy
- OC 20 16.11-16.21 Evidence of extensive transcriptionally active HBV integrations involving genetic regions crucial for cell proliferation in the early phases of chronic infection even in the setting of limited liver damage**  
*S. D'Anna<sup>1</sup>, L. Carioti<sup>1</sup>, L. Piermatteo<sup>1</sup>, A. Battisti<sup>1,2</sup>, L. Benedetti<sup>1</sup>, F. Ceccherini-Silberstein<sup>1</sup>, U.S. Gill<sup>2</sup>, P.T.F. Kennedy<sup>2</sup>, V. Svicher<sup>1</sup>, R. Salpini<sup>1</sup>*  
<sup>1</sup>University of Rome Tor Vergata, Department of Experimental Medicine, Rome, <sup>2</sup>Barts Liver Centre, Blizard Institute, Barts and The London SMD, QMUL, London





**INTERACTIVE EXPERT MEETING** 15.35-16.35

**ALABASTRO A**

**Affairs of the heart in HIV: redundant or a key challenge?**

Moderator: C. Gervasoni (Milano)

Con la sponsorizzazione non condizionante di MSD Italia

Discussants: A. Cattelan (Padova), R. Gagliardini (Roma), A. Saracino (Bari)

PLWH may be predisposed to higher risk of Cardiometabolic Disorders such as dyslipidemia, cardiovascular disease and diabetes. In fact, metabolic syndrome affects up to 52% of PLWH. In this interactive round table, innovative individualized treatment strategies for the management of PLWH at risk or with cardiometabolic disorders will be discussed.



**ORAL POSTER** 15.35-16.25

**ALABASTRO B**

**Neuropsychological complications in COVID-19**

Chairs: V. Spagnuolo (Milano), A. Vergori (Roma)

**OP 55 15.35-15.40 Dementia and COVID-19 outcomes: findings from a multicentric study in Campania region**

R. Astorri<sup>1</sup>, M. Pisaturo<sup>1</sup>, A. Russo<sup>1</sup>, P. Maggi<sup>2</sup>, F.G. Numis<sup>3</sup>, I. Gentile<sup>4</sup>, V. Sangiovanni<sup>5</sup>, V. Esposito<sup>6</sup>, R. Punzi<sup>7</sup>, G. Calabria<sup>8</sup>, C. Rescigno<sup>9</sup>, A. Salomone Megna<sup>10</sup>, A. Masullo<sup>11</sup>, E. Manzillo<sup>12</sup>, G. Russo<sup>13</sup>, R. Parrella<sup>14</sup>, G. Dell'Aquila<sup>15</sup>, M. Gambardella<sup>16</sup>, A. Ponticello<sup>17</sup>, N. Coppola<sup>1</sup> on behalf of CoviCam group

<sup>1</sup>Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania "L. Vanvitelli", Napoli, Italy, <sup>2</sup>Infectious Diseases Unit, A.O. S Anna e S Sebastiano Caserta, Italy, <sup>3</sup>Emergency unit, PO Santa Maria delle Grazie, Pozzuoli, Italy, <sup>4</sup>Infectious disease unit; University Federico II, Naples, Italy, <sup>5</sup>Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, <sup>6</sup>IV Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>7</sup>Hepatic Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>8</sup>IX Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>9</sup>First Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>10</sup>Infectious Disease Unit, A.O. San Pio, PO Rummo, Benevento, Italy, <sup>11</sup>Infectious disease unit, A.O. San Giovanni di Dio e Ruggi D'Aragona Salerno, Italy, <sup>12</sup>VIII Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>13</sup>Infectious Disease Unit, Ospedale Maria S.S. Addolorata di Eboli, ASL Salerno, Italy, <sup>14</sup>Respiratory Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>15</sup>Infectious Diseases Unit, AO Avellino, Italy, <sup>16</sup>Infectious Disease Unit, PO S. Luca, Vallo della Lucania, ASL Salerno, Italy, <sup>17</sup>Pneumology Unit, AORN Caserta, Italy

**OP 56 15.42-15.47 COVID-19 neurocognitive impairment (COVID-19-NCI): an attempt for definition and clinical assessment**

G. Del Duca, A.C. Brita, I. Mastroiosa, A. Vergori, S. Lanini, M. Camici, M. Annalisa, C. Caligiuri, C. Pinnetti, A. Antinori  
Lazzaro Spallanzani National Institute for Infectious Diseases, Rome, Italy

**OP 57 15.49-15.54 Neuropsychological performance (NP) following COVID-19: prevalence and predictors**

A. Vergori<sup>1</sup>, G. Del Duca<sup>1</sup>, S. Lanini<sup>1</sup>, A.C. Brita<sup>2</sup>, C. Pinnetti<sup>1</sup>, I. Mastroiosa<sup>1</sup>, M. Camici<sup>1</sup>, A. Mondì<sup>1</sup>, V. Mazzotta<sup>1</sup>, P. Chinello<sup>1</sup>, P. Mencarini<sup>1</sup>, M.L. Giancola<sup>1</sup>, A. Abdeddaim<sup>1</sup>, E. Girardi<sup>3</sup>, F. Vaia<sup>4</sup>, A. Antinori<sup>1,5</sup>

<sup>1</sup>Clinical Department, National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy, <sup>2</sup>Psychology Unit, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, <sup>3</sup>Scientific Direction, National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy, <sup>4</sup>General Direction, National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy, <sup>5</sup>Health Direction, National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy

**OP 58 15.56-16.01 Is plasma neurofilament light chain measurement relevant in long-COVID?**

M.A. Zingaropoli<sup>1</sup>, P. Pasculli<sup>1</sup>, T. Latronico<sup>2</sup>, F. Dominelli<sup>1</sup>, M. Guardiani<sup>1</sup>, E. Tortellini<sup>1</sup>, G. Saracino<sup>2</sup>, G.M. Liuzzi<sup>2</sup>, M. Lichtner<sup>1,3</sup>, C.M. Mastroianni<sup>1</sup>, M.R. Ciardi<sup>1</sup>

<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza, University of Rome, <sup>2</sup>Department of Biosciences, Biotechnology and Biopharmaceutics, Aldo Moro, University of Bari, <sup>3</sup>Infectious Diseases Unit, SM Goretti Hospital, Latina, Sapienza, University of Rome

**OP 59 16.03-16.08 SARS-CoV-2 hampers Dopamine production in iPS-derived dopaminergic neurons**

G. Cappelletti<sup>1</sup>, E.M. Carsana<sup>2</sup>, G. Lunghi<sup>2</sup>, S. Breviario<sup>2</sup>, C. Vanetti<sup>1</sup>, A. Barnaba Di Fonzo<sup>3</sup>, M. Clerici<sup>3</sup>, M. Aureli<sup>2</sup>, C. Fenizia<sup>3</sup>

<sup>1</sup>Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, <sup>2</sup>Department of Medical Biotechnologies and Translational Medicine, University of Milan, Milan, Italy, <sup>3</sup>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

**OP 60 16.10-16.15 Early phase approach in SARS CoV-2 infection: a single center one-year real life experience**

D. Di Trento<sup>1</sup>, S. Garattini<sup>1</sup>, M. De Masi<sup>2</sup>, A. Gasperin<sup>1</sup>, A. Grimaldi<sup>1</sup>, S.G. De Maria<sup>1</sup>, S. Corazza<sup>1</sup>, S. Gismondi<sup>2</sup>, B. Bartolozzi<sup>2</sup>, D. Caianiello<sup>3</sup>, S. De Filippis<sup>1</sup>, B. Kertusha<sup>2</sup>, A. Carraro<sup>2</sup>, O. D'Onofrio<sup>2</sup>, G. Bagagnini<sup>1</sup>, G. Bonanni<sup>1</sup>, D. Alunni Fegatelli<sup>5</sup>, A. Spagnoli<sup>5</sup>, S. Di Somma<sup>6</sup>, C. Del Borgo<sup>2</sup>, M. Lichtner<sup>1</sup>

<sup>1</sup>Department of Public Health and Infectious Disease, "Sapienza University of Rome", <sup>2</sup>Infectious Disease Unit, SM Goretti Hospital Latina, <sup>3</sup>General practitioner, AUSL Latina, <sup>4</sup>Pharmacy Service Unit, SM Goretti Hospital Latina, <sup>5</sup>Statistic Department, "Sapienza University of Rome", <sup>6</sup>Department of Medical-Surgical Sciences and Translational Medicine, "Sapienza University of Rome"





ORAL POSTER 15.35-16.25

BERGAMO SCIENCE CENTER

## New issues on dual therapy

Chairs: M. De Gennaro (Lucca), S. Nozza (Milano)

### OP 61 15.35-15.40 Efficacy and Durability of Dual Antiretroviral Regimens as switch therapy in treatment-experienced People Living with HIV (PLWH): data from the ARCA cohort

M. Polisenò<sup>1</sup>, A. Borghetti<sup>2</sup>, F. Conti<sup>3</sup>, G. Di Teodoro<sup>4,5</sup>, F. Lombardi<sup>6</sup>, L. Montemurro<sup>1</sup>, L. Pezzati<sup>3</sup>, A. Shallvari<sup>5,7</sup>, A. Bezenchek<sup>5,7</sup>, V. Borghi<sup>8</sup>, S. Rusconi<sup>3,9</sup>

<sup>1</sup>U.O. Malattie Infettive Universitaria, University of Foggia, Foggia, Italy, <sup>2</sup>Policlinico Gemelli, Roma, Italy, <sup>3</sup>Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milano, Italy, <sup>4</sup>Dipartimento di Ingegneria informatica automatica e gestionale A. Ruberti, Sapienza Università di Roma, Roma, Italy, <sup>5</sup>EuResist Network GEIE, Roma, Italy, <sup>6</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Malattie Infettive, Roma, Italy, <sup>7</sup>InformaPRO SRL, Roma, Italy, <sup>8</sup>Clinica Malattie Infettive, Azienda Ospedaliero Universitaria di Modena, Modena, Italy, <sup>9</sup>OC Malattie Infettive, ASST Ovest Milanese, Ospedale di Legnano, Milano, Italy

### OP 62 15.42-15.47 Characterization of virologically suppressed HIV infected individuals potential eligible to the long-acting combination of cabotegravir plus rilpivirine: results from the Italian ARCA cohort

A. Cervo<sup>1</sup>, A. Russo<sup>2</sup>, D. Di Carlo<sup>3</sup>, A. De Vito<sup>4</sup>, L. Fabeni<sup>5</sup>, S. D'Anna<sup>6</sup>, L. Duca<sup>6</sup>, A. Colpani<sup>4</sup>, M. Fois<sup>4</sup>, B. Zauli<sup>4</sup>, G. Mancarella<sup>7</sup>, A. Carraro<sup>7</sup>, A. Bezenchek<sup>8</sup>, A. Cozzi-Lepri<sup>9</sup>, M.M. Santoro<sup>6</sup>

<sup>1</sup>Infectious Diseases Clinic, University Hospital of Modena, Italy, <sup>2</sup>Infectious Diseases Unit, Department of Mental Health, University of Campania "Luigi Vanvitelli", Naples, Italy, <sup>3</sup>Pediatric Clinical Research Center "Romeo and Enrica Invernizzi", Department of Biomedical and Clinical Sciences "L. Sacco" University of Milan, Italy, <sup>4</sup>Unit of Infectious Diseases, Department of Medical, Surgical, and Experimental Sciences, University of Sassari, Sassari, Italy, <sup>5</sup>National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, <sup>6</sup>University of Rome "Tor Vergata", Rome, Italy, <sup>7</sup>Infectious Disease Unit, Sapienza University of Rome - Polo Pontino, Latina, Italy, <sup>8</sup>InformaPRO SRL, Rome, Italy; EuResist Network GEIE, Rome, Italy, <sup>9</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, London, UK

### OP 63 15.49-15.54 Long acting cabotegravir plus rilpivirine compassionate use program: a narrative description of the Italian experience

R. Rossotti<sup>1</sup>, G. Orofino<sup>2</sup>, B. Canovari<sup>3</sup>, R. Viglietti<sup>4</sup>, F. D'Amico<sup>1</sup>, N.B. Bana<sup>1</sup>, L. Carani<sup>2</sup>, M.C. Moiola<sup>1</sup>, F. Barchiesi<sup>3</sup>, M. Puoti<sup>1,5</sup>

<sup>1</sup>Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, <sup>2</sup>Unit of Infectious Diseases, "Divisione A," Amedeo di Savoia Hospital, Turin, <sup>3</sup>Unit of Infectious Diseases, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, <sup>4</sup>UOC Infezioni Sistemiche e dell'Immunodepresso, AORN Ospedali dei Colli, PO D. Cotugno, Naples, <sup>5</sup>School of Medicine, University of Milano Bicocca, Milan

### OP 64 15.56-16.01 Immunological recovery in PLWHIV starting dolutegravir plus lamivudine as first-line regimen: data from the ODOACRE cohort

A. Ciccullo<sup>1</sup>, A. Dusina<sup>2</sup>, A. Borghetti<sup>2</sup>, M.V. Cossu<sup>3</sup>, D. Farinacci<sup>4</sup>, F. Lamanna<sup>4</sup>, R.A. Passerotto<sup>4</sup>, F. Lombardi<sup>4</sup>, A. Capetti<sup>3</sup>, G. Baldin<sup>2,5</sup>, S. Di Giambenedetto<sup>2,4</sup>

<sup>1</sup>UOC Malattie Infettive, Ospedale San Salvatore, L'Aquila, Italia, <sup>2</sup>UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia, <sup>3</sup>Division of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy, <sup>4</sup>Università Cattolica del Sacro Cuore, Roma, Italia, <sup>5</sup>Ospedale Mater Olbia, Olbia, Italia

### OP 65 16.03-16.08 Comparison of efficacy and tolerability of Dolutegravir / Rilpivirine and Dolutegravir / Lamivudine in experienced HIV-1 positive patients switched from a three-drug regimen based on Non-Nucleoside Reverse Transcriptase Inhibitors: a multicenter cohort study in Italy

F. Lagi<sup>1</sup>, A. Giacomelli<sup>2</sup>, V. Borghi<sup>3</sup>, A. Ciccullo<sup>4</sup>, L. Taramasso<sup>5</sup>, G. Madeddu<sup>6</sup>, G. D'Ettore<sup>7</sup>, A. Giacometti<sup>8</sup>, F. Ducci<sup>9</sup>, A. De Vito<sup>6</sup>, R. Pincino<sup>10</sup>, S. Di Giambenedetto<sup>4</sup>, C. Mussini<sup>3</sup>, S. Antinori<sup>2</sup>, G. Sterrantino<sup>9</sup>

<sup>1</sup>Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy, <sup>2</sup>Luigi Sacco Department of Biomedical and Clinical Sciences, University of Milan, Italy; Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milan, Italy, <sup>3</sup>Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy, <sup>4</sup>UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, <sup>5</sup>Infectious Diseases Unit, Ospedale Policlinico San Martino - IRCCS, Genoa, Italy, <sup>6</sup>Infectious Diseases Operative Unit, University Hospital of Sassari, Sassari, Italy, <sup>7</sup>Department of Public Health and Infectious Diseases, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy, <sup>8</sup>Institute of Infectious Diseases and Public Health, Università Politecnica delle Marche, Ancona, Ancona, Italy, <sup>9</sup>Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, <sup>10</sup>Infectious Diseases Unit, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy

### OP 66 16.10-16.15 Comparing the efficacy and tolerability of dolutegravir plus rilpivirine versus dolutegravir plus lamivudine in a multicenter cohort

A. Ciccullo<sup>1</sup>, G. Baldin<sup>2,3</sup>, M.V. Cossu<sup>3</sup>, A. Giacomelli<sup>4</sup>, F. Lagi<sup>5</sup>, F. Lamanna<sup>6</sup>, D. Farinacci<sup>6</sup>, V. Iannone<sup>6</sup>, R.A. Passerotto<sup>6</sup>, A. Capetti<sup>3</sup>, G. Sterrantino<sup>5</sup>, S. Antinori<sup>4</sup>, S. Di Giambenedetto<sup>2,6</sup>

<sup>1</sup>UOC Malattie Infettive, Ospedale San Salvatore, L'Aquila, Italia, <sup>2</sup>UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy, <sup>3</sup>Division of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy, <sup>4</sup>UOC Malattie Infettive III, DIBIC Luigi Sacco, University of Milan, Milano, Italy, <sup>5</sup>Division of Tropical and Infectious Diseases, "Careggi" Hospital, Florence, Italy, <sup>6</sup>Catholic University of the Sacred Heart, Rome, Italy




**SYMPOSIUM** 16.40-17.40

**AUDITORIUM SALA OGGIONI**

## Monoclonal antibodies and antiviral agents in COVID-19: rational for use and best candidates

Chairs: A. Antinori (Roma), M. Zazzi (Siena)

The development of therapeutic monoclonal antibodies and direct antiviral agents is currently at the front line of fighting against the COVID-19 pandemic. However, the emergence of SARS-CoV-2 variants, as BA.1 and BA.2 lineages, inducing escape from most of monoclonal antibodies represents a great challenge. Furthermore, as additional variants of concern will likely continue to emerge, there is a high unmet medical need for therapeutics that, alone or in combination, can remain effective as the virus evolves. The Symposium will present the state of the art of virological, clinical and immunological research against COVID-19 with a look at the promising clinical data emerging from the use of monoclonal antibodies and the most recent clinical experiences in the field.

- 16.40-16.55 **Neutralizing antibodies overcome SARS-CoV-2 BA.1 and BA.2 antigenic shift** D. Corti, Bellinzona CH
- 16.55-17.10 **Evolving clinical use and real-life strategies for early treatment of not-hospitalized COVID-19 patients** V. Mazzotta, Roma
- 17.10-17.25 **Could monoclonal antibodies early exposure antagonize anomalies of innate and adaptive immune response in COVID-19?** A. Bandera, Milano
- 17.25-17.40 **Discussion on Symposium issues**


**ORAL COMMUNICATIONS** 16.40-17.40

**SALA STUCCHI**

## From HIV to SARS-CoV-2

Chairs: A. Callegaro (Bergamo), F. Maggi (Varese)

- OC 21 16.40-16.50 Intact proviral DNA and chromosome integration sites in peripheral blood lympho-monocytes of early treated acute HIV infections**  
G. Rozera<sup>1</sup>, G. Sberna<sup>1</sup>, G. Berno<sup>1</sup>, C. Gruber<sup>1</sup>, N. Orchi<sup>2</sup>, V. Puro<sup>2</sup>, A. Mondì<sup>3</sup>, A. Antinori<sup>3</sup>, L. Abbate<sup>1</sup>  
<sup>1</sup>Virology Unit, <sup>2</sup>AIDS Referral Center, <sup>3</sup>HIV/AIDS Clinical Department of the National Institute for Infectious Diseases I.R.C.C.S. L. Spallanzani, Rome, Italy
- OC 22 16.52-17.02 Plasma, Intracellular and Lymph node Antiretroviral Concentrations and HIV DNA Change in Patients Treated During Primary HIV Infection: Results from the INACTION P25 Study**  
A. De Nicolò<sup>1</sup>, E. De Vivo<sup>1</sup>, S. Dispinseri<sup>2</sup>, G. Marchetti<sup>3</sup>, M. Trunfio<sup>4</sup>, A. Ianniello<sup>1</sup>, A. D'Avolio<sup>1</sup>, A. Muscatello<sup>5</sup>, A. Gori<sup>5</sup>, S. Rusconi<sup>6,7</sup>, E. Bruzzeri<sup>8</sup>, A. Gabrieli<sup>9</sup>, D.P. Bernasconi<sup>10</sup>, S. Nozza<sup>11</sup>, A. Calcagno<sup>4</sup> on behalf of the INACTION (Italian Network of Acute HIV Infection) study group  
<sup>1</sup>Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Turin, <sup>2</sup>Viral Evolution and Transmission Unit, IRCCS Ospedale San Raffaele, Milan, <sup>3</sup>Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, <sup>4</sup>Unif of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, <sup>5</sup>Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, <sup>6</sup>UOC Malattie Infettive, Ospedale Civile di Legnano, ASST Ovest Milanese, Legnano, <sup>7</sup>University of Milan, Milan, <sup>8</sup>Vita-Saluta San Raffaele University, Milan, <sup>9</sup>Dipartimento di Scienze Biomediche e Cliniche, Ospedale L Sacco, Milan, <sup>10</sup>Bicocca Bioinformatics Biostatistics and Bioimaging Centre - B4 School of Medicine and Surgery, University of Milano-Bicocca, Monza, <sup>11</sup>Department of Infectious Diseases, IRCCS Ospedale san Raffaele, Milan, Italy
- OC 23 17.04-17.14 Efficacy, tolerability and pharmacokinetics of doravirine in the clinical setting**  
S. Fantino<sup>1</sup>, M. Ferrara<sup>1</sup>, G. Trevisan<sup>1</sup>, G. Accardo<sup>1</sup>, F. Alladio<sup>1</sup>, E. Drappero<sup>1</sup>, S. Biffi<sup>1</sup>, A. Serra<sup>1</sup>, L. Trentini<sup>1</sup>, M. Tettoni<sup>1</sup>, E. De Vivo<sup>2</sup>, A. Ianniello<sup>2</sup>, J. Mula<sup>2</sup>, A. De Nicolò<sup>2</sup>, A. D'Avolio<sup>2</sup>, A. Calcagno<sup>1</sup>, G. Di Perri<sup>1</sup>, S. Bonora<sup>1</sup>  
<sup>1</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, <sup>2</sup>Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Torino, Torino
- OC 24 17.16-17.26 Are Minions useful in the lab workflow? Comparison between long and short sequencing in COVID-19 surveillance**  
B. Bruzzone<sup>1</sup>, V. Ricucci<sup>1</sup>, V. De Pace<sup>1</sup>, F. Stefanelli<sup>1</sup>, N. Randazzo<sup>1</sup>, G. Garzillo<sup>2</sup>, M. Cavaletti<sup>3</sup>, S. Casali<sup>3</sup>, M. Rossi<sup>3</sup>, A. Domnich<sup>1</sup>, C. Trombetta<sup>2</sup>, A. Orsi<sup>1,2</sup>, G. Icardi<sup>1,2</sup>  
<sup>1</sup>Hygiene Unit, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, Genoa, Italy, <sup>2</sup>Department of Health Science, Genoa University, Genoa, Italy, <sup>3</sup>4bases Italia srl, Campospinoso, Pavia, Italy



**OC 25** 17.28-17.38 **In vitro activity of molnupiravir in combination with GC-376 or PF-07321332 against SARS-CoV-2**

A. Gidari<sup>1</sup>, S. Bastianelli<sup>1</sup>, S. Pierucci<sup>1</sup>, C. Busti<sup>1</sup>, S. Sabbatini<sup>2</sup>, G. Genga<sup>1</sup>, E. Svizzeretto<sup>1</sup>, A. Tommasi<sup>1</sup>, E. Schiaroli<sup>1</sup>, D. Francisci<sup>1</sup>

<sup>1</sup>Department of Medicine and Surgery, Clinic of Infectious Diseases, "Santa Maria della Misericordia" Hospital, University of Perugia, Perugia, Italy, <sup>2</sup>Department of Medicine and Surgery, Medical Microbiology Section, University of Perugia, Perugia, Italy



**EXPERT MEETING** 16.40-17.40

**ALABASTRO A**

**Evolving models of care in the management of Gram+ infectious diseases: the role of long-acting antibiotic therapies**

Chairs: F. De Iaco (Torino), C.M. Mastroianni (Roma)

The increase of multidrug resistance among Gram-positive pathogens, particularly among staphylococci and enterococci, represents a major health care problem, since it results in significant morbidity, mortality, and health care costs. The emergence of such resistant bacterial strains highlights the need to optimize treatment approaches. In this view, novel lipoglycopeptides endowed with long-term activity allowing single-shot administration would be extremely useful and may represent an attractive therapeutic option alternative for early hospital discharge, a cost-saving and a resource-saving approach. Furthermore, long-term intravenous antibiotic therapy poses a particular challenge, specially in this ongoing pandemic situation, for treating patients classified as vulnerable or at high risk for complications, such as PWID (persons who inject drugs) or those lacking social support, including frail elderly and/or those who are homeless or with an underlying psychiatric illness. This approach may offer improved quality of life for patients, considering benefits, such as no need for a central line for daily infusions, fast hospital discharge, and less need for laboratory monitoring.

16.40-16.45	<b>Introduction</b>	C.M. Mastroianni, Roma
16.45-17.05	<b>Bacterial Infections in difficult-to-treat patients</b>	A.M. Cattelan, Padova
17.05-17.25	<b>Interaction between emergency medicine and infectious disease</b>	S. Di Maggio, Padova
17.25-17.35	<b>Questions &amp; Answers</b>	F. De Iaco, Torino; C.M. Mastroianni, Roma
17.35-17.40	<b>Final considerations and take-home messages</b>	F. De Iaco, Torino



**ORAL POSTER** 16.40-17.30

**ALABASTRO B**

**Cardiovascular diseases, osteoporosis but not only**

Chairs: L. Calza (Bologna), G. Mazzola (Caltanissetta)

**OP 67** 16.40-16.45 **Weight gain in people living with HIV under antiretroviral therapy: do our strategies make a difference?**

C. Muccini<sup>1,2</sup>, D. Ceccarelli<sup>1</sup>, R. Lolatto<sup>1</sup>, V. Spagnuolo<sup>1</sup>, C. Oltolini<sup>1</sup>, A. Danise<sup>1</sup>, I. Mainardi<sup>1,2</sup>, R. Monardo<sup>1,2</sup>, A. Castagna<sup>1,2</sup>

<sup>1</sup>Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>2</sup>Vita-Salute San Raffaele University, Milan, Italy

**OP 68** 16.47-16.52 **PLWH (People Living With HIV): a single centre retrospective observational study on cardiovascular risk factors**

G. Gasparro<sup>1</sup>, B. Rossetti<sup>2</sup>, M. Ruggeri<sup>1,3</sup>, M. Tumbarello<sup>4,5</sup>

<sup>1</sup>Corso Formazione Specifica in Medicina Generale AOU Meyer/Formas, Regione Toscana, Firenze, Italy, <sup>2</sup>Infectious Disease Department, USL SUDEST, Toscana, Misericordia Hospital, Grosseto, Italy, <sup>3</sup>General Practitioner, Società Italiana di Medicina Generale e delle cure primarie, SIMG, Firenze, Italy, <sup>4</sup>Dipartimento di Biotecnologie Mediche, Università degli Studi di Siena, Siena, Italy, <sup>5</sup>UOC Malattie Infettive e Tropicali, Azienda Ospedaliero Universitaria Senese, Siena, Italy

**OP 69** 16.54-16.59 **Relationship between vitamin D deficiency and cardiovascular disease in virologically suppressed HIV-1-infected patients**

L. Calza<sup>1</sup>, V. Colangeli<sup>1</sup>, M. Borderi<sup>1</sup>, R. Riccardi<sup>1</sup>, F. Malerba<sup>1</sup>, I. Bon<sup>2</sup>, P. Viale<sup>1</sup>

<sup>1</sup>Unit of Infectious Diseases, IRCCS S.Orsola Hospital, <sup>2</sup>Unit of Microbiology, IRCCS S.Orsola Hospital, University of Bologna, Bologna, Italy

**OP 70** 17.01-17.06 **Effect of bisphosphonates on vertebral fractures in HIV infected males: a 7-years study**

L. Pezzaoli<sup>1</sup>, T. Porcelli<sup>1</sup>, S. Storti<sup>2</sup>, G. Tiecco<sup>2</sup>, M. degli Antoni<sup>2</sup>, S. Amadasi<sup>2</sup>, F. Castelli<sup>2</sup>, E. Quiros-Roldan<sup>2</sup>

<sup>1</sup>Unit of Endocrinology and Metabolism, Department of Clinical and Experimental Sciences, University of Brescia and ASST Spedali Civili Brescia, Brescia, Italy, <sup>2</sup>Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali di Brescia, Brescia, Italy



- OP 71** 17.08-17.13 **Association between Health Literacy, care engagement and assessment of risk behaviours in an Italian cohort of people living with HIV**  
*V. Massaroni<sup>1</sup>, V. Delle Donne<sup>1</sup>, A. Borghetti<sup>2</sup>, S. Pierluigi<sup>2</sup>, F. Lamanna<sup>2</sup>, D. Farinacci<sup>2</sup>, A. Ciccullo<sup>3</sup>, G. Baldin<sup>4</sup>, S. Di Giambenedetto<sup>1,2</sup>*  
<sup>1</sup>Infectious Diseases Institute, Department of Safety and Bioethics, Catholic University of Sacred Heart, Rome, Italy, <sup>2</sup>UOC Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, <sup>3</sup>UOC Infectious Diseases, Ospedale S. Salvatore, L'Aquila; Italy, <sup>4</sup>Mater Olbia Hospital, Olbia, Italy
- OP 72** 17.15-17.20 **Mental health assessment in people living with HIV/AIDS (PLWHA): preliminary data from a referral HIV center**  
*F. Di Gennaro<sup>1</sup>, D. Montalbò<sup>2</sup>, R. Schiavoni<sup>1</sup>, G.G. Panico<sup>1</sup>, D.F. Bavaro<sup>1</sup>, L. Diella<sup>1</sup>, M. Di Tullio<sup>3</sup>, A. Calluso<sup>3</sup>, C.R. Santoro<sup>1</sup>, G. Brindicci<sup>1</sup>, E. Balena<sup>1</sup>, N. De Gennaro<sup>1</sup>, A. Belati<sup>1</sup>, D. Fiordelisi<sup>1</sup>, M. Sgambati<sup>2</sup>, A. Bertolino<sup>2</sup>, A. Saracino<sup>1</sup>*  
<sup>1</sup>Clinic of Infectious Diseases, Department of Biomedical Sciences and Human Oncology, University of Bari, University of Bari "Aldo Moro", Bari, Italy, <sup>2</sup>Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari "Aldo Moro", Bari, Italy, <sup>3</sup>C.A.M.A. – L.I.L.A, sezione Bari



ORAL POSTER 16.40-17.30

BERGAMO SCIENCE CENTER

**Vulnerable and key population: local experiences**

Chairs: E. Girardi (Roma), A. Moznich (Milano)

- OP 73** 16.40-16.45 **Community-Based Centers (CBCs): sexual health needs and prevention knowledge among MSM in Lazio**  
*G.M. Corbelli<sup>1</sup>, V. Lingardi<sup>2</sup>, F.M. Nimbi<sup>2</sup>*  
<sup>1</sup>Plus Roma – APS, Rome, <sup>2</sup>Dept. of Dynamic, Clinical and Health Psychology, Sapienza University of Rome
- OP 74** 16.47-16.52 **Injecting drug use, irrespective of harm reduction measures, is strongly associated with HCV infection: results of a structured questionnaire administered during HCV screening sessions in low threshold harm reduction services**  
*A. Soria<sup>1</sup>, G. Ghilardi<sup>1</sup>, M. Comolatti<sup>1</sup>, M. Di Gennaro<sup>1</sup>, C. Gaboardi<sup>2</sup>, A. De Pace<sup>3</sup>, P. Di Gloria<sup>2</sup>, C. Bregamo<sup>2</sup>, R. Gallizzi<sup>3</sup>, A. Barni<sup>3</sup>, MG. Marconi<sup>4</sup>, GM. Migliorino<sup>1</sup>, P. Bonfanti<sup>1,5</sup>, G. Lapadula<sup>1,5</sup>*  
<sup>1</sup>Infectious Diseases San Gerardo Hospital ASST Monza, Monza, <sup>2</sup>Cooperativa Lotta Contro l'Emarginazione, Monza, <sup>3</sup>Comunità Nuova, Monza, <sup>4</sup>ATS Brianza, Monza, <sup>5</sup>University of Milano-Bicocca, Monza
- OP 75** 16.54-16.59 **High prevalence of HCV infection among people screened in unconventional low threshold settings: results of an outreach program of screening and linkage to care for people using drugs**  
*A. Soria<sup>1</sup>, G. Lapadula<sup>1,2</sup>, M. Comolatti<sup>1</sup>, M. Di Gennaro<sup>1</sup>, C. Gaboardi<sup>3</sup>, A. De Pace<sup>3</sup>, P. Di Gloria<sup>3</sup>, C. Bregamo<sup>3</sup>, R. Gallizzi<sup>3</sup>, A. Barni<sup>4</sup>, MG. Marconi<sup>5</sup>, G. Scaffidi<sup>6</sup>, M. Bramani-Araldi<sup>6</sup>, A. Caruso<sup>6</sup>, D. Leto<sup>7</sup>, A. Cardia<sup>7</sup>, P. Fortuna<sup>8</sup>, G. Galimberti<sup>8</sup>, S. Torlasco<sup>9</sup>, C. Fanzaga<sup>10</sup>, M. Belloni<sup>10</sup>, E. Chiesa<sup>11</sup>, GM. Migliorino<sup>1</sup>, P. Bonfanti<sup>1,2</sup>*  
<sup>1</sup>Infectious Diseases San Gerardo Hospital ASST Monza, Monza, <sup>2</sup>University of Milano-Bicocca, Monza, <sup>3</sup>Cooperativa Lotta Contro l'Emarginazione, Monza, <sup>4</sup>Comunità Nuova, Monza, <sup>5</sup>ATS Brianza, Monza, <sup>6</sup>SerD Carate-Brianza ASST Brianza, Carate-Brianza, <sup>7</sup>SerD Limbiate ASST Brianza, Limbiate, <sup>8</sup>SerD Monza ASST Monza, Monza, <sup>9</sup>Corpo Italiano Soccorso Ordine di Malta Monza Brianza, Monza, <sup>10</sup>Servizi Sociali Comune di Monza, Monza, <sup>11</sup>Casa Circondariale di Monza, Monza
- OP 76** 17.01-17.06 **Descriptive analysis and retention in care of a cohort of HIV-positive migrants (AMIGO: A HIV-positive MIGRANTS cohort at AOU Careggi)**  
*F. Lagi<sup>1</sup>, S.T. Kiros<sup>1</sup>, M. Turco<sup>3</sup>, B. Borchi<sup>1</sup>, F. Bartalesi<sup>1</sup>, P. Corsi<sup>1</sup>, E. Gotuzzo<sup>4</sup>, G. Sterrantino<sup>2</sup>, A. Bartoloni<sup>1,2</sup>*  
<sup>1</sup>SOD Malattie Infettive e Tropicali, AOU Careggi, <sup>2</sup>Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi Di Firenze, Firenze, <sup>3</sup>Sezione di Dermatologia, Dipartimento di Scienze della Salute, Università degli studi di Firenze, Firenze, <sup>4</sup>Universidad Peruana Cayetano Heredia, Lima, Peru
- OP 77** 17.08-17.13 **A qualitative survey on facilitating factors and barriers to access and continuum of care: point of view of HIV-positive transgender migrant women living in Florence**  
*F. Lagi<sup>1</sup>, C. Gatteschi<sup>2</sup>, M. Tili<sup>3</sup>, N. Zocco<sup>4</sup>, A. Avarello<sup>1</sup>, S. Bellini<sup>5</sup>, S. Contanessi<sup>4</sup>, M.R. Zigliani<sup>5</sup>, M. Stagnitta<sup>4</sup>, L. Mariano<sup>4</sup>, E. Gazzarri<sup>4</sup>, L. Belloni<sup>6</sup>, A. Bartoloni<sup>1,3</sup>, G. Sterrantino<sup>3</sup>, F. Ierardi<sup>2</sup>*  
<sup>1</sup>SOD Malattie Infettive e Tropicali, AOU Careggi, Firenze, <sup>2</sup>Agenzia Regionale di Sanità di Toscana, <sup>3</sup>Dipartimento di medicina Sperimentale e Clinica, Università degli studi di Firenze, Firenze, <sup>4</sup>CAT Cooperativa sociale Firenze, <sup>5</sup>Lega Italiana Lotta all' AIDS, LILA, <sup>6</sup>Centro di riferimento regionale criticità relazionali, AOU Careggi, Firenze







**SYMPOSIUM** 17.45-18.45

**AUDITORIUM SALA OGGIONI**

**Challenges in HIV cure: getting to zero reservoir**

Chairs: F. Ceccherini - Silberstein (Roma), M. Clementi (Milano)

Despite sustained control of HIV replication is now achievable with convenient and well-tolerated antiretroviral treatments, the establishment of a lifelong persistent cellular reservoir precludes the eradication of the infection. Thus, characterizing and quantifying the intact viral reservoir is considered an essential prerequisite for the development and the clinical evaluation of curative strategies. Moreover, viral persistence has been demonstrated in several organs and tissues with the highest amount in lymph nodes, gastrointestinal tract, and central nervous system. Understanding the dynamics of drug penetration in the different cellular reservoirs is vital for increasing the efficacy of both antiretroviral therapy and investigational curative approaches. This symposium aims to show and discuss the recent results and advances in laboratory techniques and pharmacology that might lead to pave the way for the eradication of HIV infection.

- 17.45-18.00 **Characterizing and quantifying the HIV reservoir** F.R. Simonetti, Baltimore USA
- 18.00-18.15 **Pharmacology of the HIV reservoir** A. Calcagno, Torino
- 18.15-18.45 **Round table** Discussants: A. Calcagno, Torino; A. De Maria, Genova; G. Nunnari, Messina; F. Simonetti, Baltimore USA; O. Turriziani, Roma



**ORAL COMMUNICATIONS** 17.45-18.45


**SALA STUCCHI**

**Metabolic alterations: effect of drugs and diseases**

Chairs: V. Borghi (Modena), L. Rancilio (Milano)

- OC 26 17.45-17.55 From NAFLD to MAFLD: implications of change in terminology in PWH**  
L. Gozzi<sup>1</sup>, J. Milic<sup>2</sup>, S. Renzetti<sup>3</sup>, F. Motta<sup>2</sup>, A. Cervo<sup>1</sup>, G. Burastero<sup>1</sup>, V. Iadisernia<sup>1</sup>, B. Lebouche<sup>4</sup>, S. Al Hinai<sup>4</sup>, M. Deschenes<sup>4</sup>, M. Menozzi<sup>1</sup>, P. Raggi<sup>5</sup>, S. Calza<sup>3</sup>, C. Mussini<sup>1,2</sup>, G. Sebastiani<sup>4</sup>, G. Guaraldi<sup>1,2</sup>  
<sup>1</sup>Azienda Ospedaliero - Universitaria, Policlinico of Modena, Modena, Italy, <sup>2</sup>University of Modena and Reggio Emilia, Modena, Italy, <sup>3</sup>University of Brescia, Brescia, Italy, <sup>4</sup>McGill University Health Centre, Montreal, Canada, <sup>5</sup>University of Alberta, Edmonton, Canada
- OC 27 17.57-18.07 The pathway of NAFLD vs MAFLD toward significant fibrosis**  
J. Milic<sup>1</sup>, S. Renzetti<sup>2</sup>, F. Motta<sup>1</sup>, L. Gozzi<sup>3</sup>, G. Besutti<sup>4</sup>, G. Burastero<sup>3</sup>, V. Iadisernia<sup>3</sup>, A. Dessilani<sup>3</sup>, M. Del Monte<sup>3</sup>, M. Faltoni<sup>3</sup>, S. Volpi<sup>3</sup>, B. Lebouche<sup>5</sup>, S. Al Hinai<sup>5</sup>, M. Deschenes<sup>5</sup>, S. Calza<sup>6</sup>, P. Raggi<sup>6</sup>, G. Mancini<sup>3</sup>, C. Mussini<sup>1,2</sup>, G. Sebastiani<sup>4</sup>, G. Guaraldi<sup>1,2</sup>  
<sup>1</sup>University of Modena and Reggio Emilia, Modena, Italy, <sup>2</sup>University of Brescia, Italy, <sup>3</sup>Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy, <sup>4</sup>Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Emilia-Romagna, Italy, <sup>5</sup>McGill University Health Centre, Montreal, Canada, <sup>6</sup>University of Alberta, Edmonton, Canada
- OC 28 18.09-18.19 With or Without TAF? What is the difference? Data from a real-life setting**  
N. Squillace<sup>1</sup>, L. Taramasso<sup>2</sup>, E. Ricci<sup>3</sup>, B. Menzaghi<sup>4</sup>, G. De Socio<sup>5</sup>, G. Orofino<sup>6</sup>, B.M. Celesia<sup>7</sup>, E. Sarchi<sup>8</sup>, C. Molteni<sup>9</sup>, G. Pellicano<sup>10</sup>, F. Conti<sup>11</sup>, F. Vichi<sup>12</sup>, A. Di Biagio<sup>2</sup>, P. Bonfanti<sup>1</sup>, for the CISAI Study Group  
<sup>1</sup>Infectious Diseases Unit ASST-MONZA, San Gerardo Hospital-University of Milano-Bicocca, Monza, <sup>2</sup>Infectious Diseases, San Martino Hospital Genoa, University of Genoa, Genoa <sup>3</sup>Fondazione ASIA Onlus, Buccinasco (MI), <sup>4</sup>Unit of Infectious Diseases, ASST della Valle Olona – Busto Arsizio (VA), <sup>5</sup>Unit of Infectious Diseases, Santa Maria Hospital, Perugia, <sup>6</sup>Division I of Infectious and Tropical Diseases, ASL Città di Torino, <sup>7</sup>Unit of Infectious Diseases, Garibaldi Hospital, Catania, <sup>8</sup>Infectious Diseases Unit, S. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, <sup>9</sup>Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, <sup>10</sup>Infectious Diseases, G. Martino Hospital -University of Messina, Messina, <sup>11</sup>Department of Infectious Diseases, Luigi Sacco Hospital, Milan, Italy, <sup>12</sup>Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence
- OC 29 18.21-18.31 Impact of COVID-19 pandemic on incidence and prevalence of metabolic syndrome in PLWH**  
R. Papaioannu Borjesson<sup>1</sup>, L. Galli<sup>2</sup>, C. Muccini<sup>1,2</sup>, A. Poli<sup>2</sup>, T. Clemente<sup>1</sup>, M. Bottanelli<sup>1</sup>, N. Gianotti<sup>2</sup>, S. Nozza<sup>2</sup>, A. Castagna<sup>1,2</sup>, V. Spagnuolo<sup>2</sup>  
<sup>1</sup>Vita-Salute San Raffaele University - Milan (Italy), <sup>2</sup>Infectious Diseases Unit, San Raffaele Scientific Institute - Milan (Italy)





ORAL COMMUNICATIONS 17.45-18.45

ALABASTRO A

Special issues in clinical HIV

Chairs: G. Parruti (Pescara), A. Saracino (Bari)

**OC 30 17.45-17.55 Final immunovirological data from the p25- Italian Network of Acute HIV Infection (INACTION) cohort**

E. Bruzzesi<sup>1</sup>, A. Gabrieli<sup>2</sup>, D. Bernasconi<sup>3</sup>, G. Marchetti<sup>4</sup>, M. Trunfio<sup>5</sup>, D. Ripamonti<sup>6</sup>, A. Antinori<sup>7</sup>, N. Squillace<sup>8</sup>, R. Cauda<sup>9,10</sup>, M. Parisi<sup>11</sup>, A. Muscatello<sup>12</sup>, A. Bandera<sup>12,13</sup>, G. Tambussi<sup>11</sup>, S. Nozza<sup>11</sup>, S. Rusconi<sup>14</sup> on behalf of INACTION study group

<sup>1</sup>Vita-Salute San Raffaele University, Milan, Italy, <sup>2</sup>Dipartimento di Scienze Biomediche e Cliniche, Ospedale L. Sacco, Milan, Italy, <sup>3</sup>Bicocca Bioinformatics Biostatistics and Bioimaging Centre - B4 School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy, <sup>4</sup>Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy, <sup>5</sup>Unif of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy, <sup>6</sup>Infectious Disease Unit; ASST Papa Giovanni XXIII; Bergamo, Italy, <sup>7</sup>National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS; Rome, Italy, <sup>8</sup>Infectious Diseases Unit; Department of Internal Medicine; ASST San Gerardo; Monza, Italy, <sup>9</sup>Istituto Clinica di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy, <sup>10</sup>UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, <sup>11</sup>Unit of Infectious Diseases, IRCCS Ospedale san Raffaele, Milan, Italy, <sup>12</sup>Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, <sup>13</sup>School of Medicine and Surgery, University of Milan, Milan, Italy, <sup>14</sup>UOC Malattie Infettive, Ospedale Civile di Legnano, ASST Ovest Milanese, Legnano, Italy

**OC 31 17.57-18.07 Effect of 12-week cART on gut mucosal immunity and microbiome in PHI**

C. Tincati<sup>1</sup>, M. Hadla<sup>1</sup>, M. Falleni<sup>2</sup>, D. Tosi<sup>2</sup>, V. Yellenki<sup>1</sup>, R. Rovito<sup>1</sup>, V. Bono<sup>1</sup>, S. Rusconi<sup>3</sup>, A. Giacomelli<sup>4</sup>, A. Muscatello<sup>5</sup>, S. Di-spinseri<sup>6</sup>, A. d'Arminio Monforte<sup>1</sup>, A. Calcagno<sup>7</sup>, S. Nozza<sup>6</sup>, A. Gori<sup>5</sup>, G. Marchetti<sup>1</sup> for the Inaction (Italian Network of Acute HIV Infection) Study Group

<sup>1</sup>Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, <sup>2</sup>Pathology Unit, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, <sup>3</sup>UOC Malattie Infettive, Ospedale Civile di Legnano, ASST Ovest Milanese, Legnano, <sup>4</sup>Clinic of Infectious Diseases, Department of Biomedical and Clinical Sciences, L. Sacco Hospital, University of Milan, Milan, <sup>5</sup>Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, <sup>6</sup>Viral Evolution and Transmission Unit, IRCCS Ospedale San Raffaele, Milan, <sup>7</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin

**OC 32 18.09-18.19 PLWH with advanced HIV disease are at higher risk for becoming difficult to treat: data from a large cohort of PLWH starting modern ART regimens**

R. Gagliardini<sup>1</sup>, A. Cozzi-Lepri<sup>2</sup>, A. Tavelli<sup>3</sup>, S. Rusconi<sup>4,5</sup>, V. Spagnuolo<sup>6</sup>, A. Giacomelli<sup>7</sup>, G. Burastero<sup>8</sup>, C. Agrati<sup>1</sup>, M.M. Santoro<sup>9</sup>, G. Madeddu<sup>10</sup>, A. d'Arminio Monforte<sup>11</sup>, A. Antinori<sup>1</sup>

<sup>1</sup>INMI Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>2</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, <sup>3</sup>Icna Foundation, Milan, Italy, <sup>4</sup>Unità Operativa Malattie Infettive, Ospedale Civile di Legnano, Legnano, Italy, <sup>5</sup>Dipartimento di Scienze Biomediche e Cliniche "Luigi Sacco" Università degli Studi di Milano, Milan, Italy, <sup>6</sup>IRCCS San Raffaele Scientific Institute, Infectious Diseases Unit, Milan, Italy, <sup>7</sup>III Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Ospedale Luigi Sacco, Milan, Italy, <sup>8</sup>Infectious Disease Clinic, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy, <sup>9</sup>University of Rome Tor Vergata, Department of Experimental Medicine, Rome, Italy, <sup>10</sup>Infectious Diseases Department of Medical, Surgical, and Experimental Sciences University of Sassari, Italy <sup>11</sup>University of Milan, Department of Health Sciences, Milan, Italy

**OC 33 18.21-18.31 Weight change in obese and overweight PWH: the impact of SARS-CoV-2 pandemic**

S. Dettori<sup>1,2</sup>, S. Lerta<sup>1</sup>, L. Taramasso<sup>2</sup>, S. Bianchi<sup>1</sup>, F. Magnè<sup>2</sup>, S. Mora<sup>3</sup>, M. Giacomini<sup>3</sup>, M. Bassetti<sup>1,2</sup>, A. Di Biagio<sup>1,2</sup>

<sup>1</sup>Department of Health Sciences (DISSAL), University of Genoa - Genoa, Italy, <sup>2</sup>Infectious Diseases Unit, Ospedale Policlinico San Martino IRCCS - Genoa, Italy, <sup>3</sup>Department of Informatics Bioengineering, Robotics, and Systems Engineering (DIBRIS), University of Genoa - Genoa, Italy



ORAL POSTER 17.45-18.35

ALABASTRO B

Measuring HIV stigma and disclosure

Chairs: B.M. Celesia (Catania), T. Di Giovanni (Roma)

**OP 78 17.45-17.50 Tackling the misunderstanding and stigma of HIV: a survey on 1007 Italian citizens**

D. Calzavara<sup>1</sup>, A. Tavelli<sup>1,2,3</sup>, A. d'Arminio Monforte<sup>1,2,3</sup>

<sup>1</sup>Associazione Milano Check Point, Milano, <sup>2</sup>ASST Santi Paolo e Carlo, Milano, <sup>3</sup>Fondazione Icona

**OP 79 17.52-17.57 HIV-related stigma among Italian adults: results of an online survey**

Y. Regine<sup>1</sup>, L. Pugliese<sup>1</sup>, B. Suligoj<sup>1</sup>, G. Briola<sup>2</sup>, A. Simonetti<sup>2</sup>, F. Marchionni<sup>2</sup>, V. Saturni<sup>2</sup>

<sup>1</sup>Istituto Superiore di Sanità, Rome, <sup>2</sup>Associazione Volontari Italiani del Sangue, Milan



- OP 80** 17.59-18.04 **Determinants of non disclosure of HIV status in PLWHIV to others than health care workers**  
*A. Cingolani<sup>1</sup>, A. Tavelli<sup>2</sup>, V. Calvino<sup>3</sup>, L. Cosmaro<sup>4</sup>, F. Bai<sup>5</sup>, C. Pinnetti<sup>6</sup>, D. Tesoro<sup>5</sup>, F. Castelli<sup>7</sup>, F. Maggiolo<sup>8</sup>, A. Antinori<sup>6</sup>, M. Cernuschi<sup>9</sup>, A. d'Arminio Monforte<sup>5</sup>*  
<sup>1</sup>Policlinico Fondazione A. Gemelli, IRCCS, Roma, <sup>2</sup>Fondazione ICONA, Milano, <sup>3</sup>ANLAIDS Onlus, Roma, <sup>4</sup>LILA Milano Onlus, Milano, <sup>5</sup>Università degli studi di Milano, Milano, <sup>6</sup>INMI L.Spallanzani, IRCCS, Roma, <sup>7</sup>Università degli studi di Brescia, Brescia, <sup>8</sup>ASST Giovanni XXIII, Bergamo, <sup>9</sup>ASA onlus, Milano
- OP 81** 18.06-18.11 **Knowledge and impact of U=U among PLHIV, healthcare professionals and the general population in Italy: a qualitative study**  
*M. Oldrini<sup>1</sup>, M.L. Cosmaro<sup>1</sup>, S. Curradori<sup>1</sup>, S. Penon<sup>1</sup>, D. Savarino<sup>1</sup>, S. Mazzilli<sup>2</sup>, D. Paganini<sup>2</sup>, L. Tavošchi<sup>2</sup>*  
<sup>1</sup>Fondazione LILA Milano – Lega Italiana per la Lotta contro l'AIDS, Milano, <sup>2</sup>Dipartimento di Ricerca traslazionale e delle nuove tecnologie in Medicina e Chirurgia, Università di Pisa, Pisa
- OP 82** 18.13-18.18 **Do people living with HIV have a better knowledge of HIV and STIs compared to people without HIV? A survey study in Sardinia, Italy**  
*A. Colpani<sup>1</sup>, A. De Vito<sup>1</sup>, B. Zauli<sup>1</sup>, V. Fiore<sup>1</sup>, M.C. Meloni<sup>1</sup>, M. Fois<sup>1</sup>, A. Bitti<sup>1</sup>, S. Bacciu<sup>1</sup>, N. Leoni<sup>2</sup>, G. Angioni<sup>2</sup>, S. Babudieri<sup>1</sup>, G. Madeddu<sup>1</sup>*  
<sup>1</sup>Unit of Infectious Disease, Department of Medical, Surgery, and Experimental Sciences, University of Sassari, Sassari, Italy, <sup>2</sup>Infectious Diseases Unit, SS Trinità Hospital, Cagliari, Italy
- OP 83** 18.20-18.25 **Impact of HIV-related stigma on social support, mental health and quality of life in an Italian cohort of people living with HIV**  
*V. Delle Donne<sup>1</sup>, V. Massaroni<sup>1</sup>, A. Borghetti<sup>2</sup>, A. Dusina<sup>2</sup>, R.A. Passerotto<sup>2</sup>, R.J. Steiner<sup>2</sup>, A. Ciccullo<sup>3</sup>, G. Baladin<sup>4</sup>, S. Di Giambenedetto<sup>1,2</sup>*  
<sup>1</sup>Infectious Diseases Institute, Department of Safety and Bioethics, Catholic University of Sacred Heart, Rome, Italy, <sup>2</sup>UOC Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, <sup>3</sup>UOC Infectious Diseases, Ospedale S. Salvatore, L'Aquila, Italy, <sup>4</sup>Olbia Mater Hospital, Olbia, Italy



ORAL POSTER 17.45-18.35

BERGAMO SCIENCE CENTER

**Models of COVID-19 pathogenesis and response to vaccination**

Chairs: C. Tincati (Milano), A. Riva (Milano)

- OP 84** 17.45-17.50 **Human iPSC-derived motor neurons are productively infected by SARS-CoV-2**  
*G. Cappellelli<sup>1</sup>, C. Colombrita<sup>2</sup>, F. Limanaqi<sup>1,5</sup>, D. Trabattoni<sup>1</sup>, C. Moscheni<sup>1</sup>, A. Tosoni<sup>6</sup>, M. Nebuloni<sup>1,6</sup>, S. Santangelo<sup>2,3</sup>, V. Silani<sup>2,4</sup>, A. Ratti<sup>2,3</sup>, M. Biasin<sup>1</sup>*  
<sup>1</sup>Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Italy, <sup>2</sup>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy, <sup>3</sup>Department of Medical Biotechnology and Translational Medicine, University of Milan, Italy, <sup>4</sup>Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, University of Milan, Italy, <sup>5</sup>Department of Pathophysiology and Transplantation, Milan, Italy, <sup>6</sup>Pathology Unit, L. Sacco Hospital, Milan, Italy
- OP 85** 17.52-17.57 **SARS-CoV-2 infection of airway epithelium triggers endothelial cells activation**  
*D. Mariotti<sup>1</sup>, G. Matusali<sup>1</sup>, F. Colavita<sup>1</sup>, C. Agrati<sup>1</sup>, V. Bordoni<sup>1</sup>*  
INMI L. Spallanzani, Roma
- OP 86** 17.59-18.04 **Specific CD4+ and CD8+ T cell response of SARS-CoV-2 S epitopes using tetramers & monocyte dysregulation in fully vaccinated donors and recovered patients**  
*A. Parente<sup>2</sup>, M. Iuliano<sup>1</sup>, R. Mongiovi<sup>1</sup>, B. Kertusha<sup>2</sup>, A. Carraro<sup>2</sup>, R. Marocco<sup>2</sup>, G. Mancarella<sup>2</sup>, S. Garattini<sup>2</sup>, F. Izzo<sup>2</sup>, C. Del Borgo<sup>2</sup>, T. Tieghi<sup>2</sup>, L. Fondaco<sup>2</sup>, G. Mangino<sup>1</sup>, M. Lichtner<sup>2</sup>, G. Romeo<sup>1</sup>*  
<sup>1</sup>Dept. of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Italy, <sup>2</sup>Dept. of Public Health and Infectious Disease, S. Maria Goretti Hospital, Sapienza University of Rome, Latina, Italy
- OP 87** 18.06-18.11 **Immune responses after three doses of BNT162b2 mRNA vaccine in a cohort of HIV-vertically transmitted patients**  
*C. Vanetti<sup>1</sup>, M. Stracuzzi<sup>2</sup>, F. Cicilano<sup>1</sup>, V. Rubinacci<sup>2,4</sup>, C. Fenizia<sup>3</sup>, G. Meraviglia<sup>2</sup>, Clerici<sup>3,5</sup>, M. Biasin<sup>1</sup>, G.V. Zuccotti<sup>2,4</sup>, V. Giacomè<sup>2</sup>, D. Trabattoni<sup>1</sup>*  
<sup>1</sup>University of Milan, Department of Biomedical and Clinical Sciences "L. Sacco", Milan, <sup>2</sup>Ospedale L. Sacco, University of Milan, Department of Pediatric Infectious Diseases, Milan, <sup>3</sup>University of Milan, Department of Pathophysiology and Transplantation, Milan, <sup>4</sup>Ospedale dei Bambini V. Buzzi, Department of Paediatrics, Milan, <sup>5</sup>IRCCS Fondazione Don Carlo Gnocchi



**OP 88 18.13-18.18 Comparison between QuantiFERON SARS-CoV 2 kit and Activation Induced Cell Markers (AIMs) assay in 21 non-vaccinated patients with late COVID19 infection**

*A. Gatti<sup>1</sup>, M. De Paschale<sup>2</sup>, P. Clerici<sup>2</sup>, M.P. Faggioli<sup>3</sup>, A. Tamburello<sup>3</sup>, L. Castelnuovo<sup>3</sup>, M. Franzetti<sup>4</sup>, S. Rusconi<sup>4</sup>, A. Mazzone<sup>3</sup>*

<sup>1</sup>Haematology Laboratory - Transfusion Center, <sup>2</sup>Microbiology Unit, <sup>3</sup>Internal Medicine Unit, <sup>4</sup>Infectious Diseases Unit, Legnano Hospital, Milano, Italy; <sup>5</sup>Department of Biomedical and Clinical Sciences DIBIC "Luigi Sacco", University of Milan, Italy

**OP 89 18.20-18.25 An in-depth characterization of VOCs circulation by using NGS analysis of the Spike protein**

*M.C. Bellocchi<sup>1</sup>, L. Carioti<sup>1</sup>, R. Scutari<sup>1</sup>, M. Iannetta<sup>2</sup>, L. Piermatteo<sup>1</sup>, M. Alkhatib<sup>1</sup>, S. Tedde<sup>2</sup>, L. Duca<sup>1</sup>, L. Coppola<sup>2</sup>, V. Malagnino<sup>2</sup>, A. Crea<sup>2</sup>, L. Ansaldo<sup>2</sup>, S. D'Anna<sup>1</sup>, M.M. Santoro<sup>1</sup>, A. Bertoli<sup>1,2</sup>, A. Di Lorenzo<sup>2</sup>, R. Salpini<sup>1</sup>, V. Svicher<sup>1</sup>, E. Teti<sup>2</sup>, N. Braccialarghe<sup>2</sup>, R.A. Cavasio<sup>2</sup>, L. Sarmati<sup>2</sup>, M. Andreoni<sup>2</sup>, F. Ceccherini-Silberstein<sup>1</sup>*

<sup>1</sup>University of Rome Tor Vergata, Rome, Italy, <sup>2</sup>University Hospital of Rome Tor Vergata, Rome, Italy





**KEYNOTE LECTURES** 09.00-10.00

**AUDITORIUM SALA OGGIONI**

Chairs: M.L. Cosmaro (Milano), M. Galli (Milano)

09.00-09.30 **Anti-HIV therapy as a guide to treat COVID-19**

C.F. Perno, Roma

09.30-10.00 **Comparing the Mental Health Trajectories of PLWH during the pandemic period with the prepandemic situation: impact of geographic differences and different access to health care facilities**

F. Lampe, London UK



**SYMPOSIUM** 10.05-11.05

**AUDITORIUM SALA OGGIONI**

**Comorbidities of contemporary relevance**

Chairs: P. Maggi (Caserta), B. Marchini (Roma)

*Until recent years, the comorbidities of HIV infection, initially associated with side effects of ART, have turned into pathological conditions more often related to aging and lifestyles. Among ART side effects, weight gain remains a concern especially in PWVH receiving integrase inhibitors, and mechanisms are still unclear. Beyond ART, sexually transmitted infections are among those more clinically relevant in PWVH because of their high frequency and transmissibility, despite most can be prevented or treated. In this context, HPV infection is of particular interest because it is implicated in the development of tumors, which remain a relevant cause of mortality in PWVH.*

10.05-10.20 **Pathogenetic aspects of weight gain under ART**

L. Taramasso, Genova

10.20-10.35 **Evolving concepts in Sexually Transmitted Infections**

G. Villa, Brighton UK

10.35-10.50 **HPV infection and its consequences: where we stand now**

N. Squillace, Monza

10.50-11.05 **Discussion on Symposium issues**



**EXPERT MEETING** 10.05-11.05

**SALA STUCCHI**

**Heavily-treatment experienced (HTE) patients: who are they?  
And how should be managed?**

Moderator: S. Lo Caputo (Foggia)

Con la sponsorizzazione non condizionante di ViiV Healthcare

Discussants: A. Castagna (Milano), C.F. Perno (Roma)

*Despite the availability of new classes of antiretroviral (ARV) therapy with improved efficacy, some usually heavily-treatment experienced (HTE) patients eventually experience treatment failure due to various factors including viral resistance, drug toxicity, drug intolerance, and poor adherence. Long-term ARV therapy use could lead to decreased efficacy of multiple classes of ARVs, requiring increasingly tailored regimens, and few, if any, ARV options remaining. Therefore, it is important to consider new ARVs with different mechanism of action in the therapeutic approach of these patients: in this context, the oral attachment inhibitor has demonstrated efficacy in adults with multidrug resistant HIV-1 infection in urgent need of new treatment due to resistance, safety, or tolerability issues with their current regimens.*





**SYMPOSIUM** 10.05-12.10

## The Italian Fast-Track Cities Network

**ALABASTRO A**

Chairs: A. d'Arminio Monforte, S. Patrucco

Con la sponsorizzazione non condizionante di Gilead Sciences

The Fast-Track Cities initiative (FTCI) is a global partnership between cities and municipalities around the world and four core partners: the International Association of Providers of AIDS-Care (IAPAC), the Joint United Nations Programme on HIV/AIDS (UNAIDS), the United Nations Human Settlements Programme (UN-Habitat) and the City of Paris. Launched on World AIDS Day 2012, the Network has grown to include more than 330 Cities and municipalities that are committed to attain the UNAIDS 95-95-95 targets by 2030. The aim of the Symposium is to focus on the Italian Fast-Track Cities state of the art as now 12 Italian townships are potentially involved. Even if FTCI is mostly a locally organized micro-program, sharing good practice and ideas may improve the effect of single realities and may lead to common actions able to engrave deeply on the HIV epidemics.

- |             |  |  |
|-------------|--|--|
| 10.05-10.20 | <b>The Global Network example of good practice</b>                   | B. Audoin, Paris F                     |
| 10.20-10.35 | <b>FTC experience from the municipality point of view</b>            | M. Messina, Bergamo                    |
| 10.35-11.10 | <b>Italian Fast Track Cities calls Ukraine</b>                       | B. Audoin, Paris F                     |
| 11.10-11.40 | <b>Common projects already in place and sharing of Cobatest data</b> | M.L. Cosmaro, Milano; P. Meli, Bergamo |
| 11.40-12.10 | <b>Future common projects and actions. FTCI delegates</b>            |  |



**ORAL POSTER** 10.05-10.55

## COVID-19: considerations of special populations

**ALABASTRO B**

Chairs: V. Giacomel (Milano), F. Vichi (Firenze)

**OP 90 10.05-10.10 Impact of patients' characteristics and comorbidities on in-hospital mortality during the first three waves of COVID-19 pandemic. Results from the Brescia HUB project**

E. Focà<sup>1</sup>, S. Calza<sup>2</sup>, S. Piva<sup>3</sup>, L. Ettori<sup>1</sup>, F. Rasulo<sup>3</sup>, C. Agabiti Rosei<sup>4</sup>, C. Aggiusti<sup>5</sup>, B. Cerudelli<sup>6</sup>, F. Quadri<sup>7</sup>, M. Metra<sup>8</sup>, M. Castellano<sup>9</sup>, M. Nardin<sup>10</sup>, C. Ricci<sup>11</sup>, R. Badolato<sup>12</sup>, F. Odcino<sup>13</sup>, R. Orabona<sup>13</sup>, F. Scolari<sup>14</sup>, L.R. Tomasoni<sup>1</sup>, F. Marinoni<sup>15</sup>, A.M. Roccaro<sup>16</sup>, C. Rossi<sup>17</sup>, F. Castelli<sup>1</sup>

<sup>1</sup>Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili, Brescia, Italy, <sup>2</sup>Unit of Biostatistics and Bioinformatics, University of Brescia, Brescia, Italy, <sup>3</sup>Unit of Anesthesiology and Critical Care Medicine, ASST Spedali Civili, Italy, <sup>4</sup>Second Unit of Internal Medicine, University of Brescia and ASST Spedali Civili, Italy, <sup>5</sup>Unit of Emergency Internal Medicine, University of Brescia and ASST Spedali Civili, Italy, <sup>6</sup>Unit of Neurology, University of Brescia and ASST Spedali Civili, Brescia, Italy, <sup>7</sup>Unit of Pneumology, ASST Spedali Civili, Brescia, Italy, <sup>8</sup>Unit of Cardiology, University of Brescia and ASST Spedali Civili, Brescia, Italy, <sup>9</sup>Unit of Internal Medicine and Endocrinology, University of Brescia and ASST Spedali Civili, Brescia, Italy, <sup>10</sup>Third Unit of Internal Medicine, ASST Spedali Civili, Italy, <sup>11</sup>Unit of Gastroenterology University of Brescia and ASST Spedali Civili, Brescia, Italy, <sup>12</sup>Unit of Pediatrics, Children's Hospital University of Brescia and ASST Spedali Civili, Brescia, Italy, <sup>13</sup>Unit of Gynecology and Obstetrics, University of Brescia and ASST Spedali Civili, Brescia, Italy, <sup>14</sup>Unit of Nephrology and Dialysis, University of Brescia and ASST Spedali Civili, Brescia, Italy, <sup>15</sup>Unit of Planning and Management Control Service, ASST Spedali Civili, Brescia, Italy, <sup>16</sup>Unit of Clinical Research and Phase I Studies, ASST Spedali Civili, Brescia, Italy, <sup>17</sup>Chief Medical Officer Institution, ASST Spedali Civili, Brescia, Italy

**OP 91 10.12-10.17 SARS-CoV-2 infection and COVID-19 disease in PLWH**

F. Maggiolo<sup>1</sup>, D. Valenti<sup>2</sup>, M. Arosio<sup>1</sup>, D. Guarneri<sup>1</sup>, M. Rizzi<sup>1</sup>, A.P. Callegaro<sup>3</sup>

<sup>1</sup>ASST Papa Giovanni XXIII, <sup>2</sup>Associazione FROM, <sup>3</sup>ASST Bergamo Est, Bergamo, Italy

**OP 92 10.19-10.24 Evolution of SARS-CoV-2 Variants of Concern (VOC) over a period of Delta and Omicron variants co-circulation: impact on clinical outcomes among patients (pts) hospitalized for COVID-19 in an Italian reference hospital in the first trimester of 2022**

A. Mondì, I. Mastroiosa, C. Cimaglia, P. Piselli, G. Matusali, F. Carletti, L. Fabeni, E. Specchiarello, G. Giannico, E. Milozzi, E. Biliotti, S. Di Bari, P. Chinello, A. Beccacece, P. Vittozzi, S. Mosti, N. Tetaj, L. Marchioni, S. Ianniello, E. Nicastri, A.R. Garbuglia, F. Vaia, E. Girardi, A. Antinori

National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy

**OP 93 10.26-10.31 New issues in SARS-CoV-2 vaccination response among Health-care workers: slow responders and peri-vaccination infections**

S. Arsuffi<sup>1</sup>, E. Focà<sup>1</sup>, E. Sansone<sup>2</sup>, T. Diaferia<sup>2</sup>, E. Sala<sup>2</sup>, F. Castelli<sup>1</sup>, G. De Palma<sup>2</sup>, E. Quiros-Roldan<sup>1</sup>

<sup>1</sup>Unit of Infectious and tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy, <sup>2</sup>University Department of Occupational Health and Industrial Hygiene, DSMC, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy





- OP 94** 10.33-10.38 **Antibody response in women vaccinated against SARS-CoV-2 during pregnancy and respective babies at birth**  
A. Pani<sup>1</sup>, A. Proto<sup>2</sup>, S. Agliardi<sup>1</sup>, O.M. Gagliardi<sup>1</sup>, S. Renica<sup>1</sup>, F. di Ruscio<sup>1</sup>, C. Vismara<sup>3</sup>, D. Campisi<sup>3</sup>, F. Scaglione<sup>1</sup>, S. Martinelli<sup>2</sup>  
<sup>1</sup>Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy, <sup>2</sup>Neonatology and Neonatal Intensive Care Unit, Niguarda Hospital, Milan, Italy, <sup>3</sup>Microbiology Unit, Niguarda Hospital, Milan, Italy
- OP 95** 10.40-10.45 **Predictors of mortality in a cohort of oldest old subjects hospitalized for COVID-19**  
M. Mazzitelli, M. Biasin, M. Trevenzoli, S. Lo Menzo, S. Marinello, A. Ferrari, L. Sasset, M. Brundu, S. Gardin, M. Cola, A.M. Cattelan  
Infectious and Tropical Diseases Unit, Azienda Ospedale Università, Padova



ORAL POSTER 10.05-10.55

BERGAMO SCIENCE CENTER

## Toxicity of antiretroviral therapy

Chairs: C. Gervasoni (Milano), R. Gulminetti (Pavia)

- OP 96** 10.05-10.10 **Efficacy and safety of switching to lamivudine/dolutegravir in HIV-1-infected patients aged over 65 years**  
L. Calza<sup>1</sup>, V. Colangeli<sup>1</sup>, M. Borderi<sup>1</sup>, R. Riccardi<sup>1</sup>, F. Malerba<sup>1</sup>, I. Bon<sup>2</sup>, P. Viale<sup>1</sup>  
<sup>1</sup>Unit of Infectious Diseases, <sup>2</sup>Unit of Microbiology, IRCCS S.Orsola Hospital, University of Bologna, Bologna, Italy
- OP 97** 10.12-10.17 **Specific neurodevelopmental consequences of dolutegravir exposure in a zebrafish embryo model and rescue with early folate treatment**  
S. Ferretti<sup>1</sup>, E. Quiros-Roldan<sup>1</sup>, I. Zanella<sup>2</sup>, F. Castelli<sup>1</sup>, E. Massardi<sup>3</sup>, G. Borsani<sup>3</sup>, G. Tiecco<sup>1</sup>, S. Storti<sup>1</sup>, D. Zizioli<sup>3</sup>  
<sup>1</sup>Division of Infectious and Tropical Diseases, ASST Spedali Civili di Brescia, Brescia, Italy; <sup>2</sup>Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; <sup>3</sup>Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; <sup>4</sup>Clinical Chemistry Laboratory, Cytogenetics and Molecular Genetics Section, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy; <sup>5</sup>Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
- OP 98** 10.19-10.24 **Causes of HIV treatment interruption during the last 20 years: a multi-cohort real-life study**  
A. De Vito<sup>1</sup>, E. Ricci<sup>2</sup>, B. Menzaghi<sup>3</sup>, G. Orofino<sup>4</sup>, C. Martinelli<sup>5</sup>, N. Squillace<sup>6</sup>, L. Taramasso<sup>7</sup>, G.V. De Socio<sup>8</sup>, C. Molteni<sup>9</sup>, F. Conti<sup>10</sup>, L. Valsecchi<sup>11</sup>, C. Costa<sup>12</sup>, B.M. Celesia<sup>13</sup>, G. Parruti<sup>14</sup>, G. Pellicanò<sup>15</sup>, E. Sarchi<sup>16</sup>, A. Cascio<sup>17</sup>, G. Cenderello<sup>18</sup>, K. Falasca<sup>19</sup>, A. Di Biagio<sup>7</sup>, P. Bonfanti<sup>6</sup>, G. Madeddu<sup>1</sup>  
<sup>1</sup>Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, <sup>2</sup>Fondazione ASIA Onlus, Buccinasco (MI), Italy, <sup>3</sup>Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio Hospital, Busto Arsizio, Italy, <sup>4</sup>Unit of Infectious Diseases, "Divisione A", Amedeo di Savoia Hospital, Torino, Italy, <sup>5</sup>SOD Malattie Infettive e Tropicali, AOU Careggi, Firenze, Italy, <sup>6</sup>Infectious Diseases Clinic, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy, <sup>7</sup>Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Genoa, Italy, <sup>8</sup>Clinic of Infectious Diseases, Department of Medicine, Azienda Ospedaliera di Perugia, Santa Maria Hospital, Perugia, <sup>9</sup>Infectious Disease Unit, Ospedale A. Manzoni, Lecco, Italy, <sup>10</sup>Infectious Diseases Unit, Department of Biomedical and Clinical Sciences 'Luigi Sacco', Università degli Studi di Milano, Milan, Italy, <sup>11</sup>Infectious Disease Unit (I Divisione), ASST Fatebenefratelli Sacco, Milan, Italy, <sup>12</sup>Infectious Diseases Department, SOC 1, USLCENTROFIRENZE, Santa Maria Annunziata Hospital, Florence, Italy, <sup>13</sup>Unit of Infectious Diseases, University of Catania, ARNAS Garibaldi, Catania, Italy, <sup>14</sup>Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy, <sup>15</sup>Department of Human Pathology of the Adult and the Developmental Age "G. Barresi", Unit of Infectious Diseases, University of Messina, Messina, Italy, <sup>16</sup>Infectious Diseases Unit, SS. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, <sup>17</sup>Infectious and Tropical Diseases Unit- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE) - University of Palermo, Palermo, Italy, <sup>18</sup>Infectious Disease Unit, Sanremo Hospital, Sanremo, Italy, <sup>19</sup>Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy
- OP 99** 10.26-10.31 **First and second phase viral load decay in real-life using Nonlinear Bayesian Mixed Effect model**  
D. Ceccarelli<sup>1</sup>, R. Lolatto<sup>1</sup>, N. Gianotti<sup>1</sup>, C. Muccini<sup>1,2</sup>, D. Canetti<sup>1</sup>, C. Maci<sup>1,2</sup>, C. Oltolini<sup>1</sup>, B. Trentacapilli<sup>1,2</sup>, A. Castagna<sup>1,2</sup>, L. Galli<sup>1</sup>  
<sup>1</sup>Infectious Diseases Unit, IRCCS San Raffaele Hospital, Milan, Italy, <sup>2</sup>Vita-Salute San Raffaele University, Milan, Italy

- OP 100** 10.33-10.38 **The effects of switching from dolutegravir/abacavir/lamivudine to bicitegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV on neuropsychiatric symptoms: preliminary findings from a randomized study**  
B. Rossetti<sup>1,2</sup>, M. Ferrara<sup>3</sup>, L. Taramasso<sup>4</sup>, F. Bai<sup>5</sup>, F. Lombardi<sup>6</sup>, N. Ciccarelli<sup>7</sup>, M. Durante<sup>8</sup>, F. Alladio<sup>3</sup>, I. Rancan<sup>1,8</sup>, F. Montagnani<sup>1,8</sup>, A. Di Biagio<sup>9</sup>, A. d'Arminio Monforte<sup>5</sup>, M. Zazzi<sup>8</sup>, M. Fabbiani<sup>1</sup> for DOBINeuro study group  
<sup>1</sup>Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy, <sup>2</sup>Infectious Disease Department, USL SUDEST Toscana, Misericordia Hospital, Grosseto, Italy, <sup>3</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, <sup>4</sup>Infectious Diseases Clinic, Department of Internal Medicine, IRCCS Policlinico San Martino Hospital, Genoa, Italy, <sup>5</sup>Clinic of Infectious Diseases, Department of



Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy, <sup>6</sup>Infectious Diseases Unit, UOC Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, <sup>7</sup>Department of Psychology, Catholic University, Milan, Italy, <sup>8</sup>Department of Medical Biotechnologies, University of Siena, Siena, Italy, <sup>9</sup>Infectious Diseases Clinic, Department of Health Sciences, University of Genoa, San Martino Hospital-IRCCS, Genoa, Italy

**OP 101 10.40-10.45 Dynamic of lipid profile in HIV naive patients treated by TAF-based regimens: a multicenter observational study**

**S. Martini<sup>1</sup>, P. Maggi<sup>1,2</sup>, C. Gervasoni<sup>3</sup>, L. Onorato<sup>1</sup>, S. Ferrara<sup>4</sup>, L. Alessio<sup>1,2</sup>, C. Bellacosa<sup>5</sup>, V. Esposito<sup>6</sup>, G. Di Filippo<sup>7</sup>, A. Masiello<sup>8</sup>, A. Maddaloni<sup>9</sup>, S. Madonia<sup>10</sup>, G.D'Alessio<sup>11</sup>, V. Rizzo<sup>6</sup>, N. Coppola<sup>1</sup>**

<sup>1</sup>Infectious Disease, University of Campania, Luigi Vanvitelli, <sup>2</sup>AORN Sant'Anna e San Sebastiano of Caserta, <sup>3</sup>ASST FBF SACCO of Milan, <sup>4</sup>University of studies of Foggia, <sup>5</sup>University of studies of Bari, <sup>6</sup>IV Division AORN dei Colli, <sup>7</sup>University Federico II of Naples, <sup>8</sup>AO San Giuseppe Moscati of Avellino, <sup>9</sup>VII Divisione AORN dei Colli, <sup>10</sup>AOU San Giovanni di Dio e Ruggi d'Aragona of Salerno, <sup>11</sup>AORN San Pio of Benevento



SPONSORED SYMPOSIUM 11.10-12.10

AUDITORIUM SALA OGGIONI

**Remdesivir: key-role in COVID-19 management**

Chair: R. Bruno (Pavia)

Simposio promozionale di Gilead Sciences

Remdesivir, the first antiviral drug authorized in Europe for the treatment of COVID-19, has demonstrated its efficacy in three randomized controlled clinical trials, including the gold-standard ACTT-1 study, and, increasingly, in numerous evidences from the real practice. Recent international real-world retrospective analyses on large data sets and a meta-analysis of the most important real-world publications confirmed that hospitalised COVID-19 patients treated with remdesivir had a statistically significant reduction in mortality and improved survival compared to matched controls. Moreover, the PINETREE phase III study on moderate COVID-19 patients revealed high efficacy of remdesivir in reducing hospitalization or mortality rate compared to placebo, results that granted the new recent EMA indication for high risk moderate patients. This Symposium will be an opportunity to give an overview of the evolving patient profile, to present a scientific update on remdesivir efficacy data and to discuss centres organization to manage the treatment of COVID-19 outpatients. The three talks composing the Symposium will then try to address the most important topics regarding COVID-19 patient management with remdesivir.

- |               |  |                   |
|---------------|--|-------------------|
| 11.10 - 11.15 | <b>Introduction</b>  | R. Bruno, Pavia   |
| 11.15 - 11.30 | <b>The evolution of the COVID-19 patient profile</b>   | P. Viale, Bologna |
| 11.30 - 11.45 | <b>Remdesivir in the severe patient: new evidences from the Real World</b>                   | M. Falcone, Pisa  |
| 11.45 - 12.00 | <b>Remdesivir in the high risk moderate patient: efficacy profile and patient management</b> | E. Nicastri, Roma |
| 12.00 - 12.10 | <b>Discussion on Symposium issues</b>  |                   |



ORAL COMMUNICATIONS 11.10-12.10

SALA STUCCHI

**Resistance to antiretroviral**

Chairs: A. Cascio (Palermo), M. Di Pietro (Firenze)

**OC 34 11.10-11.20 Evaluation of integrase resistance and its predictors in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings**

**M.M. Santoro<sup>1</sup>, D. Armenia<sup>2</sup>, C. Charpentier<sup>3</sup>, A. Bertoli<sup>4</sup>, F. Forbici<sup>5</sup>, V. Calvez<sup>6</sup>, D. Descamps<sup>3</sup>, F. Ceccherini-Silberstein<sup>1</sup>, A.G. Marcelin<sup>6</sup>, P. Flandre<sup>7</sup>, on behalf of the ANRS-MIE AC43 group and the Italian HIV-drug resistance group**

<sup>1</sup>University of Rome "Tor Vergata", Rome, Italy, <sup>2</sup>Saint Camillus International University of Health Sciences, Rome, Italy, <sup>3</sup>Paris University, AP-HP, Hôpital Bichat-Claude-Bernard, IAME, Paris, France, <sup>4</sup>Polyclinic of Rome "Tor Vergata", Rome Italy, <sup>5</sup>National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, <sup>6</sup>Sorbonne Université, AP-HP, Hôpital Pitié Salpêtrière, INSERM UMR-S1136, Paris, France, <sup>7</sup>Sorbonne Université, INSERM UMR-S1136, Paris, France

**OC 35 11.22-11.32 Efficacy of dolutegravir versus darunavir in first-line regimens according to resistance mutations and viral subtype**

**P.F. Salvo<sup>1</sup>, D. Farinacci<sup>1,2</sup>, A. Ciccullo<sup>3</sup>, V. Borghi<sup>4</sup>, P. Laghetti<sup>5</sup>, S. Rusconi<sup>6</sup>, A. Saracino<sup>7</sup>, W. Gennari<sup>4</sup>, B. Bruzzone<sup>8</sup>, I. Vicenti<sup>9</sup>, A. Callegaro<sup>10</sup>, A. Di Biagio<sup>11</sup>, M. Zazzi<sup>9</sup>, A. Borghetti<sup>2</sup>**

<sup>1</sup>Istituto di Clinica delle Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, <sup>2</sup>UOC Malattie Infettive, Fondazione Policlinico Universitario A.Gemelli IRCCS, Roma, <sup>3</sup>Malattie Infettive, Ospedale San Salvatore, L'Aquila, <sup>4</sup>Clinica delle Malattie Infettive e Tropicali, Università di Modena e Reggio Emilia, Modena, <sup>5</sup>Microbiologia e Virologia, Università degli Studi di Bari, Bari, <sup>6</sup>UOC Malattie Infettive, Ospedale Civile di Legnano, ASST Ovest Milanese, Legnano, <sup>7</sup>Clinica Malattie Infettive, Università degli Studi di Bari, Bari, <sup>8</sup>UO Igiene, Ospedale Policlinico San





Martino, Genova, <sup>9</sup>Dipartimento di Biotecnologie Mediche, Università di Siena, Siena, <sup>10</sup>UO Microbiologia e Virologia, ASST Papa Giovanni XXIII, Bergamo, <sup>11</sup>Clinica di Malattie Infettive, Ospedale Policlinico San Martino, Dipartimento di Scienze della Salute (DISSAL), Università di Genova, Genova

**OC 36 11.34-11.44 Clinical and virological outcomes of difficult to treat patients in a large cohort of PLWH starting modern ART regimens**

*R. Gagliardini<sup>1</sup>, A. Tavelli<sup>2</sup>, S. Rusconi<sup>3,4</sup>, A. Costantini<sup>5</sup>, S. Cicalini<sup>1</sup>, F. Maggiolo<sup>6</sup>, V. Spagnuolo<sup>7</sup>, E. Quiros Roldan<sup>8</sup>, S. Lo Caputo<sup>9</sup>, A. d'Arminio Monforte<sup>10</sup>, A. Antinori<sup>1</sup>, A. Cozzi-Lepri<sup>11</sup>*

<sup>1</sup>INMI Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>2</sup>Icna Foundation, Milan, Italy, <sup>3</sup>Unità Operativa Malattie Infettive, Ospedale Civile di Legnano, Legnano, Italy, <sup>4</sup>Dipartimento di Scienze Biomediche e Cliniche "Luigi Sacco" Università degli Studi di Milano, Milan, Italy, <sup>5</sup>Clinical Immunology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti, Marche Polytechnic University, Ancona, Italy, <sup>6</sup>ASST Papa Giovanni XXIII, Bergamo, Italy, <sup>7</sup>IRCCS San Raffaele Scientific Institute, Infectious Diseases Unit, Milan, Italy, <sup>8</sup>Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili of Brescia, Brescia, Italy, <sup>9</sup>Infectious Diseases Unit, University of Foggia, Foggia, Italy, <sup>10</sup>University of Milan, Department of Health Sciences, Milan, Italy, <sup>11</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL

**OC 37 11.46-11.56 Durability of Mega ART in a large cohort of treatment experienced people living with HIV: Data from ARCA database**

*L. Labate<sup>1,2</sup>, B. Rossetti<sup>3</sup>, C. Russo<sup>1,2</sup>, M. Bottanelli<sup>4,5</sup>, C. Cassol<sup>6,7</sup>, F. Bracchitta<sup>8</sup>, L. Graziani<sup>9</sup>, M. Tili<sup>9</sup>, I. Rancan<sup>6,7</sup>, C. Malcontenti<sup>10</sup>, S. Mora<sup>11</sup>, R. Papaioannu<sup>4,5</sup>, A. Bezenchek<sup>12,13</sup>, A. Shallvari<sup>12,13</sup>, A. Di Biagio<sup>1,2</sup>*

<sup>1</sup>Infectious Diseases Unit, San Martino Policlinico Hospital - IRCCS for Oncology and Neuroscience, Genoa, Italy, <sup>2</sup>Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, <sup>3</sup>Infectious Disease Department, USL SUDEST, Toscana, Misericordia Hospital, Grosseto, Italy, <sup>4</sup>Vita-Salute San Raffaele University- Milan (Italy), <sup>5</sup>Infectious Diseases Unit, San Raffaele Scientific Institute-Milan (Italy), <sup>6</sup>Department of Medical Biotechnologies, University of Siena, Siena, Italy, <sup>7</sup>Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy, <sup>8</sup>Laboratory of Clinical Microbiology, Virology and Bioemergencies, ASST Fatebenefratelli Sacco, L. Sacco University Hospital, Milan, Italy, <sup>9</sup>Department of Experimental & Clinical Medicine, University of Florence, Florence, Italy, <sup>10</sup>SOD Malattie Infettive e Tropicali AOU Careggi, Firenze, <sup>11</sup>Department of Informatics, Bioengineering, Robotics and System Engineering, University of Genoa, Genoa, Italy, <sup>12</sup>INFORMA-PRO Srl, Rome, Italy, <sup>13</sup>EURESIST Network GEIE, Rome, Italy



ORAL POSTER 11.10-12.00

**HIV and SARS-CoV-2: from in vivo to in vitro**

ALABASTRO B

Chairs: D. Cattaneo (Milano), F. Saladini (Siena)

**OP 102 11.10-11.15 Trends of HIV-1 drug resistance and APOBEC editing in PBMC compartment over the last decade**

*D. Armenia<sup>1</sup>, R. Gagliardini<sup>2</sup>, C. Alteri<sup>3,4</sup>, V. Svicher<sup>5</sup>, V. Cento<sup>6</sup>, V. Borghi<sup>7</sup>, A. Vergori<sup>2</sup>, S. Cicalini<sup>2</sup>, F. Forbici<sup>2</sup>, L. Fabeni<sup>2</sup>, A. Bertolli<sup>5,8</sup>, W. Gennari<sup>7</sup>, V. Malagnino<sup>8</sup>, M. Andreoni<sup>9</sup>, C. Mussini<sup>7</sup>, A. Antinori<sup>2</sup>, C.F. Perno<sup>4</sup>, M.M. Santoro<sup>5</sup>, F. Ceccherini-Silberstein<sup>5</sup>*

<sup>1</sup>UniCamillus, Saint Camillus International University of Health Sciences, Rome, Italy, <sup>2</sup>National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, <sup>3</sup>University of Milan, Milan, Italy, <sup>4</sup>Bambino Gesù Children's Hospital, Rome, Italy, <sup>5</sup>University of Rome "Tor Vergata", Rome, Italy, <sup>6</sup>Humanitas Research Hospital, IRCCS, Milan, Italy, <sup>7</sup>University of Modena and Reggio Emilia, Modena, Italy, <sup>8</sup>Polyclinic of Rome "Tor Vergata", Rome, Italy

**OP 103 11.17-11.22 Trend over time of HIV-1 drug resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) and their drivers: cohort study from ARCA**

*I. Rancan<sup>1,2</sup>, C. Cassol<sup>1,2</sup>, L. Graziani<sup>3</sup>, M. Tili<sup>3</sup>, C. Malcontenti<sup>4</sup>, C. Russo<sup>5,6</sup>, M. Bottanelli<sup>7,8</sup>, F. Bracchitta<sup>9</sup>, R. Papaioannu<sup>7,8</sup>, L. Labate<sup>5,6</sup>, S. Mora<sup>12</sup>, A. Bezenchek<sup>10,11</sup>, A. Shallvari<sup>10,11</sup>, A. Di Biagio<sup>5,6</sup>, B. Rossetti<sup>13</sup>*

<sup>1</sup>Department of Medical Biotechnologies, University of Siena, Siena, Italy, <sup>2</sup>Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy, <sup>3</sup>Department of Experimental & Clinical Medicine, University of Florence, Florence, Italy, <sup>4</sup>SOD Malattie Infettive e Tropicali AOU Careggi, Florence, Italy, <sup>5</sup>Infectious Diseases Unit, San Martino Policlinico Hospital - IRCCS for Oncology and Neuroscience, Genoa, Italy, <sup>6</sup>Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, <sup>7</sup>Vita-Salute San Raffaele University, Milan, Italy, <sup>8</sup>Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, Italy, <sup>9</sup>Laboratory of Clinical Microbiology, Virology and Bioemergencies, ASST Fatebenefratelli Sacco, L. Sacco University Hospital, Milan, Italy, <sup>10</sup>INFORMA-PRO Srl, Rome, Italy, <sup>11</sup>EURESIST Network GEIE, Rome, Italy, <sup>12</sup>Department of Informatics, Bioengineering, Robotics and System Engineering, University of Genoa, Genoa, Italy, <sup>13</sup>Infectious Disease Department, USL SUDEST, Toscana, Misericordia Hospital, Grosseto, Italy

**OP 104 11.24-11.29 Sotrovimab-emergent resistance in immunocompromised COVID-19 patients**

*F. Novazzi<sup>1,2</sup>, D. Focosi<sup>3</sup>, F. Drago Ferrante<sup>1</sup>, S. Boutahar<sup>1</sup>, A. Genoni<sup>1</sup>, F. Dentali<sup>2</sup>, D. Dalla Gasperina<sup>2</sup>, A. Bai<sup>1,2</sup>, F. Maggi<sup>1,2</sup>*

<sup>1</sup>Laboratory of Microbiology, ASST SetteLaghi, Varese, Italy, <sup>2</sup>Department of Medicine and Surgery, University of Insubria, Varese, Italy, <sup>3</sup>North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy



**OP 105 11.31-11.36 Tenofovir plasma and intracellular pharmacokinetics in INSTI-based regimens**

M. Ferrara<sup>1</sup>, G. Accardo<sup>1</sup>, S. Fantino<sup>1</sup>, G. Trevisan<sup>1</sup>, F. Alladio<sup>1</sup>, E. Drappero<sup>1</sup>, M. Tettoni<sup>1</sup>, E. De Vivo<sup>2</sup>, A. Ianniello<sup>2</sup>, J. Mula<sup>2</sup>, A. De Nicolò<sup>2</sup>, A. D'Avolio<sup>2</sup>, G. Di Perri<sup>1</sup>, A. Calcagno<sup>1</sup>, S. Bonora<sup>1</sup>

<sup>1</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, <sup>2</sup>Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Torino, Torino

**OP 106 11.38-11.43 Potent antiviral activity of new generation HIV-1 maturation inhibitors on human primary cells**

L. Duca<sup>1</sup>, P. Saccomandi<sup>1</sup>, L. Piermatteo<sup>1</sup>, R. Salpini<sup>1</sup>, C. Stacchiotti<sup>1</sup>, S. Aquaro<sup>2</sup>, C.F. Perno<sup>3</sup>, V. Svicher<sup>1</sup>, F. Ceccherini-Silberstein<sup>1</sup>

<sup>1</sup>Università degli Studi di Roma Tor Vergata, Dipartimento di Medicina Sperimentale, Roma, Italia, <sup>2</sup>Università della Calabria, Dipartimento di Farmacia e Scienze della Salute e della Nutrizione, Arcavacata di Rende (CS), Italia, <sup>3</sup>Ospedale Pediatrico Bambino Gesù, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Roma, Italia

**OP 107 11.45-11.50 Evaluation of the in vitro combinatorial activity of Ibalizumab and HIV-1 antivirals**

F. Giammarino, N. Bartolini, L. Fiaschi, F. Dragoni, I. Vicenti, M. Zazzi, F. Saladini

Department of Medical Biotechnologies, University of Siena, Italy



**SYMPOSIUM** 12.15-13.15


**AUDITORIUM SALA OGGIONI**

**A practical approach to HIV patients' management**

Chairs: A. Gori (Milano), F. Vichi (Firenze)

The objectives of this symposium are to provide both clinical management insights on «late presentation in HIV» identifying the unmet needs of specific vulnerable patients, such as migrants, pregnant women, trans individuals, adolescents, and to increase the level of awareness for the HIV management in these specific populations. The program will also include new immuno-pharmacology concepts that may have a role in the future HIV therapy as well as a lecture on some new therapeutic approaches to tuberculosis that can impact the future management of people with HIV.

- 12.15-12.30 **Management of Late presentation in vulnerable populations - Interactive clinical case** C. Pinnetti, Roma
- 12.30-12.45 **Chasing inflammation: is there a role of the immunomodulant agents in HIV?**  
- Interactive clinical case G. Marchetti, Milano
- 12.45-13.00 **New therapeutic approaches to tuberculosis in people living with HIV** A. Matteelli, Brescia
- 13.00-13.15 **Discussion on Symposium issues**



**ORAL COMMUNICATIONS** 12.15-13.15

**SALA STUCCHI**

**HIV and SARS-CoV-2: two intersecting epidemics**

Chairs: M. Breveglieri (Bologna), S. Lo Caputo (Foggia)

**OC 38 12.15-12.25 The Cascade of HIV Care (CoC) of Milan as compared to Italy: data derived from the COA Registry and the Icona cohort- Milan Fast Track City**

A. d'Arminio Monforte<sup>1,3,7</sup>, A. Navarra<sup>2</sup>, A. Tavelli<sup>3,7</sup>, B. Suligoj<sup>4</sup>, V. Regine<sup>4</sup>, L. Pugliese<sup>4</sup>, L. Timelli<sup>5</sup>, A. Caraglia<sup>5</sup>, M. Oldrini<sup>6</sup>, L. Cosmaro<sup>3,7</sup>, D. Calzavara<sup>7</sup>, M. Cernuschi<sup>3,7</sup>, G. Rizzardini<sup>8</sup>, A. Gori<sup>3,9</sup>, S. Antinori<sup>10</sup>, M. Puoti<sup>3,11</sup>, A. Castagna<sup>3,12</sup>, E. Girardi<sup>2,3</sup>

<sup>1</sup>ASST Santi Paolo e Carlo, Unità Malattie Infettive e Tropicali, Milano, Italia, <sup>2</sup>Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" - IRCCS, Roma, Italia, <sup>3</sup>Fondazione Icona, Milano, Italia, <sup>4</sup>Istituto Superiore di Sanità, Roma, Italia, <sup>5</sup>Ministero della Salute, Roma, <sup>6</sup>Fondazione LILA Milano, Milano, Italia, <sup>7</sup>Milano Check Point, Milano, Italia, <sup>8</sup>ASST Fatebenefratelli-Sacco, Divisione 1 Malattie Infettive, Milano, Italia, <sup>9</sup>IRCCS Ca' Granda Ospedale Maggiore Policlinico, Clinica di Malattie Infettive, Milano, Italia, <sup>10</sup>ASST Fatebenefratelli-Sacco, Divisione 3 Malattie Infettive, Milano, Italia, <sup>11</sup>ASST Grande Ospedale Metropolitano Niguarda, Unità Malattie Infettive, Milano, Italia, <sup>12</sup>IRCCS Ospedale San Raffaele, Unità di Malattie Infettive, Milano, Italia

**OC 39 12.27-12.37 Effect of COVID-19 pandemic on the HIV cascade of care at a Provincial level**

F. Maggiolo<sup>1</sup>, R. Teocchi<sup>1</sup>, P. Meli<sup>2</sup>, D. Valenti<sup>3</sup>, F. Radici<sup>4</sup>, I. Mercurio<sup>5</sup>, A.P. Callegaro<sup>6</sup>

<sup>1</sup>ASST Papa Giovanni XXIII, <sup>2</sup>Comunità Emmaus & Caritas Bergamasca, <sup>3</sup>Associazione FROM, <sup>4</sup>Arcigay Bergamo Cives, <sup>5</sup>CRI-Comitato di Bergamo, <sup>6</sup>ASST Bergamo Est, Bergamo



**OC 40** 12.39-12.49 **SARS-CoV-2 infection and vaccination coverage among fragile populations in a Local Health Area of Northern Italy**

G. Maifredi<sup>1</sup>, I. Izzo<sup>2</sup>, C. Gasparotti<sup>1</sup>, C.V. Sileo<sup>1</sup>, S. Storti<sup>2</sup>, M. Degli Antoni<sup>2</sup>, G. Tiecco<sup>2</sup>, S. Amadasi<sup>2</sup>, E. Focà<sup>2</sup>, F. Castelli<sup>2</sup>, E. Quirós-Roldán<sup>2</sup>

<sup>1</sup>ATS Brescia (Brescia Health Protection Agency), Brescia, Italy, <sup>2</sup>Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali di Brescia, Brescia, Italy

**OC 41** 12.51-13.01 **New diagnosis of HIV among transgender women sex-workers across time: results from a multi-year street-based intervention (2017-2020)**

G. Lapadula<sup>1,2</sup>, E. Beretta<sup>1</sup>, P. Columpsi<sup>1</sup>, M. Comolatti<sup>1</sup>, N. Corti<sup>2</sup>, S. Limonta<sup>1</sup>, A. Rugova<sup>1</sup>, A. Ranzani<sup>1</sup>, A. Soria<sup>1</sup>, N. Squillace<sup>1</sup>, E. Lungu<sup>3</sup>, A. Monopoli<sup>3</sup>, V. Cristiano<sup>3</sup>, P. Bonfanti<sup>1,2</sup>

<sup>1</sup>School of Medicine, University of Milano-Bicocca, Milan, Italy, <sup>2</sup>San Gerardo Hospital, ASST Monza, Monza, Italy, <sup>3</sup>ALA Milano Onlus, Milan, Italy



**EXPERT MEETING** 12.15-13.15

**ALABASTRO A**

**Redefining management and treatment goals in antiretroviral triple therapy: results of a Delphi Consensus**

Chair: A. Di Biagio (Genova)

Con la sponsorizzazione non condizionante di Gilead Sciences

Modern antiretroviral therapy (ART) offers several treatment options characterized by high efficacy and tolerability, and new strategies with less drug regimens and new drugs are now available for the treatment of HIV infection. As definitive data on the long-term success of these new strategies are lacking, a panel of Experts in the care of HIV infection expressed their consensus on which could be the best strategy to achieve and maintain long-term virological and clinical success for PLWH in course of antiretroviral therapy, using Delphi methodology. The main consensus statements developed will be presented and discussed during this Meeting.

12.15-12.30 **Optimizing the ARV treatment focusing on long-term effectiveness and a person-centred approach: consensus guidance using Delphi process**

A. Di Biagio, Genova

12.30-13.10 **Round table - Delphi Consensus results:**

Discussants: M. Borderi, Bologna; G. Guaraldi, Modena; P. Maggi, Caserta

**- Clinical efficacy: ART-monitoring strategy**

**- Immunology and Pharmacology**

**- Long-term safety**

**- Quality of life assessment**

13.10-13.15 **Final considerations**

A. Di Biagio, Genova



**ORAL POSTER** 12.15-13.05

**ALABASTRO B**

**Acute COVID-19 and post COVID-19 syndrome**

Chairs: M. Lichtner (Latina), A. Vergori (Roma)

**OP 108** 12.15-12.20 **Long-COVID syndrome data from 126,752 patients: a systematic review and meta-analysis**

F. Di Gennaro<sup>1</sup>, A. Belati<sup>1</sup>, O. Tulone<sup>2</sup>, L. Diella<sup>1</sup>, D.F. Bavaro<sup>1</sup>, R. Bonica<sup>2</sup>, V. Genna<sup>2</sup>, L. Smith<sup>3</sup>, M. Trott<sup>3</sup>, M. Barbagallo<sup>2</sup>, L.J. Dominguez<sup>1</sup>, N. Veronese<sup>2</sup>, A. Saracino<sup>1</sup>

<sup>1</sup>Department of Biomedical Sciences and Human Oncology, Section of Infectious Diseases, University of Bari, Bari, Italy, <sup>2</sup>Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, Palermo, Italy, <sup>3</sup>Faculty of Sport Sciences, University of Murcia, Murcia, Spain

**OP 109** 12.22-12.27 **Post-Acute Sequelae of COVID-19 (PASC): An Italian Experience**

P. Pasculli<sup>1</sup>, M.A. Zingaropoli<sup>1</sup>, F. Ciccone<sup>1</sup>, F. Paribeni<sup>1</sup>, R. Merz<sup>1</sup>, F. Dominelli<sup>1</sup>, G. Siccardi<sup>1</sup>, S. Pellegrini<sup>1</sup>, G. Galardo<sup>2</sup>, C.M. Mastroianni<sup>1</sup>, M.R. Ciardi<sup>1</sup>

<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, <sup>2</sup>Medical Emergency Unit, Sapienza, University of Rome, Policlinico Umberto I, Rome, Italy



**OP 110 12.29-12.34 A multidisciplinary model to screen and treat the post COVID-19 Syndrome**

N. Squillace<sup>1</sup>, V. Cogliandro<sup>1</sup>, E. Rossi<sup>2</sup>, G. Bellelli<sup>3,9</sup>, G. Foti<sup>4,9</sup>, M. Pozzi<sup>4</sup>, F. Luppi<sup>5,9</sup>, M. Lettino<sup>6</sup>, M.G. Strepparava<sup>7,9</sup>, C. Ferrarese<sup>8,9</sup>, E. Pollastri<sup>1</sup>, A. Rugova<sup>1</sup>, E. Ricci<sup>10</sup>, P. Bonfanti<sup>1,9</sup> for the STORM Long-COVID Team

<sup>1</sup>Infectious Disease Unit, San Gerardo hospital, ASST-Monza, Italy, <sup>2</sup>Bicocca Center of Bioinformatics, Biostatistics and Bioimaging, University of Milano-Bicocca, Monza, Italy, <sup>3</sup>Acute Geriatric Unit, San Gerardo hospital, ASST-Monza, Italy, <sup>4</sup>Anesthesia and Intensive Care Unit, San Gerardo hospital, ASST-Monza, Italy, <sup>5</sup>Respiratory Disease Unit, San Gerardo hospital, ASST-Monza, Italy, <sup>6</sup>Cardiology Division, San Gerardo Hospital, ASST-Monza, Monza, Italy, <sup>7</sup>Department of Mental Health, Clinical Psychology Unit, San Gerardo Hospital, ASST-Monza, Monza, Italy, <sup>8</sup>Neurology Unit, San Gerardo hospital, ASST-Monza, Italy, <sup>9</sup>School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy, <sup>10</sup>Fondazione ASIA

**OP 111 12.36-12.41 Long term complications of COVID-19 in patients hospitalized in Clinica Malattie Infettive, Ospedali Riuniti, Ancona**

B. Candelaresi, S. Mazzanti, L. Brescini, V. Barocci, M. Di Pietrantonio, P. Mantini, S. Olivieri, F. Pallotta, F. Ginevri, G. Cesaretti  
Clinica Malattie Infettive, Ospedali Riuniti, Ancona

**OP 112 12.43-12.48 Outcome of patients with chronic liver disease hospitalized for SARS-CoV-2: a single centre matched cohort**

M. Ranzenigo<sup>1</sup>, C. Bertoni<sup>1</sup>, D. Ceccarelli<sup>2</sup>, L. Galli<sup>2</sup>, E. Messina<sup>2</sup>, H. Hasson<sup>2</sup>, A. Siribelli<sup>2</sup>, R. Lolatto<sup>2</sup>, A. Castagna<sup>1,2</sup>, C. Uberti-Foppa<sup>1,2</sup>, G. Morsica<sup>2</sup>

<sup>1</sup>Vita-Salute University, Milan, Italy, <sup>2</sup>Dept. of Infectious Diseases, San Raffaele Hospital, Milan, Italy

**OP 113 12.50-12.55 Characterization of three waves of COVID-19 occurring in southern Italy: results of a multicentre cohort study**

V. Pattapola<sup>1</sup>, M. Pisaturo<sup>1</sup>, P. Maggi<sup>2</sup>, A. Russo<sup>1</sup>, R. Astorri<sup>1</sup>, F.G. Numis<sup>3</sup>, I. Gentile<sup>4</sup>, V. Sangiovanni<sup>5</sup>, V. Esposito<sup>6</sup>, R. Punzi<sup>7</sup>, G. Calabria<sup>8</sup>, C. Rescigno<sup>9</sup>, A. Salomone Megna<sup>10</sup>, A. Masullo<sup>11</sup>, E. Manzillo<sup>12</sup>, G. Russo<sup>13</sup>, R. Parrella<sup>14</sup>, G. Dell'Aquila<sup>15</sup>, M. Gambardella<sup>16</sup>, A. Ponticello<sup>17</sup>, N. Coppola<sup>1</sup> on behalf of CoviCam group

<sup>1</sup>Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania "L. Vanvitelli", Napoli, Italy, <sup>2</sup>Infectious Diseases Unit, A.O. S Anna e S. Sebastiano Caserta, Italy, <sup>3</sup>Emergency unit, PO Santa Maria delle Grazie, Pozzuoli, Italy, <sup>4</sup>Infectious disease unit; University Federico II, Naples, Italy, <sup>5</sup>Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, <sup>6</sup>IV Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>7</sup>Hepatic Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>8</sup>IX Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>9</sup>First Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>10</sup>Infectious Disease Unit, A.O. San Pio, PO Rummo, Benevento, Italy, <sup>11</sup>Infectious disease unit, A.O. San Giovanni di Dio e Ruggi D'Aragona Salerno, Italy, <sup>12</sup>VIII Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>13</sup>Infectious Disease Unit, Ospedale Maria S.S. Addolorata di Eboli, ASL Salerno, Italy, <sup>14</sup>Respiratory Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>15</sup>Infectious Diseases Unit, AO Avellino, Italy, <sup>16</sup>Infectious Disease Unit, PO S. Luca, Vallo della Lucania, ASL Salerno, Italy, <sup>17</sup>Pneumology Unit, AORN Caserta, Italy



ORAL POSTER 12.15-13.05

BERGAMO SCIENCE CENTER

**Immunological efficacy of COVID-19 vaccination in vulnerable populations**

Chairs: G. Scarlatti (Milano), M. Tavio (Ancona)

**OP 114 12.15-12.20 TNF-alfa expression is negatively correlated to seroconversion after SARS-CoV-2 mRNA BNT162b2 vaccine in lung transplant patients**

M. Guardiani<sup>1</sup>, M.A. Zingaropoli<sup>1</sup>, F. Cogliatti-Dezza<sup>1</sup>, A. Centofanti<sup>2</sup>, C. Carillo<sup>2</sup>, E. Tortellini<sup>1</sup>, F. Dominelli<sup>1</sup>, A. Napoli<sup>3</sup>, A. Gaeta<sup>1</sup>, F. Venuta<sup>2</sup>, M. Lichtner<sup>1,4</sup>, M.R. Ciardi<sup>1</sup>, C.M. Mastroianni<sup>1</sup>, G. Russo<sup>1</sup>

<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, <sup>2</sup>Department of General and Specialistic Surgery "Paride Stefanini", Sapienza University of Rome, <sup>3</sup>Department of Molecular Medicine, Sapienza University of Rome, <sup>4</sup>Infectious Diseases Unit, Santa Maria (SM) Goretti Hospital, Sapienza University of Rome, Latina

**OP 115 12.22-12.27 Different specific T cell responses to the third dose of mRNA COVID-19 vaccine in multiple sclerosis patients under disease modifying treatments**

F. Dominelli<sup>1</sup>, M.A. Zingaropoli<sup>1</sup>, M. Tartaglia<sup>2</sup>, E. Tortellini<sup>1</sup>, M. Guardiani<sup>1</sup>, V. Perri<sup>1</sup>, P. Pasculli<sup>1</sup>, F. Ciccone<sup>1</sup>, L. Malimpensa<sup>2</sup>, V. Baione<sup>2</sup>, A. Napoli<sup>3</sup>, A. Gaeta<sup>1</sup>, M. Lichtner<sup>1,4</sup>, A. Conte<sup>2</sup>, C.M. Mastroianni<sup>1</sup>, M.R. Ciardi<sup>1</sup>

<sup>1</sup>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza, Università di Roma, <sup>2</sup>Dipartimento di Neuroscienze Umane, Centro di Sclerosi Multipla, Sapienza, Università di Roma, <sup>3</sup>Dipartimento di Medicina Molecolare, Sapienza, Università di Roma, <sup>4</sup>Unità di Malattie Infettive, Ospedale S. Maria Goretti/Sapienza Università di Roma, Latina, Italia

**OP 116 12.29-12.34 SARS-CoV-2 vaccination effectiveness in Pemphigus Vulgaris Rituximab-treated patients**

C. Fenizia<sup>1</sup>, O. Utyro<sup>2</sup>, S. Salanitro<sup>2</sup>, C. Moltrasio<sup>1</sup>, M. Clerici<sup>1</sup>, L. Ottobrini<sup>1</sup>, A. Marzano<sup>1</sup>, D. Trabattini<sup>2</sup>

<sup>1</sup>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, <sup>2</sup>Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy



**OP 117 12.36-12.41 SARS-CoV-2 antibody response in solid organ transplant patients after mRNA BNT162b2: data from an observational prospective study**

F. Cogliati Dezza<sup>1</sup>, F. Dominelli<sup>1</sup>, M. Guardiani<sup>1</sup>, E. Tortellini<sup>1</sup>, G. Savelloni<sup>1</sup>, M. Garofalo<sup>2</sup>, A. Centofanti<sup>3</sup>, C. Carillo<sup>3</sup>, A. Gaeta<sup>4</sup>, R. Pretagostini<sup>2</sup>, G. Russo<sup>1</sup>, C.M. Mastroianni<sup>1</sup>

<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome Italy, <sup>2</sup>General Surgery and Organ Transplantation Unit, Sapienza University of Rome, Rome, Italy, <sup>3</sup>Division of Thoracic Surgery and Lung Transplant, Sapienza University of Rome, Rome, Italy, <sup>4</sup>Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy

**OP 118 12.43-12.48 Durability of SARS-CoV-2 mRNA vaccine immune response in people living with HIV**

S. Cicalini<sup>1</sup>, A. Cozzi-Lepri<sup>2</sup>, A. Vergori<sup>1</sup>, S. Meschi<sup>1</sup>, V. Bordoni<sup>1</sup>, S. Lanini<sup>1</sup>, D. Lapa<sup>1</sup>, D. Mariotti<sup>1</sup>, L. De Pascale<sup>1</sup>, V. D'Aquila<sup>1</sup>, M. Fusto<sup>1</sup>, C. Castillett<sup>1</sup>, A.R. Garbuglia<sup>1</sup>, C. Agrati<sup>1</sup>, E. Girardi<sup>1</sup>, F. Vaia<sup>1</sup>, A. Antinori<sup>1</sup>

<sup>1</sup>National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Roma, Italy, <sup>2</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK

**OP 119 12.50-12.55 Decay pattern of Anti-SARS-CoV-2 Antibodies in PWH**

J. Milic<sup>1</sup>, A. Tili<sup>2</sup>, S. Renzetti<sup>3</sup>, F. Motta<sup>1</sup>, M. Meschiari<sup>2</sup>, R. Fogliani<sup>2</sup>, F. Ferrari<sup>2</sup>, B. Meccugni<sup>2</sup>, S. Mimmi<sup>2</sup>, S. Borsari<sup>2</sup>, S. Calza<sup>3</sup>, A. Cossarizza<sup>1</sup>, C. Mussini<sup>1,2</sup>, G. Guaraldi<sup>1,2</sup>

<sup>1</sup>University of Modena and Reggio Emilia, Modena, Italy, <sup>2</sup>Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy, <sup>3</sup>University of Brescia, Brescia, Italy



**SYMPOSIUM** 13.15-14.15

**AUDITORIUM SALA OGGIONI**

**Immunological control over HIV: from models of spontaneous control to immunotherapeutic approaches**

Chairs: C. Agrati (Roma), A. Cossarizza (Modena)

The symposium is intended to address different aspects of the immune control over HIV. In particular, a comprehensive review of the latest notions on known human and animal models of spontaneous control over HIV will be provided. The interaction of the virus with specific cell subpopulations, and in particular stem cell memory cells, will also be illustrated. The most novel specific immunotherapeutic approaches to overcome HIV infection will also be thoroughly reviewed during the symposium.

- |             |  |                      |
|-------------|--|----------------------|
| 13.15-13.30 | <b>HIV and stem cell memory cells: from pathogenesis to therapeutic approaches</b> | L. Manganaro, Milano |
| 13.30-13.45 | <b>Immunotherapy as a tool towards cure interventions</b>                          | M.S. Clerici, Milano |
| 13.45-14.00 | <b>Models of spontaneous control over HIV infection</b>                            | G. Poli, Milano      |
| 14.00-14.15 | <b>Discussion on Symposium issues</b>  |                      |



**ORAL COMMUNICATIONS** 13.15-14.15

**SALA STUCCHI**

**Diabetes, cardiovascular diseases and STIs. A wide range of comorbidities**

Chairs: T. Bini (Milano), G. Orofino (Torino)

**OC 42 13.15-13.25 Incident diabetes in course of antiretroviral therapy**

L. Taramasso<sup>1</sup>, N. Squillace<sup>2</sup>, E. Ricci<sup>3</sup>, B. Menzaghi<sup>4</sup>, G. Orofino<sup>5</sup>, G.V. De Socio<sup>6</sup>, C. Molteni<sup>7</sup>, C.V. Martinelli<sup>8</sup>, G. Madeddu<sup>9</sup>, F. Vichi<sup>10</sup>, L. Valsecchi<sup>11</sup>, B.M. Celesia<sup>12</sup>, P. Maggi<sup>13</sup>, F. Conti<sup>14</sup>, G.F. Pellicanò<sup>15</sup>, A. Cascio<sup>16</sup>, E. Sarchi<sup>17</sup>, R. Gulminetti<sup>18</sup>, G. Parruti<sup>19</sup>, L. Calza<sup>20</sup>, K. Falasca<sup>21</sup>, A. Di Biagio<sup>1,22</sup>, P. Bonfanti<sup>2</sup> on behalf of CISAI Study Group

<sup>1</sup>Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Genoa, Italy, <sup>2</sup>Infectious Diseases Clinic, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy, <sup>3</sup>Fondazione ASIA Onlus, Buccinasco (MI), Italy, <sup>4</sup>Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio Hospital, Busto Arsizio, Italy, <sup>5</sup>Unit of Infectious Diseases, "Divisione A", Amedeo di Savoia Hospital, Torino, Italy, <sup>6</sup>Clinic of Infectious Diseases, Department of Medicine, Azienda Ospedaliera di Perugia, Santa Maria Hospital, Perugia, <sup>7</sup>Infectious Disease Unit, Ospedale A. Manzoni, Lecco, Italy, <sup>8</sup>SOD Malattie Infettive e Tropicali AOU Careggi, Florence, Italy, <sup>9</sup>Unit of Infectious and Tropical Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, <sup>10</sup>Infectious Diseases Department, SOC 1, USLCENTROFIRENZE, Santa Maria Annunziata Hospital, Florence, Italy, <sup>11</sup>Infectious Disease Unit (I Divisione), ASST Fatebenefratelli Sacco, Milan, Italy, <sup>12</sup>Unit of Infectious Diseases, University of Catania, ARNAS Garibaldi, Catania, Italy, <sup>13</sup>Department of Infectious Disease, University of Campania Luigi Vanvitelli, Naples, Italy, <sup>14</sup>Infectious Diseases Unit, Department of Biomedical and Clinical Sciences 'Luigi Sacco', Università degli Studi di Milano, Milan, Italy, <sup>15</sup>Department of Human Pathology of the Adult and the Developmental Age 'G. Barresi', Unit of Infectious Diseases, University of Messina, <sup>16</sup>Infectious and Tropical Diseases Unit- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE) - University of Palermo, Palermo, Italy, <sup>17</sup>Infectious Diseases Unit, SS. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, <sup>18</sup>Fondazione



IRCCS Policlinico San Matteo, University of Pavia, Pavia Italy, <sup>19</sup>Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy, <sup>20</sup>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna, Bologna, Italy, <sup>21</sup>Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University 'G. d'Annunzio' Chieti-Pescara, Chieti, Italy, <sup>22</sup>Department of Health Sciences, Infectious Disease Clinic, University of Genoa, Genoa, Italy

**OC 43 13.27-13.37 Treatment with integrase inhibitors among antiretroviral naïve patients is not associated with increased risk of diabetes mellitus**

G. Lapadula<sup>1,2</sup>, A. Soria<sup>2</sup>, G. Micheli<sup>3</sup>, M.V. Cossu<sup>4</sup>, A. De Vito<sup>5</sup>, G. Guaraldi<sup>6</sup>, A. Castagna<sup>7</sup>, A. Di Biagio<sup>8</sup>, S. Cicalini<sup>9</sup>, P. Bonfanti<sup>1,2</sup>, A. Cozzi-Lepri, A. d'Arminio Monforte for ICONA cohort Study

<sup>1</sup>School of Medicine, University of Milano Bicocca, Milano, Italy, <sup>2</sup>Clinic of Infectious Diseases, San Gerardo Hospital, ASST Monza, Monza, Italy, <sup>3</sup>Università Cattolica del Sacro Cuore, Infectious Diseases Unit, Roma, Italy, <sup>4</sup>1st Division of Infectious Diseases, 'Luigi Sacco' University Hospital, Milan, Italy, <sup>5</sup>Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, <sup>6</sup>Unit of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy, <sup>7</sup>University "Vita Salute", San Raffaele Hospital, Milano, Italy, <sup>8</sup>Unit of Infectious Diseases, University of Genoa, Genoa, Italy, <sup>9</sup>National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy

**OC 44 13.39-13.49 Non-Alcoholic to Metabolic Associated Fatty Liver Disease: Cardiovascular Implications of a Change in Terminology in Patients Living With HIV**

J. Milic<sup>1</sup>, S. Renzetti<sup>2</sup>, F. Motta<sup>2</sup>, L. Gozzi<sup>3</sup>, A. Cervo<sup>3</sup>, G. Burastero<sup>3</sup>, V. Iadernia<sup>3</sup>, G. Franceschi<sup>3</sup>, M. Faltoni<sup>3</sup>, S. Volpi<sup>3</sup>, A. Mazzocchi<sup>3</sup>, C. Mussini<sup>2,3</sup>, G. Sebastiani<sup>4</sup>, S. Calza<sup>2</sup>, P. Raggi<sup>5</sup>, G. Guaraldi<sup>1,3</sup>

<sup>1</sup>University of Modena and Reggio Emilia, Modena, Italy, <sup>2</sup>University of Brescia, Brescia, Italy, <sup>3</sup>Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy, <sup>4</sup>McGill University Health Centre, Montreal, Canada, <sup>5</sup>University of Alberta, Edmonton, Canada

**OC 45 13.51-14.01 Syphilis infection and re-infection in PLWH and PrEP users: new insights into epidemic dynamics**

R. Rossotti<sup>1,5</sup>, D. Tesoro<sup>2,5</sup>, L. Gazzola<sup>2</sup>, A. Tavelli<sup>3</sup>, A. De Bona<sup>2,5</sup>, V. Licari<sup>4</sup>, F. D'Amico<sup>1</sup>, C. Baiguera<sup>1</sup>, D. Calzavara<sup>5</sup>, N.B. Bana<sup>1</sup>, V. Ferrara<sup>2</sup>, R. Repposi<sup>5</sup>, M. Cernuschi<sup>5,6</sup>, M. Puoti<sup>1,4</sup>, A. d'Arminio Monforte<sup>2,7</sup>

<sup>1</sup>Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, <sup>2</sup>Department of Infectious Diseases, ASST Santi Paolo e Carlo, Milan, <sup>3</sup>ICONA Foundation, Milan, <sup>4</sup>University of Milano-Bicocca, Milan, <sup>5</sup>Milano Checkpoint, Milan, <sup>6</sup>Unit of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, <sup>7</sup>University of Milano, Milan



**ORAL COMMUNICATIONS** 13.15- 14.15

**ALABASTRO A**

**Immunological efficacy of SARS-CoV-2 vaccine II**

Chairs: S. Parisi (Padova)

**OC 46 13.15-13.25 Monitoring saliva and plasma neutralizing activity induced by the administration of a third BNT162B2 vaccine dose**

M. Garziano<sup>1,2</sup>, O. Utyro<sup>3</sup>, S. Strizzi<sup>1</sup>, C. Vanetti<sup>1</sup>, I. Saulle<sup>1</sup>, C. Conforti<sup>1</sup>, F. Cicilano<sup>1</sup>, M. Clerici<sup>1,2</sup>, M. Biasin<sup>1</sup>

<sup>1</sup>Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milan, Italy, <sup>2</sup>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, <sup>3</sup>Department of Medical surgical and experimental sciences University of Sassari

**OC 47 13.27-13.37 Lower neutralization level against SARS-CoV-2 Omicron (BA.1) variant than against reference strain after a third dose of mRNA vaccine in PLWH**

A. Vergori<sup>1</sup>, A. Cozzi Lepri<sup>2</sup>, G. Matusali<sup>3</sup>, F. Colavita<sup>3</sup>, S. Cicalini<sup>1</sup>, P. Galli<sup>4</sup>, A.R. Garbuglia<sup>3</sup>, M. Fusto<sup>1</sup>, V. Puro<sup>5</sup>, E. Girardi<sup>6</sup>, F. Vaia<sup>7</sup>, A. Antinori<sup>1,4</sup>

<sup>1</sup>HIV/AIDS Unit, National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy, <sup>2</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK, <sup>3</sup>Virology Unit, National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy, <sup>4</sup>Health Direction, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, <sup>5</sup>Risk Management Unit, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, <sup>6</sup>Scientific Direction, National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy, <sup>7</sup>General Direction, National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy

**OC 48 13.39-13.49 T-cell responses to SARS-CoV-2 Spike protein after 3 doses of BNT162b2 mRNA vaccination in healthy individuals, crossrecognize Alpha, Delta and Omicron variants of concern**

M. Iannetta, A. Di Lorenzo, A. Imeneo, A. Lodi, L. Ferrari, I. Fato, B. Massa, P.G. Pace, I. Spalliera, P. Vitale, B. Rossi, T. Mulas, L. Campogiani, L. Coppola, M. Compagno, V. Malagnino, E. Teti, M. Andreoni, L. Sarmati

Department of System Medicine Tor Vergata University, Rome



**OC 49 13.51-14.01 CD4 cell count is critical for specific T cell-mediated response in PLWH before and after third dose of COVID-19 vaccine**

*E. Tortellini<sup>1</sup>, M.A. Zingaropoli<sup>1</sup>, G. Mancarella<sup>1,2</sup>, R. Marocco<sup>2</sup>, A. Carraro<sup>1,2</sup>, M. Jhamour<sup>2</sup>, V. Perri<sup>1</sup>, M. Guardiani<sup>1</sup>, F. Dominelli<sup>1</sup>, A. Napoli<sup>3</sup>, A. Gaeta<sup>1</sup>, F. Mengoni<sup>1</sup>, P. Zuccalà<sup>2</sup>, V. Belvisi<sup>2</sup>, B. Kertusha<sup>1,2</sup>, A. Parente<sup>1,2</sup>, C. Del Borgo<sup>2</sup>, V. Vullo<sup>1</sup>, M.R. Ciardi<sup>1</sup>, C.M. Mastroianni<sup>1</sup>, M. Lichtner<sup>1,2</sup> and LATINA COVID-19 Group*

<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, <sup>2</sup>Infectious Diseases Unit, SM Goretti Hospital, Sapienza University of Rome, Latina, <sup>3</sup>Department of Molecular Medicine, Sapienza University of Rome



ORAL POSTER 13.15-14.05

**Open questions about ART efficacy**

**ALABASTRO B**

Chairs: M. Borderi (Bologna), R. Gulminetti (Pavia)

**OP 120 13.15-13.20 Blood telomere length gain in virologically suppressed patients switching to dolutegravir plus lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study**

*F. Lombardi<sup>1</sup>, A. Sanfilippo<sup>2</sup>, M. Fabbiani<sup>3</sup>, A. Borghetti<sup>1</sup>, A. Ciccullo<sup>4</sup>, S. Di Giambenedetto<sup>1,2</sup>*

<sup>1</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Malattie Infettive, Roma, Italia, <sup>2</sup>Università Cattolica del Sacro Cuore, Dipartimento di Sicurezza e Bioetica, Roma Italia, <sup>3</sup>UOC Malattie Infettive e Tropicali, Azienda Ospedaliero-Universitaria Senese, Siena, Italia, <sup>4</sup>Unità di Malattie infettive, Ospedale San Salvatore, L'Aquila, Italia

**OP 121 13.22-13.27 Real-life use of Doravirine in treatment-experienced people living with HIV: an Italian multicentre study**

*M. Mazzitelli<sup>1</sup>, M. Degli Antoni<sup>2</sup>, F. Castelli<sup>2</sup>, D. Ripamonti<sup>3</sup>, G. Zuglian<sup>3</sup>, G. Lapadula<sup>4</sup>, M. Fabbiani<sup>5</sup>, A. Ferraresi<sup>6</sup>, C. Putaggio<sup>1</sup>, A.M. Cattelan<sup>1</sup>, E. Quiros-Roldan<sup>2</sup>*

<sup>1</sup>Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, <sup>2</sup>Department of Infectious and Tropical Diseases, ASST Spedali Civili General Hospital and University of Brescia, Brescia, <sup>3</sup>Infectious Diseases Unit, ASST Papa Giovanni XXIII, Bergamo, <sup>4</sup>University of Milan Bicocca, Monza, <sup>5</sup>Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Senese, Siena, <sup>6</sup>Division of Infectious Diseases, Cremona Hospital, Cremona

**OP 122 13.29-13.34 Forgiveness to imperfect adherence to bicitegravir/emtricitabine/tenofovir alafenamide**

*F. Maggiolo<sup>1</sup>, D. Valenti<sup>1,2</sup>, R. Teocchi<sup>3</sup>, L. Comi<sup>1</sup>, E. Di Filippo<sup>1</sup>, M. Rizzi<sup>1</sup>*

<sup>1</sup>UOC Infectious Diseases, <sup>2</sup>FROM foundation, <sup>3</sup>Informatics department, ASST Papa Giovanni XXII, Bergamo Italy

**OP 123 13.36-13.41 Evaluation of metabolic safety profile in naive and virologically suppressed HIV-1 infected individuals starting/switching to a bicitegravir single-tablet-regimen in a real-life setting**

*M. Trizzino, C. Gioè, E. Di Marco, A. Mancuso, M. Tolomeo, A. Cascio*

Infectious and Tropical Disease Unit, AOU Policlinico "P. Giaccone", Palermo, Italy

**OP 124 13.43-13.48 Real-world effectiveness of switching to bicitegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in women living with HIV: subgroup analysis from ICONA-BIC**

*A. d'Arminio Monforte<sup>1</sup>, A. Tavelli<sup>2</sup>, A. Cingolani<sup>3</sup>, C. Mussini<sup>4</sup>, S. Piconi<sup>5</sup>, A. Calcagno<sup>6</sup>, G. Orofino<sup>7</sup>, S. Cicalini<sup>8</sup>, A. Castagna<sup>9</sup>, F. Ceccherini Silberstein<sup>10</sup>, A. Gori<sup>11</sup>, A. Antinori<sup>8</sup>*

<sup>1</sup>Department of Health Sciences, Clinic of Infectious Diseases, 'San Paolo' Hospital, University of Milan, Milan, Italy, <sup>2</sup>Icona Foundation, Milan, Italy, <sup>3</sup>Infectious Diseases Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Department of Safety and Bioethics, Catholic University of the Sacred Heart, Rome, Italy, <sup>4</sup>Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, University of Modena and Reggio Emilia, Modena, Italy, <sup>5</sup>Infectious Diseases, ASST Lecco, Lecco, Italy, <sup>6</sup>Unit of Infectious Diseases, Ospedale Amedeo di Savoia, Department of Medical Sciences, University of Turin, Turin, Italy, <sup>7</sup>"Divisione A" Unit of Infectious Diseases, Ospedale Amedeo di Savoia, ASL Città di Torino, Italy, <sup>8</sup>Clinical Department, HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy, <sup>9</sup>Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, <sup>10</sup>Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, <sup>11</sup>Clinic of Infectious Diseases, IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

**OP 125 13.50-13.55 Tolerability, viro-immunological, metabolic effects, and costs of switching to BIC/TAF/FTC in a cohort of people living with HIV: a 48-week analysis**

*M. Mazzitelli<sup>1</sup>, M. Trunfio<sup>2</sup>, D. Mengato<sup>3</sup>, C. Putaggio<sup>1</sup>, L. Sasseti<sup>1</sup>, D. Leoni<sup>1</sup>, E. Castelli<sup>1</sup>, A.M. Cattelan<sup>1</sup>*

<sup>1</sup>Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, <sup>2</sup>Infectious Disease Unit, Department of Medical Sciences at Amedeo di Savoia Hospital, University of Torino, Torino, Italy, <sup>3</sup>Hospital Pharmacy Department, Padua University Hospital, Padua, Italy





ORAL POSTER 13.15-14.05

BERGAMO SCIENCE CENTER

## Immunological complexity in COVID-19

Chairs: E. Focà (Brescia), E. Nicastri (Roma)

**OP 126 13.15-13.20 Development of SARS-CoV-2 IgM after 1st vaccine dose predicts longer immunity**

*A. Ruggiero<sup>1</sup>, C. Piubelli<sup>2</sup>, L. Calciano<sup>1</sup>, G. Siracusano<sup>3</sup>, M.T. Valenti<sup>1</sup>, L.G. Delle Carbonare<sup>1</sup>, T. Fantoni<sup>1</sup>, L. Lopalco<sup>3</sup>, S. Accordini<sup>1</sup>, A. Beretta<sup>4</sup>, Z. Bisoffi<sup>2</sup>, D. Zipeto<sup>1</sup>*

<sup>1</sup>University of Verona, Verona, Italy, <sup>2</sup>IRCCS Sacro Cuore Don Calabria Hospital, Verona, Italy, <sup>3</sup>Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy, <sup>4</sup>Solongevity Research, Milan, Italy

**OP 127 13.22-13.27 Affinity maturation and neutralizing activity of anti-SARS-CoV-2 Spike antibodies**

*S. Caucci<sup>1</sup>, R. Longo<sup>1</sup>, B. Corvaro<sup>1</sup>, A. Valenza<sup>2</sup>, K. Marinelli<sup>2</sup>, P. Bagnarelli<sup>1,2</sup>, S. Menzo<sup>1,2</sup>*

<sup>1</sup>Department of Biomedical Sciences and Public Health, Università Politecnica delle Marche, Ancona, Italy, <sup>2</sup>Virology Laboratory, Azienda Ospedaliera Ospedali Riuniti di Ancona, Ancona, Italy

**OP 128 13.29-13.34 Correlation between clinical aspects and serum/CSF cytokine levels in early versus classic onset SARS-CoV-2-related Guillain-Barré Syndrome**

*S. Boni<sup>1</sup>, L. Benedetti<sup>2</sup>, M. Feasi<sup>1</sup>, A. Assini<sup>3</sup>, E. Blasi Vacca<sup>1</sup>, S. Grisanti<sup>2,4</sup>, A. Parisini<sup>1</sup>, D. Franciotta<sup>2</sup>, F. Del Puente<sup>1</sup>, F. Massa<sup>2,4</sup>, N. Bobbio<sup>1</sup>, T. Vigo<sup>2</sup>, R. Prinapori<sup>1</sup>, D. Giunti<sup>2</sup>, E. Mobilia<sup>2</sup>, D. Visigalli<sup>2</sup>, A. Beronio<sup>5</sup>, P. Rivera<sup>6</sup>, F. Bandini<sup>7</sup>, A. Granata<sup>8</sup>, E. Narciso<sup>7</sup>, A. Schenone<sup>2,4</sup>, E. Pontali<sup>1</sup>*

<sup>1</sup>Department of Infectious Diseases - Galliera Hospital, Genova, Italy, <sup>2</sup>IRCCS, Ospedale Policlinico San Martino, Genova, Italy, <sup>3</sup>Neurology Unit, Galliera Hospital Genova, Italy, <sup>4</sup>Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genova, Italy, <sup>5</sup>Department of Neurology, Sant'Andrea Hospital, La Spezia, Italy, <sup>6</sup>Department of Neurology, Imperia Hospital, Imperia, Italy, <sup>7</sup>Department of Neurology, ASL3 Genovese, Genova, Italy, <sup>8</sup>Department of Neurology Santa Corona Hospital, Pietra Ligure, Savona, Italy

**OP 129 13.36-13.41 A real-life single-center study on the impact of anti-SARS-CoV2 vaccination**

*C. Leanza<sup>1</sup>, S. Covino<sup>1</sup>, R.A. Valia<sup>1</sup>, A. Destro<sup>1</sup>, F. Petrucci<sup>1</sup>, E. Motta<sup>1</sup>, M. Aneuchoum<sup>1</sup>, R. Donà<sup>1</sup>, F. Cancelli<sup>1</sup>, C.M. Mastroianni<sup>1</sup>*

Department of Public Health and Infectious Diseases, Sapienza University, Rome

**OP 130 13.43-13.48 Short course remdesivir in early Covid-19 as an effective and useful option in both out- and in-patients**

*C. Del Borgo<sup>1</sup>, A. Gasperin<sup>2</sup>, R. Marocco<sup>1</sup>, D. Di Trento<sup>2</sup>, S. Garattini<sup>2</sup>, M. De Masi<sup>1</sup>, A. Grimaldi<sup>2</sup>, S. Corazza<sup>2</sup>, S.G. De Maria<sup>2</sup>, S. Gismondi<sup>1</sup>, P. Fabietti<sup>1</sup>, B. Bartolozzi<sup>1</sup>, G. Bagaglini<sup>3</sup>, G. Bonanni<sup>3</sup>, M. Lichtner<sup>1,2</sup>*

<sup>1</sup>Infectious Diseases Unit, SM Goretti Hospital Latina, <sup>2</sup>Department of Public Health and Infectious Diseases, "La Sapienza" University, Rome, <sup>3</sup>Pharmacy Service Unit, SM Goretti Hospital Latina

**OP 131 13.50-13.55 Dendritic cell maturation after infection with a clone of Leishmania tarentolae expressing the SARS-CoV-2 spike protein as a vaccine vehicle**

*M. Garziano<sup>1,2</sup>, I. Varotto-Boccazzi<sup>3,4</sup>, C. Conforti<sup>1</sup>, G.M. Cattaneo<sup>3</sup>, B. Bisaglia<sup>3</sup>, P. Gabrieli<sup>3,4</sup>, M. Paroni<sup>3,4</sup>, A. Manenti<sup>5</sup>, D. Rubolini<sup>6,7</sup>, M. Clerici<sup>2,8</sup>, E. Montomoli<sup>5,9</sup>, G. Zuccotti<sup>1,4</sup>, C. Vanetti<sup>1</sup>, S. Epis<sup>3,4</sup>, M. Biasin<sup>1</sup>, C. Bandi<sup>3,4</sup>, D. Trabattoni<sup>1</sup>*

<sup>1</sup>Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, <sup>2</sup>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, <sup>3</sup>Department of Biosciences, University of Milan, Milan, Italy, <sup>4</sup>Pediatric CRC 'Romeo ed Enrica Invernizzi', University of Milan, Milan, Italy, <sup>5</sup>VisMederi, Siena, Italy, <sup>6</sup>Department of Environmental Science and Policy, University of Milan, Milan, Italy, <sup>7</sup>Water Research Institute-National Research Council of Italy, IRSA-CNR, Brugherio, Italy, <sup>8</sup>IRCCS Fondazione don Carlo Gnocchi, Milan, Italy, <sup>9</sup>Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy







**SYMPOSIUM** 14.15-15.15

**AUDITORIUM SALA OGGIONI**

**COVID-19 from early treatment to long-term care**

Chairs: G. Rizzardini (Milano), M. Rizzi (Bergamo)

This symposium will offer insights in the early and late management of COVID-19. On one end, we will discuss risk stratification of vulnerable individuals who qualify for early treatment of SARS-CoV-2 infection. On the other end, we will discuss pathogenesis and care of Post-Acute COVID Syndrome (PACS). A clinical case presentation of a vaccinated individual living with HIV will offer the framework to discuss risk stratification for early treatment of immunologically vulnerable populations, as well as how to assess and manage post-acute COVID Syndrome.

- 14.15-14.30 **From risk stratification to early treatment. How to keep a patient with SARS-CoV-2 out of hospital?** D. Peppia, London UK
- 14.30-14.45 **From acute to post acute SARS-CoV-2 disease: can we prevent or reverse PACS?** S.G. Deeks, San Francisco USA
- 14.45-15.15 **Panel discussion - Clinical models in managing PACS. Is resilience our goal?** Discussants:  
S. Deeks, San Francisco USA; G. d'Ettore, Roma; A. M. Geretti, Roma;  
G. Guaraldi, Modena; D. Peppia, London UK; A. Vergori, Roma



**ORAL COMMUNICATIONS** 14.15-15.15

**SALA STUCCHI**

**Dual therapy in naive and switched PLWH**

Chairs: S. Carbonara (Bari), B. Celesia (Catania)

- OC 50** 14.15-14.25 **Adherence rates and forgiveness to uncomplete adherence to 3TC/DTG**  
*F. Maggiolo<sup>1</sup>, D. Valenti<sup>1,2</sup>, R. Teocchi<sup>3</sup>, L. Comi<sup>1</sup>, E. Di Filippo<sup>1</sup>*  
<sup>1</sup>UOC Infectious Diseases, <sup>2</sup>FROM foundation, <sup>3</sup>Informatics department, ASST Papa Giovanni XXII, Bergamo Italy
- OC 51** 14.27-14.37 **12-Month immunological changes in patients randomized to switch either to BIC/TAF/FTC or DTG/3TC (DEBATE study)**  
*A. Cossarizza<sup>1</sup>, M. Mattioli<sup>1</sup>, A. Paolini<sup>1</sup>, A. Neroni<sup>1</sup>, S. De Biasi<sup>1</sup>, D. Lo Tartaro<sup>1</sup>, R. Borella<sup>1</sup>, L. Fidanza<sup>1</sup>, L. Gibellini<sup>1</sup>, B. Beghetto<sup>2</sup>, E. Roncaglia<sup>2</sup>, G. Nardini<sup>2</sup>, M. Menozzi<sup>2</sup>, G. Cuomo<sup>2</sup>, M. Di Gaetano<sup>2</sup>, G. Orlando<sup>2</sup>, V. Borghi<sup>2</sup>, C. Mussini<sup>1,2</sup>*  
<sup>1</sup>University of Modena and Reggio Emilia, School of Medicine, <sup>2</sup>AOU Policlinico di Modena
- OC 52** 14.39-14.49 **Switch to doravirine with dolutegravir dual regimen compared to other dual dolutegravir-based regimens in clinical practice: a 96-week analysis**  
*R. Rossotti<sup>1</sup>, F. D'Amico<sup>1</sup>, A. Nava<sup>2</sup>, A. Raimondi<sup>1</sup>, D. Fanti<sup>2</sup>, N.B. Bana<sup>1</sup>, E. Inglese<sup>2</sup>, L.G. Chianura<sup>1</sup>, M.C. Moiola<sup>1</sup>, C. Vismara<sup>2</sup>, M. Puoti<sup>1</sup>*  
<sup>1</sup>Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, <sup>2</sup>Chemical-Clinical and Microbiological Analyses, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
- OC 53** 14.51-15.01 **Clinical and virological characteristics of people living with HIV who fail to maintain virological suppression after switching to dolutegravir-based two drug regimens. Results from the prospective observational ARCA cohort**  
*L. Taramasso<sup>1</sup>, R. Gagliardini<sup>2</sup>, C. Sepulcri<sup>3</sup>, A. Shallvari<sup>4</sup>, W. Gennari<sup>5</sup>, F. Lombardi<sup>6</sup>, S. Di Giambenedetto<sup>6,7</sup>, F. Maggiolo<sup>8</sup>, I. Vicenti<sup>9</sup>, V. Borghi<sup>10</sup>, V. Micheli<sup>11</sup>, D. Francisci<sup>12</sup>, E. Pontali<sup>13</sup>, S. Rusconi<sup>14</sup>, R. Maserati<sup>15</sup>, P. Laghetti<sup>16</sup>, B. Bruzzone<sup>17</sup>, S.T. Kiro<sup>18</sup>, A. Di Biagio<sup>1,3</sup>, ARCA collaborative group*  
<sup>1</sup>Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Genoa, Italy, <sup>2</sup>HIV/AIDS Unit, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>3</sup>Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, <sup>4</sup>InformaPRO S.r.l., Rome, Italy, <sup>5</sup>Clinical Microbiology, Ospedale Civile di Baggiovara-Policlinico di Modena, Modena, Italy, <sup>6</sup>Infectious Diseases Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, <sup>7</sup>Department of Safety and Bioethics, Catholic University of the Sacred Heart, Rome, Italy, <sup>8</sup>Infectious Disease Unit, ASST Papa Giovanni XXIII, Bergamo, Italy, <sup>9</sup>Department of Medical Biotechnologies, University of Siena, Siena, Italy, <sup>10</sup>Clinica Malattie infettive, Azienda Ospedaliero Universitaria di Modena, <sup>11</sup>Laboratory of Clinical Microbiology, Virology and Bioemergencies, ASST Fatebenefratelli Sacco L. Sacco Hospital, Milan, Italy, <sup>12</sup>Department of Medicine and Surgery, Clinic of Infectious Diseases, "Santa Maria della Misericordia" Hospital, University of Perugia, Perugia, Italy, <sup>13</sup>Department of Infectious Diseases, Galliera Hospital, Genoa, Italy, <sup>14</sup>Infectious Disease Unit, ASST Ovest Milanese, Legnano (MI), Italy; Department of Biomedical and Clinical Sciences DIBIC L. Sacco, University of Milan, Milan, Italy, <sup>15</sup>Dipartimento Scienze mediche e malattie infettive, Fondazione IRCCS Policlinico "San Matteo", Pavia, Italy, <sup>16</sup>Clinic of Infectious Diseases, University Hospital Policlinico, University of Bari, Bari, Italy, <sup>17</sup>Hygiene Unit, IRCCS AOU San Martino-IST, Genoa, Italy, <sup>18</sup>Infectious Disease Unit, Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy





ORAL COMMUNICATIONS 14.15-15.15

ALABASTRO A

**Mental health and predictors of AIDS and non-AIDS defining co-pathologies**

Chairs: M. Farinella (Roma), P. Maggi (Caserta)

**OC 54 14.15-14.25 Relation between genetic polymorphisms or variants and cognitive impairment in a group of HIV-infected people**

M. Degli Antoni<sup>1</sup>, I. Zanella<sup>2</sup>, E. Zacchi<sup>2</sup>, C. Fornari<sup>1</sup>, B. Fumarola<sup>1</sup>, E. Focà<sup>1</sup>, F. Castelli<sup>1</sup>, E. Quiros-Roldan<sup>1</sup>

<sup>1</sup>University Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, <sup>2</sup>Department of Molecular and Translational Medicine, University of Brescia and Clinical Chemistry Laboratory, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia

**OC 55 14.27-14.37 A higher CPE score in PLWH with HAND switched to a less neurotoxic regimen is associated to improved memory test (MARAND-X study)**

A. Lazzaro<sup>1</sup>, D. Vai<sup>2</sup>, A. Barco<sup>3</sup>, G. Stroppolini<sup>4,5</sup>, V. Pirriatore<sup>6</sup>, G. Guastamacchia<sup>2</sup>, M. Nigra<sup>7</sup>, V. Ghisetti<sup>8</sup>, M.C. Tettoni<sup>4</sup>, M. Trunfio<sup>4</sup>, A. Trentalange<sup>4</sup>, S. Bonora<sup>4</sup>, G. Di Perri<sup>4</sup>, A. Calcagno<sup>4</sup>

<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, Roma Italy, <sup>2</sup>Unit of Neurology, Maria Vittoria Hospital, ASL Città di Torino, Turin, Italy, <sup>3</sup>Infectious Diseases Unit, Ospedale Maggiore della Carità, Novara, Italy, <sup>4</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy <sup>5</sup>Department of Infectious-Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Italy, <sup>6</sup>SC Tropical and Infectious Disease ASL Città di Torino, <sup>7</sup>Biochemistry and Immunology Laboratory, Maria Vittoria Hospital, ASL "Città di Torino", Turin, Italy, <sup>8</sup>Microbiology and Molecular Biology Laboratory, Amedeo di Savoia Hospital, ASL Città di Torino, Turin, Italy

**OC 56 14.39-14.49 Pre-ART platelet-to-lymphocyte ratio and the risk of serious non-AIDS-events, AIDS-events and mortality in PLWH starting first-line ART**

P. Saltini<sup>1,2,3</sup>, A. Cozzi-Lepri<sup>4</sup>, G. Bozzi<sup>1</sup>, G. Marchetti<sup>5</sup>, L. Taramasso<sup>6</sup>, S. Mazzanti<sup>7</sup>, V. Rizzo<sup>8</sup>, A. Antinori<sup>9</sup>, C. Mussini<sup>10</sup>, A. Gori<sup>1,2,3</sup>, A. D'Arminio Monforte<sup>5</sup>, A. Bandera<sup>1,2,3</sup>

<sup>1</sup>Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, <sup>2</sup>Department of Pathophysiology and Transplantation, University of Milano, Milano, Italy, <sup>3</sup>Centre for Multidisciplinary Research in Health Science (MACH), University of Milano, Milano, Italy, <sup>4</sup>Institute for Global Health UCL, University College London, London, UK, <sup>5</sup>Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Italy, <sup>6</sup>Infectious Diseases Unit, San Martino Policlinico Hospital, IRCCS for Oncology and Neuroscience, Genoa, Italy, <sup>7</sup>Infectious Diseases Clinic, Ospedali Riuniti Umberto I, Ancona, Torrette, Italy, <sup>8</sup>Immunodeficiency and Gender Related Infectious Diseases Unit, Department of Infectious Disease and Infectious Emergencies, AORN dei Colli, P.O. Cotugno, Naples, Italy, <sup>9</sup>Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>10</sup>Clinic of Infectious Diseases, University of Modena, Modena, Italy

**OC 57 14.51-15.01 Association between HIV-1 DNA and clinical outcome in people living with HIV**

M. Bottanelli<sup>1</sup>, D. Ceccarelli<sup>2</sup>, R. Lolatto<sup>2</sup>, L. Galli<sup>2</sup>, M. Guffanti<sup>2</sup>, R. Dell'Acqua<sup>2</sup>, G. Ponta<sup>1</sup>, G. Mori<sup>1</sup>, A. Castagna<sup>1,2</sup>, C. Muccini<sup>1,2</sup>

<sup>1</sup>School of Medicine and Surgery, Vita Salute San Raffaele University, Milan, Italy, <sup>2</sup>Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, Italy



ORAL POSTER 14.20-15.10

ALABASTRO B

**Prevention and access to services during COVID pandemic**

Chairs: D. Calzavara (Milano), N. Gianotti (Milano)

**OP 132 14.20-14.25 Narratives at the time of SARS-CoV-2 vaccination**

M.G. Marini<sup>1</sup>, E. Volpato<sup>2,3</sup>, L. Reale<sup>1</sup>, M. Portaro<sup>4</sup>, A. Uglietti<sup>4</sup>

<sup>1</sup>Fondazione ISTUD, Milan (Italy), <sup>2</sup>Department of Psychology, Università Cattolica del Sacro Cuore, Milan (Italy), <sup>3</sup>IRCCS Fondazione Don Carlo Gnocchi, Milan (Italy), <sup>4</sup>Infectious Diseases&Vaccines Medical Affairs Department, Janssen-Cilag SpA, Cologno Monzese (MI) (Italy)

**OP 133 14.27-14.32 Vaccine-preventable diseases in PLWH: adherence to recommendations in a single center in Northern Italy**

F. Pennati, V. Marchese, R. Zilocchi, S. Arsuffi, I. Polesini, F. Gaffurini, D. Castelli, E. Quiros Roldan, F. Castelli, E. Focà

Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy





- OP 134** 14.34-14.39 **Impact of COVID-19 pandemic on sexual exposure and post-exposure prophylaxis (PEP) prescription appropriateness in a large Hospital, Northern Italy**  
*S. Arsuffi<sup>1</sup>, D. Minisci<sup>1</sup>, F. Pennati<sup>1</sup>, I. Polesini<sup>1</sup>, S. di Luglio<sup>1</sup>, E. Quiros-Roldan<sup>1</sup>, S. Calza<sup>2</sup>, F. Castelli<sup>1</sup>, E. Focà<sup>1</sup>*  
<sup>1</sup>Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy, <sup>2</sup>Unit of Biostatistics and Bioinformatics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
- OP 135** 14.41-14.46 **Looking for 90-90-90 goals: a real life experience during SARS-CoV-2 pandemia**  
*G. Brucci<sup>1,2</sup>, S. Dettori<sup>1,2</sup>, V. Busin<sup>3</sup>, L. Taramasso<sup>2</sup>, A. Vena<sup>1,2</sup>, F. Mina<sup>3</sup>, S. Beltrami<sup>3</sup>, D. Malucelli<sup>4</sup>, S. Mara<sup>5</sup>, M. Giacomini<sup>5</sup>, M. Bassetti<sup>1,2</sup>, A. Di Biagio<sup>1,2</sup>*  
<sup>1</sup>Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, <sup>2</sup>Infectious Diseases Unit, Ospedale Policlinico San Martino IRCCS, Genoa, Italy, <sup>3</sup>Pharmacy Unit, Ospedale Policlinico San Martino IRCCS, Genoa, Italy, <sup>4</sup>Deenova srl, Piacenza, Italy, <sup>5</sup>Department of Engineering and Informatics University of Genoa, Genoa, Italy
- OP 136** 14.48-14.53 **The impact of COVID-19 pandemic on access to HIV services at urban context-based health facilities supported by CUAMM in collaboration with UNICEF, in Beira Mozambique**  
*N. Ronzoni<sup>1,2</sup>, C. Di Chiara<sup>1</sup>, V. Casigliani<sup>2</sup>, E. Barbieri<sup>1</sup>, A. Agazzi<sup>1</sup>, A. Zin<sup>1</sup>, A. Merolle<sup>2</sup>, F. Chenene<sup>2</sup>, V. Cinturao<sup>2</sup>, E. Ocça<sup>2</sup>, D. Donà<sup>1</sup>, G. Putoto<sup>3</sup>, C. Giaquinto<sup>1</sup>*  
<sup>1</sup>Department for Women's and Children's Health, University of Padua, Italy, <sup>2</sup>Doctors with Africa CUAMM, Beira 2100, Mozambique, <sup>3</sup>Operational Research Unit, Doctors with Africa CUAMM, Italy, <sup>4</sup>Department of translational research and new technologies in medicine and surgery - University of Pisa, Italy
- OP 137** 14.55-15.00 **HAV, HBV and HPV vaccination coverage rate in a community-based pre-exposure prophylaxis program in Milan**  
*C. Muccini<sup>1,2</sup>, A. Tavelli<sup>1,3</sup>, R. Rossotti<sup>1,4</sup>, D. Calzavara<sup>1</sup>, P. Vinti<sup>1</sup>, A. De Bona<sup>1,3</sup>, S. Bossolasco<sup>1,2</sup>, D. Canetti<sup>1,2</sup>, D. Tesoro<sup>1,3</sup>, G. Mulè<sup>1,3</sup>, A. Foschi<sup>1,5</sup>, R. Repposi<sup>1</sup>, V. Ferrara<sup>1</sup>, A. D'Arminio Monforte<sup>1,3</sup>, M. Cernuschi<sup>1,2</sup>*  
<sup>1</sup>Milano Checkpoint, Milano, <sup>2</sup>IRCCS San Raffaele Scientific Institute, Milano, <sup>3</sup>ASST Santi Paolo e Carlo, Milano, <sup>4</sup>ASST Niguarda Hospital, Milano, <sup>5</sup>ASST Fatebenefratelli Sacco



ORAL POSTER 14.20-15.10

**SARS-CoV-2: from in vivo to in vitro**

**BERGAMO SCIENCE CENTER**

Chairs: V. Micheli (Milano), M. Santoro (Roma)

- OP 138** 14.20-14.25 **Characterization of SARS-CoV-2 epidemic and transmission dynamics in children over the four COVID-19 waves**  
*R. Scutari<sup>1,2</sup>, V. Costabile<sup>1,2</sup>, L. Colagrossi<sup>2</sup>, K. Yu La Rosa<sup>2</sup>, V. Fini<sup>2</sup>, A. Granaglia<sup>2</sup>, E. Agolini<sup>2</sup>, V. Lanari<sup>2</sup>, S. Chiurchiù<sup>4</sup>, L. Romani<sup>4</sup>, A. Markowicz<sup>4</sup>, P. Bernaschi<sup>3</sup>, C. Russo<sup>3</sup>, A. Novelli<sup>2</sup>, S. Bernardi<sup>4</sup>, A. Campana<sup>4</sup>, A. Villani<sup>4</sup>, C.F. Perno<sup>2,3</sup>, C. Alteri<sup>1,2</sup>*  
<sup>1</sup>Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy, <sup>2</sup>Multimodal Research Area, Bambino Gesù Children Hospital IRCCS, Rome, Italy, <sup>3</sup>Microbiology and Diagnostics in Immunology, Bambino Gesù Children Hospital IRCCS, Rome, Italy, <sup>4</sup>Academic Department of Pediatrics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
- OP 139** 14.27-14.32 **Rapid change in epidemiological and clinical characteristics of SARS-CoV-2 circulating variants in Italy in April-December 2021**  
*A. Bergna<sup>1</sup>, A. Lai<sup>1</sup>, C. Della Ventura<sup>1</sup>, B. Bruzzone<sup>2</sup>, F. Sagradi<sup>3</sup>, F. Ceccherini Silberstein<sup>4</sup>, A. Weisz<sup>5</sup>, N. Clementi<sup>6</sup>, G. Brindicci<sup>7</sup>, I. Vicenti<sup>8</sup>, V. De Pace<sup>2</sup>, L. Lanfranchi<sup>3</sup>, M.C. Bellocchi<sup>4</sup>, G. Giurato<sup>5</sup>, R. Ferrarese<sup>6</sup>, A. Lagioia<sup>7</sup>, D. Francisci<sup>9</sup>, M. Lucente<sup>2</sup>, M.R. Cappelletti<sup>3</sup>, M. Iannetta<sup>4</sup>, F. Rizzo<sup>5</sup>, C. R. Santoro<sup>7</sup>, C. Fraccalvieri<sup>2</sup>, S. Testa<sup>3</sup>, L. Carioti<sup>4</sup>, T. Rocco<sup>5</sup>, M. Clementi<sup>6</sup>, L. Sarmati<sup>4</sup>, S. Antinori<sup>1</sup>, G. Zehender<sup>1</sup> and SCIRE-SARS-CoV-2 Italian research enterprise-collaborative group*  
<sup>1</sup>Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy, <sup>2</sup>Hygiene Unit, IRCCS AOU San Martino-IST, Genoa, Italy, <sup>3</sup>Unit of Infectious Diseases, Azienda Socio Sanitaria Territoriale Cremona, Cremona, Italy, <sup>4</sup>Infectious Diseases, Tor Vergata University, Rome, Italy, <sup>5</sup>Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Salerno, Italy, <sup>6</sup>Laboratory of Microbiology and Virology, Università "Vita-Salute" San Raffaele, Milan, Italy, <sup>7</sup>Infectious Diseases Unit, University of Bari, Bari, Italy, <sup>8</sup>Department of Medical Biotechnologies, University of Siena, Siena, Italy, <sup>9</sup>Department of Medicine and Surgery, Clinic of Infectious Diseases, "Santa Maria della Misericordia" Hospital, University of Perugia, Perugia, Italy
- OP 140** 14.34-14.39 **Higher viral load (VL) in nasopharyngeal swab (NPS) of individuals infected with Omicron BA.2 SARS-CoV-2, compared to Alpha, Gamma, Delta and Omicron BA.1 Variants Of Concern (VOCs)**  
*I. Mastroianni<sup>1</sup>, A. Cozzi-Lepri<sup>1</sup>, F. Colavita<sup>1</sup>, E. Lalle<sup>1</sup>, V. Mazzotta<sup>1</sup>, G. Matusali<sup>1</sup>, C. Cimaglia<sup>1</sup>, J. Paulicelli<sup>1</sup>, L. Fabeni<sup>1</sup>, F. Carletti<sup>1</sup>, S. Rosati<sup>1</sup>, S. Vita<sup>1</sup>, G. Giannico<sup>1</sup>, P. Piselli<sup>1</sup>, E. Biliotti<sup>1</sup>, S. Al Moghazi<sup>1</sup>, S. Mosti<sup>1</sup>, E. Girardi<sup>1</sup>, E. Nicastrì<sup>1</sup>, A.R. Garbuglia<sup>1</sup>, F. Vaia<sup>1</sup>, A. Antinori<sup>1</sup>*  
<sup>1</sup>National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>2</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, United Kingdom



**OP 141 14.41-14.46 Dopamine reduces SARS-CoV-2 replication through downregulation of D2 receptors and upregulation of Type-I Interferons**

F. Limanaqi<sup>1,2</sup>, D. Borana<sup>2</sup>, S. Zecchini<sup>2</sup>, G. Cappelletti<sup>2</sup>, S. Strizzi<sup>2</sup>, D. Trabattoni<sup>2</sup>, M. Clerici<sup>1,3</sup>, M. Biasin<sup>2</sup>

<sup>1</sup>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, <sup>2</sup>Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Milan, Italy, <sup>3</sup>Don C. Gnocchi Foundation, IRCCS Foundation, Milan, Italy

**OP 142 14.48-14.53 Developmental safety of nirmatrelvir in zebrafish embryos**

S. Ferretti<sup>1</sup>, E. Quiros-Roldan<sup>1</sup>, F. Castelli<sup>1</sup>, E. Massardi<sup>3</sup>, G. Borsani<sup>3</sup>, S. Storti<sup>1</sup>, G. Tiecco<sup>1</sup>, I. Zanella<sup>2</sup>, D. Zizioli<sup>3</sup>

<sup>1</sup>Division of Infectious and Tropical Diseases, ASST Spedali Civili di Brescia, Brescia, Italy; Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, <sup>2</sup>Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; Clinical Chemistry Laboratory, Cytogenetics and Molecular Genetics Section, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy, <sup>3</sup>Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy

**OP 143 14.55-15.00 Peptidomimetic covalent reversible inhibitors exhibit broad-spectrum inhibition of CoVs Main protease and cellular activity against SARS-CoV-2: design, synthesis, biological evaluation, and structural biology**

R. Cannalire<sup>1</sup>, F. Esposito<sup>2</sup>, I. Stefanelli<sup>1</sup>, A. Corona<sup>2</sup>, C. Cerchia<sup>1</sup>, E. Cassese<sup>1</sup>, S. Improta<sup>1</sup>, P. Storici<sup>3</sup>, E. Costanzi<sup>3</sup>, E. Tramontano<sup>2</sup>, V. Summa<sup>1</sup>

<sup>1</sup>Dipartimento di Farmacia - Università degli Studi di Napoli Federico II, Napoli, Italy, <sup>2</sup>Dipartimento di Scienze della vita e dell'ambiente, Università degli Studi di Cagliari, Cittadella Universitaria di Monserrato, Cagliari, Italy, <sup>3</sup>Eletra-Sincrotrone Basovizza, Trieste, Italy



**SYMPOSIUM** 15.20-16.20

**AUDITORIUM SALA OGGIONI**

**Update on antiretroviral therapy: answers and suggestions during a pandemic era**

Chairs: T. Bini (Milano), P. Cinque (Milano)

Antiretroviral therapy (TARV) has changed the life expectancy of people living with HIV infection and has drastically improved the quality of life of people we care for. The high efficacy of TARV is still hampered by the impossibility of clearing the viral reservoir. Nevertheless, new drugs for modern needs are flourishing and will reach the clinical arena. These compounds will be instrumental for the rapid start of TARV, even in the context of the COVID-19 pandemic, and in the challenge of treating HTE individuals, a polymorphic situation where novel answers are eagerly awaited.

- 15.20-15.35 **New drugs for modern needs: from phase II trials up to now** A. Di Biagio, Genova
- 15.35-15.50 **Rapid start in COVID-19 era: what is needed?** C. Mussini, Modena
- 15.50-16.15 **Clinical case: Novel strategies for HTE people** Presenter: D. Canetti, Milano  
Discussants: D. Ripamonti, Bergamo; S. Rusconi, Legnano (MI)
- 16.15-16.20 **Discussion on Symposium issues**



**ORAL COMMUNICATIONS** 15.20-16.20

**SALA STUCCHI**

**Complexities of SARS-CoV-2 infection**

Chairs: P. Bonfanti (Monza), A. Saracino (Bari)

**OC 58 15.20-15.30 Prevalence and epidemiological, clinical and microbiological characteristics of bacterial infections in a large cohort of patients admitted for COVID-19 in Campania: a multicentre cohort study**

L. Onorato<sup>1</sup>, M. Palamone<sup>1</sup>, P. Maggi<sup>2</sup>, F.G. Numis<sup>3</sup>, I. Gentile<sup>4</sup>, V. Sangiovanni<sup>5</sup>, V. Esposito<sup>6</sup>, R. Punzi<sup>7</sup>, G. Calabria<sup>8</sup>, C. Rescigno<sup>9</sup>, A. Salomone Megna<sup>10</sup>, A. Masullo<sup>11</sup>, E. Manzillo<sup>12</sup>, G. Russo<sup>13</sup>, R. Parrella<sup>14</sup>, G. Dell'Aquila<sup>15</sup>, M. Gambardella<sup>16</sup>, A. Ponticillo<sup>17</sup>, M. Pisaturo<sup>1</sup>, N. Coppola<sup>1</sup>, on behalf of CoviCam group

<sup>1</sup>Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania "L. Vanvitelli", Napoli, Italy, <sup>2</sup>Infectious Diseases Unit, A.O. S Anna e S Sebastiano Caserta, Italy, <sup>3</sup>Emergency Department, PO Santa Maria delle Grazie, Pozzuoli, Italy, <sup>4</sup>Infectious Diseases Unit, University Federico II, Naples, Italy, <sup>5</sup>Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, <sup>6</sup>IV Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>7</sup>Hepatic Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>8</sup>IX Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>9</sup>First Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>10</sup>Infectious Diseases Unit, A.O. San Pio, PO Rummo, Benevento, Italy, <sup>11</sup>Infectious disease unit, A.O. San Giovanni di Dio e Ruggi D'Aragona Salerno, Italy, <sup>12</sup>VIII Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>13</sup>Infectious Diseases Unit, Ospedale Maria S.S. Addolorata di Eboli, ASL Salerno, Italy, <sup>14</sup>Respiratory Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>15</sup>Infectious Diseases Unit, AO Avellino, Italy, <sup>16</sup>Infectious Diseases Unit, PO S. Luca, Vallo della Lucania, ASL Salerno, Italy, <sup>17</sup>Pneumology Unit, AORN Caserta, Italy



- OC 59** 15.32-15.42 **Evaluation of SARS-CoV-2 reinfection risk during the different COVID-19 variants' spread**  
*S. Leone, A. Agresta, G. De Carli, C. De Santis, M.C. Fusco, V. Vantaggio, M. D'Amato, G. Pitti, E. Girardi, F. Vairo*  
National Institute for Infectious Diseases "L.Spallanzani" IRCCS
- OC 60** 15.44-15.54 **Pre-existent socio-economic status and its role in PASC syndrome: results from the VASCO study (VARIabili Socioeconomiche e COVID-19), on the "Surviving-COVID" Cohort, from Bergamo (Italy)**  
*S.V. Benatti<sup>1</sup>, S. Venturelli<sup>1</sup>, R. Buzzetti<sup>2</sup>, F. Binda<sup>1</sup>, L. Soavi<sup>1</sup>, L. Belotti<sup>1</sup>, A.M. Biffi<sup>1</sup>, M.S. Spada<sup>1</sup>, M. Casati<sup>1</sup>, M. Rizzi<sup>1</sup>*  
<sup>1</sup>ASST Papa Giovanni XXIII, Bergamo, <sup>2</sup>Clinical Epidemiologist, freelance, Bergamo
- OC 61** 15.56-16.06 **Depressive Symptoms Among Covid-19 Survived Patients One Year After Hospital Discharge: Prevalence and Factors Associated**  
*P. Vassalini<sup>1</sup>, R. Serra<sup>2</sup>, L. Tarsitani<sup>2</sup>, G. Ceccarelli<sup>1</sup>, A.E. Koukopoulos<sup>2</sup>, C. Borrazzo<sup>1</sup>, C. Di Nicolantonio<sup>2</sup>, C. Tosato<sup>1</sup>, F. Cherubini<sup>1</sup>, F. Alessandri<sup>3</sup>, C.M. Mastroianni<sup>1</sup>, G. d'Ettore<sup>1</sup>*  
<sup>1</sup>Department of Public Health and Infectious Diseases, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy, <sup>2</sup>Department of Human Neurosciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy, <sup>3</sup>Intensive Care Unit, Department of General and Specialist Surgery "Paride Stefanini", Policlinico Umberto I, Sapienza University of Rome, Rome, Italy



ORAL COMMUNICATIONS 15.20-16.20

ALABASTRO A

Insights on epidemiological and clinical management of hepatitis viruses

Chairs: R. Bruno (Pavia), G. Gaiera (Milano)

- OC 62** 15.20-15.30 **Serum HBsAg and highly-sensitive HBV-DNA quantification can predict HBsAg loss after nucleo(s)tide analogue systematic discontinuation in non-cirrhotic patients with chronic hepatitis B**  
*L. Piermatteo<sup>1</sup>, R. Salpini<sup>1</sup>, S. D'Anna<sup>1</sup>, A.F. Guerra<sup>2</sup>, G. Tomassoli<sup>2</sup>, G. Abbati<sup>2</sup>, A. Pietrangelo<sup>2</sup>, P. Ventura<sup>2</sup>, V. Svicher<sup>1,3</sup>*  
<sup>1</sup>Department of Experimental Medicine, University of Rome "Tor Vergata", <sup>2</sup>Internal Medicine and Centre for Hemochromatosis, University Hospital of Modena, University of Modena and Reggio Emilia, Italy, <sup>3</sup>Department of Biology, University of Rome "Tor Vergata"
- OC 63** 15.32-15.42 **Hepatitis D virus infection in a large cohort of immigrants in Southern Italy a multicenter, prospective study**  
*E. Cordua<sup>1</sup>, M. Pisaturo<sup>1,2,7</sup>, L. Alessio<sup>2,7</sup>, M. Starace<sup>1</sup>, A. Di Fraia<sup>1</sup>, C. Monari<sup>2,7</sup>, L. Onorato<sup>2,7</sup>, C. Sagnelli<sup>1,2,5</sup>, S. De Pascalis<sup>2</sup>, L. Gualdieri<sup>6</sup>, C. Minichini<sup>1</sup>, G. Di Caprio<sup>3,4</sup>, L. Occhiello<sup>1,6</sup>, G. Scotto<sup>8</sup>, M. Macera<sup>2,7</sup>, N. Coppola<sup>1,2</sup>*  
<sup>1</sup>Department of Mental and Physical Health and Preventive Medicine, Infectious Diseases section, University of Campania Luigi Vanvitelli, Naples, <sup>2</sup>L. Vanvitelli University Hospital, Naples, <sup>3</sup>UOC of Infectious Diseases, AORN Sant'Anna and San Sebastiano, Caserta, <sup>4</sup>"Abraham's Tent" Reception Center, Caserta, <sup>5</sup>Missionary Sisters of Charity Center, Naples, <sup>6</sup>Center for the Protection of Immigrant Health, Naples, <sup>7</sup>Social center "ex-canapificio", Caserta, <sup>8</sup>UOC of Infectious Diseases, Foggia
- OC 64** 15.44-15.54 **Reactivation of hepatitis B virus is a frequent event in anti-HBc-positive/HBsAg-negative HIV-infected patients switching to Tenofovir sparing therapy as revealed by highly sensitive HBV assays**  
*R. Salpini<sup>1</sup>, S. D'Anna<sup>1</sup>, M. Alkhatib<sup>1</sup>, L. Piermatteo<sup>1</sup>, A. Tavelli<sup>2</sup>, E. Quiros<sup>3</sup>, A. Cingolani<sup>4</sup>, C. Papalini<sup>5</sup>, S. Carrara<sup>6</sup>, V. Malagnino<sup>7</sup>, M. Puoti<sup>8</sup>, L. Sarmati<sup>7</sup>, A. d'Arminio Monforte<sup>9</sup>, F. Ceccherini Silberstein<sup>1</sup>, V. Svicher<sup>1</sup> for the Icona Foundation Study Group*  
<sup>1</sup>Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, <sup>2</sup>ICONA Foundation, <sup>3</sup>University Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili, Brescia, Italy, <sup>4</sup>Unit of Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli-Università Cattolica Del Sacro Cuore, Rome, Italy, <sup>5</sup>Infectious Diseases Clinic, Department of Medicine, University of Perugia, Perugia, Italy, <sup>6</sup>Microbiology Biobank and Cell Factory Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani", Rome, Italy, <sup>7</sup>Unit of Infectious Diseases, University Hospital Tor Vergata, Rome, Italy, <sup>8</sup>Dipartimento Medicina e Chirurgia, Università degli studi di Milano Bicocca, Milan, Italy, <sup>9</sup>Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Italy
- OC 65** 15.56-16.06 **Hepatitis C testing, linkage to care and treatment during COVID-19 era in a north-east Italian hospital: what can we still need to do to improve elimination?**  
*E. Garlatti Costa<sup>1</sup>, M. Da Re<sup>2</sup>, D. Villalta<sup>2</sup>, M. Tonizzo<sup>1</sup>*  
<sup>1</sup>SC Medicina Interna, Azienda sanitaria Friuli Occidentale, Pordenone, <sup>2</sup>SSD Immunologia Allergologia, Azienda sanitaria Friuli Occidentale, Pordenone





ORAL POSTER 15.20-16.10

ALABASTRO B

## Immunopathogenesis of HIV

Chairs: V. Mazzotta (Roma), G. Nunnari (Messina)

**OP 144 15.20-15.25 Distinctive features of immune markers of activation and exhaustion in adolescents and young adults people living with HIV infected perinatally vs. adult age**

*L. Taramasso<sup>1</sup>, C. Dentone<sup>1</sup>, D. Fenoglio<sup>2,3</sup>, T. Altosole<sup>2</sup>, A. Parodi<sup>2</sup>, I. Cama<sup>4</sup>, C. Campi<sup>4,5</sup>, S. Garbarino<sup>4</sup>, M. Piana<sup>4,5</sup>, S. Mora<sup>6</sup>, M. Giacomini<sup>6</sup>, L. Labate<sup>7</sup>, G. Filaci<sup>2,3</sup>, M. Bassetti<sup>1,7</sup>, A. Di Biagio<sup>1,7</sup>*

<sup>1</sup>Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Genoa, Italy, <sup>2</sup>Department of Internal Medicine-Centre of Excellence for Biomedical Research (CEBR), University of Genoa, Italy, <sup>3</sup>Biotherapy Unit, IRCCS Policlinico San Martino, <sup>4</sup>MIDA, Dipartimento di Matematica, Università degli studi di Genova, Genova, Italy, <sup>5</sup>LISCOMP, IRCCS Ospedale Policlinico San Martino, Genova, Italy, <sup>6</sup>Department of Informatics, Bioengineering, Robotics and System Engineering (DIBRIS), University of Genova, Genova, Italy, <sup>7</sup>Department of Health Science (DISSAL), University of Genova and Infectious Disease Clinic, Policlinico San Martino Hospital, Genova, Italy

**OP 145 15.27-15.32 Lack of HIV Type 1 Antibody seroconversion in Acutely Infected Individuals Treated with Early Antiretroviral Therapy**

*A. Bertoldi<sup>1</sup>, A. Primavera<sup>1</sup>, M. Tamburello<sup>2</sup>, A. Morellini<sup>2</sup>, V. Ferraro<sup>2</sup>, S. Vituliano<sup>2</sup>, V. D'Urbano<sup>2</sup>, T. Lazzarotto<sup>1</sup>, L. Calza<sup>3</sup>, I. Bon<sup>1</sup>*

<sup>1</sup>Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, <sup>2</sup>Section of Microbiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy, <sup>3</sup>Clinics of Infectious Diseases, Department of Medical and Surgical Sciences, School of Medicine, University of Bologna, Bologna, Italy

**OP 146 15.34-15.39 Evaluation of HCMV specific T-cell responses in PLwHIV and their correlation with the immunovirological status and clinical parameters**

*M. Iannetta, A. Lodi, L. Ferrari, A. Imeneo, A. Di Lorenzo, I. Fato, B. Massa, I. Spalliera, B. Rossi, M. Zordan, L. Campogiani, L. Coppola, V. Malagnino, E. Teti, M. Andreoni, L. Sarmati*

Department of System Medicine Tor Vergata University, Rome

**OP 147 15.41-15.46 Crosstalk between gut microbiota and T cell responses in ART-treated HIV-1 infected patients**

*L. Santinelli<sup>1</sup>, L. Maddaloni<sup>1</sup>, A. Lazzaro<sup>1</sup>, P. Vassalini<sup>1</sup>, F. Frasca<sup>2</sup>, C.M. Lofaro<sup>1</sup>, S. Caiazza<sup>1</sup>, G. Ceccarelli<sup>1</sup>, G. Antonelli<sup>2,3</sup>, C.M. Mastroianni<sup>1</sup>, C. Scagnolari<sup>2</sup>, G. d'Etterre<sup>1</sup>*

<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy, <sup>2</sup>Virology Laboratory, Department of Molecular Medicine, Sapienza University of Rome, Italy, <sup>3</sup>Microbiology and Virology Unit, Sapienza University Hospital "Policlinico Umberto I", Rome, Italy

**OP 148 15.48-15.53 Large proportion of new HIV diagnoses sustained by non-B subtypes – clinical and immunological correlates**

*G. Bozzi<sup>1</sup>, P. Saltini<sup>1</sup>, G. Butta<sup>2</sup>, C. Bobbio<sup>1</sup>, A. Muscatello<sup>1</sup>, S. Ludovisi<sup>1</sup>, A. Gori<sup>1,3</sup>, A. Bandera<sup>1,3</sup>, L. Manganaro<sup>1,2</sup>*

<sup>1</sup>Infection Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Milan, Italy, <sup>2</sup>Virology Unit, INGM-Istituto Nazionale di Genetica Molecolare - Milan, Italy, <sup>3</sup>Department of Pathophysiology and Transplantation, University of Milan - Milan, Italy





## ICAR 2022 SPECIAL AWARDS AND CLOSING REMARKS

AUDITORIUM  
SALA OGGIONI

Chairs: A. Antinori (Roma), M. Cernuschi (Milano), A. d'Arminio Monforte (Milano), F. Maggiolo (Bergamo), M. Zazzi (Siena)

16.25-16.40

The 14th edition of ICAR Awards:



### ICAR-CROI Awards 2022 for young Italian investigators

Selected Italian Investigators who presented their works at CROI 2022:

- **A model to eradicate HCV in undocumented migrants and low-income refugees in Italy**  
Loredana Alessio, Napoli
- **GDF-15 as a predictor of mortality in COVID-19: implications for treatment**  
Valeria Bono, Milano
- **HPV differently hijacks anal interferon response in HIV-positive and HIV-negative MSM**  
Eugenio Nelson Cavallari, Roma
- **Persistence of SARS-CoV-2 antibodies in children and adults 1 year after infection**  
Costanza Di Chiara, Padova
- **Mental health disorders in HIV-positive adolescents and youths: data from Mozambique**  
Francesco Di Gennaro, Bari
- **Methylprednisolone pulses in hospitalized patients with severe COVID-19 pneumonia**  
Giovanni Dolci, Modena
- **How HIV modulates the safety and immunogenicity of the BNT162b2 COVID-19 vaccine**  
Ludovica Ferrari, Roma
- **Detection of circulating and airway autoantibodies to IFN in severe COVID-19 patients**  
Federica Frasca, Roma
- **Longitudinal study of anti-spike antibodies in children after SARS-CoV-2 infection**  
Federica Frasca, Roma
- **The effects of type I & II IFNs disclose a role for dopamine in SARS-CoV-2 infection**  
Fiona Limanaqi, Milano
- **Sarilumab plus standard of care (soc) versus soc for severe COVID-19 (escape study)**  
Ilaria Mastroianni, Roma
- **Is there a role of novel art regimens in the declining prevalence of hand?**  
Ilaria Mastroianni, Roma
- **Post-COVID-19 quality of life: low satisfaction with physical and mental health status**  
Ilaria Mastroianni, Roma
- **A real-world comparison of bam/ete vs cas/imd for COVID-19 clinical progression risk**  
Valentina Mazzotta, Roma
- **The pathway of nafld vs mafld toward significant fibrosis**  
Jovana Milic, Modena
- **Chest ct body composition changes at 3 and 6 months after severe COVID-19 pneumonia**  
Jovana Milic, Modena
- **Real-life use of high-dose anakinra in COVID-19 patients treated with remdesivir**  
Roberta Monardo, Milano



- **Mannose-binding lectin (mbl) inhibits SARS-CoV-2 infection and replication in vitro**  
Isabel Pagani, Milano
- **Efavirenz plasma levels, cognition, and central nervous system side effects**  
Alice Ranzani, Monza
- **SARS-CoV-2 plasma viremia and dysregulated immunity in severe COVID-19**  
Roberta Rovito, Milano
- **Gut barrier integrity and microbiota in HIV patients receiving oral bacteriotherapy**  
Letizia Santinelli, Roma
- **Expression of IFN receptors in anal cells from HIV-positive men during HPV infection**  
Mirko Scordio, Roma
- **Differential IFN genes expression in the upper airways of children and adults**  
Leonardo Sorrentino, Roma
- **Reversibility of central nervous system adverse events in course of art**  
Lucia Taramasso, Genova
- **Proportion of PLWH not vaccinated for COVID-19 in Italy and predictors**  
Alessandro Tavelli, Milano
- **Syphilis reinfections among HIV+ and HIV- patients: a retrospective study**  
Giorgio Tiecco, Brescia
- **Serum and csf ultrasensitive detection of nfl and alzheimer biomarkers in PLWH**  
Mattia Trunfio, Torino
- **Characterization of HIV and SARS-CoV-2 coinfection: role of IL-10**  
Claudia Vanetti, Milano
- **Neuropsychologic performance following COVID-19: prevalence and predictors**  
Alessandra Vergori, Roma
- **Immunogenicity to COVID-19 mrna vaccine booster shot in PLWH by current cd4+ count**  
Alessandra Vergori, Roma



## ICAR 2022 Scientific Committee Awards



## SIMIT Awards to Best Oral Communications for young researchers



16.40-16.45

### ICAR 2022 Closing remarks

A. Antinori (Roma), M.Cernuschi (Milano), F. Maggiolo (Bergamo), M. Zazzi (Siena)





*Alliance to leave no-one behind*



**Italian Conference on AIDS and Antiviral Research**

Presidenza del Congresso: **A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi**

*Digital*

**POSTER  
EXHIBITION**



## Antiretroviral therapy

### ISSUES ON ANTIRETROVIRAL THERAPY

**P 1 Real-world data on the effectiveness and safety of bicitegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people living with HIV: 12-month results of the Italian BICSTaR cohort**

A. Antinori<sup>1</sup>, S. Rusconi<sup>2</sup>, D. Canetti<sup>3</sup>, V. Esposito<sup>4</sup>, E. Quiros-Roldan<sup>5</sup>, B. Candelaresi<sup>6</sup>, A. D'Arminio Monforte<sup>7</sup>, M. Andreoni<sup>8</sup>, A. Saracino<sup>9</sup>, A. Marongiu<sup>10</sup>, L. Albinì<sup>10</sup>, R. Caldera<sup>11</sup>, G. Forcina<sup>10</sup>, G. Di Perri<sup>12</sup>

<sup>1</sup>HIV/AIDS Department, National Institute of Infectious Diseases, L. Spallanzani, IRCCS, Rome, Italy, <sup>2</sup>Infectious Diseases Unit, ASST Ovest Milanese - University of Milan, Milan, Italy, <sup>3</sup>Clinic of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>4</sup>Infectious Diseases and Gender Medicine Unit D. Cotugno Hospital-A.O. dei Colli, Naples, Italy, <sup>5</sup>Division of Infectious and Tropical Medicine, ASST Spedali Civili, Brescia, Italy, <sup>6</sup>Infectious Diseases Clinic, Department of Biological Sciences and Public Health, Marche Polytechnic University, Ancona, Italy, <sup>7</sup>Clinic of Infectious Diseases, Department of Health Sciences, University of Milan, "ASST Santi Paolo e Carlo", Milan, Italy, <sup>8</sup>Infectious Diseases Clinic, University Hospital "Tor Vergata", Rome, Italy, <sup>9</sup>Division of Infectious Diseases, Bari University Hospital, University of Bari, Bari, Italy, <sup>10</sup>Gilead Sciences Europe Ltd, Stockley Park, Uxbridge, UK, <sup>11</sup>Gilead Sciences Srl, Milan, Italy, <sup>12</sup>Department of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy

**P 2 Antiretroviral therapy in naïve patients: Perugia's cohort during COVID pandemic**

A. Lanzi, G. De Socio, E. Schiaroli, S. Benedetti, P. Milani, E. Stolaj, D. Francisci

Clinic of Infectious Diseases, Department of Medicine and Surgery, University of Perugia, "Ospedale Santa Maria della Misericordia", Perugia, Italy

**P 3 Durability of doravirine co-formulated with lamivudine and tenofovir disoproxil fumarate in people living with HIV (PLWH)**

F. Alberton<sup>1</sup>, D. Ceccarelli<sup>1</sup>, R. Lolatto<sup>1</sup>, S. Nozza<sup>1</sup>, S. Bossolasco<sup>1</sup>, V. Spagnuolo<sup>1</sup>, E. Bruzzesi<sup>2</sup>, M. Chiurlo<sup>2</sup>, A. Castagna<sup>1,2</sup>, N. Gianotti<sup>1</sup>

<sup>1</sup>Unit of Infectious and Tropical Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>2</sup>Vita-Salute San Raffaele University, Milan, Italy

**P 4 Evaluation of switch therapy to antiretroviral regimens with doravirine in people living with HIV**

C. Candela<sup>2</sup>, D. Ceccarelli<sup>1</sup>, R. Lolatto<sup>1</sup>, D. Canetti<sup>1</sup>, M. Cernuschi<sup>1</sup>, P. Cinque<sup>1</sup>, M. Ranzenigo<sup>2</sup>, F. Badalucco<sup>2</sup>, A. Castagna<sup>1,2</sup>, N. Gianotti<sup>1</sup>

<sup>1</sup>Unit of Infectious and Tropical Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>2</sup>Vita-Salute San Raffaele University, Milan, Italy

**P 5 Switching to BICTegravir in Elderly people living with HIV-1 under virologic control: week 96 results from the BICTEL cohort**

A. Lazzaro<sup>1</sup>, D. Bianchini<sup>1</sup>, E. Gentilini<sup>1</sup>, E.N. Cavallari<sup>1</sup>, C. Fimiani<sup>1</sup>, I. Mezzaroma<sup>2</sup>, C.M. Mastroianni<sup>1</sup>, G. d'Ettore<sup>1</sup>

<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, Rome, Italy, <sup>2</sup>Department of Translational and Precision Medicine; Sapienza University of Rome, AOU Policlinico Um-ber-to I of Rome, Rome, Italy

**P 6 Real life experience with Doravirine: impact on metabolic aspects and immune-viral control**

C. Papalini, A. Lanzi, C. Pallotto, D. Francisci

Infectious Diseases Clinic, Santa Maria della Misericordia Hospital, Università degli studi di Perugia, Perugia, Italy

**P 7 Strength of 2DR-HIV-therapy in heavy poly-pharmacological treatment of multi-comorbidity patients**

L. Pagnucco, R. Gulminetti, R. Bruno

UOC Malattie Infettive 1, Dipartimento di Scienze Mediche e Malattie Infettive, Fondazione IRCCS Policlinico San Matteo - Università degli Studi di Pavia. Pavia

**P 8 Use of doravirine in experienced people living with HIV: a real-life experience**

A. Bitti, A. De Vito, M. Fois, A. Colpani, B. Zauli, M.C. Meloni, S. Bacciu, S. Babudieri, G. Madeddu

Unit of Infectious Diseases, Department of Medical, Surgical, and Experimental Sciences, University of Sassari, Sassari, Italy

**P 9 Statin induced anti-HMGCR myopathy in a patient undergoing ARV therapy: a case report**

A. Destro<sup>1</sup>, R.A. Valia<sup>1</sup>, D. Fago<sup>1</sup>, R. Aronica<sup>1</sup>, V. Mauro<sup>1</sup>, F. Cancelli<sup>1</sup>, M. Candy<sup>1</sup>, S. Valeri<sup>1</sup>, M. Ridolfi<sup>1</sup>, P. Pasculli<sup>1</sup>, P. Guariglia<sup>2</sup>, A. Brogi<sup>2</sup>, A. Lazzaro<sup>1</sup>, C.M. Mastroianni<sup>1</sup>, G. d'Ettore<sup>1</sup>

<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, Roma Italy, <sup>2</sup>Department of Infectious Diseases, Azienda Ospedaliera Universitaria Policlinico Umberto I of Rome, Roma Italy

**P 10 Cardiovascular risk in PLWHs with IP-based ARV**

N. Leoni, A. Leonardi, M. Garau, F. Ferrari, S. Perra, S. Bergamin, M. Buffa, F. Cabras, G. Caligaris, M.F. Nurchi, G. Sanna, G. Angioni

SC Malattie Infettive, Cagliari; Università degli Studi di Sassari, Sassari Issues on new anti-HIV drugs





## ISSUES ON NEW ANTI-HIV DRUGS

### P 11 Real-life outcomes of Doravirine-based dual regimens as salvage and simplification therapy for multidrug-resistant HIV in a series of seven cases in Lecco Hospital

V. Morena<sup>1</sup>, F. Conti<sup>1</sup>, C. Molteni<sup>1</sup>, M. Bottanelli<sup>1,2</sup>, L. Bradanini<sup>1</sup>, G. Castaldo<sup>1</sup>, L. Donghi<sup>1</sup>, A. Pandolfo<sup>1</sup>, S. Pontiggia<sup>1</sup>, S. Piconi<sup>1</sup>

<sup>1</sup>Infectious Diseases Unit, A. Manzoni Hospital, ASST Lecco, Lecco, Italy, <sup>2</sup>Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

## Clinical HIV

### LATE PRESENTERS FOR HIV/AIDS INFECTION

### P 12 Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma in the era of HAART: a case report

M. Trizzino, S. Bonura, L. Pipitò, P. Di Carlo, G. Boncori, A. Cascio

Infectious and Tropical Disease Unit, AOU Policlinico "P. Giaccone", Palermo, Italy

### P 13 A fatal case of diffuse large B-cell lymphoma with intestinal perforation in AIDS patient: a case report

M. Trizzino, R. Rubino, A. Medaglia, G. Valenti, M. Alfonzo, V. Garbo, A. Cascio

Infectious and Tropical Disease Unit, AOU Policlinico "P. Giaccone", Palermo, Italy

### P 14 Clinical management of an elderly patient, late presenter, with Kaposi's sarcoma and mycobacteriosis

G. Panto', S. A. Sofia, G. Strano, C. Iacobello

Unit of infectious diseases Cannizzaro Hospital, Catania

## MANAGEMENT OF HIV INFECTIONS

### P 15 Resolved Hepatitis B Virus (HBV) infection and lower nadir of CD4+ are risk factors for progressive increase of CD8+ T-cells absolute count in course of antiretroviral therapy (ART)

T. Mulas, V. Malagnino, E. Teti, M. Compagno, L. Ferrari, G. De Simone, F. Caldara, D. Checchi, A. Crea, S. Tedde, L. Dori, M. Iannetta, M. Andreoni, L. Sarmati

Università degli Studi di Roma Tor Vergata

### P 16 Does CD4+ T-Lymphocytes count over 200 cell/mm<sup>3</sup> affect the epidemiology of AIDS defining illnesses? An overview from a large italian clinical center

V. Iannone<sup>1</sup>, A. Dusina<sup>1</sup>, D. Farinacci<sup>1</sup>, F. Lamanna<sup>1</sup>, R. Passerotto<sup>1</sup>, A. Borghetti<sup>1</sup>, E. Visconti<sup>1</sup>, E. Tamburrini<sup>1</sup>, S. Di Giambenedetto<sup>1</sup>, A. Ciccullo<sup>2</sup>

<sup>1</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Malattie Infettive, Roma, <sup>2</sup>Ospedale San Salvatore Unità di Malattie Infettive, L'Aquila

## OPPORTUNISTIC INFECTIONS (OIS)

### P 17 Visceral leishmaniasis complicated by hemophagocytic lymphohistiocytosis associated to Immune Reconstitution Inflammatory Syndrome in a HIV-infected patient

A. Forniti, C. Caroselli, F. Almerigogna, S. Verdenelli, R. Iapoce, G. Tiseo, M. Falcone

Infectious Disease Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

## Coinfections and Hepatitis

### BACTERIAL AND FUNGAL INFECTIONS IN IMMUNOCOMPROMISED HOST

### P 18 Hansen's disease, a neglected disease? Case report of a patient with HIV and Mycobacterium Leprae infection

L. Alessio<sup>1</sup>, S. De Pascalis<sup>1</sup>, C. Curatolo<sup>2</sup>, V. Pattapola<sup>2</sup>, M. Pisaturo<sup>2</sup>, N. Coppola<sup>2</sup>

<sup>1</sup>Luigi Vanvitelli Hospital - Naples (Italy), <sup>2</sup>University of Campania, luigi Vanvitelli - Naples (Italy)





**P 19 Tropheryma whipplei infection in HIV: report of two cases and literature review**

F. Raumer<sup>1</sup>, A. Ferrari<sup>1</sup>, M. Trevenzoli<sup>1</sup>, M. Fassin<sup>2</sup>, M. Cola<sup>1</sup>, A.M. Cattelan<sup>1</sup>

<sup>1</sup>Azienda Ospedale-Università di Padova, Department of Infectious Disease, Padova, <sup>2</sup>Azienda Ospedale-Università di Padova, Department of Pathological Anatomy, Padova

## HCV ELIMINATION

**P 20 Hepatitis C infection among people who use drugs: a retrospective cohort study using administrative health records**

G. Moretti<sup>1</sup>, L. Ceccarelli<sup>1,2</sup>, M. Vainieri<sup>1</sup>, L. Tivoschi<sup>2</sup>

<sup>1</sup>Sant'Anna School of Advanced Studies – Management and Healthcare Laboratory, Pisa, Italy, <sup>2</sup>University of Pisa – Department of Translational Research and New Technologies in Medicine and Surgery, Pisa, Italy

**P 21 HCV prevalence in a over 65 years old population attending general practitioner**

A. Di Fraia<sup>1</sup>, M. Pisaturo<sup>1</sup>, V. Messina<sup>2</sup>, M. Starace<sup>1</sup>, C. Minichini<sup>1</sup>, L. Occhiello<sup>1</sup>, L. Onorato<sup>1</sup>, N. Coppola<sup>1</sup>

<sup>1</sup>Infectious Diseases Unit, Department of Mental Health and Public Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy, <sup>2</sup>Department of Infectious Diseases, Sant'Anna Hospital, Caserta, Italy

## HDV CURE

**P 22 Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24 weeks interim data of the phase 3 MYR301 study**

H. Wedemeyer<sup>1</sup>, S. Aleman<sup>2</sup>, P. Andreone<sup>3</sup>, A. Blank<sup>4</sup>, M. Brunetto<sup>5</sup>, P. Bogomolov<sup>6</sup>, V. Chulanov<sup>7</sup>, N. Geyvandova<sup>8</sup>, G. Hilgard<sup>9</sup>, N. Mamonova<sup>10</sup>, U. Merle<sup>4</sup>, M. Viacheslav<sup>11</sup>, O. Sagalova<sup>12</sup>, T. Stepanova<sup>13</sup>, J. Schulze zur Wiesch<sup>14</sup>, S. Zotov<sup>15</sup>, S. Zeuzem<sup>16</sup>, P. Lampertico<sup>17,18</sup>

<sup>1</sup>Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover, Germany, <sup>2</sup>Karolinska University Hospital/Karolinska Institutet, Department of Infectious Diseases, Stockholm, Sweden, <sup>3</sup>Internal Medicine, University of Modena and Reggio Emilia, Italy, <sup>4</sup>University Hospital Heidelberg, Clinical Pharmacology and Pharmacoepidemiology, Heidelberg, Germany, <sup>5</sup>U.O. Epatologia - Azienda Ospedaliero Universitaria Pisana, Pisa, Italy, <sup>6</sup>State budgetary institution of health care of Moscow region "Moscow regional research clinical institute after M.F. Vladimirov", Moscow, Russian Federation, <sup>7</sup>Federal Budget Institute of Science "Central Research Institute for Epidemiology" of Federal Service on Consumers Rights Protection and Human Well-Being Surveillance, Moscow, Russian Federation, <sup>8</sup>Stavropol Regional Hospital, Stavropol, Russian Federation, <sup>9</sup>Universitätsklinikum Essen (AöR), Klinik für Gastroenterologie und Hepatologie, Essen, Germany, <sup>10</sup>FSBI National Research Medical Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation, Moscow, Russian Federation, <sup>11</sup>LLC Medical Company "Hepatolog", Samara, Russian Federation, <sup>12</sup>Federal state-funded institution of higher education "Southern Ural State Medical University of Ministry of Health of the Russian Federation" of Ministry of Health of the Russian Federation, Chelyabinsk, Russian Federation, <sup>13</sup>Limited liability company "Clinic of Modern Medicine", Moscow, Russian Federation, <sup>14</sup>Universitätsklinikum Hamburg-Eppendorf Medizinische Klinik Studienambulanz Hepatologie, Hamburg, Germany, <sup>15</sup>State budgetary institution of health care "Specialized Clinical Infectious Diseases Hospital" of Ministry of Health of Krasnodar Region, Krasnodar, Russian Federation, <sup>16</sup>University Hospital Frankfurt, Department of Medicine, Frankfurt am Main, <sup>17</sup>Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy, <sup>18</sup>CRC "A. M. and A. Migliavacca" Center for Liver Disease, University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy

## HEPATITIS EPIDEMIOLOGY

**P 23 Seroprevalence of HCV-Ab and Awareness in People Who Inject Drugs (PWID) from Addiction Services**

C. Marcia<sup>1</sup>, E. Prinčič<sup>1</sup>, G. Seu<sup>2</sup>, L. Denti<sup>1</sup>, M. Fois<sup>1</sup>, S. Babudieri<sup>1</sup>, I. Maida<sup>1</sup>

<sup>1</sup>Department of Medical, Surgical and Experimental Sciences, University of Sassari, <sup>2</sup>Addiction Services of Sassari

## HIV-ASSOCIATED TUBERCULOSIS

**P 24 Socio-demographic and clinical characteristics of HIV-associated tuberculosis in Tor Vergata Hospital, Rome: a 9-year analysis**

B. Rossi, M. Zordan, A.M.A. Crea, M. Compagno, M. Iannetta, L. Campogiani, L. Coppola, L. Sarmati, M. Andreoni and the PTV group

Infectious Diseases Department, Tor Vergata Hospital, Rome, Italy





## MANAGEMENT AND TREATMENT OF VIRAL HEPATITIS

### P 25 Improving organizational effectiveness for chronic hepatitis C linkage to care and treatment: a case report

L. Ceccarelli<sup>1,2</sup>, I. Corazza<sup>2</sup>, M. Vainieri<sup>2</sup>, L. Tavoschi<sup>1</sup>

<sup>1</sup>University of Pisa, Department of Translational Research and New Technologies in Medicine and Surgery, Pisa, Italy, <sup>2</sup>Sant'Anna School of Advanced Studies, Management and Healthcare Laboratory, Pisa, Italy

### P 26 Analysis of patients characteristics and treatment profile of persons who use drugs (PWUD) with and without a co-diagnosis of viral hepatitis C: a real-world retrospective Italian study

F. Nava<sup>1</sup>, A. Mangia<sup>2</sup>, M. Riglietta<sup>3</sup>, L. Somaini<sup>4</sup>, F.G. Foschi<sup>5</sup>, E. Claar<sup>6</sup>, I. Maida<sup>7</sup>, C. Ucciferri<sup>8</sup>, F. Frigerio<sup>9</sup>, C. Hernandez<sup>10</sup>, D.D. Ancona<sup>11</sup>, M. Andretta<sup>12</sup>, A. Barbieri<sup>13</sup>, F. Bartolini<sup>14</sup>, A. Ciaccia<sup>15</sup>, A. Costantini<sup>16</sup>, S. Dell'Orco<sup>17</sup>, R. Moscogiuri<sup>18</sup>, E. Mosele<sup>19</sup>, C. Procacci<sup>11</sup>, F. Santolieri<sup>16</sup>, M. Dovizio<sup>20</sup>, D. Sangiorgi<sup>20</sup>, V. Perrone<sup>20</sup>, L. Degli Esposti<sup>20</sup>, M. Puoti<sup>21</sup>

<sup>1</sup>U.O. Sanità Penitenziaria e Area Dipendenze, Azienda ULSS 6 Euganea, Padova, Italy, <sup>2</sup>UOS Epatologia, Istituto di Ricovero e Cura 'Casa Sollievo della Sofferenza', S. Giovanni Rotondo, Italy, <sup>3</sup>UOC Dipendenze, ASST Papa Giovanni XXIII, Bergamo, Italy, <sup>4</sup>Servizio per le Dipendenze, SERT di Cossato, Biella, Italy, <sup>5</sup>UOC Medicina Interna, Ospedale di Faenza, Faenza, Italy, <sup>6</sup>UOC Medicina Interna, Ospedale Evangelico Villa Betania, Napoli, Italy, <sup>7</sup>UOC Malattie Infettive e Parassitarie, Azienda Ospedaliera Universitaria, Sassari, Italy, <sup>8</sup>Clinica di Malattie Infettive Ospedale "SS Annunziata" Chieti, Italy, <sup>9</sup>Gilead Sciences, Milano, Italy, <sup>10</sup>Gilead Sciences, Global Medical Affairs, Stockley Park, London, UK 16, <sup>11</sup>Pharmaceutical Department, Local Health Unit BAT, Andria, Italy, <sup>12</sup>UOC Territoriale Farmaceutica, Azienda ULSS 8 Berica, Vicenza, Italy, <sup>13</sup>Territoriale Farmaceutica Complex Structure, Local Health Unit VC, Vercelli, Italy, <sup>14</sup>Pharmaceutical Department, Local Health Unit Umbria 2, Terni, Italy, <sup>15</sup>Territoriale Farmaceutica Service, Local Health Unit Foggia, Italy, <sup>16</sup>Hospital Pharmacy, "Santo Spirito" Hospital, Pescara, Italy, <sup>17</sup>Local Pharmaceutical Service, Roma 6 Local Health Unit, Albano Laziale RM, Italy, <sup>18</sup>Pharmaceutical Department of Taranto Local Health Unit, Hospital SS. Annunziata, Taranto, Italy, <sup>19</sup>U.O.C. Territoriale Farmaceutica Assistenza, ULSS 7 Pedemontana, Bassano del Grappa, Vicenza, Italy, <sup>20</sup>CliCon S.R.L. Società Benefit, Health Economics and Outcomes Research, Bologna, Italy, <sup>21</sup>SC Malattie Infettive, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy

## Comorbidities

### CANCERS IN HIV

### P 27 Rare bone involvement of Kaposi's sarcoma in HIV late presenter: a case report

V. Crosato<sup>1</sup>, S. Arsuffi<sup>1</sup>, F. Pennati<sup>1</sup>, V. Ferrari<sup>2</sup>, M.A. Forleo<sup>1</sup>, E. Quiros-Roldan<sup>1</sup>, A. Berruti<sup>2</sup>, F. Castelli<sup>1</sup>, E. Focà<sup>1</sup>

<sup>1</sup>Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy, <sup>2</sup>Division of Medical Oncology, University of Brescia at ASST Spedali Civili, Brescia, Italy

### P 28 Outcomes in HIV carriers with or without recurrence of hepatocellular carcinoma after invasive therapy

C. Bertoni<sup>1</sup>, L. Galli<sup>2</sup>, E. Messina<sup>2</sup>, H. Hasson<sup>2</sup>, A. Siribelli<sup>2</sup>, S. Bagaglio<sup>2</sup>, A. Castagna<sup>1</sup>, C. Uberti-Foppa<sup>1</sup>, G. Morsica<sup>2</sup>

<sup>1</sup>Vita-Salute University, Milan, Italy, <sup>2</sup>Dept. of Infectious Diseases, San Raffaele Hospital, Milan, Italy

### P 29 AIDS-defining cancers and non AIDS-defining cancers in a cohort of PLWH

F. Ginevri, S. Mazzanti, L. Brescini, V. Barocci, M. Di Pietrantonio, G. Cesaretti, B. Candelaesi, S. Olivieri, F. Pallotta, P. Mantini

Clinica Malattie Infettive Ospedali Riuniti Ancona

### P 30 Don't forget prevention, screening with cytology, genotyping and high resolution anoscopy for anal HPV-related precancerous lesions in PLWH continues during COVID19 pandemic

M. Digaetano<sup>1</sup>, A. Catania<sup>1</sup>, M.D. Di Trapani<sup>1</sup>, M. Menozzi<sup>1</sup>, R.P. Iachetta<sup>2</sup>, R.D. Villani<sup>2</sup>, A. Farinetti<sup>3,5</sup>, G. Rolando<sup>3</sup>, S. Tagliazucchi<sup>4</sup>, M. Pecorari<sup>4</sup>, R. Gelmini<sup>3,5</sup>, C. Mussini<sup>1,5</sup>

<sup>1</sup>Infectious Diseases Unit, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy, <sup>2</sup>Pelvic Floor Center, Department of Proctology, Nuovo Ospedale Civile di Sassuolo, Modena, Italy, <sup>3</sup>Surgery Unit, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy, <sup>4</sup>Microbiology and Virology Unit, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy, <sup>5</sup>Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy





## HIV AND NERVOUS SYSTEM

### P 31 A rare case of HIV-related vacuolar myelopathy in a living patient

A. Giacinta, A. Londero, P. Della Siega, C. De Carlo, C. Tascini  
Unit of Infectious Diseases "Santa Maria della Misericordia (University Hospital)", Udine, Italy

## NON INFECTIOUS COMORBIDITIES IN HIV

### P 32 Positive correlation between bone and endothelial damage in patients with HIV

A. Masiello, V. Zollo, F. Simeone, A. Iodice, P. Maggi  
AORN "S. Anna e San Sebastiano", Caserta, University of Campania "L. Vanvitelli"

### P 33 Limb-girdle muscular dystrophy in a patient with recent diagnosis of HIV infection

D. Checchi<sup>1</sup>, A. Lodi<sup>1</sup>, P.G. Pace<sup>1</sup>, S. Tedde<sup>1</sup>, F. Barreca<sup>1</sup>, F. Caldara<sup>1</sup>, A. Crea<sup>1</sup>, T. Mulas<sup>1</sup>, L. Ferrari<sup>1</sup>, G. De Simone<sup>1</sup>, M. Compagno<sup>1</sup>, G. Merlonghi<sup>2</sup>, M. Garibaldi<sup>2</sup>, L. Sarmati<sup>1</sup>, M. Andreoni<sup>1</sup>, M. Iannetta<sup>1</sup>  
<sup>1</sup>Fondazione PTV and University of Rome Tor Vergata, Rome, <sup>2</sup>SAPIENZA University of Rome, Sant'Andrea Hospital, Rome

## SEXUALLY TRANSMITTED INFECTIONS (STIS)

### P 34 Sense and hypersensitivity - A case series of Jarisch-Herxheimer Reaction following gonorrhea treatment

D. Moschese<sup>1</sup>, M.V. Cossu<sup>1</sup>, S. Merli<sup>1</sup>, R. Giorgi<sup>1</sup>, L. Caron<sup>2</sup>, A. Capetti<sup>1</sup>, G. Rizzardini<sup>1</sup>  
<sup>1</sup>Division of Infectious Diseases - Department of Infectious Diseases - Luigi Sacco University Hospital - Milan, Italy, <sup>2</sup>Allergology Unit - Department of Infectious Diseases - Luigi Sacco University Hospital - Milan, Italy

### P 35 On the importance of the sexual health screening: the impact of a newborn service in the post Covid-19 era in Southern Italy

E. Milano<sup>1</sup>, L. Ronga<sup>2</sup>, D. Fiordelisi<sup>1</sup>, A. Ricciardi<sup>1</sup>, E. Pallara<sup>1</sup>, M. Camporeale<sup>1</sup>, E. De Vita<sup>1</sup>, R. Novara<sup>1</sup>, G. Patti<sup>1</sup>, V. Totaro<sup>1</sup>, E. M. Ranieri<sup>2</sup>, R. Del Prete<sup>2</sup>, M.T. Montagna<sup>2</sup>, A. Saracino<sup>1</sup>  
<sup>1</sup>Clinic of Infectious Diseases, University of Bari, Bari, <sup>2</sup>Section of Microbiology and Virology, University of Bari

### P 36 Malignant syphilis and a newly HIV infection diagnosis

G. Quartini<sup>1</sup>, A. Lavagna<sup>1</sup>, L. Ricci<sup>2</sup>, M.E. Laurenti<sup>2</sup>, M. Papini<sup>3</sup>, M.B. Pasticcini<sup>1</sup>  
<sup>1</sup>Clinica di Malattie Infettive, Università degli Studi di Perugia, Ospedale Santa Maria di Terni, Terni, <sup>2</sup>Struttura Complessa di Anatomia Patologica, Università degli Studi di Perugia, Ospedale Santa Maria di Terni, Terni, <sup>3</sup>Clinica Dermatologica, Università degli Studi di Perugia, Ospedale Santa Maria di Terni, Terni

## COVID-19

### COVID-19 THERAPIES

### P 37 Monlupiravir for the early treatment of COVID-19

D. Altobelli, G.V. De Socio, G. Gamboni, S. Benedetti, M. Albagini, E. Baranello, D. Veramonti, E. Schiaroli, D. Francisci  
Department of Medicine and Surgery, Clinic of Infectious Diseases, "Santa Maria della Misericordia" Hospital, University of Perugia, Perugia, Italy

### P 38 Baricitinib alone and in combination with Remdesivir for the late treatment of adults hospitalized with COVID-19

M. Niglio<sup>1</sup>, M. Poliseo<sup>1</sup>, D. Lacedonia<sup>2</sup>, F. De Gregorio<sup>1</sup>, G. Minafra<sup>1</sup>, T. Campanino<sup>2</sup>, I. Cassiti<sup>2</sup>, T.A. Santantonio<sup>1</sup>, M.P. Foschino Barbaro<sup>2</sup>, S. Lo Caputo<sup>1</sup>  
<sup>1</sup>Unit of Infectious Diseases, Foggia University Hospital - Foggia, Italy, <sup>2</sup>Unit of Respiratory Diseases, Foggia University Hospital - Foggia, Italy

### P 39 Type of patients treated with mAb in COVID-19: the reality of Amedeo di Savoia

C. Marchiaro<sup>1</sup>, E. Catellani<sup>1</sup>, D. Piccioni<sup>1</sup>, S. Bertini<sup>1</sup>, F. Donato<sup>1</sup>, M. Ferrara<sup>2</sup>, G. Cinnirella<sup>1</sup>  
<sup>1</sup>ASL Città di Torino, SSD Infectious Diseases Pharmacy - HCV, Hospital Amedeo di Savoia, <sup>2</sup>Unity of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino

### P 40 Efficacy of Sotrovimab as early COVID treatment of BA.1 sublineage of Omicron variant

E. Drappero<sup>1</sup>, M. Ferrara<sup>1</sup>, A. Gaviraghi<sup>1</sup>, F. Alladio<sup>1</sup>, F. Venuti<sup>1</sup>, G. Stroffolini<sup>1</sup>, G. Accardo<sup>1</sup>, S. Fantino<sup>1</sup>, F. Traverso<sup>1</sup>, G. Trevisan<sup>1</sup>, D. Vita<sup>1</sup>, L. Di Girolamo<sup>1</sup>, L. Ponzetta<sup>1</sup>, M. Quaranta<sup>1</sup>, F. Ranzani<sup>1</sup>, A. Serra<sup>1</sup>, L. Trentini<sup>1</sup>, E. Burdino<sup>2</sup>, G. Gregori<sup>2</sup>, F. Cerutti<sup>2</sup>, V. Ghisetti<sup>2</sup>, C. Marchiaro<sup>3</sup>, E. Catellani<sup>3</sup>, G. Cinnirella<sup>3</sup>, G. Di Perri<sup>1</sup>, S. Bonora<sup>1</sup>  
<sup>1</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, <sup>2</sup>Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital, ASL Città di Torino, Torino, <sup>3</sup>SDD Infectious Diseases Pharmacy - HCV, Amedeo di Savoia Hospital, ASL Città di Torino, Torino



**P 41 Cysteamine exerts in vitro antiviral activity against the SARS-CoV-2 Delta and Omicron variants**

T. Alonzi<sup>1</sup>, A. Aiello<sup>1</sup>, F. Repele<sup>1</sup>, L. Falasca<sup>1</sup>, M. Francalancia<sup>1</sup>, A.R. Garbuglia<sup>1</sup>, G. Delogu<sup>3,4</sup>, M. Piacentini<sup>1,2</sup>, D. Goletti<sup>1</sup>

<sup>1</sup>National Institute for Infectious Diseases "L. Spallanzani" IRCCS, <sup>2</sup>Department of Biology, University of Rome "Tor Vergata", <sup>3</sup>Institute of Microbiology, Università Cattolica del Sacro Cuore - Fondazione Policlinico Gemelli, <sup>4</sup>Mater Olbia Hospital

**P 42 A possible treatment algorithm for the use of antiviral therapies and monoclonal antibodies against COVID-19**

L. Diella<sup>1</sup>, D.F. Bavaro<sup>1</sup>, D. Fiordelisi<sup>1</sup>, G. Guido<sup>1</sup>, A. Belati<sup>1</sup>, G. Brindicci<sup>1</sup>, G. Loseto<sup>2</sup>, C. Minoia<sup>2</sup>, A. Guarini<sup>2</sup>, I. Attolico<sup>3</sup>, T. Perrone<sup>3</sup>, P. Musto<sup>4</sup>, S. Simone<sup>5</sup>, L. Gesualdo<sup>5</sup>, M. Rendina<sup>6</sup>, A. Di Leo<sup>6</sup>, M. Santoro<sup>7</sup>, M. Dell'Aera<sup>7</sup>, F. Di Gennaro<sup>1</sup>, A. Saracino<sup>1</sup>

<sup>1</sup>Clinic of Infectious Diseases, Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", Bari, Italy, <sup>2</sup>Hematology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy, <sup>3</sup>Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy, <sup>4</sup>Department of Emergency and Organ Transplantation, "Aldo Moro" University School of Medicine and Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy, <sup>5</sup>Nephrology, Dialysis and Transplantation Unit, Department of Emergency and Organ Transplantation (DETO), University of Bari Aldo Moro, Bari, Italy, <sup>6</sup>Section of Gastroenterology, Department of Emergency and Organ Transplantation, University "Aldo Moro" of Bari, Bari, Italy, <sup>7</sup>Farmacia Ospedaliera AOU Policlinico di Bari – Bari, Italy

**P 43 Therapies consumption to treat COVID-19 patients hospitalized in a large tertiary Hospital in Northern Italy during the first three pandemic waves**

E. Focà<sup>1</sup>, S. Calza<sup>2</sup>, S. Piva<sup>3</sup>, I. Ettori<sup>1</sup>, C. De Ciuceis<sup>4</sup>, F. Rasulo<sup>3</sup>, A. Paini<sup>5</sup>, S. Gipponi<sup>6</sup>, G. Levi<sup>7</sup>, M. Metra<sup>8</sup>, M. Castellano<sup>9</sup>, M. Nardin<sup>10</sup>, C. Ricci<sup>11</sup>, R. Badolato<sup>12</sup>, F. Odicino<sup>13</sup>, R. Orabonai<sup>13</sup>, F. Scolari<sup>14</sup>, E. Quiros Roldan<sup>1</sup>, F. Marinoni<sup>15</sup>, A.M. Roccaro<sup>16</sup>, C. Rossi<sup>17</sup>, F. Castelli<sup>1</sup>

<sup>1</sup>Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili, Brescia, Italy, <sup>2</sup>Unit of Biostatistics and Bioinformatics, University of Brescia, Brescia, Italy, <sup>3</sup>Unit of Anesthesiology and Critical Care Medicine, ASST Spedali Civili, Italy, <sup>4</sup>Second Unit of Internal Medicine, University of Brescia and ASST Spedali Civili, Italy, <sup>5</sup>Unit of Emergency Internal Medicine, University of Brescia and ASST Spedali Civili, Italy, <sup>6</sup>Unit of Neurology, University of Brescia and ASST Spedali Civili, Brescia, Italy, <sup>7</sup>Unit of Pneumology, ASST Spedali Civili, Brescia, Italy, <sup>8</sup>Unit of Cardiology, University of Brescia and ASST Spedali Civili, Brescia, Italy, <sup>9</sup>Unit of Internal Medicine and Endocrinology, University of Brescia and ASST Spedali Civili, Brescia, Italy, <sup>10</sup>Third Unit of Internal Medicine, ASST Spedali Civili, Italy, <sup>11</sup>Unit of Gastroenterology University of Brescia and ASST Spedali Civili, Brescia, Italy, <sup>12</sup>Unit of Pediatrics, Children's Hospital University of Brescia and ASST Spedali Civili, Brescia, Italy, <sup>13</sup>Unit of Gynecology and Obstetrics, University of Brescia and ASST Spedali Civili, Brescia, Italy, <sup>14</sup>Unit of Nephrology and Dialysis, University of Brescia and ASST Spedali Civili, Brescia, Italy, <sup>15</sup>Unit of Planning and Management Control Service, ASST Spedali Civili, Brescia, Italy, <sup>16</sup>Unit of Clinical Research and Phase I Studies, ASST Spedali Civili, Brescia, Italy, <sup>17</sup>Chief Medical Officer Institution, ASST Spedali Civili, Brescia, Italy

**P 44 Remdesivir in combination with casirivimab/imdevimab monoclonal antibodies for the treatment of severe COVID-19**

I. Gentile, I. Di Filippo, N. Esposito, M. Sarno, L. Fusco, F. Licciardi, A. Truono, N. Schiano Moriello, R. Scotto, B. Pinchera, G. Viceconte, A. Iuliano, E. Zap-pulo, M. Foggia, A.R. Buonomo

Department of Clinical Medicine and Surgery, Infectious Diseases Unit, University "Federico II", Naples, Italy

**P 45 Monoclonal antibodies administration against SARS-CoV-2. The experience of the Tor Vergata Hospital**

R.A. Cavasio<sup>1</sup>, N. Braccialarghe<sup>1</sup>, D. Zaçe<sup>1</sup>, I. Spalliera<sup>1</sup>, L. Coppola<sup>1</sup>, L. Campogiani<sup>1</sup>, L. Piermatteo<sup>2</sup>, M.C. Bellocchi<sup>2</sup>, F. Ceccherini Silberstein<sup>2</sup>, M. Iannetta<sup>1</sup>, L. Sarmati<sup>1</sup>, M. Andreoni<sup>1</sup> and the Tor Vergata Hospital group

<sup>1</sup>Infectious Diseases Department, University of Rome Tor Vergata, Rome, Italy, <sup>2</sup>Virology Department, University of Rome Tor Vergata, Rome, Ital

**P 46 Oral antivirals against SARS-CoV-2: the experience of the Tor Vergata Hospital**

N. Braccialarghe, R.A. Cavasio, D. Zaçe, I. Spalliera, L. Coppola, M. Iannetta, L. Sarmati, M. Andreoni and the Tor Vergata Hospital group

Infectious Diseases Department, University of Rome Tor Vergata, Rome, Italy

**P 47 SARS COV 2 viral variants and mabs: the results of a cohort study in southern Italy**

S. De Pascalis<sup>1</sup>, L. Alessio<sup>1</sup>, M. Pisaturo<sup>1</sup>, A. Russo<sup>1</sup>, R. Palladino<sup>1</sup>, A.R. Buonomo<sup>2</sup>, B. Pinchera<sup>2</sup>, I. Gentile<sup>2</sup>, C. Tiberio<sup>3</sup>, L. Atripaldi<sup>3</sup>, N. Coppola<sup>1</sup>

<sup>1</sup>AOU L.Vanvitelli, Naples, <sup>2</sup>AOU FedericoII, Naples, <sup>3</sup>AORN dei Colli, PO D.Cotugno, Naples

**HIV AND COVID-19****P 48 Lack of anti-N IgG after symptomatic COVID-19 in an immunocompetent PLWH: a case report**

Y. Rusotto<sup>1</sup>, C. Micali<sup>1</sup>, G. Nunnari<sup>1</sup>, E. Venanzi Rullo<sup>1</sup>, G.F. Pellicanò<sup>2</sup>

<sup>1</sup>Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy, <sup>2</sup>Unit of Infectious Diseases, Department of Adult and Childhood Human Pathology "Gaetano Barresi", University of Messina, Messina, Italy





**P 49 COVID-19 Outcomes among people living with HIV in comparison to the General Population of the Lombardy Region**

L. Galli<sup>1</sup>, D. Ceccarelli<sup>1</sup>, O. Leoni<sup>3</sup>, D. Cereda<sup>4</sup>, A. D'Arminio-Monforte<sup>5</sup>, G. Rizzardini<sup>6</sup>, R. Rossotti<sup>7</sup>, M. Rizzi<sup>8</sup>, F. Castelli<sup>9</sup>, F. Franzetti<sup>10</sup>, L. Pusterla<sup>11</sup>, S. Dal Zoppo<sup>12</sup>, P. Bonfanti<sup>13</sup>, S. Rusconi<sup>14</sup>, A. Regazzetti<sup>15</sup>, L. Palvarini<sup>16</sup>, S. Antinori<sup>17</sup>, A. Gori<sup>18</sup>, S. Piconi<sup>19</sup>, R. Bruno<sup>20</sup>, P.A. Grossi<sup>21</sup>, A. Lazzarin<sup>2</sup>, A. Castagna<sup>1,2</sup>

<sup>1</sup>Infectious Diseases Unit, IRCCS San Raffaele Hospital, Milan, Italy, <sup>2</sup>Vita-Salute San Raffaele University, Milan, Italy, <sup>3</sup>Struttura Epidemiologia e Valutazione delle performance, U.O. Osservatorio Epidemiologico Regionale, Milan, Italy, <sup>4</sup>UO Prevenzione Direzione Generale Welfare di Regione Lombardia, Milan, Italy, <sup>5</sup>ASST Santi Paolo e Carlo Ospedale San Paolo, Milan, Italy, <sup>6</sup>ASST BFB-Sacco Ospedale Luigi Sacco, UOC Malattie Infettive 1-2, Milan, Italy, <sup>7</sup>ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, <sup>8</sup>ASST Papa Giovanni XXIII, Bergamo, Italy, <sup>9</sup>ASST Spedali Civili, UOC Malattie Infettive, Brescia, Italy, <sup>10</sup>ASST Valle Olona Ospedale di Busto Arsizio, Busto Arsizio, Italy, <sup>11</sup>ASST Lariana Ospedale Sant'Anna, Como, Italy, <sup>12</sup>ASST Cremona Ospedale di Cremona, Cremona, Italy, <sup>13</sup>ASST Monza Ospedale San Gerardo, Monza, Italy, <sup>14</sup>ASST Ovest Milanese Ospedale Nuovo di Legnano, Legnano, Italy, <sup>15</sup>ASST Lodi Ospedale Dalmati, Sant'Angelo Lodigiano, Italy, <sup>16</sup>ASST Mantova Ospedale Carlo Poma, Mantova, Italy, <sup>17</sup>ASST BFB-Sacco Ospedale Luigi Sacco, UOC Malattie Infettive 3, Milan, Italy, <sup>18</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, <sup>19</sup>ASST Lecco Ospedale A. Manzoni, Lecco, Italy, <sup>20</sup>Fondazione IRCCS Policlinico San Matteo, UOC Malattie Infettive, Pavia, Italy, <sup>21</sup>ASST Sette Laghi Ospedale di Circolo, Varese, Italy

**P 50 Who's no-vax? SARS-CoV2 vaccination adherence in PLWHA: a single center experience. Check to help**

G. Orofino<sup>1</sup>, M. Guastavigna<sup>1</sup>, L. Carani<sup>2</sup>, M. Farenga<sup>1</sup>, F. Berf<sup>3</sup>, A. Pivi<sup>3</sup>, B. Mollero<sup>3</sup>, A. Russo<sup>3</sup>, GD Greco<sup>4</sup>, G. Calleri<sup>1</sup>

<sup>1</sup>Divisione A di Malattie Infettive e Tropicali, Ospedale Amedeo di Savoia, Torino, <sup>2</sup>Dipartimento di Scienze Mediche, Università di Torino, Torino, <sup>3</sup>Dipartimento di Salute Pubblica, Università di Torino, Torino, <sup>4</sup>SSD SISP Emergenze infettive e Prevenzione, ASL Città di Torino, Torino

**P 51 The "Unknown"- Lost to follow-up and virological failure in the COVID-19 era: comparison between the three waves, determinants of VF and failure for all causes in PLWH in cART**

L. Montemurro<sup>1</sup>, G. Di Teodoro<sup>2,3</sup>, A. Borghetti<sup>4</sup>, F. Conti<sup>5</sup>, F. Lombardi<sup>6</sup>, L. Pezzati<sup>5</sup>, M. Poliseo<sup>1</sup>, A. Shallvari<sup>3,7</sup>, A. Bezenchek<sup>3,7</sup>, S. Rusconi<sup>5,8</sup>, V. Borghi<sup>9</sup>

<sup>1</sup>U.O. Malattie Infettive Universitaria, University of Foggia, Foggia, Italy, <sup>2</sup>Dipartimento di Ingegneria informatica automatica e gestionale A. Ruberti, Sapienza Università di Roma, Roma, Italy, <sup>3</sup>EuResist Network GEIE, Roma, Italy, <sup>4</sup>Policlinico Gemelli, Roma, Italy, <sup>5</sup>Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milano, Italy, <sup>6</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Malattie Infettive, Roma, Italy, <sup>7</sup>InformaPRO SRL, Roma, Italy, <sup>8</sup>UOC Malattie Infettive, ASST Ovest Milanese, Ospedale di Legnano, Milano, Italy, <sup>9</sup>Clinica Malattie Infettive, Azienda Ospedaliero Universitaria di Modena, Modena, Italy

**MANAGEMENT OF COVID-19**

**P 52 Acute mesenteric ischemia in a patient with COVID-19 infection: a case report**

G. D'Aguanno<sup>1</sup>, F. Savalli<sup>1</sup>, G. Consuelo<sup>1</sup>, P. Miraglia<sup>1</sup>, M.C. Morsellino<sup>1</sup>, S. Cianchino<sup>1</sup>, G. Ribauda<sup>2</sup>, P. Colletti<sup>1</sup>

<sup>1</sup>Department of Infection Diseases, Paolo Borsellino Hospital, Marsala TP, <sup>2</sup>Department of Surgery, Paolo Borsellino Hospital, Marsala TP

**P 53 Obesity and Covid-19: the results of a multicentric cohort study in Campania**

V. Zollo<sup>1</sup>, M. Pisaturo<sup>1</sup>, P. Maggi<sup>2</sup>, F. G. Numis<sup>3</sup>, I. Gentile<sup>4</sup>, V. Sangiovanni<sup>5</sup>, V. Esposito<sup>6</sup>, R. Punzi<sup>7</sup>, G. Calabria<sup>8</sup>, C. Rescigno<sup>9</sup>, A. Salomone Megna<sup>10</sup>, A. Masullo<sup>11</sup>, E. Manzillo<sup>12</sup>, G. Russo<sup>13</sup>, R. Parrella<sup>14</sup>, G. Dell'Aquila<sup>15</sup>, M. Gambardella<sup>16</sup>, A. Ponticciello<sup>17</sup>, N. Coppola<sup>1</sup> on behalf of CoviCam group

<sup>1</sup>Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania "L. Vanvitelli", Napoli, Italy, <sup>2</sup>Infectious Diseases Unit, A.O. S Anna e S Sebastiano Caserta, Italy, <sup>3</sup>Emergency unit, PO Santa Maria delle Grazie, Pozzuoli, Italy, <sup>4</sup>Infectious disease unit; University Federico II, Naples, Italy, <sup>5</sup>Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, <sup>6</sup>IV Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>7</sup>Hepatic Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>8</sup>IX Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>9</sup>First Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>10</sup>Infectious Disease Unit, A.O. San Pio, PO Rummo, Benevento, Italy, <sup>11</sup>Infectious disease unit, A.O. San Giovanni di Dio e Ruggi D'Aragona Salerno, Italy, <sup>12</sup>VIII Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>13</sup>Infectious Disease Unit, Ospedale Maria S.S. Addolorata di Eboli, ASL Salerno, Italy, <sup>14</sup>Respiratory Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>15</sup>Infectious Diseases Unit, AO Avellino, Italy, <sup>16</sup>Infectious Disease Unit, PO S. Luca, Vallo della Lucania, ASL Salerno, Italy, <sup>17</sup>Pneumology Unit, AORN Caserta, Italy

**P 54 Epidemiological and clinical factors related to late negativization of SARS-CoV 2 nasopharyngeal swab**

P. Grimaldi<sup>1</sup>, M. Pisaturo<sup>1</sup>, P. Maggi<sup>2</sup>, F. G. Numis<sup>3</sup>, I. Gentile<sup>4</sup>, V. Sangiovanni<sup>5</sup>, V. Esposito<sup>6</sup>, R. Punzi<sup>7</sup>, G. Calabria<sup>8</sup>, C. Rescigno<sup>9</sup>, A. Salomone Megna<sup>10</sup>, A. Masullo<sup>11</sup>, E. Manzillo<sup>12</sup>, G. Russo<sup>13</sup>, R. Parrella<sup>14</sup>, G. Dell'Aquila<sup>15</sup>, M. Gambardella<sup>16</sup>, A. Ponticciello<sup>17</sup>, N. Coppola<sup>1</sup> on behalf of CoviCam group

<sup>1</sup>Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania "L. Vanvitelli", Napoli, <sup>2</sup>Infectious Diseases Unit, A.O. S Anna e S Sebastiano Caserta, <sup>3</sup>Emergency unit, PO Santa Maria delle Grazie, Pozzuoli, <sup>4</sup>Infectious disease unit; University Federico II, Naples, <sup>5</sup>Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, <sup>6</sup>IV Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, <sup>7</sup>Hepatic Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, <sup>8</sup>IX Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, <sup>9</sup>First Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, <sup>10</sup>Infectious Disease Unit, A.O. San Pio, PO Rummo, Benevento, <sup>11</sup>Infectious disease unit, A.O. San Giovanni di Dio e Ruggi D'Aragona Salerno, <sup>12</sup>VIII Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, <sup>13</sup>Infectious Disease Unit, Ospedale Maria S.S. Addolorata di Eboli, ASL Salerno, <sup>14</sup>Respiratory Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, <sup>15</sup>Infectious Diseases Unit, AO Avellino, <sup>16</sup>Infectious Disease Unit, PO S. Luca, Vallo della Lucania, ASL Salerno, <sup>17</sup>Pneumology Unit, AORN Caserta





**P 55 Major bleeding events in COVID-19 patients admitted to hospital: a case series**

G. Casalini<sup>1,2</sup>, A. Giacomelli<sup>2</sup>, G. Pozza<sup>1,2</sup>, A. Poloni<sup>1,2</sup>, V. Colombo<sup>1</sup>, F. Petri<sup>1</sup>, M. Gerbi<sup>1</sup>, C. Fusetti<sup>1</sup>, G. Carrozzo<sup>1,2</sup>, G. Rizzardini<sup>1</sup>, S. Antinori<sup>1,2</sup>

<sup>1</sup>Luigi Sacco Department of Biomedical and Clinical Sciences, University of Milan, Italy, <sup>2</sup>III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy

**P 56 Secondary organizing pneumonia (SOP) in two late Covid-19 haematological patients**

A. Tommasi<sup>1</sup>, A. Tosti<sup>1</sup>, N. Murgia<sup>2</sup>, E. Stojaj<sup>1</sup>, G. Genga<sup>1</sup>, L. Malincarne<sup>1</sup>, S. Morosi<sup>1</sup>, D. Francisci<sup>1</sup>

<sup>1</sup>Infectious Disease Clinic, Department of Medicine and Surgery, Santa Maria della Misericordia Hospital, University of Perugia - Perugia (Italy),

<sup>2</sup>Occupational and Respiratory Medicine, Department of Medicine and Surgery, Santa Maria della Misericordia Hospital, University of Perugia - Perugia (Italy)

**P 57 Campylobacter coli bacteremia in patient with Common Variable Immunodeficiency (CVID) and SARS-CoV-2 infection**

N. Esposito<sup>1</sup>, S. Di Bari<sup>2,3</sup>, F. Taglietti<sup>3</sup>, M. Sarno<sup>1</sup>, F. Gavaruzzi<sup>2,3</sup>, S. Al Moghazi<sup>3</sup>, D.R. Donno<sup>3</sup>, E. Caraffa<sup>3</sup>, G. Granata<sup>3</sup>, P. Chinello<sup>3</sup>

<sup>1</sup>Department of Clinical Medicine and Surgery, Infectious Diseases Unit, University "Federico II", Naples, Italy, <sup>2</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy, <sup>3</sup>Clinical and Research Department for Infectious Diseases, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy

**P 58 Haematological malignancies and COVID-19: do we have effective treatments? A case report**

E. Binetti, A. Pupo, R. Donà, D. Giangiulio, S. Lobello, F. Romano, V. Vola, F. Cogliati Dezza, G. Russo, G. Siccardi, C. M. Mastroianni

Università La Sapienza, Roma

**P 59 Pre-existing chronic kidney disease (CKD) is associated with an increase in the duration of hospitalization in Covid-19 patients but not with increased mortality: results of a case-control study**

M.G. Palamone<sup>1</sup>, F. Calò<sup>10</sup>, A. Russo<sup>1</sup>, P. Maggi<sup>1,2</sup>, V. Sangiovanni<sup>3</sup>, F.G. Numis<sup>4</sup>, I. Gentile<sup>5</sup>, A. Masullo<sup>6</sup>, C. Rescigno<sup>3</sup>, G. Calabria<sup>3</sup>, A. Salomone Megna<sup>7</sup>, M. Gambardella<sup>8</sup>, E. Manzillo<sup>3</sup>, G. Russo<sup>9</sup>, V. Esposito<sup>3</sup>, N. Coppola<sup>1,10</sup>, Simit Campania Group

<sup>1</sup>Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania "Luigi Vanvitelli" Naples, Italy, <sup>2</sup>Infectious Diseases Unit, A.O. S. Anna e S. Sebastiano Caserta, Italy, <sup>3</sup>Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, <sup>4</sup>Emergency Unit, PO Santa Maria delle Grazie, Pozzuoli, Italy, <sup>5</sup>Infectious Diseases Unit; University Federico II, Naples, Italy, <sup>6</sup>Infectious Diseases Unit, A.O. San Giovanni di Dio e Ruggi D'Aragona, Salerno, Italy, <sup>7</sup>Infectious Diseases Unit, A.O. San Pio, PO Rummo, Benevento, Italy, <sup>8</sup>Infectious Diseases Unit, PO S. Luca, Vallo della Lucania, ASL Salerno, Italy, <sup>9</sup>Infectious Diseases Unit, Ospedale Maria S.S. Addolorata di Eboli, ASL Salerno, Italy, <sup>10</sup>AOU L. Vanvitelli, Naples, Italy

**P 60 Evolution of mortality among the first three waves in the largest Italian Hospital receiving SARS-CoV-2 infected patients. Results from the Brescia HUB project**

E. Focà<sup>1</sup>, S. Calza<sup>2</sup>, S. Piva<sup>3</sup>, I. Ettori<sup>1</sup>, M.L. Muesan<sup>4</sup>, M. Salvetti<sup>5</sup>, F. Rasulo<sup>3</sup>, A. Padovani<sup>6</sup>, M. Bezzi<sup>7</sup>, M. Metra<sup>8</sup>, M. Castellano<sup>9</sup>, F. Legati<sup>10</sup>, C. Ricci<sup>11</sup>, R. Badolato<sup>12</sup>, F. Odicina<sup>13</sup>, R. Orabona<sup>13</sup>, F. Scolari<sup>14</sup>, F. Marinoni<sup>15</sup>, A.M. Roccaro<sup>16</sup>, C. Rossi<sup>17</sup>, F. Castelli<sup>1</sup>

<sup>1</sup>Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili, Brescia, Italy, <sup>2</sup>Unit of Biostatistics and Bioinformatics, University of Brescia, Brescia, Italy, <sup>3</sup>Unit of Anesthesiology and Critical Care Medicine, ASST Spedali Civili, Italy, <sup>4</sup>Second Unit of Internal Medicine, University of Brescia and ASST Spedali Civili, Italy, <sup>5</sup>Unit of Emergency Internal Medicine, University of Brescia and ASST Spedali Civili, Italy, <sup>6</sup>Unit of Neurology, University of Brescia and ASST Spedali Civili, Brescia, Italy, <sup>7</sup>Unit of Pneumology, ASST Spedali Civili, Brescia, Italy, <sup>8</sup>Unit of Cardiology, University of Brescia and ASST Spedali Civili, Brescia, Italy, <sup>9</sup>Unit of Internal Medicine and Endocrinology, University of Brescia and ASST Spedali Civili, Brescia, Italy, <sup>10</sup>Third Unit of Internal Medicine, ASST Spedali Civili, Italy, <sup>11</sup>Unit of Gastroenterology University of Brescia and ASST Spedali Civili, Brescia, Italy, <sup>12</sup>Unit of Pediatrics, Children's Hospital University of Brescia and ASST Spedali Civili, Brescia, Italy, <sup>13</sup>Unit of Gynecology and Obstetrics, University of Brescia and ASST Spedali Civili, Brescia, Italy, <sup>14</sup>Unit of Nephrology and Dialysis, University of Brescia and ASST Spedali Civili, Brescia, Italy, <sup>15</sup>Unit of Planning and Management Control Service, ASST Spedali Civili, Brescia, Italy, <sup>16</sup>Unit of Clinical Research and Phase I Studies, ASST Spedali Civili, Brescia, Italy, <sup>17</sup>Chief Medical Officer Institution, ASST Spedali Civili, Brescia, Italy

**P 61 A case report of adenovirus infection and HSV-1 hepatitis in a non-transplanted hematological patient with COVID-19 pneumonia**

N. Corti<sup>1,2</sup>, G. Lapadula<sup>1,2</sup>, M. Rossi<sup>1</sup>, E. Colella<sup>1</sup>, A. Rugova<sup>1</sup>, P. Columpsi<sup>1</sup>, A. Soria<sup>1</sup>, E. Pollastri<sup>1</sup>, L. Bisi<sup>1</sup>, S. Limonta<sup>1</sup>, F. Sabbatini<sup>1</sup>, A. Cappelletti<sup>1</sup>, A. Ranzani<sup>1</sup>, N. Squillace<sup>1</sup>, G.M. Migliorino<sup>1</sup>, S. Foresti<sup>1</sup>, P. Bonfanti<sup>1,2</sup>

<sup>1</sup>Infectious Disease Unit, San Gerardo Hospital, ASST Monza-Brianza, <sup>2</sup>Department of Medicine and Surgery, University of Milano-Bicocca, Monza

**P 62 Overlooked clinical signs in early SARS-CoV-2 infection among elderly people: acute kidney injury and altered state of consciousness**

C. Fanelli, A. Puggioni, L. Firino, I. Maida, G. Madeddu, S. Rubino, S. Babudieri

University of Sassari, Italy



**P 63 Comparative analysis between the different epidemic waves of SARS - CoV-2 infection: the experience of the Pontine hospital**

P. Zuccalà<sup>1</sup>, R. Marocco<sup>1</sup>, S. Gismondi<sup>1</sup>, V. Belvisi<sup>1</sup>, B. Kertusha<sup>1</sup>, T. Tieghi<sup>1</sup>, M. Del Borgo<sup>1</sup>, A. Gasperin<sup>1,2</sup>, S. Cacace<sup>1,2</sup>, A. Carraro<sup>1,2</sup>, A. Parente<sup>1,2</sup>, A. R. Cacciotti<sup>3</sup>, S. Parrocchia<sup>3</sup>, M. Lichtner<sup>1,2</sup>

<sup>1</sup>UOC Infectious Diseases, "S.Maria Goretti Hospital", Latina, <sup>2</sup>Department of Public Health, Microbiology and Infectious Diseases, Sapienza University of Rome, Polo Pontino <sup>3</sup>Health Management, "S.Maria Goretti Hospital", Latina

**P 64 Invasive cryptococcal disease in COVID-19: a case report, Systematic Review of the literature and analysis**

G. Pipitone<sup>1</sup>, G. Ciusa<sup>1</sup>, D. Spicola<sup>1</sup>, F. Di Lorenzo<sup>1</sup>, A. Sanfilippo<sup>1</sup>, F. Onorato<sup>1</sup>, A. Ficalora<sup>1</sup>, C. Buscemi<sup>1</sup>, T. Prestileo<sup>1</sup>, C. Imburgia<sup>1</sup>, I. Alongi<sup>1</sup>, F. Guida Marascia<sup>2</sup>, A. Gizzi<sup>2</sup>, M. Abbott<sup>2</sup>, M.S. Verde<sup>3</sup>, F. Di Bernardo<sup>3</sup>, A. Scafidi<sup>4</sup>, V. Mazzaresse<sup>4</sup>, A. Cascio<sup>2</sup>, N. Petrosillo<sup>5</sup>, C. Iaria<sup>1</sup>

<sup>1</sup>Infectious Disease Unit - ARNAS Civico-Di Cristina Hospital, Palermo, <sup>2</sup>Infectious Disease Unit - University Hospital "P. Giaccone", Palermo, <sup>3</sup>Microbiology Unit - ARNAS Civico-Di Cristina Hospital, Palermo, <sup>4</sup>Intensive Care Unit - ARNAS Civico-Di Cristina Hospital, Palermo, <sup>5</sup>Infectious Disease Unit - University Hospital "Campus Bio-Medico", Rome

**POST-ACUTE COVID-19 SYNDROME (PASC)****P 65 The use of lung ultrasound to monitoring the lung damage after Covid19 pneumonia**

S. Mazzanti, L. Brescini, V. Barocci, P. Mantini, M. Di Pietrantonio, B. Candelaresi, F. Pallotta, S. Olivieri, G. Cesaretti, F. Ginevri  
Clinica Malattie Infettive, Ospedali Riuniti di Ancona, Università Politecnica delle Marche

**SARS-COV-2 VACCINES****P 66 Safety and immunogenicity of a third-dose COVID-19 BNT162b2 boosting vaccination in People Living with HIV**

L. Gianserra<sup>1</sup>, M.G. Donà<sup>1</sup>, E. Giuliani<sup>2</sup>, C. Stingone<sup>1</sup>, M. Pontone<sup>3</sup>, A.R. Buonomini<sup>1</sup>, M. Giuliani<sup>1</sup>, F. Pimpinelli<sup>3</sup>, A. Morrone<sup>2</sup>, A. Latini<sup>1</sup>

<sup>1</sup>STI/HIV Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy, <sup>2</sup>Scientific Direction, San Gallicano Dermatological Institute IRCCS, Rome, Italy, <sup>3</sup>Microbiology and Clinical Pathology, San Gallicano Dermatological Institute IRCCS, Rome, Italy

**P 67 Fatal outcome of COVID-19 relapse in a fully vaccinated patient with Non-Hodgkin's lymphoma in maintenance therapy with anti-B cells monoclonal antibodies: a case report**

F. Calò<sup>1</sup>, L. Onorato<sup>1</sup>, C. Monari<sup>1</sup>, M. Pisaturo<sup>1</sup>, L. Alessio<sup>1</sup>, A. Di Fraia<sup>1</sup>, C. Minichini<sup>1</sup>, L. Atripaldi<sup>2</sup>, A. Pinto<sup>3</sup>, N. Coppola<sup>1</sup>

<sup>1</sup>Department of Mental Health and Public Medicine – Infectious Diseases Unit. University of Campania Luigi Vanvitelli, Naples, Italy, <sup>2</sup>Unit of Microbiology and Virology, AORN Ospedali dei Colli, Cotugno-Monaldi Hospital, Naples, Italy, <sup>3</sup>Hematology-Oncology & Stem Cell Transplantation Unit. National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, Italy

**P 68 A recent SARS-CoV-2 Omicron variant re-infection shortly after SARS-CoV-2 Delta variant related severe pneumonia in an immunocompromised patient with three-dose vaccination (BNT162b2 mRNA vaccine): immunological characterization and therapeutic approach**

A. Di Lorenzo<sup>1</sup>, M. Iannetta<sup>1</sup>, B. Rossi<sup>1</sup>, V. Malagnino<sup>1</sup>, M. Zordan<sup>1</sup>, L. Ansaldo<sup>1</sup>, N. Braccialarghe<sup>1</sup>, M. L. Minardi<sup>1</sup>, C. Sorace<sup>1</sup>, C. Cerini<sup>1</sup>, D. Zace<sup>1</sup>, L. Alborghetti<sup>1</sup>, S. Tedde<sup>1</sup>, L. Piermatteo<sup>2</sup>, E. Andreassi<sup>2</sup>, M.C. Bellocchi<sup>2</sup>, F. Ceccherini Silberstein<sup>2</sup>, L. Sarmati<sup>1</sup>, M. Andreoni<sup>1</sup>

<sup>1</sup>Department of System Medicine, Tor Vergata University, Rome, Italy, <sup>2</sup>Virology department, University of Rome Tor Vergata, Rome, Italy

**P 69 Evaluation of humoral and T-specific responses after the booster dose of BNT162b2 COVID-19 vaccine in residents of a Long Term Care Facility**

A. Lai<sup>1</sup>, B. Caimi<sup>2</sup>, A. Bergna<sup>1</sup>, A. Gatti<sup>2</sup>, M. Franzetti<sup>3</sup>, A. Gabrieli<sup>1</sup>, M. Tarkowski<sup>1</sup>, P.L. Rossi<sup>2</sup>, M. D'Orso<sup>4</sup>, F. Pregliasco<sup>5</sup>, C. Balotta<sup>1,2</sup>, A. Riva<sup>1</sup>, G. Calicchio<sup>2</sup>

<sup>1</sup>Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Milan, Italy, <sup>2</sup>Azienda Servizi alla Persona, Istituti Milanese Martinitt e Stelline e Pio Albergo Trivulzio, Milan, Italy, <sup>3</sup>Infectious Diseases Unit, Legnano General Hospital, ASST Ovest Milanese, Legnano, Italy, <sup>4</sup>Department of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy, <sup>5</sup>Department of Biomedical Sciences, University of Milan and IRCCS Istituto Ortopedico Galeazzi, Milan, Italy

**P 70 Detection of maternal antibodies elicited by COVID-19 vaccination in amniotic fluid**

F. Colavita, A. Oliva, A. Bettini, E. Girardi, A. Antinori, C. Castilletti, F. Vaia, G. Liuzzi

National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Rome, Italy

**P 71 Humoral and T-cell mediated response after administration of mRNA vaccine BNT162b2 in frail patients**

R. Campagna<sup>1</sup>, L. Mazzuti<sup>1</sup>, G. Guerrizio<sup>1</sup>, C. Nonne<sup>1</sup>, G. Migliara<sup>2</sup>, C. De Vito<sup>2</sup>, I. Mezzaroma<sup>3</sup>, V. Pistolesi<sup>4</sup>, S. Morabito<sup>4</sup>, O. Turriziani<sup>1</sup>

<sup>1</sup>Department of Molecular Medicine Sapienza University, Rome, <sup>2</sup>Department of Public Health and Infectious Diseases Sapienza University, Rome,

<sup>3</sup>Department of Translational and Precision Medicine Sapienza University, Rome, <sup>4</sup>Department of Internal Medicine and Medical Specialties Sapienza University, Rome



**P 72 Early evidence on vaccine effectiveness of COVID Vaccines in PLWHA**

M. Sane Schepisi<sup>1</sup>, A. Meggiolaro<sup>1</sup>, A. Mammone<sup>1</sup>, S. Farina<sup>2</sup>, C. Castagna<sup>2</sup>, A. Siddu<sup>1</sup>, A. Caraglia<sup>1</sup>, F. Maraglino<sup>1</sup>, S. Boccia<sup>2</sup>, G. Rezza<sup>1</sup>

<sup>1</sup>Italian Ministry of Health, General Directorate for Health Prevention, Rome, Italy, <sup>2</sup>Department of Life Sciences and Public Health, Section of Hygiene, Università Cattolica del Sacro Cuore, Rome, Italy

**Pathogenesis and Immunology****COVID-19 PATHOGENESIS****P 73 Longitudinal evaluation of QuantiFERON-TB gold plus responses in COVID-19 patients**

G. Alessio, A. Imeneo, A. Di Lorenzo, B. Rossi, M. Compagno, L. Coppola, L. Campogiani, M. Andreoni, L. Sarmati, M. Iannetta  
Policlinico Tor Vergata, Roma

**P 74 Humoral and cellular responses to spike of  $\delta$  SARS-CoV-2 variant in vaccinated patients with Immune Mediated Inflammatory Diseases**

L. Petrone<sup>1</sup>, A. Picchianti-Diamanti<sup>2</sup>, G.D. Sebastiani<sup>3</sup>, A. Aiello<sup>1</sup>, B. Laganà<sup>2</sup>, G. Cuzzi<sup>1</sup>, V. Vanini<sup>1,4</sup>, G. Gualano<sup>5</sup>, A. Grifoni<sup>6</sup>, M. Ferraioli<sup>7</sup>, C. Castilletti<sup>8</sup>, S. Meschi<sup>9</sup>, F. Vaia<sup>9</sup>, E. Nicastrì<sup>10</sup>, A. Sette<sup>6</sup>, D. Goletti<sup>1</sup>

<sup>1</sup>Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy, <sup>2</sup>Department of Clinical and Molecular Medicine, "Sapienza" University, S. Andrea University Hospital, Rome, Italy, <sup>3</sup>Department of Rheumatology, San Camillo Hospital, Rome, Italy, <sup>4</sup>Unità Operativa Semplice (UOS) Professioni Sanitarie Tecniche, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy, <sup>5</sup>Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy, <sup>6</sup>Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA, <sup>7</sup>Rheumatology, Allergology and Clinical Immunology, Dipartimento di medicina dei sistemi, University of Rome Tor Vergata, Rome, Italy, <sup>8</sup>Virology Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy, <sup>9</sup>UOC Direzione Sanitaria, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy, <sup>10</sup>UOC Malattie Infettive ad Alta Intensità di Cura, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy

**P 75 Serum levels of Surfactant Proteins A and D in SARSCoV2 infected patients**

L. Maddaloni<sup>1</sup>, L. Santinelli<sup>1</sup>, V. Zullino<sup>2</sup>, C. De Panfilis<sup>2</sup>, A. Lazzaro<sup>1</sup>, C.M. Lofaro<sup>1</sup>, S. Caiazza<sup>1</sup>, F. Ruberto<sup>2</sup>, C. Scagnolari<sup>3</sup>, C.M. Mastroianni<sup>1</sup>, G. d'Ettore<sup>1</sup>, G. Ceccarelli<sup>1</sup>

<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy, <sup>2</sup>Department of Anesthesia, Sapienza University of Rome, Italy, <sup>3</sup>Virology Laboratory, Department of Molecular Medicine, Sapienza University of Rome, Italy

**P 76 Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave**

A. Aiello<sup>1</sup>, A. Grossi<sup>2</sup>, S. Meschi<sup>3</sup>, M. Meledandri<sup>4</sup>, V. Vanini<sup>1,5</sup>, L. Petrone<sup>1</sup>, R. Casetti<sup>6</sup>, G. Cuzzi<sup>1</sup>, A. Salmi<sup>1</sup>, A.M.G. Altera<sup>1</sup>, L. Pierelli<sup>7</sup>, G. Gualano<sup>8</sup>, T. Ascoli Bartoli<sup>9</sup>, C. Castilletti<sup>8</sup>, C. Agrati<sup>4</sup>, E. Girardi<sup>10</sup>, F. Palmieri<sup>9</sup>, E. Nicastrì<sup>9</sup>, E. di Rosa<sup>2</sup>, D. Goletti<sup>1</sup>

<sup>1</sup>Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy, <sup>2</sup>UOC Public Health Hygiene Service, ASL Roma 1, <sup>3</sup>Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy, <sup>4</sup>UOC Microbiology and Virology, ASL Roma 1-San Filippo Neri Hospital, Rome, Italy, <sup>5</sup>UOS Professioni Sanitarie Tecniche, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, <sup>6</sup>Laboratory of Cellular Immunology, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy, <sup>7</sup>UOC Transfusion Medicine and Stem Cell Unit, San Camillo Forlanini Hospital, Rome, Italy, <sup>8</sup>Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy, <sup>9</sup>Clinical Division of Infectious Diseases, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy, <sup>10</sup>Clinical Epidemiology, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy

**Social science, Epidemiology and Prevention****HIV EPIDEMIOLOGY AND RETENTION IN CARE****P 77 Creation of a model of data collection and survey on long-acting HIV medications in the transgender population**

M. Formisano, M. Errico, A. Moznich, M. Cascio, A. Lascari, L. Brogonzoli  
NPS ITALIA, Milano

**P 78 Anti-HIV antibodies and Avidity Index: comparison between two fourth-generation immunoassays**

A. Morellini<sup>1</sup>, M. Tamburello<sup>1</sup>, S. Vituliano<sup>1</sup>, V. Ferraro<sup>1</sup>, A. Primavera<sup>2</sup>, A. Bertoldi<sup>2</sup>, G. Gallinella<sup>3</sup>, T. Lazzarotto<sup>1,2</sup>, I. Bon<sup>2</sup>

<sup>1</sup>Section of Microbiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, <sup>2</sup>Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, <sup>3</sup>Department of Pharmacy and Biotechnology, University of Bologna, Bologna





## HIV PREVENTION (PREP AND PEP)

### P 79 The ANLAIDS forum between old and new tools for HIV prevention

A. Venturelli, C. Balotta, R. Galipò, G.V. Calvino, B. Marchini  
Anlaids Onlus, Rome, Italy

### P 80 Anlaids in the Schools - What usefulness for adolescents and what impact on their behaviors

R. Galipò<sup>1</sup>, V. Calvino<sup>1</sup>, F. Caramaschi<sup>2</sup>, L. Carniato<sup>3</sup>, A. De Faveri<sup>4</sup>, P. Ferri<sup>5</sup>, S. Negrì<sup>6</sup>, A. Palummieri<sup>1</sup>, M. Viscoli<sup>4</sup>, B. Marchini<sup>1</sup>  
<sup>1</sup>Anlaids, Rome, <sup>2</sup>Anlaids Lazio, Rome, <sup>3</sup>Anlaids Lombardia, Milan, <sup>4</sup>Anlaids Liguria, Genoa, <sup>5</sup>Anlaids Mantova, Mantua, <sup>6</sup>Anlaids Torino, Turin,  
<sup>7</sup>Anlaids Treviso, Treviso

### P 81 Role of general practitioners in HIV early diagnosis and prevention: an online local survey

M. Jamhour<sup>1</sup>, G. Mancarella<sup>2</sup>, S. Garattini<sup>2</sup>, A. Carraro<sup>1,2</sup>, R. Marocco<sup>1</sup>, V. Belvisi<sup>1</sup>, M. De Masi<sup>1</sup>, M. Lichtner<sup>1,2</sup>  
<sup>1</sup>Infectious Diseases Unit, S.M. Goretti Hospital, Latina, <sup>2</sup>Department of Public Health and Infectious Diseases, "Sapienza" University, Rome

### P 82 Trend of sexually transmitted infections in patients on HIV pre-exposure prophylaxis (PrEP): the experience of two Italian centre between 2019 and 2022

M. Menozzi<sup>1</sup>, A. Di Biagio<sup>2</sup>, G.J. Burastero<sup>1</sup>, S. Volpi<sup>1</sup>, L. Labate<sup>3</sup>, M. Fasce<sup>3</sup>, L. Gozzi<sup>1</sup>, A. Tili<sup>1</sup>, V. Todisco<sup>1</sup>, M. Pellegrino<sup>1</sup>, C. Mussini<sup>1</sup>  
<sup>1</sup>Infectious Disease Clinic, University Hospital of Modena, Italy, <sup>2</sup>Infectious Diseases Unit, Ospedale Policlinico San Martino IRCCS – Genoa, Italy,  
<sup>3</sup>Department of Health Sciences (DISSAL), University of Genoa – Genoa, Italy

## IMPACT OF COVID-19 ON HIV CARE

### P 83 Home Care Assistance: has Covid-19 had an impact on the complex management of HIV patients?

A. Dusina<sup>1</sup>, F. Lombardi<sup>1</sup>, E. Tamburrini<sup>1,2</sup>, F. Onorati<sup>1</sup>, M. Petrucci<sup>1</sup>, S. Di Giambenedetto<sup>1,2</sup>  
<sup>1</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Malattie Infettive, Rome, Italy, <sup>2</sup>Università Cattolica del Sacro Cuore, Dipartimento di Sicurezza e Bioetica Sezione Malattie Infettive, Rome, Italy

### P 84 Impact of COVID-19 on HIV testing: our Lab experience

E. Garlati Costa<sup>1</sup>, M. Da Re<sup>2</sup>, D. Villalta<sup>2</sup>, M. Tonizzo<sup>1</sup>  
<sup>1</sup>SC Medicina Interna, Azienda sanitaria Friuli Occidentale, Pordenone, <sup>2</sup>SSD Immunologia Allergologia, Azienda sanitaria Friuli Occidentale, Pordenone

### P 85 Has COVID-19 pandemic changed the epidemiology of AIDS-defining illnesses? Data from a large Italian clinical center

V. Iannone<sup>1</sup>, A. Dusina<sup>1</sup>, D. Farinacci<sup>1</sup>, A. D'Angelillo<sup>1</sup>, P.F. Salvo<sup>1</sup>, A. Borghetti<sup>1</sup>, E. Visconti<sup>1</sup>, E. Tamburrini<sup>1</sup>, S. Di Giambenedetto<sup>1</sup>, A. Ciccullo<sup>2</sup>  
<sup>1</sup>Fondazione Policlinico Universitario Agostino Gemelli IRCCS UOC di Malattie Infettive, Roma IT, <sup>2</sup>Ospedale San Salvatore Unità di Malattie Infettive, L'Aquila IT

### P 86 COVID-19 pandemic's impact on the clinical-care management of naïve HIV + patients

C. Bitello, R. Caprara, S. Vitale, G. Ferraro, L. Appolloni, G. Pensalfine, A. Stancari  
IRCCS S. Orsola-Malpighi, Bologna

### P 87 Impact of COVID-19 pandemic on a HIV Counselling and Testing Site at "D. Cotugno" Hospital, Naples: what lessons can be learned?

F.M. Fusco<sup>1</sup>, P. Piselli<sup>2</sup>, M. De Cenzo<sup>1</sup>, O. Tambaro<sup>1</sup>, N. Cuomo<sup>3</sup>, F. Borrelli<sup>1</sup>, R. Viglietti<sup>1</sup>, V. Bruner<sup>1</sup>, C. Camaioni<sup>1</sup>, N. Sangiovanni<sup>1</sup>, A. Mariniello<sup>1</sup>, A. Galano<sup>1</sup>, A. Laudiero<sup>1</sup>, V. Sangiovanni<sup>1</sup>  
<sup>1</sup>UOC Infezioni sistemiche e dell'Immunodepresso, "D. Cotugno" Hospital, AOS dei Colli, Napoli, <sup>2</sup>Dipartimento di Epidemiologia e Ricerca Pre-clinica, INMI "L. Spallanzani", Roma, <sup>3</sup>UOC Microbiologia e Virologia, "D. Cotugno" Hospital, AOS dei Colli, Napoli

## SARS-COV-2 EPIDEMIOLOGY

### P 88 SARS-CoV-2 infection in dialysis patients in Marsala Hospital, Southern Italy: a single-centre experience in a pre- and postvaccination era, preliminary data

G. Marino<sup>1</sup>, P. Colletti<sup>2</sup>, P. Di Carlo<sup>3</sup>, C. Barracco<sup>4</sup>, G. Oddo<sup>5</sup>  
<sup>1</sup>Student in degree course of Medicine and Surgery, University of Palermo (Hypatia), Caltanissetta, Italy, <sup>2</sup>MD, Head of Infectious Disease Unit at "Paolo Borsellino" hospital, Marsala, Italy, <sup>3</sup>MD, PROMISE Department, University of Palermo, Italy, <sup>4</sup>Head Nurse of Dialysis Unit at "Paolo Borsellino" hospital, Marsala, Italy, <sup>5</sup>MD, Head of Dialysis Unit at "Paolo Borsellino" hospital, Marsala, Italy



**P 89 Distribution of SARS-CoV-2 viral variants in a cohort of subjects treated with monoclonal antibodies targeting spike protein in Campania**

A. Di Fraia<sup>1</sup>, M. Pisaturo<sup>1</sup>, M. Starace<sup>1</sup>, C. Minichini<sup>1</sup>, L. Occhiello<sup>1</sup>, I. Gentile<sup>2</sup>, L. Atripaldi<sup>3</sup>, C. Tiberio<sup>3</sup>, I. Cavallaro<sup>3</sup>, F. Ferrentino<sup>3</sup>, N. Coppola<sup>1</sup>

<sup>1</sup>Infectious Diseases Unit, Department of Mental Health and Public Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy, <sup>2</sup>Department of Clinical Medicine and Surgery, University of Naples "Federico II", Napoli, Italy, <sup>3</sup>Cotugno Hospital, AORN Ospedali dei Colli, Napoli, Italy

**SOCIAL AND BEHAVIOURAL SCIENCE, MARGINALIZED GROUPS, COMMUNITY ASPECTS AND COMMUNITY SURVEYS****P 90 Perceptions of an online serious game activity as formative assessment in higher education applied to a lecture on HIV and sexual health**

S. Licchelli, L. Barnett

University of Surrey, Guildford

**P 91 Determinants of Quality of Life in PLWH effectively treated with ART**

F. Maggiolo<sup>1</sup>, E. Di Filippo<sup>1</sup>, P. Meli<sup>2</sup>, D. Valenti<sup>3</sup>, F. Radici<sup>4</sup>, I. Mercurio<sup>5</sup>, L. Comi<sup>1</sup>

<sup>1</sup>ASST Papa Giovanni XXIII, <sup>2</sup>Comunità Emmaus & Caritas Bergamasca, <sup>3</sup>Associazione FROM, <sup>4</sup>Arcigay Bergamo Cives, <sup>5</sup>CRI-Comitato di Bergamo, Bergamo

**P 92 A Theatre-Counseling workshop on chemsex: the experience of Plus Roma**

A. Infante, F. Leserri, G.M. Corbelli

Plus Roma, Roma

**P 93 PAMP: Prevention among migrant people: a pilot project**

G.V. Calvino<sup>1</sup>, C. Sforza<sup>2</sup>, C. Vajiro<sup>3</sup>, C. Sfara<sup>4</sup>, S. Ondedei<sup>5</sup>, E. Teti<sup>6</sup>, B. Rossi<sup>6</sup>, V. Barchi<sup>6</sup>, L. Ansaldo<sup>6</sup>, L. Campogiani<sup>6</sup>, S. Tedde<sup>6</sup>, A. Cavasio<sup>6</sup>, M.L. Minardi<sup>6</sup>, D. Kontogiannis<sup>6</sup>, M. Andreoni<sup>6</sup>, B. Marchini<sup>1</sup>

<sup>1</sup>Anlaidi Onlus-Ets, <sup>2</sup>Consiglio Italiano per i Rifugiati, <sup>3</sup>Cooperativa Famiglia Nuova, <sup>4</sup>Anlaidi Umbria, <sup>5</sup>INMI L. Spallanzani, Roma, <sup>6</sup>UOC Malattie Infettive Policlinico Tor Vergata, Roma

**P 94 Mapping Italian HIV checkpoints and testing centers: the Check Point Index**

M. Carlevari<sup>1</sup>, S. Mattioli<sup>2</sup>, P. Meli<sup>3</sup>, M. Viscoli<sup>4</sup>, G.M. Corbelli<sup>5</sup>, L. Saracini<sup>6</sup>, D. Calzavara<sup>7</sup>

<sup>1</sup>Director Public Affairs Gilead sciences Italy, <sup>2</sup>BLQ Checkpoint, <sup>3</sup>Bergamo Checkpoint, <sup>4</sup>Checkpoint IOC'ENTRO Genova, <sup>5</sup>Roma Checkpoint, <sup>6</sup>Ancona Checkpoint, <sup>7</sup>Milano Checkpoint, Elma Research Srl

**P 95 People with HIV - The psychological and social intervention of Anlaidi Lazio**

R. Galipò<sup>1</sup>, V. Calvino<sup>2</sup>, M. Falaguasta<sup>2</sup>, P. Ferri<sup>1</sup>

<sup>1</sup>Anlaidi Lazio, Rome, <sup>2</sup>Anlaidi, Rome

**P 96 A protocol for a systematic review of predictors of quality of life and health-related quality of life in OPLWHIV**

S. Licchelli, K. Smith, A. King, F. Trevisan

University of Surrey, Guildford

**P 97 HIV and STI awareness project among adolescent population**

F. Rossi<sup>1</sup>, A. Bianchi<sup>1</sup>, P. Testoni<sup>1</sup>, D. Zagato<sup>1</sup>, R. Repossi<sup>1</sup>, A. Antonino<sup>1</sup>, E. Garavaglia<sup>1</sup>, D. Pennisi<sup>1</sup>, M. Cernuschi<sup>2</sup>

<sup>1</sup>ASA Associazione Solidarietà AIDS, Milano, Italy, <sup>2</sup>San Raffaele Hospital, Milano, Italy

**P 98 Nathan Never character by Bonelli Editore combats AIDS and STIGMA**

G. Dessi, V. Mascia, B. Mocchi, A. Pontis

Lila Cagliari OdV, Cagliari

**P 99 Villa Maraini: syndemic approach against social stigma**

T. Di Giovanni<sup>1</sup>, P. Sammarco<sup>1</sup>, D. Masci<sup>1</sup>, G. F. M. Direnzo<sup>1</sup>, E. Teti<sup>2</sup>, B. Coladarce<sup>1</sup>, G. Rodoquino<sup>1</sup>, M. Andreoni<sup>2</sup>, E. Rossi<sup>1</sup>, M. Barra<sup>1</sup>

<sup>1</sup>Fondazione Villa Maraini, Rome, Italy, <sup>2</sup>Infectious Disease Clinic, Tor Vergata University, Rome, Italy

**P 100 The rise and fall of the news media interest for HIV/AIDS impact on people's life: an observational study of the Italian press**

C. Capelli<sup>1</sup>, M. Pasquali<sup>1</sup>, G.M. Corbelli<sup>2</sup>, P. Lalli<sup>1</sup>

<sup>1</sup>Department of Political and Social Sciences, University of Bologna, <sup>2</sup>Plus, Network persone LGBT+ sieropositivo





**P 101 Covid 19: let's go with the vaccine Accompanying the booking of the anticovid-19 vaccine for migrants and LGBTI migrants + APS Arcigay Cassero**

R. Cerbo, S. Degasperi

APS Arcigay Cassero, Gruppo Salute, Bologna

**P 102 Measuring impact of a scalable peer education-based sexuality education programme in multiple Arcigay local committees**

B. Allegretti, A. Barretta, A. Biondi, W. Bravi, M. Breveglieri, G. Cioffi, G. D'Ambrosio, B. Diana, D. Enicchiario, M. Marocco, I. Mele, F. Merolle, N. Piazza  
Arcigay, Caserta

**P 103 In and Out testing/counseling approach in pandemic era: a nine months experience at Checkpoint and Hospital center**

G. Mancarella<sup>2</sup>, M. Jamhour<sup>1</sup>, A. Carraro<sup>1,2</sup>, S. Garattini<sup>2</sup>, A. Pontrelli<sup>2</sup>, A. Gasperin<sup>2</sup>, D. Di Trento<sup>2</sup>, R. Marocco<sup>1</sup>, A. Petrillo<sup>3</sup>, V. Vitale<sup>3</sup>, D. Coletta<sup>4</sup>, M. Lichtner<sup>1,2</sup>

<sup>1</sup>Infectious Diseases Unit, S.M. Goretti Hospital, Latina, <sup>2</sup>Department of Public Health and Infectious Diseases, "Sapienza" University, Rome, <sup>3</sup>Arci Gay Latina/Sei come sei, <sup>4</sup>Municipality of Latina

**P 104 HIV Written Informed Consent: Time to Reconsider the Italian Standard?**

J. Testa<sup>1,2</sup>, N. Cocco<sup>2,3</sup>, F. Nicolini<sup>2,4</sup>, D. Radrizzani<sup>1</sup>, C. Abeli<sup>1</sup>, M. Farinazzo<sup>1,2</sup>, B. Menzaghi<sup>1</sup>

<sup>1</sup>Infectious Diseases Unit, ASST Valle Olona, Busto Arsizio, <sup>2</sup>Research Group of Italian Society of Migration Medicine (SIMM), <sup>3</sup>Infectious Diseases Service, Penitentiary Health System, ASST Santi Paolo e Carlo, Milan; <sup>4</sup>Clinical Ethics Service "Domus Salutis" Clinic, Teresa Camplani Foundation, Brescia

**P 105 Chemsex in Milan**

S. Giacalone<sup>2</sup>, S. Ramoni<sup>1</sup>, M. Cusini<sup>1</sup>

<sup>1</sup>UOC Dermatologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, <sup>2</sup>Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Milan, Italy

**P 106 Bringing comprehensive sexuality education into Italian lower secondary schools' practice: a pilot study**

E. Torri<sup>1</sup>, A. Chinelli<sup>1</sup>, L. Ceccarelli<sup>1</sup>, L. Rancilio<sup>6</sup>, M. Farinella<sup>7</sup>, R. Galipò<sup>3</sup>, P. Meli<sup>4</sup>, A. Camposeragna<sup>5</sup>, L. Colaprico<sup>8</sup>, M. Oldrini<sup>9</sup>, M.C. Salfa<sup>10</sup>, A. Cellini<sup>11</sup>, M. Ubbiali<sup>12</sup>, A. Caraglia<sup>13</sup>, L. Mortari<sup>12</sup>, A.T. Palamara<sup>11</sup>, B. Suligo<sup>10</sup>, L. Tavoschi<sup>1</sup>, D. Martinelli<sup>2</sup>

<sup>1</sup>University of Pisa, Department of Translational Research on New Technologies in Medicine and Surgery, <sup>2</sup>University of Foggia, Department of Medical and Surgical Sciences, <sup>3</sup>ANLAIDS - National Association for the Fight against AIDS, Rome, <sup>4</sup>CICA - Italian Coordination of HIV/AIDS Housing Homes, Bergamo, <sup>5</sup>CNCA - National Coordination of the Hospitality Community, Rome, <sup>6</sup>Caritas Ambrosiana, Milan, <sup>7</sup>Circolo di cultura omosessuale Mario Mieli, Rome, <sup>8</sup>Italian Red Cross, Rome, <sup>9</sup>LILA - Italian league for the fight against AIDS, Rome, <sup>10</sup>Italian National Institute of Health, Rome, <sup>11</sup>Sapienza University of Rome, <sup>12</sup>University of Verona, Department of Human Sciences, <sup>13</sup>Ministry of Health, Department of Prevention, Rome

**P 107 Sexual Health in Migrant Population: Analysis of the risk of contracting HIV and STDs**

V. Manca<sup>1</sup>, V. Fiore<sup>1</sup>, A. De Vito<sup>1</sup>, N. Geremia<sup>2</sup>, E. Prinic<sup>1</sup>, G. Madeddu<sup>1</sup>, S. Babudieri<sup>1</sup>

<sup>1</sup>Unit of Infection Diseases, Department of Medical, Surgical and Experimental Sciences, AOU, Sassari, <sup>2</sup>Unit of Infection Diseases, Department of Clinical Medicine, Ospedale dell'Angelo, Venezia

## Virology and Pharmacology

### HIV VIROLOGY

**P 108 Evaluating the dual-target Aptima HIV-1 Quant Dx assay: comparison between viral loads measured with the pol and LTR targets in the same samples**

G. Sberna<sup>1</sup>, S. Sarti<sup>1</sup>, A. Antinori<sup>2</sup>, S. Cicalini<sup>2</sup>, A.R. Garbuglia<sup>1</sup>, A. Amendola<sup>1</sup>

<sup>1</sup>Laboratory of Virology, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy, <sup>2</sup>HIV/AIDS Department, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy

**P 109 Inhibitory activity of the polyphenolic extract of Cistus Monspelienensis L. against HIV-1 under cell culture conditions**

M. Tamburello<sup>1</sup>, V. Ferraro<sup>1</sup>, S. Vituliano<sup>1</sup>, A. Morellini<sup>1</sup>, A. Primavera<sup>2</sup>, A. Bertoldi<sup>2</sup>, M. Mandrone<sup>3</sup>, F. Poli<sup>3</sup>, G. Gallinella<sup>3</sup>, T. Lazzarotto<sup>1,2</sup>, I. Bon<sup>2</sup>

<sup>1</sup>Section of Microbiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, <sup>2</sup>Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, <sup>3</sup>Department of Pharmacy and Biotechnology, University of Bologna, Bologna

**P 110 Evaluation of a new real-time PCR commercial test for HIV-DNA quantification in PBMC**

T. Allice, M.G. Milia, E. Burdino, G. Gregori, F. Cerutti, S. Crisavola, S. Monteleone, E. Scuccimarra, V. Ghisetti

Laboratory of Microbiology and Virology, ASL Città di Torino, Italy





## PHARMACOLOGY, PHARMACOGENOMICS AND DRUG INTERACTIONS

### P 111 Exploratory analysis of potential drug-drug interactions between molnupiravir and HAART in PLWH with COVID-19 in Udine

D. D'Elia<sup>1</sup>, A. Londero<sup>1</sup>, F. Pratavera<sup>1</sup>, L.M. Ditaranto<sup>1</sup>, M. Fusi<sup>2</sup>, C. Resnati<sup>2</sup>, C. Tascini<sup>1</sup>, D. Cattaneo<sup>2</sup>

<sup>1</sup>Unit of Infectious Disease, Santa Maria della Misericordia University Hospital, Udine, Italy, <sup>2</sup>Unit of Clinical Pharmacology, Luigi Sacco University Hospital, Milano, Italy

### P 112 Dolutegravir plasma and intracellular pharmacokinetics in the clinical setting

F. Alladio<sup>1</sup>, M. Ferrara<sup>1</sup>, G. Accardo<sup>1</sup>, S. Fantino<sup>1</sup>, G. Trevisan<sup>1</sup>, E. Drappero<sup>1</sup>, A. Serra<sup>1</sup>, L. Trentini<sup>1</sup>, M. Tettoni<sup>1</sup>, E. De Vivo<sup>2</sup>, A. Ianniello<sup>2</sup>, J. Mula<sup>2</sup>, A. De Nicolò<sup>2</sup>, A. D'Avolio<sup>2</sup>, A. Calcagno<sup>1</sup>, G. Di Perri<sup>1</sup>, S. Bonora<sup>1</sup>

<sup>1</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, <sup>2</sup>Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Torino, Torino

### P 113 Isoenzymes subfamilies and symptomatic adverse events: is there a link?

E. Gentilini Cacciola, A. Lazzaro, P. Vassalini, C. Borrazzo, C.M. Mastroianni, G. d'Ettore

University of Roma "LaSapienza", Roma

## SARS-COV-2 VIROLOGY

### P 114 Discerning the molecular mechanism beyond the UV-photoinactivation of SARS-CoV-2

S. Strizzi<sup>1</sup>, L. Bernardo<sup>2</sup>, A. Bianco<sup>3</sup>, D. Trabattoni<sup>1</sup>, A. De Palma<sup>2</sup>, G. Pareschi<sup>3</sup>, P. D'Ursi<sup>2</sup>, M. Clerici<sup>1</sup>, P. Mauri<sup>2</sup>, M. Biasin<sup>1</sup>

<sup>1</sup>DIBIC University of Milan, <sup>2</sup>Proteomic Unit of Institute for Biomedical Technologies – CNR, Segrate (MI), Italy, <sup>3</sup>INAF- Brera Astronomical Observatory Merate

### P 115 Qualitative and quantitative approach to SARS-CoV-2 RNA detection

C. Orlandi<sup>1</sup>, A. De Maria<sup>2</sup>, M. Magnani<sup>1</sup>, A. Casabianca<sup>1</sup>

<sup>1</sup>Department of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy, <sup>2</sup>Department of Internal Medicine, Centre of Excellence for Biomedical Research, University of Genoa, Genoa, Italy


## VACCINES (OTHER THAN SARS-COV-2)

### P 116 Persistence of immune responses after the administration of the meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) in HIV-vertically transmitted young patients

C. Vanetti<sup>1</sup>, C. Fenizia<sup>2</sup>, F. Ardizzone<sup>1</sup>, I. Saulle<sup>1</sup>, M. Stracuzzi<sup>3</sup>, F. Da Pozzo<sup>3</sup>, L. Paradiso<sup>3</sup>, E. Longoni<sup>3</sup>, L. Barcellini<sup>4</sup>, M. Biasin<sup>1</sup>, M. Clerici<sup>2,5</sup>, G.V. Zuccotti<sup>3,4</sup>, V. Giacomo<sup>3</sup>, D. Trabattoni<sup>1</sup>

<sup>1</sup>University of Milan, Department of Biomedical and Clinical Sciences "Luigi Sacco", Milan, <sup>2</sup>University of Milan, Department of Pathophysiology and Transplantation, Milan, <sup>3</sup>Ospedale "Luigi Sacco", University of Milan, Department of Pediatric Infectious Diseases, Milan, <sup>4</sup>University of Milan, Ospedale dei Bambini V. Buzzi, Department of Pediatrics, Milan, <sup>5</sup>IRCCS Fondazione Don Gnocchi, Milan







*Alliance to leave no-one behind*



**Italian Conference on AIDS and Antiviral Research**

Presidenza del Congresso: **A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi**

# **GENERAL INFORMATION**





## Congress Venue



### Centro Congressi Giovanni XXIII

Viale Papa Giovanni XXIII, 106  
24121 Bergamo BG  
[www.centrocongressibergamo.com](http://www.centrocongressibergamo.com)



### Bergamo Science Center

Viale Papa Giovanni XXIII, 57  
24121 Bergamo BG  
[www.bergamoscienza.it](http://www.bergamoscienza.it)

## How to reach the Conference Venue



### Railway Station

Bergamo: 150 m from station



### Bergamo Orio al Serio Airport

5 Km from the airport – 10 minutes by car



### Car

Wide pay parking available near the Conference Venue

## Conference registration

It is possible to attend the conference in both residential and webinar mode.

For both of them, participants must submit the registration form through **MyICAR on the Conference website [www.icar2022.it](http://www.icar2022.it)**. After completing the form, you will receive an email with a link to confirm the activation of your personal account; you will receive a message with the instruction to access the congress webinar or you will be contacted by the Organizing Secretariat for your participation.

## Official languages

Italian and English. No simultaneous translation provided.





## Pre-conference advanced courses and Congress dates

**Pre-conference advanced courses:** Tuesday, June 14 from 14.30 to 16.30

**Conference:** from Tuesday, June 14 h. 17.00 to Thursday, June 16 h. 16.45

## Conference Secretariat opening times

- **Tuesday, June 14** from 10.30 to 20.00
- **Wednesday, June 15** from 08.30 to 19.00
- **Thursday, June 16** from 08.30 to 17.00

## Exhibition Area opening times

- **Tuesday, June 14** from 13.30 to 20.00
- **Wednesday, June 15** from 09.00 to 18.45
- **Thursday, June 16** from 09.00 to 16.45

## Lunches

- **Tuesday, June 14** from 12.30 to 14.30 (only for Pre-conference advanced Courses)
- **Wednesday, June 15** from 12.00 to 14.30
- **Thursday, June 16** from 12.00 to 14.30



Registered participants will receive lunch coupons from the Organizing Secretariat

Two different locations for lunches in the congress venue, just outside the Conference Center:

- Hotel NH Bergamo
- Hotel Piemontese - Sapore Puro

Same menu in both restaurants





## Instructions for Speakers

It is not possible to bring presentations directly to the lecture hall. All presentations have to be handed over at the Slide Center Room at least **2 hours before the session**. At the Slide Center Room, Speakers will have the possibility of:

- Reviewing power point presentations
- Last minute changes of power point presentations
- Being supported by technical staff
- Uploading power point presentation in the dedicated session conference room


**All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide.**

A slides template for Speakers' presentations is available for download on the Conference website [www.icar2022.it](http://www.icar2022.it)

## Oral Communication Sessions

Selected abstract will be presented in Oral Communication Sessions. Authors of the selected abstract are requested to attend their sessions and **provide max 8/10 (power point) slides** resuming their abstract. Time allowed for presentation: **10 minutes followed by 2 minutes for discussion**.

**All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide.**



## Oral Poster Sessions

Selected abstract will be presented in Oral Poster Sessions. Authors of the selected abstract are requested to attend their sessions and **provide max 5 (power point) slides** resuming their abstract. Time allowed for presentation: **5 minutes followed by 2 minutes for discussion**.

**All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide.**



## Digital Poster Exhibition

All the posters can be viewed through dedicated monitors located at **Centro Congressi Giovanni XXIII**.

*Con la sponsorizzazione non condizionante di Gilead Sciences*



## Official events

### Quick test for HIV, HCV and Syphilis

In front of Bergamo Science Center:

- **Tuesday, June 14** from 11.00 to 13.00  
and from 16.00 to 19.00
- **Wednesday, June 15** from 11.00 to 13.00  
and from 16.00 to 19.00
- **Thursday, June 16** from 11.00 to 13.00

Healthcare personnel will perform free rapid testing for HIV, HCV and Syphilis at the request of citizens in a confidential and anonymous way. The test is noninvasive, requires few minutes and is highly reliable.



Con la sponsorizzazione non condizionante di ViiV Healthcare  
In collaborazione con Abbott e Meridian Biosciences

### RaccontART


Presentation of the finalist works

- **Tuesday, June 14, Centro Congressi Giovanni XXIII**  
**Auditorium Sala Oggioni** from 13.30 to 16.00

Winners' Awards

- **Auditorium Sala Oggioni** from 18.20 to 18.40

The art competition launched by ICAR to students who are invited to present their views on HIV/AIDS, Covid and STIs through various forms of expression. During the Conference Opening Session the winners will be awarded by the Jury composed of leading representatives of the national cultural, scientific and technical world.



Con la sponsorizzazione di Gilead Sciences





## Exhibition “40 anni POSITIVI, dalla pandemia di AIDS ad una generazione HIV free”

Forty years ago New York Times published an article documenting the arrival of a new and unknown disease later identified as AIDS, an acronym for “Acquired Immunodeficiency Syndrome.”

To celebrate four decades of battles against HIV infection, the Bergamo Science Center is hosting, from 1 to 16 June, 2022, the exhibition “40 ANNI POSITIVI - dalla pandemia di AIDS ad una generation HIV free”, after the great success of the Milan 2021 edition.

Promoted and organized by **Milano Check Point**, with the support of **Bergamo Fast Track City**, in collaboration with **ICAR2022**, the exhibition presents **archival documents, posters and installations** that tell the story of the great revolution in HIV treatment, scientific research and civil society resistance movements.

### Bergamo Science Center

- **Tuesday, June 14**  
from 09.00 to 20.00
- **Wednesday, June 15**  
from 09.00 to 20.00
- **Thursday, June 16**  
from 09.00 to 16.00

**June 1-16, 2022**

**Bergamo Science Center**  
Viale Papa Giovanni XXIII, 57  
Bergamo

Progetto a cura di:



Sponsorizzato da ViiV Healthcare





## Special Awards

The work of young researchers and community representatives continues to be widely recognized by ICAR, not only through Scholarships, but also with special prizes. The 14th edition of ICAR awards as follows:

### ICAR-CROI Awards 2022

The absolute winners among the young Italian investigators who presented their work at CROI 2022

- **N. 1 Award** of € 1.000,00 for the best work in **Clinical**
- **N. 1 Award** of € 1.000,00 for the best work in **Basic Sciences**

**Winners will be announced during the ICAR-CROI Awards 2022 session in Auditorium Sala Oggioni on Thursday June 16 from 16.25**



### ICAR 2022 Scientific Committee Awards

The 14th ICAR Chairs and Scientific Secretariat will announce the "Scientific Committee Awards": the ICAR awards to the best abstracts

- **N. 1 Award** of € 1.000,00 for the best **Clinical** abstract
- **N. 1 Award** of € 1.000,00 for the best **Basic Science** abstract
- **N. 1 Award** of € 1.000,00 for the best **Social Science** abstract

**Winners will be announced during the ICAR 2022 Special Awards Session in Auditorium Sala Oggioni on Thursday June 16 from 16.25**



### SIMIT Special Awards

The 14th ICAR Chairs and Scientific Secretariat wish to thank SIMIT for the Special Awards dedicated to Young Investigators, whose abstracts have been accepted as Oral Communications:

- **N. 1 Award** of € 2.000,00 for the best **Clinical HIV** abstract
- **N. 1 Award** of € 2.000,00 for the best **Clinical Hepatitis Virus** abstract
- **N. 1 Award** of € 2.000,00 for the best **Clinical SARS-CoV-2** abstract
- **N. 1 Award** of € 2.000,00 for the best **Virology and Immunopathogenesis** abstract
- **N. 1 Award** of € 2.000,00 for the best **Epidemiology and Social Science** abstract



Only young investigators under 45 years of age and regularly registered to SIMIT for years 2021 and 2022 have been selected.

**Abstracts will be evaluated at the Congress Venue by a dedicated SIMIT Commission and winners will be announced during the ICAR 2022 Special Awards Session in Auditorium Sala Oggioni on Thursday June 16 from 16.25**





## ICAR 2022 APP

Designed to facilitate participation in ICAR 2022 and to respond to request for effective and high performance digital tools and supports. Two simple steps to access:

1. Download the ICAR App for free from the main stores (Apple Store and Google Play) "Minimum system requirements required for the App: Android 8.0 and iOS 13"
2. Login App: enter your personal login credentials (username and password) sent to you by the Organizing Secretariat Effetti



### Menu Functions

**HOME:** Simple and immediate with a usability designed specifically for the Conference. Each menu item corresponds to a precise and useful feature.

**PROGRAMMA SCIENTIFICO:** Complete Scientific Programme day by day with detailed information about each session (title, speaker, time, room). Users can also select favorite Lectures, clicking on the calendar icon: these will be saved in My Agenda

**MY AGENDA:** User can customize their own Agenda using this function. ICAR 2022 App will create the list of favorite selected sessions in a chronological order

**PROGRAMME AT A GLANCE:** to quickly check Programme, rooms and sessions schedule

**VOTAZIONE:** It allows user to vote when sessions require this functionality

**RACCONTART:** To access the Art Contest, consult the works in competition, learn about participating schools, and much more

**ABSTRACT:** All abstracts accepted, broken down by type of presentation (Oral, Oral poster, Poster) and Abstract Reviewers. From June 14, the Abstract Repository at your fingertips with keyword search, Authors names, Abstract IDs

**ICAR AWARDS:** The official rewards that ICAR assign to young investigators and Community ambassadors


**WORDCLOUD:** Allows to select the key-words that represent the Congress main concept, creating a "cloud" that will highlight the most selected words

**TEST RAPIDO HIV-HCV- SYPHILIS:** Where, when and at what times: all the appointments of the Quick test for HIV, HCV and Syphilis

**MOSTRA 40 ANNI POSITIVI:** Archival documents, posters and installations retrace the forty years of the fight against the HIV virus

**ICAR SOCIAL:** Direct links to ICAR 2022 Social. Stay connect #ICAR2022

**INFORMAZIONI GENERALI:** A menu item for the most useful and important links: Congress Venue, Transportation and much more...



Con la sponsorizzazione non condizionante di Gilead Sciences







## Community Village

A specific area of the Bergamo Science Center dedicated to the Community Village: a meeting point for all participants to visit the booths of patient associations and meet the Community activists.



## Nice to ICAR YOU

The ICAR 2022 welcome point, in front of **Centro Congressi Giovanni XXIII**: all registered participants can ask for all the information and collect the ICAR 2022 T-shirt.



## POSTER 4 YOU

A free service for selected posters' Authors to create their own posters and record their comments. ICAR Poster-4-you USB pendrive can be requested showing the coupon at the Gilead Sciences booth.

*Con la sponsorizzazione non condizionante di Gilead Sciences*



## Abstract USB Pendrive


All registered participants can ask for the ICAR Abstract USB pendrive showing the coupon at the ViiV Healthcare booth: it contains all accepted abstracts.

*Con la sponsorizzazione non condizionante di ViiV Healthcare*



## ICAR On-Demand and Web Repository

After the congress, on the official website [www.icar2022.it](http://www.icar2022.it) you will find: ICAR 2022 web repository of abstracts, presentations, oral communications and accepted posters, podcasts and photo gallery.



## ICAR SOCIAL

 Direct links to ICAR 2022 Social.

Stay connect #ICAR2022

[www.instagram.com/icarcongress](http://www.instagram.com/icarcongress)

[www.twitter.com/ICARcongress](http://www.twitter.com/ICARcongress)

[www.facebook.com/ICARcongress](http://www.facebook.com/ICARcongress)



*Participants are hereby informed that in some spaces where the conference and ancillary activities will take place, photographs/video footage intended for online publication may be taken; participants will be notified through dedicated signage.*





## Conference

The 14th ICAR Conference has been accredited to the Italian Ministry of Health for 14 CME Credits.

Every single day has been accredited for the following professionals:

ID ECM Number	Credits	Professionals
<b>Tuesday, June 14</b> 150-345043	<b>2,1</b>	<b>Medical Doctor</b> (all disciplines)
<b>Wednesday, June 15</b> 150-345052	<b>7,0</b>	<b>Healthcare Assistant, Biologist, Hospital Pharmacist, Nurse, Medical laboratory technician, Psychologist, Psychotherapist, Professional Educator</b>
<b>Thursday, June 16</b> 150-345056	<b>4,9</b>	

## Pre-conference advanced Courses

The 14th ICAR advanced Courses have been accredited to the Italian Ministry of Health for each single course:

ID ECM Number	Credits	Professionals
<b>Focus on viral resistance and variability</b> 150-345000	<b>2</b>	<b>Medical Doctor</b> Allergology and Clinical Immunology; Hygiene, Epidemiology and Public Health; Gastroenterology; Infectious and Tropical Diseases; Internal Medicine; Microbiology and Virology; Clinical pathology; <b>Biologist; Medical laboratory technician</b>
<b>Clinical and point of care diagnostics for STIs in PreP service</b> 150-345015	<b>2</b>	<b>Medical Doctor</b> Allergology and Clinical Immunology; Hygiene, Epidemiology and Public Health; Gastroenterology; Infectious and Tropical Diseases; Internal Medicine; Microbiology and Virology; Clinical pathology; Dermatology and Venereology; Psychotherapy; Clinical pharmacology and toxicology <b>Healthcare Assistant, Biologist, Hospital Pharmacist, Nurse, Psychologist, Psychotherapist</b>
<b>New psychoactive substances and chemsex. David Stuart course</b> 150-345026	<b>2</b>	<b>Medical Doctor</b> Allergology and Clinical Immunology; Hygiene, Epidemiology and Public Health; Gastroenterology; Infectious and Tropical Diseases; Internal Medicine; Microbiology and Virology; Clinical pathology; Clinical pharmacology and toxicology; Dermatology and Venereology - <b>Healthcare Assistant, Hospital Pharmacist, Professional educator, Psychologist, Psychotherapist</b>





## Obtaining credits

### Participants

To obtain credits, registered participants are required to:

- Wear the identification badge during working sessions
- Provide their signature and write entrance/exit times before and after attending working sessions
- Complete assessment and satisfaction questionnaires for each day on the official website [www.icar2022.it](http://www.icar2022.it)  
(questionnaires will remain available from Friday 17 to Friday 24 June)

### Speakers

Speakers will be given 1 credit for each half-hour of consecutive teaching.

Speakers, moderators and discussants can decide to obtain credits as participants (see participants).

### Attendance Tracking

Attendance will be tracked through participants' signature at the start/end of each day, and through assessment and satisfaction questionnaires.

### CME certification

Credits will be given only if a participant attends 90% of the working sessions and provides correct answers to at least 75% of the questions included in the final assessment questionnaire. The Provider will send CME certificates to the participants after the Conference.

### SVC Assobiomedica

The pre-conference courses and the Congress were assessed as compliant with the Ethics' Code by the Assobiomedica Conference Evaluation System (SVC).





## Pre-conference advanced Courses

**Free of charge** (registrations available on a "first come, first served" basis).

## Conference

### Conference registration fees (22% VAT not included)

Physicians	€ 750,00
Physicians < 35 years of age, Biologist, Biotechnologist, Pharmacist, Nurse, Psychologist	€ 350,00
Students/PhD and Post-graduate medical trainees	Free
Members of HIV/AIDS Community	Free

**The registration fee includes:** congress kit (delegate bag, badge, certificate of attendance), Opening Session and Welcome Cocktail on June 14, coffee breaks and lunches on June 15 and 16, CME registration, Conference USB/abstract and poster.

### Daily Conference registration fees (22% VAT not included)

Physicians	€ 330,00
Physicians < 35 years of age, Biologist, Biotechnologist, Pharmacist, Nurse, Psychologist	€180,00
Students/PhD and Post-graduate medical trainees	Free
Members of HIV/AIDS Community	Free

**The registration fee includes:** congress kit (delegate bag, badge, certificate of attendance to the sessions of the day), coffee break and lunch for the day, CME registration, Conference USB/abstract and poster.

*Alliance to leave no-one behind*



**Italian Conference on AIDS and Antiviral Research**

Presidenza del Congresso: **A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi**

**CONGRESS  
MAP**



**CENTRO CONGRESSI  
PAPA GIOVANNI XXIII  
SPAZIO ESPOSITIVO**

**GROUND FLOOR**

**Exhibition area Ground floor**

1a



1b

2



3



4



5

**LED TOWERS Ground floor**

A



B



D



E



F



**DIGITAL AREA Ground floor**

Y




**ENTRATA  
CENTRO CONGRESSI**



**ICAR 2022 Welcome area  
the ICONA and ReadFiles  
meeting points**






- |   |  |    |  |
|---|--|----|--|
| 1 | Anlaids ONLUS  | 7  | LEGA ITALIANA PER LA LOTTA CONTRO L'AIDS       |
| 2 | ARCIGAY Associazione LGBTI+ Italiana   | 8  | mariomieli                                     |
| 3 | ARCOBALENOAIDS ODV   | 9  | Milano CHECKPOINT                              |
| 4 | ASA ONLUS  | 10 | NPS Italia onlus Network Persone Sieropositive |
| 5 | C.I.C.A. COORDINAMENTO ITALIANO DELLE CASE ALLOGGIO PER PERSONE CON HIV/AIDS | 11 | SECRETARIATO ITALIANO STUDENTI MEDICINA        |
| 6 | FONDAZIONE VILLA MARAINI   | 12 | PLUS PERSONE LGBT+ SIEROPOSITIVE               |

**BERGAMO SCIENCE CENTER SPAZIO ESPOSITIVO**

**GROUND FLOOR**



**1st FLOOR**





**CENTRO CONGRESSI  
PAPA GIOVANNI XXIII  
SPAZIO ESPOSITIVO**

**1st FLOOR**

**EXHIBITION AREA 1st floor**

- 6 **GILEAD**  
Creating Possible

---

- 7

---

- 8 **janssen Infectious Diseases & Vaccines**  
PHARMACEUTICAL COMPANIES OF Johnson & Johnson

---

- 9

---

- 10 **Abbott**

**LED TOWERS 1st floor**


- C **SHIONOGI**

**POP UP 1st floor**

- 11 **SHIONOGI**

---

- 12 **VIATRIS**









**CENTRO CONGRESSI  
PAPA GIOVANNI XXIII  
SPAZIO ESPOSITIVO**

**2nd FLOOR**

**EXHIBITION AREA 2nd floor**

12 **sobi**  
more strength

**ICAR ENERGY HALL 2nd floor**

13 **Agilent**

14 **meridian** BIOSCIENCE  
LIFE DISCOVERED. LIFE DRUGSSED.


15 **JSS** BIO PHARMA  
Strategic Partners

18 **Cepheid.**  
A better way.

**HOSPITALITY SUITE 2nd floor**

16 **GILEAD**  
Creating Possible

17 **ICAR TG**







## Italian Conference on AIDS and Antiviral Research

effetti

### THANKS TO THE SPONSORS

The Chairs, the Scientific Secretariat and CME Provider wish to thank the following Companies for the support given to the Congress, as unrestricted educational grants:

#### Platinum



#### Gold



#### Silver



#### Others



Seguici su



[www.icar2022.it](http://www.icar2022.it)

